Introducing PHARMAC

June 2013

Volume 20 Number 1

Editors: Kaye Wilson, Donna Jennings & Sarah Le Leu email: schedule@pharmac.govt.nz Telephone +64 4 460 4990 Facsimile +64 4 460 4995 Level 9, 40 Mercer Street PO Box 10 254 Wellington

Freephone Information Line 0800 66 00 50 (9am - 5pm weekdays)

Circulation

Published each April, August and December. Changes to the contents are published in monthly updates.

Accessible in an electronic format at no cost from the Health Professionals section of the PHARMAC website www.pharmac.govt.nz

You can register to have an electronic version of the Pharmaceutical Schedule (link to PDF copy) emailed to your nominated email address each month. Alternatively there is a nominal charge for an annual subscription to the printed Schedule publications. To access either of these subscriptions visit our subscription website www.schedule.co.nz.

Production

Typeset automatically from XML and T_EX. XML version of the Schedule available from www.pharmac.govt.nz/schedule/pub/archive/

Programmers

Anrik Drenth & John Geering email: texschedule@pharmac.govt.nz

© Pharmaceutical Management Agency



ISSN 1179-3686 pdf ISSN 1172-9376 print

This work is licensed under the Creative Commons Attribution 3.0 New Zealand licence. In essence, you are free to copy, distribute and adapt it, as long as you attribute the work to PHARMAC and abide by the other licence terms. To view a copy of this licence, visit:

creativecommons.org/licenses/by/3.0/nz/.

Attribution to PHARMAC should be in written form and not by reproduction of the PHARMAC logo. While care has been taken in compiling this Schedule, PHARMAC takes no responsibility for any errors or omissions, and shall not be liable for any consequences arising there from.

Section B

General Rules 11

2

Alimentary Tract & Metabolism 24

- Blood & Blood Forming Organs 45 Cardiovascular System 52 Dermatologicals 64
- Genito Urinary System 76
- Hormone Preparations Systemic 82
- Infections Agents For Systemic Use 89
 - Musculoskeletal System 110
- Nervous System 118 Oncology Agents & Immunosuppressants 147
 - Respiratory System & Allergies 175
 - Sensory Organs 183
 - Various 187

Section C Extemporaneous Compounds (ECPs) 188

Section D Special Foods 195 Section E Practitioner's Supply Orders 216 Rural Areas 220 Section F Dispensing Period Exemptions 221 Section G Safety Cap Medicines 223 Section I National Immunisation Schedule 226

Index 228

Introducing PHARMAC

PHARMAC, the Pharmaceutical Management Agency, is a Crown entity established pursuant to the New Zealand Public Health and Disability Act 2000 (The Act). The primary objective of PHARMAC is to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided.

The PHARMAC Board consists of up to six members appointed by the Minister of Health. All decisions relating to PHARMAC's operation are made by or under the authority of the Board. In particular, Board members decide on the strategic direction of PHARMAC and may decide which community pharmaceuticals should be subsidised and at what levels, and determine national prices for some pharmaceuticals to be purchased by and used in DHB Hospitals, and whether or not special conditions are to be applied to such purchases.

Members of the PHARMAC Board

Stuart McLauchlan	Kura Denness	David Kerr
Anne Kolbe	Jens Mueller	Jan White

Decisions taken by the PHARMAC Board members, or made under the authority of the Board, incorporate a balanced view of the needs of prescribers and patients. The aim is to achieve long-term gains and efficient ways of making pharmaceuticals available to the community and for DHB Hospitals to purchase them.

The following attend PHARMAC's Board meetings as observers

- Murray Georgel, CE MidCentral DHB
- Kate Russell, Chair Consumer Advisory Committee
- Carl Burgess, Chair Pharmacology and Therapeutics Advisory Committee (PTAC)

The functions of PHARMAC are to perform the following, within the amount of funding provided to it in the Pharmaceutical Budget or to DHBs from their own budgets for the use of pharmaceuticals in their hospitals, as applicable, and in accordance with its annual plan and any directions given by the Minister (Section 103 of the Crown Entities Act):

- a) to maintain and manage a pharmaceutical schedule that applies consistently throughout New Zealand, including determining eligibility and criteria for the provision of subsidies;
- b) to manage incidental matters arising out of (a), including in exceptional circumstances providing for subsidies for the supply of pharmaceuticals not on the pharmaceutical schedule;
- c) to engage as it sees fit, but within its operational budget, in research to meet its objectives as set out in Section 47(a) of the Act;
- d) to promote the responsible use of pharmaceuticals;
- e) to manage the purchasing of any or all pharmaceuticals, whether used either in a hospital or outside it, on behalf of DHBs;
- f) any other functions given to PHARMAC by or under any enactment or authorised by the Minister.

The policies and criteria set out in the Pharmaceutical Schedule and PHARMAC's Operating Policies and Procedures arise out of, and are designed to help PHARMAC achieve and perform, PHARMAC's objective and functions under the Act.

However PHARMAC may, having regard to its public law obligations, depart from the strict application of those policies and criteria in certain exceptional cases where it considers this necessary or appropriate in the proper exercise of its statutory discretion and to give effect to its objective and functions, particularly with respect to:

- Determining eligibility and criteria for the provision of subsidies; and
- In exceptional circumstances providing for subsidies for the supply of pharmaceuticals not on the Pharmaceutical Schedule.

Decision Criteria

PHARMAC updates the Pharmaceutical Schedule at regular intervals to notify prescribers, pharmacists, hospital managers and patients of changes to Community Pharmaceutical subsidies and the prices for Hospital Pharmaceuticals. In making decisions about amendments to the Pharmaceutical Schedule, PHARMAC is guided by its Operating Policies and Procedures, as amended or supplemented from time to time. PHARMAC takes into account the following criteria when making decisions about Community Pharmaceuticals:

- the health needs of all eligible people within New Zealand (eligible defined by the Government's then current rules of eligibility);
- the particular health needs of Maori and Pacific peoples;
- the availability and suitability of existing medicines, therapeutic medical devices and related products and related things;
- the clinical benefits and risks of pharmaceuticals;
- the cost-effectiveness of meeting health needs by funding pharmaceuticals rather than using other publicly funded health and disability support services;
- the budgetary impact (in terms of the pharmaceutical budget and the Government's overall health budget) of any changes to the Pharmaceutical Schedule;
- the direct cost to health service users;

- the Government's priorities for health funding, as set out in any objectives notified by the Crown to PHARMAC, or in PHARMAC's Funding Agreement, or elsewhere; and
- such other criteria as PHARMAC thinks fit. PHARMAC will carry out appropriate consultation when it intends to take any such "other criteria" into account.

The Operating Policies and Procedures, including any supplements, also describe the way in which PHARMAC determines the level of subsidy or purchase price payable for each Community Pharmaceutical or Hospital Pharmaceutical, respectively.

The decision criteria for Hospital Pharmaceuticals are set out in the hospital supplement to the Operating Policies and Procedures and in the introductory part of Section H of the Pharmaceutical Schedule.

Copies of PHARMAC's Operating Policies and Procedures and of any applicable supplements are available on the PHARMAC website (www.pharmac.govt.nz), or on request.

PHARMAC and the Pharmaceutical Schedule:

PHARMAC manages the national Pharmaceutical Schedule, which lists:

- Pharmaceuticals available in the community and subsidised by the Government with funding from the Pharmaceutical Budget; and
- some Pharmaceuticals purchased by DHBs for use in their hospitals, and includes those Hospital Pharmaceuticals for which national prices have been negotiated by PHARMAC.

In the community approximately 1848 Pharmaceuticals are subsidised by the Government. Most are available to all eligible people within New Zealand on prescription by a medical doctor. Some are listed with guidelines or conditions such as 'only if prescribed for a dialysis patient' or 'Special Authority - Retail Pharmacy', to ensure that Pharmaceuticals are used by those people who are most likely to benefit from them. Pharmaceuticals provided to patients for use while in DHB hospitals are not covered by Sections A to G of the Pharmaceutical Schedule.

Section H of the Pharmaceutical Schedule is not a comprehensive list of Pharmaceuticals that are used within the DHB Hospitals. Section H of the Pharmaceutical Schedule includes Pharmaceuticals that can be purchased at a national price by DHBs for use in their hospitals. These are referred to as National Contract Pharmaceuticals.

A list of Discretionary Community Supply Pharmaceuticals, in Section H of the Pharmaceutical Schedule, identifies those products that currently are not subsidised from the Pharmaceutical Budget as Community Pharmaceuticals in Sections A to G of the Pharmaceutical Schedule but which DHBs can at their discretion fund for use in the community from their own budgets Hospital Pharmaceuticals in the Community approval.

PHARMAC's clinical advisors

Pharmacology and Therapeutics Advisory Committee (PTAC)

PHARMAC works closely with the Pharmacology and Therapeutics Advisory Committee (PTAC), an expert medical committee which provides independent advice to PHARMAC on health needs and the clinical benefits of particular pharmaceuticals for use in the community and/or in DHB Hospitals.

The committee members are all senior, practising clinicians. The chair of PTAC sits with the PHARMAC Board in an advisory capacity.

PTAC helps decide which community pharmaceuticals are to be subsidised from public monies by making recommendations to PHARMAC. Part of the role of PTAC is to review whether Community Pharmaceuticals already listed on the Schedule should continue to receive Government funds. The resources freed up can be used to subsidise other community pharmaceuticals with a greater therapeutic worth.

PHARMAC may obtain clinical advice from PTAC in relation to national purchasing strategies for Hospital Pharmaceuticals. There may be additional specialist hospital representatives on PTAC subcommittees, or additional PTAC subcommittees, where PHARMAC considers this necessary.

PTAC members are:

Sisira Jayathissa	MMBS, MMedSc (Clin Epi), MD, FRCP (Lon, Edin), FRACP, FAFPHM, FNZCPHM, Dip Clin Epi,
	Dip OHP, DipHSM, MBS, Chair
Chris Cameron	MBChB, FRACP, MClin Pharm
Melissa Copland	PhD, BPharm(Hons), RegPharmNZ, FNZCP
Stuart Dalziel	MBChB, PhD, FRACP
lan Hosford	MBChB, FRANZCP, psychiatrist
George Laking	PhD, MD, FRACP
Dee Mangin	MBChB, DPH, RNZCGP
Graham Mills	MBChB, MTropHlth, MD, FRACP, infectious disease specialist and general physician
Marius Rademaker	BM (Soton), FRCP (Edn), FRACP DM
Jane Thomas	MBChB, FANZGL
Mark Weatherall	BA, MBChB, MApplStats, FRACP
Sean Hanna	MB ChB, FRNZCGP, FRACGP, PGDipGP, PGCertClinEd

Contact PTAC C/- PTAC Secretary, Pharmaceutical Management Agency, PO Box 10 254, WELLINGTON, Email: PTAC@pharmac.govt.nz

PHARMAC's consumer advisors

Consumer Advisory Committee (CAC)

The Consumer Advisory Committee is an advisory committee to the PHARMAC Board. It provides written reports to the Board, and its Chair attends Board meetings as an observer to report on the activities and findings of the Committee, and to comment on consumer issues. While accountable to the Board, the Committee's general working relationship is with the staff of PHARMAC. The Committee is made up of people from a range of backgrounds and interests including the health of Māori people, Pacific peoples, older people, women and mental health.

For current membership of the Consumer Advisory Committee, visit our website. The Consumer Advisory Committee can be contacted by email: CAC@pharmac.govt.nz, or you can write to the Consumer Advisory Committee at PHARMAC's postal address.

Purpose of the Pharmaceutical Schedule

The purpose of the Schedule is to list:

- the Community Pharmaceuticals that are subsidised by the Government and to show the amount of the subsidy paid to contractors, as well as the manufacturer's price (if it differs from the Subsidy) and any access conditions that may apply; and
- some Hospital Pharmaceuticals that are purchased and used by DHB Hospitals, including those for which national prices have been negotiated by PHARMAC.

The purpose of the Schedule is not to show the final cost to Government of subsidising each Community Pharmaceutical or to DHBs in purchasing each Hospital Pharmaceutical since that will depend on any rebate and other arrangements PHARMAC has with the supplier and, for some Hospital Pharmaceuticals, on any logistics arrangements put in place by individual DHB Hospitals.

Finding Information in the Pharmaceutical Schedule

Community Pharmaceuticals

For Community Pharmaceuticals, the Schedule is organised in a way to help the reader find Community Pharmaceuticals, which may be used to treat similar conditions. To do this, Community Pharmaceuticals are first classified anatomically, originally based on the Anatomical Therapeutic Chemical (ATC) system, and then further classified under section headings structured for the New Zealand medical system.

- Section A lists the General Rules in relation to Community Pharmaceuticals and related products.
- Section **B** lists Community Pharmaceuticals and related products by anatomical classification, which are further divided into one or more therapeutic headings. Community Pharmaceuticals used to treat similar conditions are grouped together.
- Section C lists the rules in relation to Extemporaneously Compounded Products (ECPs) and Community Pharmaceuticals that will be subsidised when extemporaneously compounded.
- Section D lists the rules in relation to Special Foods and the Special Foods that are subsidised.
- Section E Part I lists the Community Pharmaceuticals that are subsidised on a Practitioner's Supply Order (PSO).
- Section E Part II lists rural areas for the purpose of PSOs.
- Section F lists the Community Pharmaceuticals dispensing period exemptions.
- Section G lists the Community Pharmaceuticals eligible for reimbursement of safety cap and related rules.

The listings are displayed alphabetically (where practical) within each level of the classification system. Each anatomical section contains a series of therapeutic headings, some of which may contain a further classification level. Where a Community Pharmaceutical is used in more than one therapeutic area, they may be cross-referenced.

The therapeutic headings in the Pharmaceutical Schedule do not necessarily correspond to the therapeutic groups and therapeutic subgroups, which PHARMAC establishes for the separate purpose of determining the level of subsidy to be paid for each Community Pharmaceutical.

The index located at the back of the book in which Sections A-G of the Pharmaceutical Schedule are published can be used to find page numbers for generic chemical entities, or product brand names.

Hospital Pharmaceuticals

Section H lists Pharmaceuticals that DHBs fund from their own budgets. The Hospital Pharmaceuticals are grouped into the following Parts in Section H:


- Part I lists the rules in relation to Hospital Pharmaceuticals.
- Part II lists Hospital Pharmaceuticals for which national contracts exist (National Contract Pharmaceuticals). These are
 listed alphabetically by generic chemical entity name and line item, the relevant Price negotiated by PHARMAC and, if
 applicable, an indication of whether it has Hospital Supply Status (HSS) and any associated Discretionary Variance (DV)
 Pharmaceuticals and DV Limit.
- Part III lists Discretionary Community Supply Pharmaceuticals, which are not Community Pharmaceuticals, but which a DHB Hospital can, in its discretion, fund for use in the community from its own budget.

The index located at the back of the Section H supplement can be used to find page numbers for generic chemical entities, or product brand names, for Hospital Pharmaceuticals.

Explaining drug entries

The Pharmaceutical Schedule lists pharmaceuticals subsidised by the Government, the amount of that subsidy paid to contractors, the supplier's price and the access conditions that may apply.

Example



Glossary

Units of Measure

gramg	microgram
kilogramkg	milligram
international unitiu	millilitre

microgrammcg	r
milligrammg	ι
millilitreml	

millimole	.mmol
unit	u

Abbreviations

Ampoule	Amp	Granules	Gran	Suppository	Supp
Capsule	Cap	Infusion	Inf	Tablet	Tab
Cream	Crm	Injection	Inj	Tincture	Tinc
Device	Dev	Linctus	Linc	Trans Dermal Delivery	
Dispersible	Disp	Liquid	Liq	System	TDDS
Effervescent	Eff	Long Acting	LA		
Emulsion	Emul	Ointment	Oint		
Enteric Coated	EC	Sachet	Sach		
Gelatinous	Gel	Solution	Soln		

BSO Bulk Supply Order.

CBS Cost Brand Source. There is no set manufacturer's price, and the Government subsidises the product at the price it is obtained by the pharmacy.

- CE Compounded Extemporaneously.
- CPD Cost Per Dose. The Funder (as defined in Part I of the General Rules) cost of a standard dose, without mark-ups or fees and excluding GST.
- ECP Extemporaneously Compounded Preparation.
- HSS Hospital Supply Status, the status of being the brand of the relevant Hospital Pharmaceutical listed in Section H Part II as HSS, that DHBs are obliged to purchase subject to any DV Limit for that Hospital Pharmaceutical for the period of hospital supply, as awarded under an agreement between PHARMAC and the relevant pharmaceutical supplier.
- OP Original Pack subsidy is rounded up to a multiple at whole packs.
- PSO Practitioner's Supply Order.

Sole Subsidised

Supplier Only brand of this medicine subsidised.

XPharm Pharmacies cannot claim subsidy because PHARMAC has made alternative distribution arrangements.

- ▲ Three months supply may be dispensed at one time if the exempted medicine is endorsed 'certified exemption' by the practitioner.
- * Three months dispensed all-at-once or, in the case of oral contraceptives, six months dispensed all-at-once, unless medicine is endorsed "close control" or "cc" and the endorsement is initialled by the prescriber.
- ‡ Safety cap required and subsidised for oral liquid formulations, including extemporaneously compounded preparations.
- Fully subsidised brand of a given medicine. Brands without the tick are not fully subsidised and may cost the patient a
 manufacturer's surcharge.

S29 This medicine is an unapproved medication supplied under Section 29 of the Medicines Act 1981. Practitioners prescribing this medication should:

- a) be aware of and comply with their obligations under Section 29 of the Medicines Act 1981 and otherwise under that Act and the Medicines Regulations 1984;
- b) be aware of and comply with their obligations under the Health and disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and
- c) exercise their own skill, judgement, expertise and discretions, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an indication for which it is not approved.

Note: Where medicines supplied under Section 29 that are used for emergency situations, patient details required under Section 29 of the Medicines Act may be retrospectively provided to the supplier.

	Definitions					
Abbrev.	Pharmacy Services Agreement	All other Pharmacy Agreements				
[HP3]	Subsidised when dispensed from pharmacies that	Available from selected pharmacies that have an ex-				
	have a Special Foods Service appended to their Phar-	clusive contract to dispense Special Foods.				
	macy Services Agreement by their DHB.					
[HP4]	Subsidised when dispensed from pharmacies that	Avaliable from selected pharmacies that have an ex-				
	have the Monitored Therapy Variation (for Clozapine	clusive contract to dispense 'Hospital Pharmacy' [HP4]				
	Services)	pharmaceuticals.				

Patient costs

Community Pharmaceutical costs met by the Government

Most of the cost of a subsidised prescription Community Pharmaceutical is met by the Government through the Pharmaceutical Budget. The Government pays a subsidy for the Community Pharmaceutical to Contractors, and a fee covering distribution and pharmacy dispensing services. The subsidy paid to Contractors does not necessarily represent the final cost to Government of subsidising a particular Community Pharmaceutical. The final cost will depend on the nature of PHARMAC's contractual arrangements with the supplier. Fully subsidised medicines are identified with a \checkmark in the product's Schedule listing.

Pharmaceutical Co-Payments

Some Community Pharmaceutical costs are met by the patient. Generally a patient pays a prescription charge. In addition a patient will sometimes pay a manufacturer's surcharge, after hours service fee and any special packaging fee.

PRESCRIPTION CHARGE

From 1 January 2013, everyone who is eligible for publicly funded health and disability services should in most circumstances pay only \$5 for subsidised medicines.

All prescriptions from a public hospital, a midwife and a Family Planning Clinic are covered for \$5 co-payments.

Prescriptions from the following providers are approved for \$5 co-payments on subsidised medicines if they meet the specified criteria:

- After Hours Accident and Medical Services with a DHB or a PHO contract.
- Youth Health Clinics with a DHB or a PHO contract.
- Dentists who write a prescription that relates to a service being provided under a DHB contract.
- Private specialists (for example, ophthalmologists and orthopaedics) who write a prescription for a patient receiving a publicly funded service contracted by the DHB.
- General practitioners who write a prescription during normal business hours to a person who is not enrolled in the general
 practice provided the person is eligible for publicly funded health and disability services and the general practice is part of a
 PHO.
- Hospices that have a contract with a DHB.

Patients can check whether they are eligible for publicly funded health and disability services by referring to the Eligibility Direction on the Ministry of Health's website.

To check if a medicine is fully subsidised, refer to the Pharmaceutical Schedule on PHARMAC's website or ask your pharmacist or general practitioner.

DHBs have a list of eligible providers in their respective regions. Any provider/prescriber not specifically listed by a DHB as an approved provider/prescriber should be regarded as not approved.

NOTE: Information sourced from Ministry of Health Website, for more information please visit www.moh.govt.nz

MANUFACTURER'S SURCHARGE

Not all Community Pharmaceuticals are fully subsidised. Although PHARMAC endeavours to fully subsidise at least one Community Pharmaceutical in each therapeutic group, and has contracts with some suppliers to maintain the price of a particular product, manufacturers are able to set their own price to pharmacies. When these prices exceed the subsidy, the pharmacist may recoup the difference from the patient.

To estimate the amount a patient will pay on top of the prescription charge, take the difference between the manufacturer's price and the subsidy, and multiply this by 1.86. The 1.86 factor represents the pharmacy mark-up on the surcharge plus other costs such as GST. Pharmacies charge different mark-ups so this may vary.

Manufacturer's surcharge to patient = (price - subsidy) \times 1.86

For example, a Community Pharmaceutical with a supplier (ex-manufacturer) cost of \$11.00 per pack with a \$10.00 subsidy will cost the patient a surcharge of \$1.86 on top of the prescription charge. The most a patient should pay is therefore \$16.86 - being

\$15.00 maximum prescription charge, plus \$1.86.

Hospital Pharmaceutical and Pharmaceutical Cancer Treatment Costs

The cost of purchasing Hospital Pharmaceuticals (for use in DHB hospitals and/or in association with Outpatient services provided in DHB hospitals) is met by the relevant DHB hospital Funder from its own budget. Pharmaceutical Cancer Treatments (for use in DHB hospitals and/or in association with Outpatient services provided in DHB hospitals) are funded through the Combined Pharmaceutical Budget. As required by section 23(7) of the Act, in performing any of their functions in relation to the supply of Pharmaceuticals including Pharmaceutical Cancer Treatments, DHBs must not act inconsistently with the Pharmaceutical Schedule.

PHARMAC web site

PHARMAC has set up an interactive Schedule on the Internet.

Other information about PHARMAC is also available on our website. This includes copies of the Annual Review, Annual Report and Annual Plan, as well as information such as the Pharmaceutical Schedule, Pharmaceutical Schedule Updates, National Hospital Pharmaceutical Strategy, other publications and recent press releases.

Special Authority Applications

Special Authority is an application process in which a prescriber requests government subsidy on a Community Pharmaceutical for a particular person. Applications must be submitted to the Ministry of Health by the prescriber for the request to be processed.

Subsidy

Once approved, the presciber will be provided a Special Authority number which must appear on the prescription. Specialists who make an application must communicate the valid authority number to the prescriber who will be writing the prescriptions.

The authority number can provide access to subsidy, increased subsidy, or waive certain restrictions otherwise present on the Community Pharmaceutical.

Some approvals are dependent on the availability of funding from the Pharmaceutical Budget.

Criteria

The criteria for approval of Special Authority applications are included below each Community Pharmaceutical listing, and on the application forms available on PHARMAC's website.

For some Special Authority Community Pharmaceuticals, not all indications that have been approved by Medsafe are subsidised. Criteria for each Special Authority Community Pharmaceutical are updated regularly, based on the decision criteria of PHARMAC. The appropriateness of the listing of a Community Pharmaceutical in the Special Authority category will also be regularly reviewed. Applications for inclusion of further Community Pharmaceuticals in the Special Authority category will generally be made by a pharmaceutical supplier.

Special Authority Applications

Application forms can be found at www.pharmac.govt.nz. Requests for fax copies should be made to PHARMAC, phone 04 460 4990. Applications are processed by the Ministry of Health, and should be sent to:

Ministry of Health Sector Services, Fax: (06) 349 1983 or free fax 0800 100 131

Private Bag 3015, WANGANUI 4540

For enquiries, phone the Ministry of Health Sector Services Call Centre, free phone 0800 243 666

Note: The Ministry of Health can only provide information on Special Authority applications to prescribers and pharmacists.

Each application must:

- Include the patients name, date of birth and NHI number (codes for AIDS patients' applications)
- Include the practitioner's name, address and Medical Council registration number
- Clearly indicate that the relevant criteria, have been met.
- Be signed by the practitioner.

Named Patient Pharmaceutical Assessment policy

The Named Patient Pharmaceutical Assessment (NPPA) Policy is PHARMAC's process for considering applications about named patients seeking funding for treatments not listed on the Schedule, either at all or for the named patient's clinical circumstances.

For PHARMAC to perform its legislative function of maintaining and managing a Schedule that applies consistently throughout New Zealand, the NPPA Policy will, and must, operate in a way that does not undermine the Schedule decision making process. Together, the Schedule process and the NPPA Policy, ensure there is a pathway for consideration of an individual's clinical circumstances. If an individual has a set of clinical circumstances not covered by the NPPA Policy, the Schedule decision making process is available. It is not the purpose of the NPPA Policy to provide access to every treatment not listed on the Schedule.

There are three main pathways by which named patients can be considered for funding under the NPPA Policy. PHARMAC will exercise its discretion to determine the most appropriate pathway for an application under the NPPA Policy based on the information that is provided.

PHARMAC will assess applications that meet the prerequisites described below according to its Decision Criteria before deciding whether to approve applications for funding. The Decision Criteria will be used to assess both the individual clinical circumstances of each NPPA applicant, and the implications of each NPPA funding decision on PHARMAC's ability to carry out its legislative functions. For more information on NPPA, or to apply, visit the PHARMAC website at http://www.pharmac.govt.nz/nppa, or call the Panel Coordinators at (04) 9167553 or (04) 9167521.

Unusual Clinical Circumstance (UCC)

The purpose of the Unusual Clinical Circumstances (UCC) pathway is to provide a process for consideration for funding for named patients whose clinical circumstances are so unusual that PHARMAC is unlikely, for administrative reasons, to consider listing treatments for these circumstances on the Schedule. The prerequisite requirements for UCC consideration are:

- The patient has reasonably tried and failed all alternative funded treatments (or alternative treatments have been contraindicated, or there are no other treatments available), or the patient has experienced such serious side effects with all other relevant funded treatments that treatment has been ceased or cannot reasonably be continued; and
- The patient is experiencing an indication or set of clinical circumstances that are so unusual that PHARMAC is unlikely to consider listing treatments for these on the Schedule; and
- Generally, PHARMAC has not already considered/is not considering, through the Schedule decision making process, the treatment for the patient's clinical circumstances, or has not considered the treatment at all.

Urgent Assessment (UA)

The purpose of the Urgent Assessment (UA) pathway is to provide a process for PHARMAC to consider funding treatments for named patients where PHARMAC is also considering or is likely to consider the treatment for Schedule listing, but the patient's clinical circumstances justify urgent assessment, prior to a decision on Schedule listing. The prerequisite requirements for UA are:

- The patient has reasonably tried and failed all alternative funded treatments (or alternative treatments have been contraindicated, or there are no other treatments available), or the patient has experienced such serious side effects with all other relevant funded treatments that treatment has been ceased or cannot reasonably be continued; and
- The patient is experiencing an indication or set of clinical circumstances that may be experienced by a population group (either currently or over time); and
- The patient has serious clinical circumstances and not receiving the treatment within six to 12 months would lead to either a significant deterioration in a serious clinical condition or the patient would miss the opportunity for significant improvement in clinical outcome (length or quality of life); and
- The treatment has either not been prioritised by PHARMAC, or if it has, PHARMAC has funded the treatment under the NPPA Policy for the same clinical circumstances prior to prioritisation.
- PHARMAC has not declined to list, on the Schedule, this treatment for these clinical circumstances.

Hospital Pharmaceuticals in the Community (HPC)

The purpose of the Hospital Pharmaceuticals in the Community (HPC) pathway is to allow District Health Board hospitals to fund a medicine for a patient in the community if it would be more affordable for the DHB than paying for the treatment that would otherwise need to be provided. PHARMAC's approval is required for any such funding, given DHBs' legislative obligation to act consistently with the Schedule. The prerequisite requirements for HPC are:

- The patient has reasonably tried and failed all alternative cheaper funded treatments (or these alternative treatments have been contraindicated) or the patient has experienced such serious side effects with all other cheaper relevant funded treatments that treatment has been ceased or cannot reasonably be continued; and
- The application is for a DHB hospital to fund a treatment for use in the community for a patient under the care of a DHB hospital clinician (in-patient or out-patient); and
- The treatment is not being used to treat a cancer; and
- The treatment costs less for the DHB than the most likely alternative intervention or outcome; and
- The treatment is being sought for a short-term episode of care (usually a maximum of three months) and is not generally for the treatment of a chronic condition.

INTRODUCTION

Section A contains the restrictions and other general rules that apply to Subsidies on Community Pharmaceuticals. The amounts payable by the Funder to Contractors are currently determined by:

- the quantities, forms, and strengths, of subsidised Community Pharmaceuticals dispensed under valid prescription by each Contractor;
- the amount of the Subsidy on the Manufacturer's Price payable for each unit of the Community Pharmaceuticals dispensed by each Contractor and;
- the contractual arrangements between the Contractor and the Funder for the payment of the Contractor's dispensing services.

The Pharmaceutical Schedule shows the level of subsidy payable in respect of each Community Pharmaceutical so that the amount payable by the Government to Contractors, for each Community Pharmaceutical, can be calculated. The Pharmaceutical Schedule also shows the standard price (exclusive of GST) at which a Community Pharmaceutical is supplied ex-manufacturer to wholesalers if it differs from the subsidy. The manufacturer's surcharge to patients can be estimated using the subsidy and the standard manufacturer's price as set out in this Schedule.

The cost to Government of subsidising each Community Pharmaceutical and the manufacturer's prices may vary, in that suppliers may provide rebates to other stakeholders in the primary health care sector, including dispensers, wholesalers, and the Government. Rebates are not specified in the Pharmaceutical Schedule.

This Schedule is dated 1 June 2013 and is to be referred to as the Pharmaceutical Schedule Volume 20 Number 1, 2013. Distribution will be from 20 June 2013. This Schedule comes into force on 1 June 2013.

PART I

INTERPRETATIONS AND DEFINITIONS

1.1 In this Schedule, unless the context otherwise requires:

"90 Day Lot" means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 90 consecutive days' treatment;

"180 Day Lot" means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 180 consecutive days' treatment;

"Access Exemption Criteria" means the criteria under which patients may receive greater than one Month's supply of a Community Pharmaceutical covered by Section F Part II (b) subsidised in one Lot. The specifics of these criteria are conveyed in the Ministry of Health guidelines, which are issued from time to time. The criteria the patient must meet are that they:

a) have limited physical mobility;

- b) live and work more than 30 minutes from the nearest pharmacy by their normal form of transport;
- c) are relocating to another area;
- d) are travelling extensively and will be out of town when the repeat prescriptions are due.

"Act" means the New Zealand Public Health and Disability Act 2000.

"Advisory Committee" means the Pharmaceutical Services Advisory Committee convened by the Ministry of Health under the terms of the Advice Notice issued to Contractors pursuant to Section 88 of the Act.

"Alternate Subsidy" means a higher level of subsidy that the Government will pay contractors for a particular community Pharmaceutical dispensed to a person who has either been granted a Special Authority for that pharmaceutical, or where the prescription is endorsed in accordance with the requirements of this Pharmaceutical Schedule.

"Annotation" means written annotation of a prescription by a dispensing pharmacist in the pharmacist's own handwriting following confirmation from the Prescriber if required, and "Annotated" has a corresponding meaning. The Annotation must include the details specified in the Schedule, including the date the prescriber was contacted (if applicable) and be initialled by the dispensing pharmacist.

"Assessed Pharmaceuticals" means the list of Pharmaceuticals set out in Section H Part III of the Schedule, that have been or are being assessed by PHARMAC.

"Authority to Substitute" means an authority for the dispensing pharmacist to change a prescribed medicine in accordance with regulation 42(4) of the Medicines Regulations 1984. An authority to substitute letter, which may be used by Practitioners, is available on the final page of the Schedule.

"Bulk Supply Order" means a written order, on a form supplied by the Ministry of Health, or approved by the Ministry of Health, made by the licensee or manager of an institution certified to provide hospital care under the Health and Disability

SECTION A: GENERAL RULES

Services (Safety) Act 2001 for the supply of such Community Pharmaceuticals as are expected to be required for the treatment of persons who are under the medical or dental supervision of such a Private Hospital or institution.

"Class B Controlled Drug" means a Class B controlled drug within the meaning of the Misuse of Drugs Act 1975.

"Community Pharmaceutical" means a Pharmaceutical listed in Sections A to G of the Pharmaceutical Schedule that is subsidised by the Funder from the Pharmaceutical Budget for use in the community.

"Contractor" means a person who is entitled to receive a payment from the Crown or a DHB under a notice issued by the Crown or a DHB under Section 88 of the Act or under a contract with the Ministry of Health or a DHB for the supply of Community Pharmaceuticals.

"Controlled Drug" means a controlled drug within the meaning of the Misuse of Drugs Act 1975 (other than a controlled drug specified in Part VI of the Third Schedule to that Act).

"Cost, Brand, Source of Supply" means that the Community Pharmaceutical is eligible for Subsidy on the basis of the Contractor's annotated purchase price, brand, and source of supply. Alternatively a copy of the invoice for the purchase of the Pharmaceutical may be attached to the prescription, in the place of an annotation, in order to be eligible for Subsidy.

"Dentist" means a person registered with the Dental Council, and who holds a current annual practising certificate, under the HPCA Act 2003.

"Diabetes Nurse Prescriber" means a registered nurse practising in diabetes health who has authority to prescribe specified diabetes medicines in accordance with regulations made under the Medicines Act 1981, and who is practicing in an approved DHB demonstration site.

"Dietitian" means a person registered as a dietitian with the Dietitians Board, and who holds a current annual practicing certificate under the HPCA Act 2003.

"DHB" means an organisation established as a District Health Board by or under Section 19 of the Act.

"DHB Hospital" means a DHB, including its hospital or associated provider unit that the DHB purchases Hospital Pharmaceuticals for.

"Discretionary Community Supply Pharmaceutical" means the list of Pharmaceuticals set out in Section H Part IV of the Schedule, which may be funded by a DHB Hospital from its own budget for use in the community.

"Dispensing Frequency Rule" means the rule in Part IV, Section A of the Pharmaceutical Schedule that defines patient groups or medicines eligible for more frequent dispensing periods.

"Doctor" means a medical Practitioner registered with the Medical Council of New Zealand and, who holds a current annual practising certificate under the HPCA Act 2003.

"DV Limit" means, for a particular Hospital Pharmaceutical with HSS, the National DV Limit or the Individual DV Limit.

"DV Pharmaceutical" means a discretionary variance Pharmaceutical, that does not have HSS and which:

- a) is either listed in Section H Part II of the Schedule as being a DV Pharmaceutical in association with the relevant Hospital Pharmaceutical with HSS; or
- b) is the same chemical entity, at the same strength, and in the same or a similar presentation or form, as the relevant Hospital Pharmaceutical with HSS, but which is not yet listed as being a DV Pharmaceutical.

"Endorsements" - unless otherwise specified, endorsements should be either handwritten or computer generated by the practitioner prescribing the medication. The endorsement can be written as "certified condition", or state the condition of the patient, where that condition is specified for the Community Pharmaceutical in Section B of the Pharmaceutical Schedule. Where the practitioner writes "certified condition" as the endorsement, he/she is making a declaration that the patient meets the criteria as set out in Section B of the Pharmaceutical Schedule.

"Funder" means the body or bodies responsible, pursuant to the Act, for the funding of pharmaceuticals listed on the Schedule (which may be one or more DHBs and/or the Ministry of Health) and their successors.

"GST" means goods and services tax under the Goods and Services Tax Act 1985.

"Hospital Care Operator" means a person for the time being in charge of providing hospital care, in accordance with the Health and Disability Services (Safety) Act 2001.

"Hospital Pharmaceuticals" means National Contract Pharmaceuticals, DV Pharmaceuticals, Discretionary Community Supply Pharmaceuticals and Assessed Pharmaceuticals.

"Hospital Pharmaceuticals in the Community (HPC)" means the pathway under the Named Patient Pharmaceutical Assessment policy to allow District Health Board hospitals to fund a medicine for a patient in the community if this is more affordable for the DHB than paying for the treatment that would otherwise need to be provided.

"Hospital Pharmacy" means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy to an person on the Prescription of a Practitioner.

"Hospital Pharmacy-Specialist" means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy to an Outpatient either:

- a) on a Prescription signed by a Specialist, or
- b) where the treatment with the Community Pharmaceutical has been recommended by a Specialist, on the Prescription of a practitioner which is either:
 - endorsed with the words "recommended by [name of specialist and year of authorisation]" and signed by the Practitioner, or
 - ii) endorsed with the word 'protocol' which means "initiated in accordance with DHB hospital approved protocol",
 - iii) annotated by the dispensing pharmacist, following verbal confirmation from the Practitioner of the name of the Specialist and date of recommendation, with the words "recommended by [name of specialist and date of authorisation], confirmed by [practitioner]". Where the Contractor has an electronic record of such an Endorsement or Annotation from a previous prescription for the same Community Pharmaceutical written by a prescriber for the same patient, they may annotate the prescription accordingly.

"As recommended by a Specialist" to be interpreted as either:

- a)
- i) follows a substantive consultation with an appropriate Specialist;
- ii) the consultation to relate to the Patient for whom the Prescription is written;
- iii) consultation to mean communication by referral, telephone, letter, facsimile or email;
- iv) except in emergencies consultation to precede annotation of the Prescription; and
- v) both the specialist and the General Practitioner must keep a written record of the consultation; or
- b) treatment with the Community Pharmaceutical has been initiated in accordance with a DHB hospital approved protocol.

For the purposes of the definition it makes no difference whether or not the Specialist is employed by a hospital.

"Hospital Pharmacy-Specialist Prescription" means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied by a hospital or pharmacy contracted to the Funder to dispense as a hospital pharmacy:

- a) to an Outpatient; and
- b) on a Prescription signed by a Specialist.

For the purposes of this definition, a "specialist" means a doctor who holds a current annual practicing certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) of the definitions of Specialist below.

"HSS" means hospital supply status, the status of being the brand of the relevant Hospital Pharmaceutical listed in Section H Part II as HSS, that DHBs are obliged to purchase subject to any DV Limit for that Hospital Pharmaceutical for the period of hospital supply, as awarded under an agreement between PHARMAC and the relevant pharmaceutical supplier.

"In Combination" means that the Community Pharmaceutical is only subsidised when prescribed in combination with another subsidised pharmaceutical as specified in Section B or C of the Pharmaceutical Schedule.

"Individual DV Limit" means, for a particular Hospital Pharmaceutical with HSS and a particular DHB Hospital, the discretionary variance limit, being the specified percentage of that DHB Hospital's Total Market Volume up to which that DHB Hospital may purchase DV Pharmaceuticals of that Hospital Pharmaceutical.

"Licensed Hospital" means a place or institution that is certified to provide hospital care within the meaning of the Health and Disability Services (Safety) Act 2001.

"Lot" means a quantity of a Community Pharmaceutical supplied in one dispensing.

"Manufacturer's Price" means the standard price at which a Community Pharmaceutical is supplied to wholesalers (excluding GST), as notified to PHARMAC by the supplier.

"Maternity hospital" means that the Community Pharmaceutical is not eligible for Subsidy unless it is supplied pursuant to a Bulk Supply Order to a maternity hospital certified under the Health and Disability Services (Safety) Act 2001.

"Midwife" means a person registered as a midwife with the Midwifery Council, and who holds a current annual practising certificate under the HPCA Act 2003.

"Month" means a period of 30 consecutive days.

"Monthly Lot" means the quantity of a Community Pharmaceutical required for the number of days' treatment covered by the Prescription, being up to 30 consecutive days' treatment;

"Named Patient Pharmaceutical Assessment Advisory Panel" means the panel of clinicians, appointed by the PHARMAC Board, that is responsible for advising, within its Terms of Reference, on Named Patient Pharmaceutical Assessment applications and Exceptional Circumstances renewal applications submitted after 1 March 2012 (EC renewal application form located at http://www.pharmac.govt.nz/healthpros/EC/ECForms)

"National Contract Pharmaceutical" means a Hospital Pharmaceutical for which PHARMAC has negotiated a national contract and the Price.

"National DV Limit" means, for a particular Hospital Pharmaceutical with HSS, the discretionary variance limit, being the specified percentage of the Total Market Volume up to which all DHB Hospitals may collectively purchase DV Pharmaceuticals of that Hospital Pharmaceutical.

"National Immunisation Schedule" means Section I of the Pharmaceutical Schedule, which is a schedule administered by PHARMAC, being a schedule specifying a programme of vaccinations to promote immunity against the diseases specified in the schedule.

"Not In Combination" means that no Subsidy is available for any Prescription containing the Community Pharmaceutical in combination with other ingredients unless the particular combination of ingredients is separately specified in Section B or C of the Schedule, and then only to the extent specified.

"Nurse Prescriber" means a nurse registered with the Nursing Council and who holds a current annual practicing certificate under the HPCA Act 2003 and who is approved by the Nursing Council, to prescribe specified prescription medicines relating to his/her scope of practice including, for the avoidance of doubt, a Diabetes Nurse Prescriber.

"Optometrist" means a person registered as an optometrist with the Optometrists and Dispensing Opticians Board, who holds a current annual practising certificate under the HPCA Act 2003, and who is authorised by regulations under the Medicines Act 1981 and approved by the Optometrists and Dispensing Opticians Board to prescribe specified medicines.

"Outpatient", in relation to a Community Pharmaceutical, means a person who, as part of treatment at a hospital or other institution under the control of a DHB, is prescribed the Community Pharmaceutical for consumption or use in the person's home.

"PCT" means Pharmaceutical Cancer Treatment in respect of which DHB hospital pharmacies and other Contractors can claim Subsidies.

"PCT only" means Pharmaceutical Cancer Treatment in respect of which only DHB hospital pharmacies can claim Subsidies.

"Penal Institution" means a penal institution, as that term is defined in The Penal Institutions Act 1954;

"PHARMAC" means the Pharmaceutical Management Agency established by Section 46 of the Act (PHARMAC).

"Pharmaceutical" means a medicine, therapeutic medical device, or related product or related thing listed in Sections B to H of the Schedule.

"Pharmaceutical Benefits" means the right of:

a) a person; and

b) any member under 16 years of age of that person's family, to have made by the Government on his or her behalf, subject to any conditions for the time being specified in the Schedule, such payment in respect of any Community Pharmaceutical supplied to that person or family member under the order of a Practitioner in the course of his or her practice.

"Pharmaceutical Budget" means the pharmaceutical budget set for PHARMAC by the Crown for the subsidised supply of Community Pharmaceuticals and Pharmaceutical Cancer Treatments including for named patients in exceptional circumstances.

"Pharmaceutical Cancer Treatment" means Pharmaceuticals for the treatment of cancer, listed in Sections A to G of the Schedule and identified therein as a "PCT" or "PCT only" Pharmaceutical that DHBs must provide access to, for use in their hospitals, and/or in association with Outpatient services provided in their DHB Hospitals, in relation to the treatment of cancers.

"Pharmacist" means a person registered with the Pharmacy Council of New Zealand and who holds a current annual practicing certificate under the HPCA Act 2003.

"Practitioner" means a Doctor, a Dentist, a Dietitian, a Midwife, a Nurse Prescriber, an Optometrist or a Pharmacist as those terms are defined in the Pharmaceutical Schedule.

"Practitioner's Supply Order" means a written order made by a Practitioner on a form supplied by the Ministry of Health, or approved by the Ministry of Health, for the supply of Community Pharmaceuticals to the Practitioner, which the Practitioner requires to ensure medical supplies are available for emergency use, teaching and demonstration purposes, and for provision to certain patient groups where individual prescription is not practicable.

"Prescription" means a quantity of a Community Pharmaceutical prescribed for a named person on a document signed by a Practitioner.

"Prescription Medicine" means any Pharmaceutical listed in Part I of Schedule 1 of the Medicines Regulations 1984.

"Private Hospital" means a hospital certified under the Health and Disability Services (Safety) Act 2001 that is not owned or operated by a DHB.

"Residential Disability Care Institution" means premises used to provide residential disability care in accordance with the Health and Disability Services (Safety) Act 2001.

"Rest Home" means premises used to provide rest home care in accordance with the Health and Disability Services (Safety) Act 2001.

"Restricted Medicine" means any Pharmaceutical listed in Part II of Schedule 1 of the Medicines Regulations 1984.

"Retail Pharmacy-Specialist" means that the Community Pharmaceutical is only eligible for Subsidy if it is either:

- a) supplied on a Prescription or Practitioner's Supply Order signed by a Specialist, or,
 - b) in the case of treatment recommended by a Specialist, supplied on a Prescription or Practitioner's Supply Order and either:
 - i) endorsed with the words "recommended by [name of Specialist and year of authorisation]" and signed by the Practitioner, or
 - ii) endorsed with the word 'protocol' which means "initiated in accordance with DHB hospital approved protocol", or
 - iii) Annotated by the dispensing pharmacist, following verbal confirmation from the Practitioner of the name of the Specialist and date of recommendation, with the words "recommended by [name of specialist and year of authorisation], confirmed by [practitioner]". Where the Contractor has an electronic record of such an Endorsement or Annotation from a previous prescription for the same Community Pharmaceutical written by a prescriber for the same patient, they may annotate the prescription accordingly.

"As recommended by a Specialist" to be interpreted as either:

- a)
- i) follows a substantive consultation with an appropriate Specialist;
- ii) the consultation to relate to the Patient for whom the Prescription is written;
- iii) consultation to mean communication by referral, telephone, letter, facsimile or email;
- iv) except in emergencies consultation to precede annotation of the Prescription; and
- v) both the Specialist and the General Practitioner must keep a written record of consultation; or
- b) treatment with the Community Pharmaceutical has been initiated in accordance with a DHB hospital approved protocol.

"Retail Pharmacy-Specialist Prescription" means that the Community Pharmaceutical is only eligible for Subsidy if it is supplied on a Prescription, or Practitioner's Supply Order, signed by a Specialist. For the purposes of this definition, a "specialist" means a doctor who holds a current annual practicing certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) of the definitions of Specialist below.

"Schedule" means this Pharmaceutical Schedule and all its sections and appendices.

"Special Authority" means that the Community Pharmaceutical or Pharmaceutical Cancer Treatment is only eligible for Subsidy or additional Subsidy for a particular person if an application meeting the criteria specified in the Schedule has been approved, and the valid Special Authority number is present on the prescription.

"Specialist", in relation to a Prescription, a doctor who holds a current annual practising certificate and who satisfies the criteria set out in paragraphs (a) or (b) or (c) or (d) below:

- a)
- i) the doctor is vocationally registered in accordance with the criteria set out by the Medical Council of New Zealand and the HPCA Act 2003 and who has written the Prescription in the course of practising in that area of medicine; and
- ii) the doctor's vocational scope of practice is one of those listed below: anaesthetics, cardiothoracic surgery, dermatology, diagnostic radiology, emergency medicine, general surgery, internal medicine, neurosurgery, obstetrics and gynaecology, occupational medicine, ophthalmology, oral and maxillofacial surgery, otolaryngology head and neck surgery, orthopaedic surgery, paediatric surgery, paediatrics, pathology, plastic and reconstructive surgery, psychological medicine or psychiatry, public health medicine, radiation oncology, rehabilitation medicine, urology and venereology;
- b) the doctor is recognised by the Ministry of Health as a specialist for the purposes of this Schedule and receives remuneration from a DHB at a level which that DHB considers appropriate for specialists and who has written that Prescription in the course of practising in that area of medicine;
- c) the doctor is recognised by the Ministry of Health as a specialist in relation to a particular area of medicine for the purpose of writing Prescriptions and who has written the Prescription in the course of practising in that area of medicine;
- d) the doctor writes the Prescription on DHB stationery and is appropriately authorised by the relevant DHB to do so.

"Subsidy" means the maximum amount that the Government will pay Contractors for a Community Pharmaceutical dis-

pensed to a person eligible for Pharmaceutical Benefits and is different from the cost to Government of subsidising that Community Pharmaceutical. For the purposes of a DHB hospital pharmacy claiming for Pharmaceutical Cancer Treatments, Subsidy refers to any payment made to the DHB hospital pharmacy or service provider to which that pharmacy serves, and does not relate to a specific payment that might be made on submission of a claim.

"Supply Order" means a Bulk Supply Order or a Practitioner's Supply Order.

"Unapproved Indication" means, for a Pharmaceutical, an indication for which it is not approved under the Medicines Act 1981. Practitioners prescribing Pharmaceuticals for Unapproved Indications should be aware of, and comply with, their obligations under Section 25 and/or Section 29 of the Medicines Act 1981 and as set out in Section A: General Rules, Part IV (Miscellaneous Provisions) rule 5.5.

"Unusual Clinical Circumstances (UCC)" means the pathway under the Named Patient Pharmaceutical Assessment policy for funding consideration for named patients whose clinical circumstances are so unusual that PHARMAC is unlikely, for administrative reasons, to consider listing treatments for these circumstances on the Schedule.

"Urgent Assessment (UA)" means the pathway under the Named Patient P harmaceutical Assessment policy for funding consideration for treatments for named patients where PHARMAC is also considering or is likely to consider the treatment for Schedule listing, but the patient's clinical circumstances justify urgent assessment, prior to a decision on Schedule listing.

- 1.2 In addition to the above interpretations and definitions, unless the content requires otherwise, a reference in the Schedule to:
 - a) the singular includes the plural; and
 - b) any legislation includes a modification and re-enactment of, legislation enacted in substitution for, and a regulation, Order in Council, and other instrument from time to time issued or made under that legislation, where that legislation, regulation, Order in Council or other instrument has an effect on the prescribing, dispensing or subsidising of Community Pharmaceuticals.

PART II

COMMUNITY PHARMACEUTICALS SUBSIDY

- 2.1 Community Pharmaceuticals eligible for Subsidy include every medicine, therapeutic medical device or related product, or related thing listed in Sections B to G and I of the Schedule subject to:
 - 2.1.1 clauses 2.2 of the Schedule; and
 - 2.1.2 clauses 3.1 to 5.4 of the Schedule; and
 - 2.1.3 the conditions (if any) specified in Sections B to G and I of the Schedule;
- 2.2 No claim by a Contractor for payment in respect of the supply of Community Pharmaceuticals will be allowed unless the Community Pharmaceuticals so supplied:
 - 2.2.1 comply with the appropriate standards prescribed by regulations for the time being in force under the Medicines Act 1981; or
 - 2.2.2 in the absence of any such standards, comply with the appropriate standards for the time being prescribed by the British Pharmacopoeia; or
 - 2.2.3 in the absence of the standards prescribed in clauses 2.3.1 and 2.3.2, comply with the appropriate standards for the time being prescribed by the British Pharmaceutical Codex; or
 - 2.2.4 in the absence of the standards prescribed in clauses 2.3.1, 2.3.2 and 2.3.3, are of a grade and quality not lower than those usually applicable to Community Pharmaceuticals intended to be used for medical purposes.

PART III PERIOD AND QUANTITY OF SUPPLY

3.1 Doctors', Dentists', Dietitians', Midwives', Nurse Prescribers' and Optometrists' Prescriptions (other than oral contraceptives)

The following provisions apply to all Prescriptions, other than those for an oral contraceptive, written by a Doctor, Dentist, Dietitian, Midwife, Nurse Prescriber or Optometrist unless specifically excluded:

- 3.1.1 For a Community Pharmaceutical other than a Class B Controlled Drug, only a quantity suffcient to provide treatment for a period not exceeding three Months will be subsidised.
- 3.1.2 For methylphenidate hydrochloride and dexamphetamine sulphate (except for Dentist prescriptions), only a quantity sufficient to provide treatment for a period not exceeding one Month will be subsidised.
- 3.1.3 For a Class B Controlled Drug:
 - a) other than Dentist prescriptions and methylphenidate hydrochloride and dexamphetamine sulphate,

- only a quantity:
 - i) sufficient to provide treatment for a period not exceeding 10 days; and
 - ii) which has been dispensed pursuant to a Prescription sufficient to provide treatment for a period not exceeding one Month, will be subsidised.
- b) for a Dentist prescription only such quantity as is necessary to provide treatment for a period not exceeding five days will be subsidised.
- 3.1.4 Subject to clauses 3.1.3 and 3.1.7, for a Doctor, Dentist, Dietitian, Midwife or Nurse Prescriber and 3.1.7 for an Optometrist, where a practitioner has prescribed a quantity of a Community Pharmaceutical sufficient to provide treatment for:
 - a) one Month or less than one Month, but dispensed by the Contractor in quantities smaller than the quantity prescribed, the Community Pharmaceutical will only be subsidised as if that Community Pharmaceutical had been dispensed in a Monthly Lot;
 - b) more than one Month, the Community Pharmaceutical will be subsidised only if it is dispensed:
 - i) in a 90 Day Lot, where the Community Pharmaceutical is a Pharmaceutical covered by Section F Part I of the Pharmaceutical Schedule; or
 - ii) if the Community Pharmaceutical is not a Pharmaceutical referred to in Section F Part I of the Pharmaceutical Schedule, in Monthly Lots, unless:
 - A) the eligible person or his/her nominated representative endorses the back of the Prescription form with a statement identifying which Access Exemption Criterion (Criteria) applies and signs that statement to this effect; or
 - B) both:
 - the Practitioner endorses the Community Pharmaceutical on the Prescription with the words "certified exemption" written in the Practitioner's own handwriting, or signed or initialled by the Practitioner; and
 - every Community Pharmaceutical endorsed as "certified exemption" is covered by Section F Part II of the Pharmaceutical Schedule.
- 3.1.5 A Community Pharmaceutical is only eligible for Subsidy if the Prescription under which it has been dispensed was presented to the Contractor:
 - a) for a Class B Controlled Drug, within eight days of the date on which the Prescription was written; or
 - b) for any other Community Pharmaceutical, within three Months of the date on which the Prescription was written.
- 3.1.6 No subsidy will be paid for any Prescription, or part thereof, that is not fulfilled within:
 - a) in the case of a Prescription for a total supply of from one to three Months, three Months from the date the Community Pharmaceutical was first dispensed; or
 - b) in any other case, one Month from the date the Community Pharmaceutical was first dispensed. Only that part of any Prescription that is dispensed within the time frames specified above is eligible for Subsidy.
- 3.1.7 If a Community Pharmaceutical:
 - a) is stable for a limited period only, and the Practitioner has endorsed the Prescription with the words "unstable medicine" and has specified the maximum quantity that may be dispensed at any one time; or
 - b) is stable for a limited period only, and the Contractor has endorsed the Prescription with the words "unstable medicine" and has specified the maximum quantity that should be dispensed at any one time in all the circumstances of the particular case; or
 - c) is under the Dispensing Frequency Rule,
 - The actual quantity dispensed will be subsidised in accordance with any such specification.

3.2 Oral Contraceptives

The following provisions apply to all Prescriptions written by a Doctor, Midwife or Nurse Prescriber for an oral contraceptive:

- 3.2.1 The prescribing Doctor, Midwife or Nurse Prescriber must specify on the Prescription the period of treatment for which the Community Pharmaceutical is to be supplied. This period must not exceed six Months.
- 3.2.2 Where the period of treatment specified in the Prescription does not exceed six Months, the Community Pharmaceutical is to be dispensed:
 - a) in Lots as specified in the Prescription if the Community Pharmaceutical is under the Dispensing Frequency Rule; or

b) where no Lots are specified, in one Lot sufficient to provide treatment for the period prescribed.

- 3.2.3 An oral contraceptive is only eligible for Subsidy if the Prescription under which it has been dispensed was presented to the Contractor within three Months of the date on which it was written.
- 3.2.4 Where a Community Pharmaceutical on a Prescription is under the Dispensing Frequency Rule and a repeat on the Prescription remains unfulfilled after six Months from the date the Community Pharmaceutical was first dispensed only the actual quantity supplied by the Contractor within this time limit will be eligible for Subsidy.
- 3.3 Original Packs, Certain Antibiotics and Unapproved Medicines
 - 3.3.1 Notwithstanding clauses 3.1 and 3.3 of the Schedule, if a Practitioner prescribes or orders a Community Pharmaceutical that is identified as an Original Pack (OP) on the Pharmaceutical Schedule and is packed in a container from which it is not practicable to dispense lesser amounts, every reference in those clauses to an amount or quantity eligible for Subsidy, is deemed to be a reference:
 - a) where an amount by weight or volume of the Community Pharmaceutical is specified in the Prescription, to the smallest container of the Community Pharmaceutical, or the smallest number of containers of the Community Pharmaceutical, sufficient to provide that amount; and
 - b) in every other case, to the amount contained in the smallest container of the Community Pharmaceutical that is manufactured in, or imported into, New Zealand.
 - 3.3.2 If a Community Pharmaceutical is either:
 - a) the liquid oral form of an antibiotic to which a diluent must be added by the Contractor at the time of dispensing; or
 - b) an unapproved medicine supplied under Section 29 of the Medicines Act 1981, but excluding any medicine listed as Cost, Brand, Source of Supply,

and it is prescribed or ordered by a Practitioner in an amount that does not coincide with the amount contained in one or more standard packs of that Community Pharmaceutical, Subsidy will be paid for the amount prescribed or ordered by the Practitioner in accordance with either clause 3.1 or clause 3.3 of the Schedule, and for the balance of any pack or packs from which the Community Pharmaceutical has been dispensed. At the time of dispensing the Contractor must keep a record of the quantity discarded. To ensure wastage is reduced, the Contractor should reduce the amount dispensed to make it equal to the quantity contained in a whole pack where:

- a) the difference between the amount dispensed and the amount prescribed by the Practitioner is less than 10% (eg; if a prescription is for 105 mls then a 100ml pack would be dispensed); and
- b) in the reasonable opinion of the Contractor the difference would not affect the efficacy of the course of treatment prescribed by the Practitioner.

Note: For the purposes of audit and compliance it is an act of fraud to claim wastage and then use the wastage amount for any subsequent prescription.

3.4 Dietitians' Prescriptions

The following provisions apply to every Prescription written by a Dietitian:

- 3.4.1 Prescriptions written by a Dietitian for a Community Pharmaceutical will only be subsidised where they are for either:
 - a) special foods, as listed in Section D; or
 - b) any other Pharmaceutical that has been identified in Section D of the Pharmaceutical Schedule as being able to be prescribed by a Dietitian,

providing that the products being prescribed are not classified as Prescription Medicines or Restricted Medicines.

3.4.2 For the purposes of Dietitians prescribing pursuant to this clause 3.5, the prescribing and dispensing of these products is required to be in accordance with regulations 41 and 42 of the Medicines Regulations 1984.

3.5 Diabetes Nurse Prescribers' Prescriptions

- The following provisions apply to every Prescription written by a Diabetes Nurse Prescriber:
- 3.5.1 Prescriptions written by a Diabetes Nurse Prescriber for a Community Pharmaceutical will only be subsidised where they are for either:
 - a) a Community Pharmaceutical classified as a Prescription Medicine or a Restricted Medicine and which a Diabetes Nurse Prescribers is permitted under regulations to prescribe; or
 - b) any other Community Pharmaceutical listed below:

aspirin, blood glucose diagnostic test meter, blood glucose diagnostic test strip, blood ketone diagnostic test meter, glucagon hydrochloride inj 1 mg syringe kit, insulin pen needles, insulin syringes disposable with attached needle, insulin pump accessories, insulin pump infusion set, insulin pump reservoir,

ketone blood beta-ketone electrodes test strip, nicotine, sodium nitroprusside test strip,

3.5.2 Any Diabetes Nurse Prescribers' prescription for a medication requiring a Special Authority will only be subsidised if it is for a repeat prescription (ie after the initial prescription with Special Authority approval was dispensed).

Note: A list of Diabetes Nurse Prescribers will be published periodically in the Update of the Pharmaceutical Schedule for the duration of an initial pilot scheme. After this period there will be no approved DHB demonstration sites and hence no Diabetes Nurse Prescribers.

3.6 Pharmacists' prescriptions

The following apply to every prescription written by a Pharmacist:

- 3.6.1 Prescriptions written by a Pharmacist for a Community Pharmaceutical will only be subsidised where they are for the CareSens, CareSens N and CareSens N POP blood glucose diagnostic meters and annotated appropriately.
- 3.6.2 The prescribing and dispensing of blood glucose diagnostic meters by Pharmacists must be in accordance with regulations 41 and 42 of the Medicines Regulations 1984.

PART IV DISPENSING FREQUENCY RULE

The Pharmaceutical Schedule specifies, for community patients, a default period of supply for each Community Pharmaceutical (a Monthly Lot, 90 Day Lot or for oral contraceptives 180 Day Lot). This Dispensing Frequency rule defines patient groups or medicines eligible for more frequent dispensing periods; and the conditions that must be met to enable any claim for payment of handling fees for the additional dispensings made.

- "Frequent Dispensing" means:
 - for a Community Pharmaceutical referred to in Section F Part I, dispensing in quantities less than one 90 Day Lot (or for oral contraceptives, less than one 180 Day Lot); or
 - for any other Community Pharmaceutical, where any of 4.1, 4.2 or 4.3 of Part IV apply, dispensing in quantities less than a Monthly Lot

NOTE patients who have had more frequent dispensings due to being "intellectually impaired, frail, infirm or unable to manage their medicines" will continue to receive the same frequency of dispensings until they are assessed to see if they are eligible for additional support under the Long-Term Condition (LTC) service. The structure of the remainder fee payment provides funding for pharmacy to continue to provide more frequent dispensings for patients until they are assessed.

4.1 Frequent Dispensings for persons in residential care

- 4.1.1 Pharmaceuticals can be dispensed in quantities of not less than 28 days to:
 - any person whose placement in a Residential Disability Care Institution is funded by the Ministry of Health or a DHB; or
 - a person assessed as requiring long term residential care services and residing in an age related residential care facility;

on the request of the person, their agent or caregiver or community residential service provider, provided the following conditions are met:

- a) the quantity or period of supply to be dispensed at any one time is not less than 28 days' supply (except under conditions outlined in 4.2.2 below); and
- b) the prescribing Practitioner or dispensing pharmacist has
 - i) included the name of the patient's residential placement or facility on the Prescription; and
 - ii) included the patient's NHI number on the Prescription; and
 - iii) specified the maximum quantity or period of supply to be dispensed at any one time.
- 4.1.2 Any person meeting the criteria above who is being initiated onto a new medicine or having their dose changed is able to have their medicine dispensed in accordance with 4.2.2 below.

4.2 Frequent Dispensings for trial periods or safety medicines

- 4.2.1 If a Pharmacist considers more frequent dispensing is required, this can occur as follows:
 - For Long Term Condition (LTC) patients dispensing frequency can occur as often as the dispensing pharmacist deems appropriate to meet the patients compliance and adherence needs;
 - For non-LTC patients the dispensing frequency should be no more often than monthly. If Frequent Dispensing more often than monthly is necessary for non-LTC patients, prescriber approval is required.

Verbal approval is acceptable, provided that it is annotated by the pharmacist on the Prescription and dated.

NOTE this rule does not override alternative dispensing frequencies as expressly stated in the Medicines Act, Medicines Regulations, Pharmacy Services Agreement, Pharmaceutical Schedule or under rule 4.2.2 Trial Periods or rule 4.2.3 safety and co-prescribed medicines below.

Pharmacy would claim handling fees only on repeats under the above scenarios.

Prescribers can request, and pharmacists may dispense a higher frequency of dispensing in the following circumstances:

4.2.2 Trial Periods

The Community Pharmaceutical has been prescribed for a patient who requires close monitoring due to recent initiation onto, or dose change for, the Community Pharmaceutical (applicable to the patient's first changed Prescription only);

and the prescribing Practitioner has:

- endorsed each Community Pharmaceutical on the Prescription clearly with the words "Trial Period", or "Trial"; and
- specified the maximum quantity or period of supply to be dispensed for each Community Pharmaceutical at any one time.

Patients who reside in Penal Institutions are not eligible for Trial Periods.

- 4.2.3 Safety and co-prescribed medicines
 - a) The Community Pharmaceutical is any of the following:
 - i) a tri-cyclic antidepressant; or
 - ii) an antipsychotic; or
 - iii) a benzodiazepine; or
 - iv) a Class B Controlled Drug; or
 - v) codeine (includes combination products)
 - vi) buprenorphine with naloxone

All of the following conditions must be met:

The Community Pharmaceutical has been prescribed for a patient who is not a resident in a Penal Institution, or one of the residential placements or facilities referenced in 4.1 above. The prescribing Practitioner has:

- Assessed clinical risk and determined the patient requires Frequent Dispensing; and
- Specified the maximum quantity or period of supply to be dispensed for each Community Pharmaceutical at any one time.
- b) The Community Pharmaceutical is co-prescribed with one of the Community Pharmaceuticals listed in 4.2.3(a) above and has been prescribed for a patient who is not a resident in a Penal Institution, or one of the residential placements or facilities referenced in 4.1 above. The dispensing pharmacist has:
 - Assessed clinical risk and determined the patient requires Frequent Dispensing;
 - Annotated the Prescription with the amended dispensing quantity and frequency.

4.3 Frequent Dispensing for Pharmaceutical Supply Management

- 4.3.1 Frequent Dispensing may be required from time to time to manage stock supply issues or emergency situations. Pharmacists may dispense more frequently than the Schedule would otherwise allow when all of the following conditions are met:
 - a) PHARMAC has approved and notified pharmacists to annotate Prescriptions for a specified Community Pharmaceutical(s) "out of stock" without prescriber endorsement for a specified time; and
 - b) the dispensing pharmacist has:
 - i) clearly annotated each of the approved Community Pharmaceuticals that appear on the Prescription with the words "out of stock" or "OOS"; and
 - ii) initialled the annotation in their own handwriting; and
 - iii) has complied with maximum quantity or period of supply to be dispensed at any one time, as specified by PHARMAC at the time of notification.

Note – no claim shall be made to any DHB for subsidised dispensing where dispensing occurs more frequently than specified by PHARMAC to manage the supply management issue.

PART V MISCELLANEOUS PROVISIONS

5.1 Bulk Supply Orders

- The following provisions apply to the supply of Community Pharmaceuticals under Bulk Supply Orders:
- 5.1.1 No Community Pharmaceutical supplied under a Bulk Supply Order will be subsidised unless all the requirements in Section B, C or D of the Schedule applicable to that pharmaceutical are met.
- 5.1.2 The person who placed the Bulk Supply Order may be called upon by the Ministry of Health to justify the amount ordered.
- 5.1.3 Class B Controlled Drugs will be subsidised only if supplied under Bulk Supply Orders placed by an institution certified to provide hospital care under the Health and Disability Services (Safety) Act 2001.
- 5.1.4 Any order for a Class B Controlled Drug or for buprenorphine hydrochloride must be written on a Special Bulk Supply Order Controlled Drug Form supplied by the Ministry of Health.
- 5.1.5 Community Pharmaceuticals listed in Part I of the First Schedule to the Medicines Regulations 1984 will be subsidised only if supplied under a Bulk Supply Order placed by an institution certified to provide hospital care under the Health and Disability Services (Safety) Act 2001 and:
 - a) that institution employs a registered general nurse, registered with the Nursing Council and who holds a current annual practicing certificate under the HPCA Act 2003; and
 - b) the Bulk Supply Order is supported by a written requisition signed by a Hospital Care Operator.
- 5.1.6 No Subsidy will be paid for any quantity of a Community Pharmaceutical supplied under a Bulk Supply Order in excess of what is a reasonable monthly allocation for the particular institution, after taking into account stock on hand.
- 5.1.7 The Ministry of Health may, at any time, by public notification, declare that any approved institution within its particular region, is not entitled to obtain supplies of Community Pharmaceuticals under Bulk Supply Orders with effect from the date specified in that declaration. Any such notice may in like manner be revoked by the Ministry of Health at any time.

5.2 Practitioner's Supply Orders

The following provisions apply to the supply of Community Pharmaceuticals to Practitioners under a Practitioner's Supply Order:

- 5.2.1 Subject to clause 5.2.3, a Practitioner may only order under a Practitioner's Supply Order those Community Pharmaceuticals listed in Section E Part I and only in such quantities as set out in Section E Part I that the Practitioner requires to ensure medical supplies are available for emergency use, teaching and demonstration purposes, and for provision to certain patient groups where individual prescription is not practicable.
- 5.2.2 Any order for a Class B Controlled Drug or for buprenorphine hydrochloride must be written on a Special Practitioner's Supply Order Controlled Drug Form supplied by the Ministry of Health.
- 5.2.3 A Practitioner may order such Community Pharmaceuticals as he or she expects to be required for personal administration to patients under the Practitioner's care if:
 - a) the Practitioner's normal practice is in the specified areas listed in Section E Part II of the Schedule, or if the Practitioner is a locum for a Practitioner whose normal practice is in such an area.
 - b) the quantities ordered are reasonable for up to one Month's supply under the conditions normally existing in the practice. (The Practitioner may be called on by the Ministry of Health to justify the amounts of Community Pharmaceuticals ordered.)
- 5.2.4 No Community Pharmaceutical ordered under a Practitioner's Supply order will be eligible for Subsidy unless:
 - a) the Practitioner's Supply Order is made on a form supplied for that purpose by the Ministry of Health, or approved by the Ministry of Health and which:
 - i) is personally signed and dated by the Practitioner; and
 - ii) sets out the Practitioner's address; and
 - iii) sets out the Community Pharmaceuticals and quantities, and;
 - b) all the requirements of Sections B and C of the Schedule applicable to that pharmaceutical are met.
- 5.2.5 The Ministry of Health may, at any time, on the recommendation of an Advisory Committee appointed by the Ministry of Health for that purpose, by public notification, declare that a Practitioner specified in such a notice is not entitled to obtain supplies of Community Pharmaceuticals under Practitioner's Supply Orders until such time as the Ministry of Health notifies otherwise.
- 5.3 Retail Pharmacy and Hospital Pharmacy-Specialist Restriction

The following provisions apply to Prescriptions for Community Pharmaceuticals eligible to be subsidised as "Retail Pharmacy-Specialist" and "Hospital Pharmacy-Specialist":

5.3.1 Record Keeping

It is expected that a record will be kept by both the General Practitioner and the Specialist of the fact of consultation and enough of the clinical details to justify the recommendation. This means referral by telephone will need to be followed up by written consultation.

5.3.2 Expiry

The recommendation expires at the end of two years and can be renewed by a further consultation.

- 5.3.3 The circulation by Specialists of the circumstances under which they are prepared to recommend a particular Community Pharmaceutical is acceptable as a guide. It must however be followed up by the procedure in subclauses 5.3.1 and 5.3.2, for the individual Patient.
- 5.3.4 The use of preprinted forms and named lists of Specialists (as circulated by some pharmaceutical companies) is regarded as inappropriate.
- 5.3.5 The Rules for Retail Pharmacy-Specialist and Hospital Pharmacy-Specialist will be audited as part of the Ministry of Health's routine auditing procedures.

5.4 Pharmaceutical Cancer Treatments

- 5.4.1 DHBs must provide access to Pharmaceutical Cancer Treatments for the treatment of cancers in their DHB hospitals, and/or in association with Outpatient services provided in their DHB hospitals.
- 5.4.2 DHBs must only provide access to Pharmaceuticals for the treatment of cancer that are listed as Pharmaceutical Cancer Treatments in Sections A to G of the Schedule, provided that DHBs may provide access to an unlisted pharmaceutical for the treatment of cancer where that unlisted pharmaceutical:
 - a) has Named Patient Pharmaceutical Assessment (NPPA) approval;
 - b) is being used as part of a bona fide clinical trial which has Ethics Committee approval;
 - c) is being used and funded as part of a paediatric oncology service; or
 - d) was being used to treat the patient in question prior to 1 July 2005.
- 5.4.3 A DHB hospital pharmacy that holds a claiming agreement for Pharmaceutical Cancer Treatements with the Funder may claim a Subsidy for a Pharmaceutical Cancer Treatment marked as "PCT" or "PCT only" in Sections A to G of this Schedule subject to that Pharmaceutical Cancer Treatment being dispensed in accordance with:
 - a) Part 1;
 - b) clauses 2.1 to 2.3;
 - c) clauses 3.1 to 3.4; and
 - d) clause 5.4,
 - of Section A of the Schedule
- 5.4.4 A Contractor (other than a DHB hospital pharmacy) may only claim a Subsidy for a Pharmaceutical Cancer Treatment marked as "PCT" in Sections A to G of the Schedule subject to that Pharmaceutical Cancer Treatment being dispensed in accordance with the rules applying to Sections A to G of the Schedule.
- 5.4.5 Some indications for Pharmaceutical Cancer Treatments listed in the Schedule are Unapproved Indications. Some of these formed part of the October 2001 decision by the Minister of Health as to pharmaceuticals and indications for which DHBs must provide access. As far as reasonably practicable, these Unapproved Indications are marked in the Schedule. However, PHARMAC makes no representation and gives no guarantee as to the accuracy of this information. Practitioners prescribing Pharmaceutical Cancer Treatments for such Unapproved Indications should:
 - a) be aware of and comply with their obligations under sections 25 and 29 of the Medicines Act 1981, as applicable, and otherwise under that act and the Medicines Regulations 1984;
 - b) be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and
 - c) exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical Cancer Treatment or a Pharmaceutical Cancer Treatment for an Unapproved Indication.
- 5.4.6 Applications to add pharmaceuticals, and add or amend indications for Pharmaceutical Cancer Treatments, may be made in writing by pharmaceutical suppliers and/or clinicians to PHARMAC. Applications should follow the Guidelines for Funding Applications to PHARMAC 2010 and Recommended methods to derive clinical

inputs for proposals to PHARMAC, copies of which are available from PHARMAC or PHARMAC's website.

5.5 Practitioners prescribing unapproved Pharmaceuticals

Practitioners should, where possible, prescribe Pharmaceuticals that are approved under the Medicines Act 1981. However, the access criteria under which a Pharmaceutical is listed on the Pharmaceutical Schedule may:

- a) in some case, explicitly permit Government funded access to a Pharmaceutical that is not approved under the Medicines Act 1981 or for an Unapproved Indication; or
- b) not explicitly preclude Government funded access to a Pharmaceutical when it is used for an Unapproved Indication;

Accordingly, if Practitioners are planning on prescribing an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication, Practitioners should:

- a) be aware of and comply with their obligations under sections 25 and 29 of the Medicines Act 1981, as applicable, and otherwise under that Act and the Medicines Regulations 1984;
- b) be aware of and comply with their obligations under the Health and Disability Commissioner's Code of Consumer Rights, including the requirement to obtain informed consent from the patient (PHARMAC recommends that Practitioners obtain written consent); and
- c) exercise their own skill, judgment, expertise and discretion, and make their own prescribing decisions with respect to the use of an unapproved Pharmaceutical or a Pharmaceutical for an Unapproved Indication.

Practitioners should be aware that simply by listing a Pharmaceutical on the Pharmaceutical Schedule PHARMAC makes no representations about whether that Pharmaceutical has any form of approval or consent under, or whether the supply or use of the Pharmaceutical otherwise complies with, the Medicines Act 1981. Further, the Pharmaceutical Schedule does not constitute an advertisement, advertising material or a medical advertisement as defined in the Medicines Act or otherwise.

5.6 Substitution

Where a Practitioner has prescribed a brand of a Community Pharmaceutical that has no Subsidy or has a Manufacturer's Price that is greater than the Subsidy and there is an alternative fully subsidised Community Pharmaceutical available, a Contractor may dispense the fully subsidised Community Pharmaceutical, unless either or both of the following circumstances apply:

a) there is a clinical reason why substitution should not occur; or

b) the prescriber has marked the prescription with a statement such as 'no brand substitution permitted'

Such an Authority to Substitute is valid whether or not there is a financial implication for the Pharmaceutical Budget. When dispensing a subsidised alternative brand, the Contractor must annotate and sign the prescription and inform the patient of the brand change.

5.7 Alteration to Presentation of Pharmaceutical Dispensed

A Contractor, when dispensing a subsidised Community Pharmaceutical, may alter the presentation of a Pharmaceutical dispensed to another subsidised presentation but may not alter the dose, frequency and/or total daily dose. This may only occur when it is not practicable for the contractor to dispense the requested presentation. If the change will result in additional cost to the DHBs, then annotation of the prescription by the dispensing pharmacist must occur stating the reason for the change, and the Contractor must initial the change for the purposes of Audit.

5.8 Conflict in Provisions

If any rules in Sections B-G and Section I of this Schedule conflict with the rules in Section A, the rules in Sections B-G and Section I apply.

SECTION B: ALIMENTARY TRACT AND METABOLISM

	Subsidy (Manufacturer's Price \$) Su Per	Fully Brand or ubsidised Generic Manufacturer	
Antacids and Antiflatulants				
Antacids and Reflux Barrier Agents				
ALGINIC ACID Sodium alginate 225 mg and magnesium alginate 87.5 mg per sachet	4.50	30	✓ Gaviscon Infant	
 Oral liq aluminium hydroxide 200 mg with magnesium hydrox- ide 200 mg and activated simethicone 20 mg per 5 ml 	1.50 (4.26)	500 ml	Mylanta P	
SODIUM ALGINATE * Tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg - peppermint flavour	1.80 (8.60)	60	Gaviscon Double Strength	
* Oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml	1.50 (4.95)	500 ml	Acidex	
Phosphate Binding Agents				
ALUMINIUM HYDROXIDE * Tab 600 mg	12.56	100	🖌 Alu-Tab	
CALCIUM CARBONATE Oral liq 1,250 mg per 5 ml (500 mg elemental per 5 ml) – Subsidy by endorsement Only when prescribed for children under 12 years of age endorsed accordingly.		500 ml phate bir	✓ Roxane nding agent and the prese	cription i
Antidiarrhoeals				
Agents Which Reduce Motility				
DIPHENOXYLATE HYDROCHLORIDE WITH ATROPINE SULPH. * Tab 2.5 mg with atropine sulphate 25 mcg LOPERAMIDE HYDROCHLORIDE – Up to 30 cap available on a		100	🖌 Diastop	
* Tab 2 mg * Cap 2 mg		400 400	 ✓ Nodia ✓ Diamide Relief 	
Rectal and Colonic Anti-inflammatories				
BUDESONIDE Cap 3 mg – Special Authority see SA1155 on the next page – Retail pharmacy		90	Entocort CIR	

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	~	Manufacturer

➡SA1155 Special Authority for Subsidy

Initial application — (Crohn's disease) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Mild to moderate ileal, ileocaecal or proximal Crohn's disease; and
- 2 Any of the following:
 - 2.1 Diabetes; or
 - 2.2 Cushingoid habitus; or
 - 2.3 Osteoporosis where there is significant risk of fracture; or
 - 2.4 Severe acne following treatment with conventional corticosteroid therapy; or
 - 2.5 History of severe psychiatric problems associated with corticosteroid treatment; or
 - 2.6 History of major mental illness (such as bipolar affective disorder) where the risk of conventional corticosteroid treatment causing relapse is considered to be high; or
 - 2.7 Relapse during pregnancy (where conventional corticosteroids are considered to be contraindicated).

Initial application — (collagenous and lymphocytic colitis (microscopic colitis)) from any relevant practitioner. Approvals valid for 6 months where patient has a diagnosis of microscopic colitis (collagenous or lymphocytic colitis) by colonoscopy with biopsies.

Initial application — (gut Graft versus Host disease) from any relevant practitioner. Approvals valid for 6 months where patient has a gut Graft versus Host disease following allogenic bone marrow transplantation*.

Note: Indication marked with * is an Unapproved Indication.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

Note: Clinical trials for Entocort CIR use beyond three months demonstrated no improvement in relapse rate.

HYDROCORTISONE ACETATE

Rectal foam 10%, CFC-Free (14 applications)	80 21.1 g OP	✓ Colifoam
MESALAZINE		
Tab 400 mg	50 100	Asacol
Tab EC 500 mg	50 100	Asamax
Tab long-acting 500 mg59.0	05 100	Pentasa
Enema 1 g per 100 ml44.1	2 7	Pentasa
Suppos 500 mg22.8	30 20	✓ Asacol
Suppos 1 g50.9	6 28	Pentasa
OLSALAZINE		
Tab 500 mg59.8	36 100	Dipentum
Cap 250 mg	51 100	 Dipentum
SODIUM CROMOGLYCATE		
Cap 100 mg	1 100	Valcrom
		• • • • • • • • • • • • • • • • • • • •
SULPHASALAZINE		
* Tab 500 mg – For sulphasalazine oral liquid formulation refer,	NO 100	
page 189		Salazopyrin
* Tab EC 500 mg12.8	39 100	Salazopyrin EN

	Cubaidu		E. Illy	Drand ar
	Subsidy (Manufacturer's Price) \$	Subs Per	Fully idised	Brand or Generic Manufacturer
Local preparations for Anal and Rectal Disorder	S			
Antihaemorrhoidal Preparations				
FLUOCORTOLONE CAPROATE WITH FLUOCORTOLONE PIVA		CAINE		
Oint 950 mcg, with fluocortolone pivalate 920 mcg, and cin- chocaine hydrochloride 5 mg per g Suppos 630 mcg, with fluocortolone pivalate 610 mcg, and	6.35 3	0 g OP	🗸 U	ltraproct
cinchocaine hydrochloride 1 mg	2.66	12	🗸 ()	ltraproct
HYDROCORTISONE WITH CINCHOCAINE Oint 5 mg with cinchocaine hydrochloride 5 mg per g Suppos 5 mg with cinchocaine hydrochloride 5 mg per g		0 g OP 12		roctosedyl roctosedyl
Management of Anal Fissures				
GLYCERYL TRINITRATE – Special Authority see SA1329 below * Oint 0.2%		0 g OP	🗸 R	ectogesic
⇒SA1329 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valic chronic anal fissure that has persisted for longer than three weeks		ewal unless	notifie	d where the patient has a
Antispasmodics and Other Agents Altering Gut	Motility			
HYOSCINE N-BUTYLBROMIDE * Tab 10 mg * Inj 20 mg, 1 ml – Up to 5 inj available on a PSO		20 5		astrosoothe uscopan
MEBEVERINE HYDROCHLORIDE * Tab 135 mg		90	✓ <u>C</u>	olofac
Antiulcerants				
Antisecretory and Cytoprotective				
MISOPROSTOL * Tab 200 mcg	52.70	120	✔ C	ytotec
Helicobacter Pylori Eradication				
CLARITHROMYCIN Tab 500 mg – Subsidy by endorsement a) Maximum of 14 tab per prescription		14	✓ <u>A</u>	po-Clarithromycin
 b) Subsidised only if prescribed for helicobacter pylori erac Note: the prescription is considered endorsed if clarithromycin is amoxycillin or metronidazole. 				
H2 Antagonists				
CIMETIDINE – Only on a prescription * Tab 200 mg	5.00	100		
* Tab 200 mg	(7.50)	100	A	oo-Cimetidine
-	(12.00)		A	po-Cimetidine

26

 Iuly Brand or sed Generic Manufacturer Arrow-Ranitidine Peptisoothe Zantac Solox Solox <u>Solox</u> <u>Solox</u> <u>Solox</u> <u>Omezol Relief</u> <u>Omezol Relief</u> <u>Omezol Relief</u> <u>Omezol Relief</u> <u>Midwest</u> <u>Dr Reddy's</u> <u>Omeprazole</u> <u>Dr Reddy's</u> <u>Pantoprazole</u>
Arrow-Ranitidine Arrow-Ranitidine Peptisoothe Zantac Solox <u>Solox</u> <u>Omezol Relief</u> Omezol Relief <u>Omezol Relief</u> <u>Midwest</u> <u>Dr Reddy's Omeprazole</u> <u>Dr Reddy's Pantoprazole</u>
Arrow-Ranitidine Peptisoothe Zantac Zantac Solox Solox Omezol Relief Omezol Relief Omezol Relief Midwest Dr Reddy's Omeprazole Dr Reddy's Pantoprazole
Arrow-Ranitidine Peptisoothe Zantac Zantac Solox Solox Omezol Relief Omezol Relief Omezol Relief Midwest Dr Reddy's Omeprazole Dr Reddy's Pantoprazole
Peptisoothe Zantac Zantac Solox Solox Omezol Relief Omezol Relief Omezol Relief Midwest Dr Reddy's Omeprazole Dr Reddy's Pantoprazole
Zantac Zantac Solox Solox Omezol Relief Omezol Relief Omezol Relief Midwest Dr Reddy's Omeprazole Dr Reddy's Pantoprazole
 <u>Solox</u> <u>Solox</u> <u>Solox</u> <u>Omezol Relief</u> <u>Omezol Relief</u> <u>Omezol Relief</u> <u>Midwest</u> <u>Dr Reddy's</u> <u>Omeprazole</u> <u>Dr Reddy's</u> <u>Pantoprazole</u>
Solox Omezol Relief Omezol Relief Omezol Relief Midwest Dr Reddy's Omeprazole Dr Reddy's Pantoprazole
Solox Omezol Relief Omezol Relief Omezol Relief Midwest Dr Reddy's Omeprazole Dr Reddy's Pantoprazole
Solox Omezol Relief Omezol Relief Omezol Relief Midwest Dr Reddy's Omeprazole Dr Reddy's Pantoprazole
<u>Omezol Relief</u> <u>Omezol Relief</u> <u>Omezol Relief</u> <u>Midwest</u> <u>Dr Reddy's</u> <u>Omeprazole</u> <u>Dr Reddy's</u> <u>Pantoprazole</u>
Omezol Relief Omezol Relief Midwest Dr Reddy's Omeprazole Dr Reddy's Pantoprazole
Omezol Relief Omezol Relief Midwest Dr Reddy's Omeprazole Dr Reddy's Pantoprazole
Omezol Relief Omezol Relief Midwest Dr Reddy's Omeprazole Dr Reddy's Pantoprazole
<u>Omezol Relief</u> <u>Midwest</u> <u>Dr Reddy's</u> <u>Omeprazole</u> <u>Dr Reddy's</u> <u>Pantoprazole</u>
 <u>Midwest</u> <u>Dr Reddy's</u> <u>Omeprazole</u> <u>Dr Reddy's</u> <u>Pantoprazole</u>
<u>Dr Reddy's</u> <u>Omeprazole</u> <u>Dr Reddy's</u> <u>Pantoprazole</u>
Omeprazole <u>Dr Reddy's</u> <u>Pantoprazole</u>
Omeprazole <u>Dr Reddy's</u> <u>Pantoprazole</u>
Dr Reddy's Pantoprazole
Pantoprazole
Pantoprazole
Dr. Daulah da
Dr Reddy's
Pantoprazole Pantocid IV
4
De Nol S29
Carafate
Proglicem S29
Proglicem S29
r rogicein 629
e treatment of confirmed hyp
s a calment of Commend NVD
e the treatment remains appr
(

	Subsidy (Manufacturer's F \$	Price) Sub Per	Fully Brand or sidised Generic Manufacturer
Insulin - Short-acting Preparations			
NSULIN NEUTRAL ▲ Inj human 100 u per ml	25.26	10 ml OP	 ✓ Actrapid ✓ Humulin R
▲ Inj human 100 u per ml, 3 ml	42.66	5	 Actrapid Penfill Humulin R
Insulin - Intermediate-acting Preparations			
NSULIN ASPART WITH INSULIN ASPART PROTAMINE ▲ Inj 100 iu per ml, 3 ml prefilled pen NSULIN ISOPHANE	52.15	5	NovoMix 30 FlexPen
Inj human 100 u per ml	17.68	10 ml OP	✓ Humulin NPH
▲ Inj human 100 u per ml, 3 ml	29.86	5	 Protaphane Humulin NPH Protaphane Penfill
NSULIN ISOPHANE WITH INSULIN NEUTRAL ▲ Inj human with neutral insulin 100 u per ml		10 ml OP 5	 ✓ Humulin 30/70 ✓ Mixtard 30 ✓ Humulin 30/70 ✓ PenMix 30 ✓ PenMix 40
NSULIN LISPRO WITH INSULIN LISPRO PROTAMINE Inj lispro 25% with insulin lispro protamine 75% 100 u per ml, 3 ml Inj lispro 50% with insulin lispro protamine 50% 100 u per ml,3	52.15	5	PenMix 50Humalog Mix 25
ml	52.15	5	 Humalog Mix 50
Insulin - Long-acting Preparations			
NSULIN GLARGINE Inj 100 u per ml, 10 ml Inj 100 u per ml, 3 ml Inj 100 u per ml, 3 ml disposable pen	94.50	1 5 5	 ✓ Lantus ✓ Lantus ✓ Lantus SoloStar
Insulin - Rapid Acting Preparations			
NSULIN ASPART ▲ Inj 100 u per ml, 3 ml ▲ Inj 100 u per ml, 10 ml NSULIN GLULISINE		5 1	 ✓ NovoRapid Penfill ✓ NovoRapid
 Inj 100 u per ml, 10 ml Inj 100 u per ml, 3 ml Inj 100 u per ml, 3 ml disposable pen 	46.07	1 5 5	 ✓ Apidra ✓ Apidra ✓ Apidra SoloStar
NSULIN LISPRO ▲ Inj 100 u per ml, 10 ml ▲ Inj 100 u per ml, 3 ml		10 ml OP 5	✓ Humalog✓ Humalog

	Subsidy (Manufacturer's Prio \$	ce) S Per	Fully Subsidised	Brand or Generic Manufacturer
Alpha Glucosidase Inhibitors				
ACARBOSE * Tab 50 mg * Tab 100 mg		90 90	✓ <u>Ac</u>	
Oral Hypoglycaemic Agents				
GLIBENCLAMIDE * Tab 5 mg	5.00	100	🖌 Da	aonil
GLICLAZIDE * Tab 80 mg GLIPIZIDE	17.60	500	✓ <u>A</u> p	po-Gliclazide
* Tab 5 mg	3.00	100	🖌 <u>Mi</u>	inidiab
METFORMIN HYDROCHLORIDE * Tab immediate-release 500 mg * Tab immediate-release 850 mg		1,000 500	✓ <u>A</u> r ✓ <u>A</u> r	
PIOGLITAZONE * Tab 15 mg * Tab 30 mg * Tab 45 mg	2.50	28 28 28	🖌 Piz	zaccord zaccord zaccord
Diabetes Management				
Ketone Testing				
BLOOD KETONE DIAGNOSTIC TEST METER Meter funded for the purposes of blood ketone diagnostics of at risk of future episodes. Only one meter per patient will be s			nore episoo	des of ketoacidosis and is
Meter		1	🖌 Fr	eestyle Optium
KETONE BLOOD BETA-KETONE ELECTRODES – Maximum of Test strip – Not on a BSO		ription 10 strip OF		eestyle Optium Ketone
SODIUM NITROPRUSSIDE – Maximum of 50 strip per prescripti * Test strip – Not on a BSO		50 strip OF		ccu-Chek Ketur-Test
	14.14			etostix

		Subsidy (Manufacturer's Pri \$	ce) Sut Per	Fully osidised	Brand or Generic Manufacturer
Blood Glucos	e Testing	ų 		•	
Meter with 50 l strips -	DIAGNOSTIC TEST METER – Maximum c ancets, a lancing device and 10 diagnostic te Subsidy by endorsement – Note differing brar nts below	st d	ption 1 OP	✓ C:	areSens II areSens N
b) CareSen c) CareSen d) No patier e) A diagno 1) is rec 2) is pre 3) is on	s N brand: Brand switch fee payable (Pharma s N POP brand: Brand switch fee payable (Ph s II brand: Brand switch fee payable (Pharma it co-payment payable stic blood glucose test meter is subsidised fo eiving insulin or sulphonylurea therapy; or gnant with diabetes; or home TPN at risk of hypoglycaemia or hyper a genetic or an acquired disorder of glucose ome.	narmacode 2423154 code 2423146) - se r a patient who: glycaemia; or	4) - see page e page 187 f	for detai 187 for or detail	details s
BLOOD GLUCOSE The number of 1) Prescribed v 2) Prescribed v or 3) Prescribed f 4) Prescribed f 5) Prescribed f and metabo	patient. No further prescriptions will be subs DIAGNOSTIC TEST STRIP test strips available on a prescription is restrivith insulin or a sulphonylurea but are on a di on the same prescription as insulin or a sulph or a pregnant woman with diabetes and endor or a patient on home TPN at risk of hypoglyc or a patient with a genetic or an acquired dis ic syndrome and endorsed accordingly. test strips – Note differing brand requirement	icted to 50 unless: fferent prescription onylurea in which ca rsed accordingly; o aemia or hyperglyca order of glucose ho	and endorse ase the preso r aemia and er	d accord cription is	lingly; or s deemed to be endorsed; accordingly; or
			50 test OP		<u>areSens</u> areSens N
a) Accu-Ch	ek Performa brand: Special Authority see SA	28.75 1294 below – Retail	pharmacy		ccu-Chek Performa reestyle Optium
b) Freestyle ■SA1294 Speci	Optium brand: Special Authority see SA Optium brand: Special Authority see SA129 al Authority for Subsidy details may be obtained from PHARMAC's w Facsimile: (04) 974 4788 Email: bgstrips@pharmac.govt.nz	I below – Retail pha	armacy	nz and c	an be sent to:
➡SA1291 Speci	al Authority for Subsidy details may be obtained from PHARMAC's w	ebsite http://www.ph	narmac.govt.i	nz and c	can be sent to:
PO Box 10 254 Wellington	Facsimile: (04) 974 4788 Email: bgstrips@pharmac.govt.nz				

	Subsidy (Manufacturer's Pric \$	ce) Su Per	Fully Ibsidised	Brand or Generic Manufacturer
BLOOD GLUCOSE TEST STRIPS (VISUALLY IMPAIRED)				
The number of test strips available on a prescription is restri				
1) Prescribed with insulin or a sulphonylurea but are on a di				0,1,
 Prescribed on the same prescription as insulin or a sulpho or 	onylurea in which ca	ise the pres	cription i	s deemed to be endorsed;
3) Prescribed for a pregnant woman with diabetes and endo				
Prescribed for a patient on home TPN at risk of hypoglyca				
5) Prescribed for a patient with a genetic or an acquired dis	order of glucose hor	meostasis (excluding	type 1 or type 2 diabetes
and metabolic syndrome and endorsed accordingly.				
SensoCard blood glucose test strips are subsidised only if preso	ribed for a patient w	ho is sever	ely visua	illy impaired and is using a
SensoCard Plus Talking Blood Glucose Monitor. Blood glucose test strips	26.20	50 test OP		ensoCard
		50 lesi OF	V 3	ensocaru
Insulin Syringes and Needles				
Subsidy is available for disposable insulin syringes, needles, an the supply of insulin or when prescribed for an insulin patient and				
INSULIN PEN NEEDLES – Maximum of 100 dev per prescription	n .			
* 29 g × 12.7 mm		30	🖌 В	-D Micro-Fine
			· · · -	
	10.50	100	🗸 🗸 🖌 🖌	-D Micro-Fine
	10.50	100	✓ B ✓ A	
卷 31 g × 5 mm		100 100	V A	
			V A	BM -D Micro-Fine
		100	✓ A ✓ B ✓ A N	BM -D Micro-Fine BM ovoFine
★ 31 g × 6 mm		100 100 30	VA VB VA N	BM -D Micro-Fine BM ovoFine -D Micro-Fine
		100 100	VA VB VA N	BM -D Micro-Fine BM ovoFine -D Micro-Fine -D Micro-Fine

	Subsidy (Manufacturor's Price		Fully Brand or
	(Manufacturer's Price \$) Si Per	ubsidised Generic Manufacturer
ISULIN SYRINGES, DISPOSABLE WITH ATTACHED NEEDLE	E – Maximum of 100	dev per p	rescription
€ Syringe 0.3 ml with 29 g × 12.7 mm needle		100	🖌 АВМ
	1.30	10	
	(1.99)		B-D Ultra Fine
	13.00	100	B-D Ultra Fine
Syringe 0.3 ml with 31 g × 8 mm needle	13.00	100	🖌 ABM
	1.30	10	
	(1.99)		B-D Ultra Fine II
	13.00	100	B-D Ultra Fine II
Syringe 0.5 ml with 29 g × 12.7 mm needle	13.00	100	🖌 ABM
	1.30	10	
	(1.99)		B-D Ultra Fine
	13.00	100	B-D Ultra Fine
Syringe 0.5 ml with 31 g × 8 mm needle	13.00	100	ABM
	1.30	10	
	(1.99)		B-D Ultra Fine II
	13.00	100	B-D Ultra Fine II
Syringe 1 ml with 29 g × 12.7 mm needle	13.00	100	ABM
	1.30	10	
	(1.99)		B-D Ultra Fine
	13.00	100	B-D Ultra Fine
Syringe 1 ml with 31 g × 8 mm needle	13.00	100	🖌 ABM
	1.30	10	
	(1.99)		B-D Ultra Fine II
NBM Syringe 0.3 ml with 29 g \times 12.7 mm needle to be delisted NBM Syringe 0.3 ml with 31 g \times 8 mm needle to be delisted 1 L NBM Syringe 0.5 ml with 29 g \times 12.7 mm needle to be delisted NBM Syringe 0.5 ml with 31 g \times 8 mm needle to be delisted 1 S	December 2013) 1 September 2013)		
Insulin Pumps			
·	na Datail sharman		
 NSULIN PUMP - Special Authority see SA1237 on the next pa a) Maximum of 1 dev per prescription b) Only on a prescription c) Maximum of 1 insulin pump per patient each four year per Maximum of 1 insulin pump per patient each four year per 	riod.		
Min basal rate 0.025 U/h; black colour		1	Animas Vibe
Min basal rate 0.025 U/h; blue colour		1	Animas Vibe
Min basal rate 0.025 U/h; green colour		1	Animas Vibe
Min basal rate 0.025 U/h; pink colour		1	Animas Vibe
Min basal rate 0.025 U/h; silver colour	,	1	Animas Vibe
Min basal rate 0.05 U/h; blue colour	4,400.00	1	✓ Paradigm 522
Min boool rate 0.05 LL/by aleast calcult	4 400 00	4	Paradigm 722
Min basal rate 0.05 U/h; clear colour	4,400.00	1	✓ Paradigm 522
Min boool rate 0.05 11/by pink antaria	4 400 00	4	Paradigm 722
Min basal rate 0.05 U/h; pink colour	4,400.00	1	Paradigm 522
Min boool rote 0.05 11/h; purch colour	4 400 00	4	Paradigm 722
Min basal rate 0.05 U/h; purple colour	4,400.00	1	✓ Paradigm 522
Min boool rote 0.05 Ll/b, amelia salaur	4 400 00	4	Paradigm 722
Min basal rate 0.05 U/h; smoke colour	4,400.00	1	Paradigm 522
			Paradigm 722

		Subsidy (Manufacturer's Price) \$	Fully Subsidised Per 🖌	Brand or Generic Manufacturer
►SA1237 Special Aut Notes: Application details	hority for Subsidy may be obtained from PHARMAC's we	bsite http://www.pharr	nac.govt.nz_or:	
The IPP Co-ordinator PHARMAC PO Box 10 254 Wellington	Phone: (04) 460 4990 Facsimile: (04) 974 7806 Email: ipp@pharmac.govt.nz			
Insulin Pump Con	sumables			
► SA1240 Special Aut Notes: Application details	hority for Subsidy may be obtained from PHARMAC's we	bsite http://www.pharr	nac.govt.nz or:	
The IPP Co-ordinator PHARMAC PO Box 10 254 Wellington	Phone: (04) 460 4990 Facsimile: (04) 974 7806 Email: ipp@pharmac.govt.nz			
a) Maximum of 1 cap b) Only on a prescrip c) Maximum of 1 pres		·		nimas Battery Cap

	Subsidy (Manufacturer's Pri \$	ce) Su Per	Fully Ibsidised	Brand or Generic Manufacturer
SULIN PUMP INFUSION SET (STEEL CANNULA) – Special a) Maximum of 3 dev per prescription b) Only on a prescription c) Maximum of 1 prescription per 90 days. d) Note: One additional pack of infusion sets will be funded p	ber year (Maximum			
6 mm steel cannula; straight insertion; 60 cm grey line × 10 with 10 needles	130.00	1 OP	🗸 C	ontact-D
with 10 needles	130.00	1 OP	🗸 C	ontact-D
with 10 needles	130.00	1 OP	🖌 C	ontact-D
10 with 10 needles		1 OP		aradigm Sure-T MMT-884
10 mm steel needle; 29 G; manual insertion; 60 cm tubing × 10 with 10 needles; luer lock	130.00	1 OP	🖌 Si	ure-T MMT-883
10 mm steel needle; 29 G; manual insertion; 80 cm tubing × 10 with 10 needles		1 OP		aradigm Sure-T MMT-886
10 mm steel needle; 29 G; manual insertion; 80 cm tubing × 10 with 10 needles; luer lock	130.00	1 OP	🖌 Si	ure-T MMT-885
6 mm steel needle; 29 G; manual insertion; 60 cm tubing × 10 with 10 needles		1 OP		aradigm Sure-T MMT-864
6 mm steel needle; 29 G; manual insertion; 60 cm tubing × 10 with 10 needles; luer lock	130.00	1 OP	🖌 Si	ure-T MMT-863
6 mm steel needle; 29 G; manual insertion; 80 cm tubing × 10 with 10 needles		1 OP		aradigm Sure-T MMT-866
6 mm steel needle; 29 G; manual insertion; 80 cm tubing × 10 with 10 needles; luer lock	130.00	1 OP	🖌 Si	ure-T MMT-865
8 mm steel needle; 29 G; manual insertion; 60 cm tubing × 10 with 10 needles		1 OP		aradigm Sure-T MMT-874
8 mm steel needle; 29 G; manual insertion; 60 cm tubing \times 10 with 10 needles; luer lock	130.00	1 OP	🖌 Si	ure-T MMT-873
8 mm steel needle; 29 G; manual insertion; 80 cm tubing × 10 with 10 needles		1 OP		aradigm Sure-T MMT-876
8 mm steel needle; 29 G; manual insertion; 80 cm tubing × 10 with 10 needles; luer lock		1 OP		ure-T MMT-875

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per 🖌	
INSULIN PUMP INFUSION SET (TEFLON CANNULA, ANGLE IN SA1240 on page 33 – Retail pharmacy a) Maximum of 3 dev per prescription b) Only on a prescription c) Maximum of 1 prescription per 90 days. d) Note: One additional pack of infusion sets will be funded p			
13 mm teflon cannula; angle insertion; insertion device; 110 cm grey line × 10 with 10 needles		1 OP 🖌	Inset 30
13 mm teflon cannula; angle insertion; insertion device; 60 cm blue line × 10 with 10 needles		1 OP 🖌	Inset 30
13 mm teflon cannula; angle insertion; insertion device; 60 cm grey line × 10 with 10 needles		1 OP 🖌	Inset 30
13 mm teflon cannula; angle insertion; insertion device; 60 cm pink line \times 10 with 10 needles		1 OP 🖌	Inset 30

	Subsidy (Manufacturer's \$	Price) Su Per	Fully Brand or Ibsidised Generic Manufacturer	
INSULIN PUMP INFUSION SET (TEFLON CANNULA, ANGLE IN	SERTION) - S	Special Author	ity see SA1240 on page	33 – Retail
pharmacy a) Maximum of 3 dev per prescription				
b) Only on a prescription				
c) Maximum of 1 prescription per 90 days.				
d) Note: One additional pack of infusion sets will be funded p		im of 13 pack	per annum).	
13 mm teflon cannula; angel insertion; 60 cm grey line \times 5 with 10 needles		1 OP	Comfort Short	
17 mm teflon cannula; angle insertion; 110 cm grey line $\times 5$		101		
with 10 needles		1 OP	Comfort	
13 mm teflon cannula; angle insertion; 120 cm line $ imes$ 10 with				
10 needles	130.00	1 OP	 Paradigm Silho 	uette
			MMT-382	
13 mm teflon cannula; angle insertion; 45 cm line \times 10 with 10 needles		1 OP	A Devediere Cilke	
To needles	130.00	IUF	 Paradigm Silho MMT-368 	uelle
13 mm teflon cannula; angle insertion; 60 cm line $ imes$ 10 with				
10 needles		1 OP	 Paradigm Silho 	uette
			MMT-381	
13 mm teflon cannula; angle insertion; 80 cm line \times 10 with		4.00		
10 needles		1 OP	 Paradigm Silho MMT-383 	uette
17 mm teflon cannula; angle insertion; 110 cm line $ imes$ 10 with			101001-303	
10 needles		1 OP	Paradigm Silho	uette
			MMT-377	
17 mm teflon cannula; angle insertion; 110 cm line \times 10 with				
10 needles; luer lock		1 OP	 Silhouette MMT 	-371
17 mm teflon cannula; angle insertion; 60 cm grey line × 5 with 10 needles		1 OP	Comfort	
17 mm teflon cannula; angle insertion; 60 cm line \times 10 with		TOF	Connort	
10 needles		1 OP	Paradigm Silho	uette
			MMT-378	
17 mm teflon cannula; angle insertion; 60 cm line \times 10 with				
10 needles; luer lock		1 OP	 Silhouette MMT 	-373
17 mm teflon cannula; angle insertion; 80 cm line × 10 with 10 needles		1 OP	Paradigm Silho	uette
	130.00	I UF	MMT-384	ucile

	Subsidy (Manufacturer's Pr \$	rice) Su Per	Fully Ibsidised	Brand or Generic Manufacturer
NSULIN PUMP INFUSION SET (TEFLON CANNULA, STRAIGH	HT INSERTION W	ITH INSERT	ION DEVI	CE) – Special Authori
ee SA1240 on page 33 – Retail pharmacy				
a) Maximum of 3 dev per prescription				
b) Only on a prescription				
c) Note: One additional pack of infusion sets will be funded p	per year (Maximum	n of 13 pack	per annun	ו).
 d) Maximum of 1 prescription per 90 days. 				
6 mm teflon cannula; straight insertion; insertion device; 11				
cm grey line \times 10 with 10 needles		1 OP	🖌 Ins	set II
6 mm teflon cannula; straight insertionl insertion device; 6				
cm blue line \times 10 with 10 needles		1 OP	🖌 Ins	et II
6 mm teflon cannula; straight insertionl insertion device; 6				
cm grey line $ imes$ 10 with 10 needles		1 OP	🖌 Ins	et II
6 mm teflon cannula; straight insertionl insertion device; 6				
cm pink line \times 10 with 10 needles		1 OP	🖌 Ins	et II
9 mm teflon cannula; straight insertion; insertion device; 6				
cm blue line \times 10 with 10 needles		1 OP	🖌 Ins	et II
9 mm teflon cannula; straight insertion; insertion device; 6				
cm grey line \times 10 with 10 needles		1 OP	🖌 Ins	set II
9 mm teflon cannula; straight insertion; insertion device; 6		1.00		
cm pink line \times 10 with 10 needles		1 OP	🖌 Ins	iet II
9 mm teflon cannula; straight insertionl insertion device; 11	0	1.00		
cm grey line \times 10 with 10 needles		1 OP	🖌 Ins	iet II
6 mm teflon cannula; straight insertion; insertion device; 4		1.00		ve diama Mia
cm blue tubing \times 10 with 10 needles $\hfill \hfill \hfi$		1 OP		radigm Mio //MT-941
6 mm teflon cannula; straight insertion; insertion device; 4	F			/11/11-941
cm pink tubing \times 10 with 10 needles		1 OP	V Da	radigm Mio
		101		AMT-921
6 mm teflon cannula; straight insertion; insertion device; 6	0			
cm blue tubing \times 10 with 10 needles		1 OP	🖌 Pa	radigm Mio
				/MT-943
6 mm teflon cannula; straight insertion; insertion device; 6	0		-	
cm pink tubing \times 10 with 10 needles		1 OP	🖌 Pa	radigm Mio
				/MT-923
6 mm teflon cannula; straight insertion; insertion device; 8	0			
cm blue tubing × 10 with 10 needles		1 OP	🖌 Pa	radigm Mio
·			N	/MT-945
6 mm teflon cannula; straight insertion; insertion device; 8	0			
cm clear tubing \times 10 with 10 needles		1 OP	🖌 Pa	radigm Mio
			N	/MT-965
6 mm teflon cannula; straight insertion; insertion device; 8				
cm pink tubing $ imes$ 10 with 10 needles		1 OP		radigm Mio
			N	AMT-925
9 mm teflon cannula; straight insertion; insertion device; 8				
cm clear tubing \times 10 with 10 needles		1 OP		radigm Mio
			N	/MT-975

	Subsidy (Manufacturer's F \$	Price) Sul Per	Fully bsidised	Brand or Generic Manufacturer
INSULIN PUMP INFUSION SET (TEFLON CANNULA, STRAIGH	IT INSERTION)	– Special A	uthority	see SA1240 on page 33 –
Retail pharmacy a) Maximum of 3 pack per prescription				
b) Only on a prescription				
c) Note: One additional pack of infusion sets will be funded p	er vear (Maximur	m of 13 pack r	oer annu	m).
d) Maximum of 1 prescription per 90 days.		in or no paorie		
6 mm teflon cannula; straight insertion; 110 cm tubing \times 10				
with 10 needles	130.00	1 OP		aradigm Quick-Set
				MMT-398
6 mm teflon cannula; straight insertion; 110 cm tubing \times 10		1 00		wiek Cet MMT 201
with 10 needles; luer lock 6 mm teflon cannula; straight insertion; 60 cm tubing × 10		1 OP	V Q	uick-Set MMT-391
6 mm terion cannula; straight insertion; 60 cm tubing \times 10 with 10 needles		1 OP	V P	aradigm Quick-Set
with to fieldies		101		MMT-399
6 mm teflon cannula; straight insertion; 60 cm tubing $ imes$ 10				
with 10 needles; luer lock		1 OP	VQ	uick-Set MMT-393
6 mm teflon cannula; straight insertion; 80 cm tubing $ imes$ 10				
with 10 needles	130.00	1 OP		aradigm Quick-Set
				MMT-387
9 mm teflon cannula; straight insertion; 106 cm tubing \times 10			4 -	
with 10 needles	130.00	1 OP		aradigm Quick-Set
				MMT-396
9 mm teflon cannula; straight insertion; 110 cm tubing \times 10		1 00		wiek Cet MMT 200
with 10 needles; luer lock		1 OP	V Q	uick-Set MMT-390
with 10 needles		1 OP	V P	aradigm Quick-Set
with to fieldies		101		MMT-397
9 mm teflon cannula; straight insertion; 60 cm tubing $ imes$ 10				
with 10 needles; luer lock		1 OP	V Q	uick-Set MMT-392
9 mm teflon cannula; straight insertion; 80 cm tubing $ imes$ 10				
with 10 needles	130.00	1 OP		aradigm Quick-Set MMT-386
INSULIN PUMP RESERVOIR - Special Authority see SA1240	on page 33 – Ret	tail pharmacy		
a) Maximum of 3 dev per prescription				
b) Only on a prescription				
c) Maximum of 1 prescription per 90 days.				
d) Note: One additional packs of reservoirs will be funded per		of 13 packs p	er annu	m).
10 \times luer lock conversion cartridges 1.8 ml for Paradigm		4.05		
pumps		1 OP	V A	DR Cartridge 1.8
10 × luer lock conversion cartridges 3.0 ml for Paradigm pumps		1 OP		DR Cartridge 3.0
Cartridge 200 U, luer lock \times 10		1 OP 1 OP		nimas Cartridge
Cartridge for 5 and 7 series pump; 1.8 ml \times 10		1 OP		aradigm 1.8
				Reservoir
Cartridge for 7 series pump; 3.0 ml \times 10		1 OP		aradigm 3.0
				Reservoir
Syringe and cartridge for 50X pump, 3.0 ml $ imes$ 10		1 OP	🖌 50	0X 3.0 Reservoir

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Digestives Including Enzymes				
PANCREATIC ENZYME				
Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease		100	✔ C	reon 10000
Cap EC 25,000 BP u lipase, 18,000 BP u amylase, 1,000 BP u protease		100	√ C	reon Forte
Cap EC 25,000 BP u lipase, 22,500 BP u amylase, 1,250 BP u protease		100	🖌 P	anzytrat
URSODEOXYCHOLIC ACID - Special Authority see SA1188 bel	ow – Retail pharmacy	y		
Cap 250 mg - For ursodeoxycholic acid oral liquid formula- tion refer, page 189	71.50	100	✓ <u>U</u>	rsosan

SA1188 Special Authority for Subsidy

Initial application — (Pregnancy/Cirrhosis) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Patient diagnosed with cholestasis of pregnancy; or

2 Both:

- 2.1 Primary biliary cirrhosis confirmed by antimitochondrial antibody titre (AMA) > 1:80, and raised cholestatic liver enzymes with or without raised serum IgM or, if AMA is negative, by liver biopsy; and
- 2.2 Patient not requiring a liver transplant (bilirubin > 170umol/l; decompensated cirrhosis).

Note: Liver biopsy is not usually required for diagnosis but is helpful to stage the disease.

Initial application — (Haematological Transplant) from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient at risk of veno-occlusive disease or has hepatic impairment and is undergoing conditioning treatment prior to allogenic stem cell or bone marrow transplantation; and
- 2 Treatment for up to 13 weeks.

Renewal — (Pregnancy/Cirrhosis) from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Note: Ursodeoxycholic acid is not an appropriate therapy for patients requiring a liver transplant (bilirubin > 170 micromol/l; decompensated cirrhosis). These patients should be referred to an appropriate transplant centre. Treatment failure – doubling of serum bilirubin levels, absence of a significant decrease in ALP or ALT and AST, development of varices, ascites or encephalopathy, marked worsening of pruritus or fatigue, histological progression by two stages, or to cirrhosis, need for transplantation.

Laxatives

Bulk-forming Agents

MUCILAGINOUS LAXATIVES - Only on a prescription * Dry	6.02	500 g OP	✓ Konsyl-D
MUCILAGINOUS LAXATIVES WITH STIMULANTS		-	
* Dry	2.41	200 g OP	
	(8.72)	Ū	Normacol Plus
	6.02	500 g OP	
	(17.32)	•	Normacol Plus

	Subsidy (Manufacturer's F \$	Price) Sub Per	Fully Brand or sidised Generic Manufacturer	
Faecal Softeners				
OCUSATE SODIUM – Only on a prescription Cap 50 mg Cap 120 mg Enema conc 18%	3.48	100 100 100 ml OP	✓ <u>Laxofast 50</u> ✓ <u>Laxofast 120</u> ✓ Coloxyl	
OCUSATE SODIUM WITH SENNOSIDES Tab 50 mg with total sennosides 8 mg OLOXAMER – Only on a prescription Not funded for use in the ear. Oral drops 10%		200 30 ml OP	✓ <u>Laxsol</u> ✓ Coloxyl	
Osmotic Laxatives				
LYCEROL Suppos 3.6 g – Only on a prescription ACTULOSE – Only on a prescription	6.50	20	✓ <u>PSM</u>	
Oral liq 10 g per 15 ml	7.68	1,000 ml	✓ Laevolac	
ACROGOL 3350 – Special Authority see SA0891 below – Retail Powder 13.125 g, sachets – Maximum of 60 sach per pre- scription		30	✓ Lax-Sachets	
	18.14		✓ Movicol	

Initial application from any relevant practitioner. Approvals valid for 6 months where the patient has problematic constipation requiring intervention with a per rectal preparation despite an adequate trial of other oral pharmacotherapies including lactulose where lactulose is not contraindicated.

Renewal from any relevant practitioner. Approvals valid for 12 months where the patient is compliant and is continuing to gain benefit from treatment.

SODIUM ACID PHOSPHATE - Only on a prescription

Enema 16% with sodium phosphate 8%	2.50	1	 Fleet Phosphate Enema
SODIUM CITRATE WITH SODIUM LAURYL SULPHOACETATE – Enema 90 mg with sodium lauryl sulphoacetate 9 mg per ml,	Only on a pres	cription	
5 ml	25.00	50	✓ <u>Micolette</u>
Stimulant Laxatives			
BISACODYL - Only on a prescription			
* Tab 5 mg	4.99	200	🖌 Lax-Tab
* Suppos 5 mg		6	Dulcolax
* Suppos 10 mg	3.00	6	Dulcolax
DANTHRON WITH POLOXAMER – Only on a prescription Note: Only for the prevention or treatment of constipation in the	e terminally ill.		
Oral lig 25 mg with poloxamer 200 mg per 5 ml		300 ml	Pinorax
Oral liq 75 mg with poloxamer 1 g per 5 ml	43.60	300 ml	Pinorax Forte
SENNA – Only on a prescription			
* Tab, standardised	0.43	20	
	(1.72)		Senokot
	2.17	100	
	(6.16)		Senokot

	Subsidy (Manufacturer's \$	Price) Su Per	Fully Ibsidised	Brand or Generic Manufacturer
Metabolic Disorder Agents				
Gaucher's Disease				
MIGLUCERASE – Special Authority see SA0473 b Inj 40 iu per ml, 200 iu vial Inj 40 iu per ml, 400 iu vial	1,072.00	1 1		erezyme erezyme
	be considered and approved		ding avail	ability.
Wellington	Email: gaucherpanel@pharr	nac.govt.nz		
Mouth and Throat				
Agents Used in Mouth Ulceration				
BENZYDAMINE HYDROCHLORIDE				
Soln 0.15%		200 ml		
	(8.50) 9.00	500 ml	Dr	fflam
	(17.01)		Dir	fflam
CHLORHEXIDINE GLUCONATE				
Mouthwash 0.2%		200 ml OP	✓ he	althE
CHOLINE SALICYLATE WITH CETALKONIUM CHL * Adhesive gel 8.7% with cetalkonium chloride 0.1		15 g OP		
* Adhesive ger 6.7 / with cetaikonium chloride 0.	(5.62)	15 y OF	Bo	onjela
SODIUM CARBOXYMETHYLCELLULOSE	()			j
With pectin and gelatin paste		56 g OP	🖌 St	omahesive
	1.52	5 g OP		
	(3.60)	15 - 00	Or	abase
	4.55 (7.90)	15 g OP	Or	abase
With pectin and gelatin powder		28 g OP	0	abase
	(10.95)	_0 g 0.	St	omahesive
TRIAMCINOLONE ACETONIDE	()			
0.1% in Dental Paste USP	4.34	5 g OP	🗸 01	acort
Oropharyngeal Anti-infectives		5		
oropharyngear Antrinieetives				
AMPHOTERICIN B Lozenges 10 mg	5.86	20	🖌 Fu	ıngilin
MICONAZOLE Oral gel 20 mg per g	1 05	40 g OP		ecozol
NYSTATIN			÷ <u>De</u>	
Oral lig 100,000 u per ml		24 ml OP	🖌 Ni	Istat
J				

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. 41

	Subsidy (Manufacturer's F \$	Price) Sub Per	Fully Brand or sidised Generic Manufacturer				
Other Oral Agents							
For folinic mouthwash, pilocarpine oral liquid or saliva substitute HYDROGEN PEROXIDE * Soln 10 vol – Maximum of 200 ml per prescription		e 192 100 ml	✔ PSM				
THYMOL GLYCERIN							
* Compound, BPC	9.15	500 ml	✔ PSM				
Vitamins Alpha tocopheryl acetate is available fully subsidised for specific patients at the Medical Director of PHARMAC's discretion. Refer to PHARMAC website www.pharmac.govt.nz for the "Alpha tocopheryl acetate information sheet and application form".							
Vitamin A							
VITAMIN A WITH VITAMINS D AND C * Soln 1000 u with Vitamin D 400 u and ascorbic acid 30 m per 10 drops	0	10 ml OP	✓ Vitadol C				
Vitamin B							
HYDROXOCOBALAMIN * Inj 1 mg per ml, 1 ml – Up to 6 inj available on a PSO	5.10	3	✓ <u>ABM</u> <u>Hydroxocobalamin</u>				
PYRIDOXINE HYDROCHLORIDE a) No more than 100 mg per dose b) Only on a prescription * Tab 25 mg – No patient co-payment payable	2.20	90	✓ <u>PyridoxADE</u>				
* Tab 50 mg THIAMINE HYDROCHLORIDE – Only on a prescription		500	Apo-Pyridoxine				
* Tab 50 mg VITAMIN B COMPLEX		100	Apo-Thiamine				
* Tab, strong, BPC	4.70	500	✓ <u>B-PlexADE</u>				
ASCORBIC ACID a) No more than 100 mg per dose b) Only on a prescription							
* Tab 100 mg	13.80	500	✓ <u>Vitala-C</u>				
Vitamin D							
ALFACALCIDOL * Cap 0.25 mcg * Cap 1 mcg * Oral drops 2 mcg per ml CALCITRIOL	87.98	100 100 20 ml OP	 ✓ One-Alpha ✓ One-Alpha ✓ One-Alpha 				
* Cap 0.25 mcg	10.10	30 100 30	 ✓ Airflow ✓ Calcitriol-AFT ✓ Airflow 				
* Cap 0.5 mcg * Oral liq 1 mcg per ml	18.73	30 100 10 ml OP	 Calcitriol-AFT Rocaltrol solution 				

	Subsidy (Manufacturer's Price \$	e) Sub Per	Fully sidised	Brand or Generic Manufacturer
CHOLECALCIFEROL * Tab 1.25 mg (50,000 iu) – Maximum of 12 tab per prescriptic	on7.76	12	🖌 Ca	al-d-Forte
Multivitamin Preparations				
MULTIVITAMINS – Special Authority see SA1036 below – Retail * Powder		200 g OP	🖌 Pa	ediatric Seravit
 SA1036 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals vali inborn errors of metabolism. Renewal from any relevant practitioner. Approvals valid without approval for multivitamins. 				·
 * Tab (BPC cap strength) * Cap (fat soluble vitamins A, D, E, K) – Special Authority see)	1,000		ultiADE
SA1002 below – Retail pharmacy ⇒SA1002 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valie the following criteria: Either: 1 Patient has cystic fibrosis with pancreatic insufficiency; or 2 Patient is an infant or child with liver disease or short gut s	d without further rer	60 newal unles:		tabdeck
Minerals	yndronno.			
Calcium				
CALCIUM CARBONATE * Tab eff 1.75 g (1 g elemental) * Tab 1.25 g (500 mg elemental) CALCIUM GLUCONATE * Inj 10%, 10 ml	6.38	30 250 10		alsource row-Calcium ayne
Fluoride				
SODIUM FLUORIDE * Tab 1.1 mg (0.5 mg elemental)	5.00	100	✔ P\$	SM
lodine				
POTASSIUM IODATE * Tab 256 mcg (150 mcg elemental iodine)	7.55	90	🖌 Ne	euroKare
Iron				
FERROUS FUMARATE * Tab 200 mg (65 mg elemental)	4.35	100	🖌 Fe	erro-tab
FERROUS FUMARATE WITH FOLIC ACID * Tab 310 mg (100 mg elemental) with folic acid 350 mcg	4.75	60	🖌 Fe	erro-F-Tabs

	Subsidy (Manufacturer's Pr \$	rice) Su Per	Fully Ibsidised	Brand or Generic Manufacturer
FERROUS SULPHATE				
* Tab long-acting 325 mg (105 mg elemental)		30		
	(4.26)	150	Fe	errograd
	5.06 (15.58)	150	F	errograd
*‡ Oral liq 30 mg per 1 ml (6 mg elemental per 1 ml)	()	500 ml		erodan
FERROUS SULPHATE WITH FOLIC ACID				
* Tab long-acting 325 mg (105 mg elemental) with folic acid				
350 mcg		30		
-	(4.29)		Fe	errograd F
IRON POLYMALTOSE				
* Inj 50 mg per ml, 2 ml	19.90	5	✓ <u>F</u>	errum H
Magnesium				
For magnesium hydroxide mixture refer, page 192				
MAGNESIUM SULPHATE				
* Inj 2 mmol per ml, 5 ml		10		artindale
	26.60		V M	ayne
Zinc				
ZINC SULPHATE				
* Cap 137.4 mg (50 mg elemental)	11.00	100	✓ <u>Zi</u>	ncaps
Agents Used in the Treatment of Poisonings				
CHARCOAL				
* Oral liq 50 g per 250 ml	43.50	250 ml OP	🗸 C	arbosorb-X
a) Up to 250 ml available on a PSO				
b) Only on a PSO				
SODIUM CALCIUM EDETATE				
* Inj 200 mg per ml, 5 ml		6	0	alcium Disodium
	(156.71)		U	Versenate

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

Antianaemics

Hypoplastic and Haemolytic

SA0922 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 Both:
 - 1.1 patient in chronic renal failure; and
 - 1.2 Haemoglobin \leq 100g/L; and
- 2 Any of the following:
 - 2.1 Both:
 - 2.1.1 patient is not diabetic; and
 - 2.1.2 glomerular filtration rate \leq 30ml/min; or
 - 2.2 Both:
 - 2.2.1 patient is diabetic; and
 - 2.2.2 glomerular filtration rate \leq 45ml/min; or
 - 2.3 patient is on haemodialysis or peritoneal dialysis.

Renewal only from a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Notes: Erythropoietin beta is indicated in the treatment of anaemia associated with chronic renal failure (CRF) where no cause for anaemia other than CRF is detected and there is adequate monitoring of iron stores and iron replacement therapy.

The Cockroft-Gault Formula may be used to estimate glomerular filtration rate (GFR) in persons 18 years and over:

GFR (ml/min) (male) = (140 - age) × Ideal Body Weight (kg) / 814 × serum creatinine (mmol/l)

GFR (ml/min) (female) = Estimated GFR (male) \times 0.85

ERYTHROPOIETIN ALPHA	- Special Authorit	y see SA0922 above	- Retail pharmacy
----------------------	--------------------	--------------------	-------------------

	Inj human recombinant 1,000 iu prefilled syringe	6	Eprex
	Inj human recombinant 2,000 iu, prefilled syringe	6	 Eprex
	Inj human recombinant 3,000 iu, prefilled syringe	6	✓ Eprex
	Inj human recombinant 4,000 iu, prefilled syringe	6	Eprex
	Inj human recombinant 5,000 iu, prefilled syringe	6	Eprex
	Inj human recombinant 6,000 iu, prefilled syringe	6	Eprex
	Inj human recombinant 10,000 iu, prefilled syringe	6	 Eprex
Е	RYTHROPOIETIN BETA – Special Authority see SA0922 above – Retail pharn	nacy	
	Inj 2,000 iu, prefilled syringe 120.18	6	NeoRecormon
	Inj 3,000 iu, prefilled syringe166.87	6	NeoRecormon
	Inj 4,000 iu, prefilled syringe	6	NeoRecormon
	Inj 5,000 iu, prefilled syringe243.26	6	NeoRecormon
	Inj 6,000 iu, prefilled syringe	6	NeoRecormon
	Inj 10,000 iu, prefilled syringe	6	✓ NeoRecormon
I	Megaloblastic		
F	DLIC ACID		
*		1,000	Apo-Folic Acid
*		500	✓ Apo-Folic Acid
-1-	Oral liq 50 mcg per ml	25 ml OP	✓ Biomed
	oral ing oo mog por mit minimum minimum minimum minimum. 24.00	20 111 01	· Biolitoa

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Antifibrinolytics, Haemostatics and Local Sclero	osants			
SODIUM TETRADECYL SULPHATE				
* Inj 0.5% 2 ml	23.20	5		
	(51.00)	_	F	ibro-vein
* Inj 1% 2 ml		5	-	"ihro voin
* Inj 3% 2 ml	(55.00)	5	F	ibro-vein
* iij 5 /0 2 iii	(73.00)	5	F	ibro-vein
(Fibro-vein Inj 0.5% 2 ml to be delisted 1 October 2013) (Fibro-vein Inj 1% 2 ml to be delisted 1 October 2013)	(10100)			
TRANEXAMIC ACID				
Tab 500 mg		100	<u>√ c</u>	yklokapron
Vitamin K				
PHYTOMENADIONE Inj 2 mg per 0.2 ml – Up to 5 inj available on a PSO Inj 10 mg per ml, 1 ml – Up to 5 inj available on a PSO		5 5		Conakion MM Conakion MM
Antithrombotic Agents				
Antiplatelet Agents				
ASPIRIN				
* Tab 100 mg	14.00	990	🖌 E	thics Aspirin EC
CLOPIDOGREL			_	
 * Tab 75 mg – For clopidogrel oral liquid formulation refer, page 				
189		90	VA	po-Clopidogrel
DIPYRIDAMOLE			_	
* Tab 25 mg - For dipyridamole oral liquid formulation refer,				
page 189		84	🖌 P	Persantin
* Tab long-acting 150 mg	11.52	60	✓ <u>P</u>	ytazen SR
PRASUGREL - Special Authority see SA1201 below - Retail pha	armacy			
Tab 5 mg		28	• =	ffient
Tab 10 mg	120.00	28	🖌 E	ffient

➡SA1201 Special Authority for Subsidy

Initial application — (coronary angioplasty and bare metal stent) from any relevant practitioner. Approvals valid for 6 months where the patient has undergone coronary angioplasty in the previous 4 weeks and is clopidogrel-allergie^{*}.

Initial application — (drug eluting stent) from any relevant practitioner. Approvals valid for 12 months where the patient has had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*.

Initial application — (stent thromobosis) from any relevant practitioner. Approvals valid without further renewal unless notified where patient has experienced cardiac stent thrombosis whilst on clopidogrel.

Renewal — (coronary angioplasty and bare metal stent) from any relevant practitioner. Approvals valid for 6 months where the patient has undergone coronary angioplasty or had a bare metal cardiac stent inserted in the previous 4 weeks and is clopidogrelallergic*.

Renewal — (drug eluting stent) from any relevant practitioner. Approvals valid for 12 months where had a drug-eluting cardiac stent inserted in the previous 4 weeks and is clopidogrel-allergic*.

Note: * Clopidogrel allergy is defined as a history of anaphylaxis, urticaria, generalised rash or asthma (in non-asthmatic patients) developing soon after clopidogrel is started and is considered unlikely to be caused by any other treatment.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer	
Heparin and Antagonist Preparations					
DALTEPARIN SODIUM - Special Authority see SA1270 below - F	Retail pharmacy				
Inj 2,500 iu per 0.2 ml prefilled syringe		10	🖌 F	ragmin	
Inj 5,000 iu per 0.2 ml prefilled syringe		10	🖌 F	ragmin	
Inj 7,500 iu per 0.75 ml graduated syringe	60.03	10	🖌 F	ragmin	

10	 Fragmin
10	🖌 Fragmin
10	Fragmin
10	 Fragmin
	10 10

SA1270 Special Authority for Subsidy

Initial application — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

Initial application — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 For the short-term treatment of venous thromboembolism prior to establishing a therapeutic INR with oral anti-coagulant treatment; or
- 2 For the prophylaxis and treatment of venous thromboembolism in high risk surgery; or
- 3 To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery; or
- 4 For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention; or
- 5 To be used in association with cardioversion of atrial fibrillation.

Renewal — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patient's pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

Renewal — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month where low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, Acute Coronary Syndrome, cardioversion, or prior to oral anti-coagulation).

ENOXAPARIN SODIUM - Special Authority see SA1174 below - Retail pharmacy

Inj 20 mg	 10	Clexane
Inj 40 mg	 10	Clexane
	 10	Clexane
Inj 80 mg	 10	Clexane
Ini 100 mg	 10	Clexane
	 10	Clexane
	 10	Clexane
, .		

SA1174 Special Authority for Subsidy

Initial application — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Low molecular weight heparin treatment is required during a patients pregnancy; or
- 2 For the treatment of venous thromboembolism where the patient has a malignancy.

continued...

Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer	

continued...

Initial application — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 For the short-term treatment of venous thromboembolism prior to establishing a therapeutic INR with oral anti-coagulant treatment; or
- 2 For the prophylaxis and treatment of venous thromboembolism in high risk surgery; or
- 3 To enable cessation/re-establishment of existing oral anticoagulant treatment pre/post surgery; or
- 4 For the prophylaxis and treatment of venous thromboembolism in Acute Coronary Syndrome surgical intervention; or
- 5 To be used in association with cardioversion of atrial fibrillation.

Renewal — (Pregnancy or Malignancy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

1 Low molecular weight heparin treatment is required during a patient's pregnancy; or

2 For the treatment of venous thromboembolism where the patient has a malignancy.

Renewal — (Venous thromboembolism other than in pregnancy or malignancy) from any relevant practitioner. Approvals valid for 1 month where low molecular weight heparin treatment or prophylaxis is required for a second or subsequent event (surgery, ACS, cardioversion, or prior to oral anti-coagulation).

HEPARIN SODIUM

Inj 1,000 iu per ml, 5 ml		10	Mayne
	66.80	50	Mayne
	11.44	10	Pfizer
	46.30	50	Pfizer
Inj 1,000 iu per ml, 35 ml		1	Mayne
Inj 5,000 iu per ml, 1 ml		5	Mayne
Inj 5,000 iu per ml, 5 ml		50	Pfizer
Inj 25,000 iu per ml, 0.2 ml	9.50	5	Mayne
HEPARINISED SALINE			
* Inj 10 iu per ml, 5 ml		50	Pfizer
PROTAMINE SULPHATE			
* Inj 10 mg per ml, 5 ml		10	
	(101.61)		Artex

Oral Anticoagulants

DABIGATRAN			
Cap 75 mg – No more than 2 cap per day		60	Pradaxa
Cap 110 mg		60	Pradaxa
Cap 150 mg		60	Pradaxa
RIVAROXABAN - Special Authority see SA1066 on the r	next page – Retail pharmacy	/	
Tab 10 mg		15	Xarelto

Subsidy (Manufacturer's Price)	Su		Brand or Generic	
\$	Per	~	Manufacturer	

➡SA1066 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 weeks for applications meeting the following criteria: Either:

1 For the prophylaxis of venous thromboembolism following a total hip replacement; or

2 For the prophylaxis of venous thromboembolism following a total knee replacement.

Note: Rivaroxaban is only currently indicated and subsidised for up to 5 weeks therapy for prophylaxis of venous thromboembolism following a total hip replacement and up to 2 weeks therapy for prophylaxis of venous thromboembolism following a total knee replacement.

Renewal from any relevant practitioner. Approvals valid for 5 weeks where prophylaxis for venous thromboembolism is required for patients following a subsequent total hip or knee replacement.

WARFARIN SODIUM

Note: Marevan and Coumadin are not interchangeable.

*	Tab 1 mg	3.46	50	Coumadin
	0	5.69	100	Marevan
*	Tab 2 mg	4.31	50	Coumadin
*	Tab 3 mg	8.00	100	Marevan
*	Tab 5 mg	5.93	50	Coumadin
	-	9.64	100	Marevan

Blood Colony-stimulating Factors

FILGRASTIM - Special Authority see SA1259 below - Retail pha	rmacy		
Inj 300 mcg per 0.5 ml prefilled syringe		5	 Zarzio
Inj 480 mcg per 0.5 ml prefilled syringe	864.00	5	Zarzio

SA1259 Special Authority for Subsidy

Initial application only from a relevant specialist, vocationally registered general practitioner or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Prevention of neutropenia in patients undergoing high risk chemotherapy for cancer (febrile neutropenia risk ≥ 20%*); or
- 2 Peripheral blood stem cell mobilisation in patients undergoing haematological transplantation; or
- 3 Peripheral blood stem cell mobilisation or bone marrow donation from healthy donors for transplantation; or
- 4 Treatment of severe chronic neutropenia (ANC < 0.5×10^9 /L); or
- 5 Treatment of drug-induced prolonged neutropenia (ANC < 0.5×10^{9} /L).

Note: *Febrile neutropenia risk \geq 20% after taking into account other risk factors as defined by the European Organisation for Research and Treatment of Cancer (EORTC) guidelines.

Fluids and Electrolytes

Intravenous Administration

DEXTROSE

Inj 50%, 10 ml – Up to 5 inj available on a PSO19.50	5	✓ <u>Biomed</u>
Inj 50%, 90 ml – Up to 5 inj available on a PSO11.25	1	✓ Biomed
TASSIUM CHLORIDE Inj 75 mg per ml, 10 ml55.00	50	

	Subsidy		Fully Brand or
	(Manufacturer's F \$	Price) Sub Per	sidised Generic Manufacturer
	Ŷ	101	
	40.05		
Inj 8.4%, 50 ml		1	Biomed
a) Up to 5 inj available on a PSO			
b) Not in combination			4
Inj 8.4%, 100 ml	20.50	1	Biomed
a) Up to 5 inj available on a PSO b) Not in combination			
SODIUM CHLORIDE			
Not funded for use as a nasal drop. Only funded for nebuliser use.		njunction with a	an antibiotic intended for nebulis
Inf 0.9% – Up to 2000 ml available on a PSO	3.06	500 ml	 Baxter
	4.06	1,000 ml	 Baxter
Only if prescribed on a prescription for renal dialysis, mate	ernity or post-nat	tal care in the I	home of the patient, or on a PS
for emergency use. (500 ml and 1,000 ml packs)			
Inj 23.4%, 20 ml	31.25	5	Biomed
For Sodium chloride oral liquid formulation refer Standard I	Formulae, page	192	
Inj 0.9%, 5 ml – Up to 5 inj available on a PSO	10.85	50	 Multichem
	15.50		 Pfizer
Inj 0.9%, 10 ml – Up to 5 inj available on a PSO	11.50	50	 Multichem
	15.50		 Pfizer
Inj 0.9%, 20 ml	4.72	6	Pharmacia
	11.79	30	Pharmacia
	8.41	20	 Multichem
OTAL PARENTERAL NUTRITION (TPN) – Retail pharmacy-Spe	cialist		
Infusion		1 OP	🖌 TPN
VATEB			
 On a prescription or Practitioner's Supply Order only when Schedule requiring a solvent or diluent; or On a bulk supply order; or When used in the extemporaneous compounding of eye dr 		orm as an injed	ction listed in the Pharmaceuti
Purified for inj, 5 ml - Up to 5 inj available on a PSO		50	 Multichem
Purified for inj, 10 ml - Up to 5 inj available on a PSO	11.25	50	 Multichem
Purified for inj, 20 ml – Up to 5 inj available on a PSO	6.50	20	 Multichem
Oral Administration			
ALCIUM POLYSTYRENE SULPHONATE Powder	160.85	300 g OP	Calcium Resonium
		000 g 01	
COMPOUND ELECTROLYTES Powder for soln for oral use 4.4 g – Up to 10 sach available		-	
on a PSO	1.12	5	Electral
DEXTROSE WITH ELECTROLYTES			
Soln with electrolytes	6.60	1,000 ml OP	Pedialyte - Bubblegum
	0.75		✓ Pedialyte - Fruit
Pedialyte - Fruit Soln with electrolytes to be delisted 1 July 2013) Pedialyte - Plain Soln with electrolytes to be delisted 1 July 2013,	6.75		Pedialyte - Plain

	Subsidy (Manufacturer's Pric	۵)	Fully Subsidised	
	(Manulactarer 31 He	Per	V	Manufacturer
POTASSIUM BICARBONATE				
Tab eff 315 mg with sodium acid phosphate 1.937 g and sodium bicarbonate 350 mg For phosphate supplementation		100	~	Phosphate-Sandoz
POTASSIUM CHLORIDE				
* Tab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq)	5.26 (11.85)	60		Chlorvescent
* Tab long-acting 600 mg	7.42	200	~	Span-K
SODIUM BICARBONATE Cap 840 mg	8.52	100	~	Sodibic
SODIUM POLYSTYRENE SULPHONATE Powder		450 g O	P 🗸	Resonium-A
Iron Overload				
DEFERIPRONE - Special Authority see SA1042 below - Retail p	harmacy			
Tab 500 mg Oral liq 100 mg per 1 ml		100 250 ml O		Ferriprox Ferriprox
►>SA1042 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals val	id without further r	enewal	unless no	tified where the patient has
been diagnosed with chronic transfusional iron overload due to co Note: For the purposes of this Special Authority, a relevant special	0			
DESFERRIOXAMINE MESYLATE * Inj 500 mg		10	~	Mayne

		Subsidy		Fully Brand or	
		(Manufacturer's Price	ce) Si	Subsidised Generic	
		\$	Per	 Manufacturer 	
A	pha Adrenoceptor Blockers				
DO	XAZOSIN				
*	Tab 2 mg	8.23	500	✓ <u>Apo-Doxazosin</u>	
*	Tab 4 mg		500	Apo-Doxazosin	
	ENOXYBENZAMINE HYDROCHLORIDE			4 - 11 - 11	
*	Cap 10 mg		30	 Dibenyline S29 Dibenyline S29 	
	170011	26.05	100	Dibenyline S29	
	AZOSIN Tob 1 mg	E E 2	100	Ano Brozo	
*	Tab 1 mg Tab 2 mg		100 100	Apo-PrazoApo-Prazo	
*	Tab 5 mg		100	✓ Apo-Prazo	
TFI	BAZOSIN	-			
*	Tab 1 mg		28	Arrow	
*	Tab 2 mg		28	Arrow	
*	Tab 5 mg	1.00	28	✓ <u>Arrow</u>	
A	gents Affecting the Renin-Angiotensin System				
A	CE Inhibitors				
CA	PTOPRIL				
*	Tab 12.5 mg	2.00	100	🖌 m-Captopril	
*	Tab 25 mg	2.40	100	m-Captopril	
	Tab 50 mg		100	<u>m-Captopril</u>	
* ‡	Oral liq 5 mg per ml		95 ml OP	Capoten	
	Oral liquid restricted to children under 12 years of age.				
	AZAPRIL Tab 0.5 mg	2.85	90	🖌 Zapril	
*	Tab 2.5 mg		90	✓ Zapril	
*	Tab 5 mg		90	✓ Zapril	
EN	ALAPRIL MALEATE				
*	Tab 5 mg	1.07	90	<u>m-Enalapril</u>	
*	Tab 10 mg	1.32	90	m-Enalapril	
*	Tab 20 mg - For enalapril maleate oral liquid formulation re-			4	
	fer, page 189	1.72	90	<u>m-Enalapril</u>	
	INOPRIL				
*	Tab 5 mg		90	Arrow-Lisinopril	
*	Tab 10 mg Tab 20 mg		90 90	 <u>Arrow-Lisinopril</u> Arrow-Lisinopril 	
	RINDOPRIL		50		
*	Tab 2 mg	3 75	30	Apo-Perindopril	
- 14	···· - ··· y	(18.50)	00	Coversyl	
*	Tab 4 mg	()	30	Apo-Perindopril	
		(25.00)		Coversyl	

	Subsidy (Manufacturer's Price) \$	S Per	Fully Subsidised	
QUINAPRIL	Ť		-	
* Tab 5 mg	1.15	30	~	Accupril
	3.44	90	~	Arrow-Quinapril 5
* Tab 10 mg	1.55	30	VI	Accupril
Ŭ	4.64	90	~	Arrow-Quinapril 10
* Tab 20 mg	2.11	30	~	Accupril
-	6.34	90	~	Arrow-Quinapril 20
(Accupril Tab 5 mg to be delisted 1 July 2013)				
(Accupril Tab 10 mg to be delisted 1 July 2013)				
(Accupril Tab 20 mg to be delisted 1 July 2013)				

TRANDOLAPRIL

Higher subsidy by endorsement is available for patients who were taking trandolapril for the treatment of congestive heart failure prior to 1 June 1998. The prescription must be endorsed accordingly. We recommend that the words used to indicate eligibility are "certified condition" or an appropriate description of the patient such as "congestive heart failure", "CHF", "congestive cardiac failure" or "CCF". For the purposes of this endorsement, congestive heart failure includes patients post myocardial infarction with an ejection fraction of less than 40%. Patients who started on trandolapril after 1 June 1998 are not eligible for full subsidy by endorsement.

* Cap 1 mg - Higher subsidy of \$18.67 per 28 cap with En- dorsement	3.06	28	
(1	8.67)		Gopten
* Cap 2 mg - Higher subsidy of \$27.00 per 28 cap with En-			
dorsement		28	
(2	27.00)		Gopten
ACE Inhibitors with Diuretics			
CILAZAPRIL WITH HYDROCHLOROTHIAZIDE			
* Tab 5 mg with hydrochlorothiazide 12.5 mg	.5.36	28 0	Inhibace Plus
ENALAPRIL MALEATE WITH HYDROCHLOROTHIAZIDE			
* Tab 20 mg with hydrochlorothiazide 12.5 mg	.3.32	30	
	(8.70)		Co-Renitec
QUINAPRIL WITH HYDROCHLOROTHIAZIDE			
* Tab 10 mg with hydrochlorothiazide 12.5 mg	.3.37	30	Accuretic 10
* Tab 20 mg with hydrochlorothiazide 12.5 mg	.4.57	30	Accuretic 20
Angiotension II Antagonists			
CANDESARTAN CILEXETIL - Special Authority see SA1223 below - Re	etail pharmacy		
* Tab 4 mg			Candestar
* Tab 8 mg		90	Candestar

➡SA1223 Special Authority for Subsidy

* Tab 32 mg 17.66

Initial application — (ACE inhibitor intolerance) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

- 1 Patient has persistent ACE inhibitor induced cough that is not resolved by ACE inhibitor retrial (same or new ACE inhibitor); or
- 2 Patient has a history of angioedema.

Initial application — (Unsatisfactory response to ACE inhibitor) from any relevant practitioner. Approvals valid without further renewal unless notified where patient is not adequately controlled on maximum tolerated dose of an ACE inhibitor.

90

90

Candestar

Candestar

	Subsidy (Manufacturer's Pric \$	ce) Su Per	Fully Brand or Ibsidised Generic Manufacturer
OSARTAN POTASSIUM			
₭ Tab 12.5 mg		90	Lostaar
₭ Tab 25 mg	3.20	90	Lostaar
✤ Tab 50 mg		90	✓ Lostaar
* Tab 100 mg	8.68	90	✓ Lostaar
Angiotension II Antagonists with Diuretics			
OSARTAN POTASSIUM WITH HYDROCHLOROTHIAZIDE			
Tab 50 mg with hydrochlorothiazide 12.5 mg	4.89	30	✓ <u>Arrow-Losartan &</u> <u>Hydrochlorothiazide</u>
Antiarrhythmics			
For lignocaine hydrochloride refer to NERVOUS SYSTEM, Ana	esthetics, Local, page	e 118	
AMIODARONE HYDROCHLORIDE			
Tab 100 mg – Retail pharmacy-Specialist		30	Aratac
			Cordarone-X
Tab 200 mg – Retail pharmacy-Specialist		30	Aratac
			Cordarone-X
Inj 50 mg per ml, 3 ml ampoule – Up to 6 inj available or	na		
PSO	22.80	6	Cordarone-X
TROPINE SULPHATE			
Inj 600 mcg per ml, 1 ml ampoule – Up to 5 inj available or	na		
PS0		50	✓ AstraZeneca
DIGOXIN			
★ Tab 62.5 mcg – Up to 30 tab available on a PSO	6.67	240	Lanoxin PG
★ Tab 250 mcg – Up to 30 tab available on a PSO		240	✓ Lanoxin
k‡ Oral liq 50 mcg per ml		60 ml	 Lanoxin
Cap 100 mg	15.00	100	
	(23.87)	100	Rythmodan
Cap 150 mg	· · · ·	100	✓ Rythmodan
ELECAINIDE ACETATE – Retail pharmacy-Specialist			
Tab 50 mg	45.82	60	Tambocor
Tab 100 mg - For flecainide acetate oral liquid formulati		00	
refer, page 189		60	Tambocor
▲ Cap long-acting 100 mg		30	✓ Tambocor CR
▲ Cap long-acting 200 mg		30	✓ Tambocor CR
Inj 10 mg per ml, 15 ml ampoule		5	✓ Tambocor
▲ Cap 150 mg	65.00	100	✓ Mexiletine
		100	Hydrochloride
			USP S29
▲ Cap 250 mg	102.00	100	 Mexiletine Hydrochloride USP (\$29)
PROPAFENONE HYDROCHLORIDE – Retail pharmacy-Spec	ialist		
		50	Rytmonorm

	Subsidy (Manufacturer's \$	Price) Sub Per	Fully Brand or sidised Generic ✓ Manufacturer
Antihypotensives			
MIDODRINE – Special Authority see SA0934 below – Retail pr Tab 2.5 mg Tab 5 mg	53.00	100 100	✔ Gutron✔ Gutron
 SA0934 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid All of the following: Disabling orthostatic hypotension not due to drugs; and Patient has tried fludrocortisone (unless contra-indicated Patient has tried non pharmacological treatments such head and trunk at night. Notes: Treatment should be started with small doses and titrate Hypertension should be avoided, and the usual target is a stance Renewal from any relevant practitioner. Approvals valid for 2 benefiting from treatment.) with unsatisfacto as support hose, d upwards as nec ling systolic blood	ory results; and increased salt ressary. I pressure of 90	intake, exercise, and elevation o mm Hg.
Beta Adrenoceptor Blockers			
ATENOLOL * Tab 50 mg * Tab 100 mg * Oral liq 25 mg per 5 ml Restricted to children under 12 years of age.	9.12	500 500 300 ml OP	 ✓ <u>Mylan Atenolol</u> ✓ <u>Mylan Atenolol</u> ✓ Atenolol AFT \$29
BISOPROLOL Tab 2.5 mg Tab 5 mg Tab 10 mg	4.74	30 30 30	 ✓ <u>Bosvate</u> ✓ <u>Bosvate</u> ✓ Bosvate
CARVEDILOL * Tab 6.25 mg * Tab 12.5 mg * Tab 25 mg – For carvedilol oral liquid formulation refer, page 100	27.00 je	30 30	✓ Dilatrend ✓ Dilatrend
189 CELIPROLOL * Tab 200 mg		30 180	 Dilatrend Celol
LABETALOL * Tab 50 mg * Tab 100 mg – For labetalol oral liquid formulation refer, page		100	✔ Hybloc
189 * Tab 200 mg * Inj 5 mg per ml, 20 ml ampoule		100 100 5	✔ Hybloc✔ Hybloc
METOPROLOL SUCCINATE	(88.60)		Trandate
 * Tab long-acting 23.75 mg * Tab long-acting 47.5 mg * Tab long-acting 95 mg * Tab long-acting 190 mg 	1.41 2.42	30 30 30 30	 ✓ <u>Metoprolol - AFT CR</u>

	Subsidy (Manufacturer's Price) \$) Per	Fully Subsidised	Brand or Generic Manufacturer
METOPROLOL TARTRATE	Ŷ	1.01	•	Manalaotaron
* Tab 50 mg - For metoprolol tartrate oral liquid formulation	1			
refer, page 189		100	1	.opresor
* Tab 100 mg		60		.opresor
* Tab long-acting 200 mg		28		Blow-Lopresor
 * Inj 1 mg per ml, 5 ml vial 		5	. –	.opresor
		0	• -	
NADOLOL				
* Tab 40 mg		100		po-Nadolol
* Tab 80 mg	23.74	100	V <u>A</u>	po-Nadolol
PINDOLOL				
* Tab 5 mg	5.40	100	🗸 A	po-Pindolol
* Tab 10 mg	9.19	100	🗸 🗸	po-Pindolol
* Tab 15 mg	13.80	100	🗸 A	po-Pindolol
PROPRANOLOL				
* Tab 10 mg	3 55	100	v 0	Cardinol
	3.65		VA	00-
				Propranolol S29
* Tab 40 mg	4 65	100	🗸 A	
			• •	Propranolol S29
* Cap long-acting 160 mg	16.06	100	~	Cardinol LA
 Corp long acting roo ing		100		
Retail pharmacy		500 m		oxane S29
(Cardinol Tab 10 mg to be delisted 1 July 2013)		000 111		IVALITE 023

SA1327 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

1 For the treatment of a child under 12 years with an haemangioma causing functional impairment (not for cosmetic reasons only); or

2 For the treatment of a child under 12 years with cardiac arrthymias or congenital cardiac abnormalities.

Renewal from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

1 For the treatment of a child under 12 years with an haemangioma causing functional impairment (not for cosmetic reasons only); or

2 For the treatment of a child under 12 years with cardiac arrthymias or congenital cardiac abnormalities.

SOTALOL

 * Tab 80 mg – For sotalol oral liquid formulation refer, page 189 * Tab 160 mg 		500 100	✔ Mylan ✔ Mylan
* Inj 10 mg per ml, 4 ml ampoule	65.39	5	✓ Sotacor
TIMOLOL MALEATE * Tab 10 mg	10.55	100	Apo-Timol
Calcium Channel Blockers			
Dihydropyridine Calcium Channel Blockers			
AMLODIPINE * Tab 2.5 mg	2.45	100	✓ <u>Apo-Amlodipine</u>
* Tab 5 mg – For amlodipine oral liquid formulation refer, page	0.05	100	4 A A A B B B B B B B B B B

(M	Subsidy lanufacturer's Price) \$	Subs Per	Fully idised	Brand or Generic Manufacturer
ELODIPINE				
* Tab long-acting 2.5 mg	2.90	30	у <u>Р</u>	lendil ER
K Tab long-acting 5 mg	3.10	30	у <u>Р</u>	lendil ER
₭ Tab long-acting 10 mg	4.60	30	✓ <u>P</u>	lendil ER
SRADIPINE				
₭ Cap long-acting 2.5 mg	7.50	30	VD	ynacirc-SRO
 Cap long-acting 5 mg 	7.85	30	V D	ynacirc-SRO
IIFEDIPINE				
Fab long-acting 10 mg	17.72	60	🗸 A	dalat 10
 Tab long-acting 20 mg 	7.30	100	🖌 N	yefax Retard
Tab long-acting 30 mg	8.56	30		defin XL
			🗸 A	rrow-Nifedipine XR
	5.50			
	(19.90)			dalat Oros
Tab long-acting 60 mg	12.28	30		defin XL
	8.00		V A	rrow-Nifedipine XR
	(29.50)		Δ	dalat Oros
Other Calcium Channel Blockers	(20.00)		7.0	
NILTIAZEM HYDROCHLORIDE				
★ Tab 30 mg	4 60	100		ilzem
 Tab 60 mg – For diltiazem hydrochloride oral liquid formula- 		100	• =	
tion refer, page 189	8.50	100	V D	ilzem
Cap long-acting 120 mg – Brand switch fee payable (Phar-				
macode 2437775) - see page 187 for details	31.83	500	🗸 A	po-Diltiazem CD
Cap long-acting 180 mg – Brand switch fee payable (Phar-				
macode 2437775) - see page 187 for details	47.67	500	🗸 A	po-Diltiazem CD
Cap long-acting 240 mg - Brand switch fee payable (Phar-			_	
macode 2437775) - see page 187 for details	63.58	500	✓ <u>A</u>	po-Diltiazem CD
ERHEXILINE MALEATE - Special Authority see SA1260 below - F			_	
Tab 100 mg		100	V Pe	exsia
NCA1260 Creasial Authority for Cubaidy				

➡SA1260 Special Authority for Subsidy

Initial application only from a cardiologist or general physician. Approvals valid for 2 years for applications meeting the following criteria:

Both:

1 Patient has refractory angina; and

2 Patient is on the maximal tolerated dose of a beta-blocker, a calcium channel blocker and a long acting nitrate.

Renewal only from a cardiologist or any relevant practitioner on the recommendation of a cardiologist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

****	the first and the patient is benefiting norm treat	iont.
VE	RAPAMIL HYDROCHLORIDE	
*	Tab 40 mg7.01	100
*	Tab 80 mg – For verapamil hydrochloride oral liquid formula-	
	tion refer, page 18911.74	100
*	Tab long-acting 120 mg15.20	250
*	Tab long-acting 240 mg25.00	250

* Inj 2.5 mg per ml, 2 ml ampoule – Up to 5 inj available on a PSO......7.54 5

✓ <u>Isoptin</u>
 ✓ <u>Isoptin</u>
 ✓ Verpamil SR
 ✓ Verpamil SR

Isoptin

	0.1.11		
	Subsidy (Manufacturer's Pri	co) Sub	Fully Brand or sidised Generic
	(Manulacturer 31 11	Per	Manufacturer
	+		
Centrally-Acting Agents			
CLONIDINE			
* Patch 2.5 mg, 100 mcg per day - Only on a prescription		4	Catapres-TTS-1
* Patch 5 mg, 200 mcg per day - Only on a prescription		4	Catapres-TTS-2
* Patch 7.5 mg, 300 mcg per day - Only on a prescription	41.20	4	Catapres-TTS-3
CLONIDINE HYDROCHLORIDE			
* Tab 25 mcg		112	Clonidine BNM
	19.25	100	✔ Dixarit
* Tab 150 mcg		100	✓ Catapres
* Inj 150 mcg per ml, 1 ml ampoule		5	✓ Catapres
METHYLDOPA			
* Tab 125 mg		100	Prodopa
* Tab 250 mg		100	✓ Prodopa
* Tab 500 mg		100	✓ Prodopa
9			
Diuretics			
Loop Divertion			
Loop Diuretics			
BUMETANIDE			
* Tab 1 mg		100	Burinex
* Inj 500 mcg per ml, 4 ml vial	7.95	5	Burinex
FUROSEMIDE [FRUSEMIDE]			
* Tab 40 mg – Up to 30 tab available on a PSO	10.25	1,000	🖌 Diurin 40
* Tab 500 mg		50	✓ Urex Forte
*‡ Oral liq 10 mg per ml		30 ml OP	✓ Lasix
* Inj 10 mg per ml, 25 ml ampoule		5	Lasix
* Inj 10 mg per ml, 2 ml ampoule - Up to 5 inj available on	а		
PSO		5	Frusemide-Claris
Potassium Sparing Diuretics			
Polassium Sparing Durenes			
AMILORIDE HYDROCHLORIDE			
Oral liq 1 mg per ml		25 ml OP	 Biomed
METOLAZONE - Special Authority see SA1349 below - Retail			
Tab 5 mg	CBS	1	Metolazone S29
		50	Zaroxolyn S29
SA1349 Special Authority for Subsidy			
Initial application from any relevant practitioner. Approvals vali	d without further re	newal unless	notified where used for the treat
ment of patients with refractory heart failure who are intolerant o	r have not responde	ed to loop diu	retics and/or loop-thiazide comb
nation therapy.			
SPIRONOLACTONE			
* Tab 25 mg	4.60	100	✓ Spirotone
* Tab 100 mg		100	✓ Spirotone
the second		25 ml OP	 Biomed
Potassium Sparing Combination Diuretics			
AMILORIDE HYDROCHLORIDE WITH FUROSEMIDE			
* Tab 5 mg with furosemide 40 mg	8 63	28	🖌 Frumil
* 100 0 HIY WITH 101000 HING *0 HIY		20	

	Subsidy (Manufacturer's Pric	e) Si	Fully Brand or ubsidised Generic
	\$	Per	Manufacturer
MILORIDE HYDROCHLORIDE WITH HYDROCHLOROTHIAZID Tab 5 mg with hydrochlorothiazide 50 mg	-	50	✓ Moduretic
Thiazide and Related Diuretics			
BENDROFLUMETHIAZIDE [BENDROFLUAZIDE]			
₭ Tab 2.5 mg – Up to 150 tab available on a PSO	6.48	500	Arrow-
May be supplied on a PSO for reasons other than emerger	ICY.		Bendrofluazide
K Tab 5 mg	9.95	500	Arrow- Bendrofluazide
CHLOROTHIAZIDE			Denaronaaziae
Oral liq 50 mg per ml		25 ml OP	 Biomed
CHLORTALIDONE [CHLORTHALIDONE]	4 90	30	✓ Igroton S29
• Tab 25 mg	8.00	50	 ✓ Hygroton
Igroton see Tab 25 mg to be delisted 1 October 2013)			
NDAPAMIDE ≰ Tab 2.5 mg	2 95	90	✔ Dapa-Tabs
Lipid-Modifying Agents	2.00	50	
Fibrates			
BEZAFIBRATE			
₭ Tab 200 mg		90	✓ <u>Bezalip</u>
Tab long-acting 400 mg	5.70	30	Bezalip Retard
GEMFIBROZIL ₭ Tab 600 mg	14.00	60	✓ <u>Lipazil</u>
Other Lipid-Modifying Agents			
CIPIMOX			
₭ Cap 250 mg		30	 Olbetam
VICOTINIC ACID ₭ Tab 50 mg	4.17	100	Apo-Nicotinic Acid
k Tab 500 mg		100	✓ Apo-Nicotinic Acid
Resins			
HOLESTYRAMINE			
Powder for oral liq 4 g		50	Questran-Lite
OLESTIPOL HYDROCHLORIDE	(02.00)		
Grans for oral liq 5 g		30	✓ Colestid
HMG CoA Reductase Inhibitors (Statins)			

Prescribing Guidelines

Treatment with HMG CoA Reductase Inhibitors (statins) is recommended for patients with dyslipidaemia and an absolute 5 year cardiovascular risk of 15% or greater.

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
ATORVASTATIN - See prescribing guideline on the preceding pa	qe			
* Tab 10 mg	•	90	✓ <u>Z</u>	arator
* Tab 20 mg	4.17	90	✓ <u>Z</u>	arator
* Tab 40 mg		90	✓ <u>Z</u>	<u>arator</u>
* Tab 80 mg	16.23	90	✓ <u>Z</u>	arator
PRAVASTATIN - See prescribing guideline on the preceding pag	e			
* Tab 20 mg		30	V	cholvastin
* Tab 40 mg	9.28	30	<u>v</u> <u>c</u>	Cholvastin
SIMVASTATIN - See prescribing guideline on the preceding page	e			
* Tab 10 mg	1.40	90	VA	Arrow-Simva 10mg
* Tab 20 mg	1.95	90	VA	Arrow-Simva 20mg
* Tab 40 mg		90	<u> </u>	Arrow-Simva 40mg
* Tab 80 mg	9.31	90	✓ <u>A</u>	Arrow-Simva 80mg
Selective Cholesterol Absorption Inhibitors				

►SA1045 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 years; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and

EZETIMIBE - Special Authority see SA1045 below - Retail pharmacy

- 3 Any of the following:
 - 3.1 The patient has rhabdomyolysis (defined as muscle aches and creatine kinase more than $10 \times$ normal) when treated with one statin; or

30

Ezetrol

3.2 The patient is intolerant to both simvastatin and atorvastatin; or

Tab 10 mg45.90

3.3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

Notes: A patient who has failed to reduce their LDL cholesterol to < 2.0 mmol/litre with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapies.

Other treatment options including fibrates, resins and nicotinic acid should be considered after failure of statin therapy.

If a patient's LDL cholesterol cannot be calculated because the triglyceride level is too high then a repeat test should be performed and if the LDL cholesterol again cannot be calculated then it can be considered that the LDL cholesterol is greater than 2.0 mmol/litre.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

EZETIMIBE WITH SIMVASTATIN - Special Authority see SA1046 below - Retail pharmacy

Tab 10 mg with simvastatin 10 mg48.90	30	🖌 Vytorin
Tab 10 mg with simvastatin 20 mg51.60	30	Vytorin
Tab 10 mg with simvastatin 40 mg55.20	30	Vytorin
Tab 10 mg with simvastatin 80 mg60.60	30	 Vytorin

➡SA1046 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: All of the following:

- 1 Patient has a calculated absolute risk of cardiovascular disease of at least 15% over 5 year; and
- 2 Patient's LDL cholesterol is 2.0 mmol/litre or greater; and
- 3 The patient has not reduced their LDL cholesterol to less than 2.0 mmol/litre with the use of the maximal tolerated dose of atorvastatin.

continued...

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

Notes: A patient who has failed to reduce their LDL cholesterol to $\leq 2.0 \text{ mmol/litre}$ with the use of a less potent statin should use a more potent statin prior to consideration being given to the use of non-statin therapies.

Other treatment options including fibrates, resins and nicotinic acid should be considered after failure of statin therapy.

If a patient's LDL cholesterol cannot be calculated because the triglyceride level is too high then a repeat test should be performed and if the LDL cholesterol again cannot be calculated then it can be considered that the LDL cholesterol is greater than 2.0 mmol/litre.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

· · · · · · · · · · · · · · · · · · ·		
Nitrates		
GLYCERYL TRINITRATE		
* Tab 600 mcg – Up to 100 tab available on a PSO8.0	00 100 OP	Lycinate
* Oral spray, 400 mcg per dose – Up to 250 dose available on		
a PSO	45 250 dose OP	
* Patch 25 mg, 5 mg per day16.		✓ <u>Nitroderm TTS</u>
* Patch 50 mg, 10 mg per day19.	50 30	Nitroderm TTS
SOSORBIDE MONONITRATE		
* Tab 20 mg17.	10 100	✓ Ismo 20
* Tab long-acting 40 mg7.		Corangin
* Tab long-acting 60 mg	94 90	 Duride
Sympathomimetics		
ADRENALINE		
Inj 1 in 1,000, 1 ml ampoule - Up to 5 inj available on a PSO4.9	98 5	Aspen Adrenaline
5.2	25	Mayne
Inj 1 in 10,000, 10 ml ampoule – Up to 5 inj available on a		
PSO27.0		Mayne
49.0	00 10	Aspen Adrenaline
SOPRENALINE		
₭ Inj 200 mcg per ml, 1 ml ampoule		
(135.	00)	Isuprel
Vasodilators		
AMYL NITRITE		
* Liq 98% in 0.3 ml cap62.9	92 12	
(73.4	40)	Baxter
IYDRALAZINE HYDROCHLORIDE		
✤ Tab 25 mg - Special Authority see SA1321 below - Retail		
pharmacyCB	S 1	 Hydralazine
	56	Onelink S29
* Inj 20 mg ampoule25.9	90 5	Apresoline
SA1321 Special Authority for Subsidy		

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Either:

1 For the treatment of refractory hypertension; or

2 For the treatment of heart failure in combination with a nitrate, in patients who are intolerant or have not responded to ACE inhibitors and/or angiotensin receptor blockers.

	Subsidy (Manufacturer's Price) \$	S Per	Fully Brand or Subsidised Generic ✓ Manufacturer
MINOXIDIL – Special Authority see SA1271 below – Retail pharn Tab 10 mg		100	✓ Loniten
SA1271 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals valid refractory hypertension which has failed to respond to extensive refractory hypertension which has failed to respond to extensive refractory hypertension which has failed to respond to extensive refractory hypertension which has failed to respond to extensive refractory hypertension which has failed to respond to extensive refractory hypertension which has failed to respond to extensive refractory hypertension which has failed to respond to extensive refractory hypertension which has failed to respond to extensive refractory hypertension which has failed to respond to extensive refractory hypertension which has failed to respond to extensive refractory hypertension which has failed to respond to extensive refractory hypertension which has failed to respond to extensive refractory hypertension which has failed to respond to extensive refractory hypertension which has failed to respond to extensive refractory hypertension which has failed to respond to extensive refractory hypertension which has failed to respond to extensive refractory hypertension which has failed to respond to extensive refractory hypertension which has failed to respond to extensive refractory hypertension which has failed to respond to extensive refractory hypertension which has failed to respond to extensive refractory hypertension which has failed to respond to extensive refractory hypertension which has failed to respond to extensive refractory hypertension which has failed to respond to extensive refractory hypertensive refractory hypertensity hypertensive refractory hypertensi	multiple therapies.	wal unle	ess notified where patient has sever
NICORANDIL – Special Authority see SA1263 below – Retail ph ▲ Tab 10 mg		60	✓ Ikorel
▲ Tab 10 mg		60 60	
Salary Special Authority for Subsidy Initial application only from a cardiologist or general physician. criteria: Both:	Approvals valid for 2	years fo	or applications meeting the followin
 Patient has refractory angina; and Patient is on the maximal tolerated dose of a beta-blocker, Renewal only from a cardiologist or any relevant practitioner on twhere the treatment remains appropriate and the patient is benefitiated and the patient is benefitiated. 	the recommendation		
APAVERINE HYDROCHLORIDE ★ Inj 12 mg per ml, 10 ml ampoule	73.12	5	🖌 Mayne
PENTOXIFYLLINE [OXPENTIFYLLINE] Tab 400 mg		50	Trental 400
Endothelin Receptor Antagonists			
➤SA0967 Special Authority for Subsidy Special Authority approved by the Pulmonary Arterial Hypertensi Notes: Application details may be obtained from PHARMAC's we The Coordinator, PAH Panel PHARMAC, PO Box 10-254, WELLINGTON Tel: (04) 916 7512, Fax: (04) 974 4858, Email: PAH@pharmac.cg	bsite http://www.pha	rmac.go	vvt.nz or:
AMBRISENTAN – Special Authority see SA0967 above – Retail			
Tab 5 mg		30	Volibris
Tab 10 mg		30	 Volibris
30SENTAN – Special Authority see SA0967 above – Retail pha Tab 62.5 mg		60	✓ pms-Bosentan ✓ Tracleer
Tab 125 mg		60	✓ pms-Bosentan ✓ Tracleer
Phosphodiesterase Type 5 Inhibitors			

SA1293 Special Authority for Subsidy

Initial application — (Raynaud's Phenomenon* - for Pulmonary Arterial Hypertension see note below)) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: All of the following:

1 Patient has Raynaud's Phenomenon*; and

2 Patient has severe digital ischaemia (defined as severe pain requiring hospital admission or with a high likelihood of digital ulceration; digital ulcers; or gangrene); and

continued...

	Subsidy (Manufacturer's Price) \$	Su Per	Fully bsidised	Brand or Generic Manufacturer
 continued 3 Patient is following lifestyle management (avoidance of caravoidance of sympathomimetic drugs) ; and 4 Patient is being treated with calcium channel blockers and response of the sympathom of	nitrates (or these are vrial Hypertension wi 1293-PAH). rmac.govt.nz age – Retail pharmac	contrain no are a	dicated/n	ot tolerated).
Tab 50 mg Tab 100 mg – For sildenafil oral liquid formulation refer, page 189	1.85	4	✓ <u>s</u>	ilagra
Prostacyclin Analogues				
► SA0969 Special Authority for Subsidy Special Authority approved by the Pulmonary Arterial Hypertensio Notes: Application details may be obtained from PHARMAC's web The Coordinator, PAH Panel PHARMAC, PO Box 10-254, WELLINGTON Tel: (04) 916 7512, Fax: (04) 974 4858, Email: PAH@pharmac.go	osite http://www.phar	mac.gov	t.nz or:	
ILOPROST – Special Authority see SA0969 above – Retail pharm Nebuliser soln 10 mcg per ml, 2 ml	,	30	V V	entavis

	Subsidy (Manufacturer's Price \$	e) Per	Fully Subsidised	Brand or Generic Manufacturer
Antiacne Preparations				
For systemic antibacterials, refer to INFECTIONS, Antibacterials,	page 89			
ADAPALENE				
a) Maximum of 30 g per prescription				
 b) Only on a prescription 				
Crm 0.1%		30 g OP	🖌 D	ifferin
Gel 0.1%		30 g OP	🖌 D	ifferin
ISOTRETINOIN - Special Authority see SA0955 below - Retail p	harmacy			
Cap 10 mg		120	V 0	ratane
Cap 20 mg		120	✓ 0	ratane

➡SA0955 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 Patient has had an adequate trial on other available treatments and has received an inadequate response from these treatments or these are contraindicated; and
- 2 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 3 Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and
- 4 Either:
 - 4.1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or
 - 4.2 Patient is male.

Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- All of the following:
 - 1 Patient has had an adequate trial on other available treatments and has received an inadequate response from these treatments or these are contraindicated; and
 - 2 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
 - 3 Applicant has an up to date knowledge of the treatment options for acne and is aware of the safety issues around isotretinoin and is competent to prescribe isotretinoin; and
 - 4 Either:
 - 4.1 Patient is female and has been counselled and understands the risk of teratogenicity if isotretinoin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of one month after the completion of the treatment; or
 - 4.2 Patient is male.

Note: Applicants are recommended to either have used or be familiar with using a decision support tool accredited by their professional body.

TRETINOIN

Crm 0.5 mg per g - Maximum of 50 g per prescription	13.90	50 g OP	ReTrieve
---	-------	---------	----------

	Subsidy		Fully Brand or
	(Manufacturer's \$	Price) Sub Per	osidised Generic Manufacturer
Antibacterials Topical			
For systemic antibacterials, refer to INFECTIONS, Antiba	cterials, page 89		
FUSIDIC ACID			
Crm 2%		15 g OP	Foban
a) Maximum of 15 g per prescription		Ū	
b) Only on a prescription			
c) Not in combination			
Oint 2%	3.25	15 g OP	Foban
 a) Maximum of 15 g per prescription 			
 b) Only on a prescription 			
c) Not in combination			
HYDROGEN PEROXIDE			
* Crm 1%	8.56	15 g OP	 Crystaderm
MUPIROCIN			
Oint 2%	6.60	15 g OP	
	(9.26)	-	Bactroban
 a) Only on a prescription 			
b) Not in combination			
SILVER SULPHADIAZINE			
Crm 1%		50 g OP	Flamazine
 a) Up to 250 g available on a PSO 			
b) Not in combination			
Antifungals Topical			
For systemic antifungals, refer to INFECTIONS, Antifunga	als, page 95		
	no, pago oo		
a) Only on a prescription			
b) Not in combination			
Nail soln 5%	37.86	5 ml OP	
	(61.87)	0 01	Loceryl
CICLOPIROX OLAMINE	(*****)		
a) Only on a prescription			
b) Not in combination			
Nail soln 8%		3 g OP	Batrafen
Nail-soln 8%		7 ml OP	✓ Apo-Ciclopirox
Soln 1%		20 ml OP	P. C. P. C.
	(11.54)		Batrafen
CLOTRIMAZOLE			
₭ Crm 1%	0.54	20 g OP	Clomazol
a) Only on a prescription		0	
b) Not in combination			
* Soln 1%	4.36	20 ml OP	
	(7.55)		Canesten
a) Only on a prescription			
b) Not in combination			

	Subsidy (Manufacturer's I	Price) Cu	Fully Brand or bsidised Generic
	(Manulacturers) \$	Price) Su Per	Manufacturer
ECONAZOLE NITRATE			
Crm 1%	1.00	20 g OP	
	(7.48)		Pevaryl
a) Only on a prescription			
b) Not in combination			
Foaming soln 1%, 10 ml sachets		3	Devend
a) Only on a pressription	(17.23)		Pevaryl
a) Only on a prescription b) Not in combination			
	0.40	15 - 00	Multichers
* Crm 2%	0.46	15 g OP	Multichem
a) Only on a prescriptionb) Not in combination			
* Lotn 2%	4 36	30 ml OP	
	(10.03)	00 111 01	Daktarin
a) Only on a prescription	(10.00)		Daktann
b) Not in combination			
* Tinct 2%		30 ml OP	
	(12.10)		Daktarin
a) Only on a prescription			
b) Not in combination			
NYSTATIN			
Crm 100,000 u per g	1.00	15 g OP	
	(7.90)		Mycostatin
a) Only on a prescription			
b) Not in combination			
Antipruritic Preparations			
CALAMINE			
a) Only on a prescription			
b) Not in combination			
Crm, aqueous, BP	1.77	100 g	Pharmacy Health
	(3.80)		Home Essential
Lotn, BP	13.45	2,000 ml	✓ <u>PSM</u>
(Home Essential Crm, aqueous, BP to be delisted 1 July 2013)			
CROTAMITON			
a) Only on a prescription			
b) Not in combination			4 1 1 1
Crm 10%	3.48	20 g OP	✓ Itch-Soothe
MENTHOL – Only in combination			
Only in combination with aqueous cream, 10% urea cream, v mineral oil lotion, and glycerol, paraffin and cetyl alcohol lotic		eral oil lotion, 1	% hydrocortisone with wool fat an
Crystals	6.50	25 g	🖌 PSM
	6.92		✓ MidWest
	29.60	100 g	MidWest

	Subsidy (Manufacturer's	Price) Sub	Fully Brand or sidised Generic
	\$	Per	Manufacturer
Corticosteroids Topical			
For systemic corticosteroids, refer to CORTICOSTEROIDS A	ND RELATED AGEN	NTS, page 82	
Corticosteroids - Plain			
BETAMETHASONE DIPROPIONATE			
Crm 0.05%		15 g OP	
	(6.91)		Diprosone
	8.97	50 g OP	-
	(18.36)		Diprosone
Crm 0.05% in propylene glycol base		30 g OP	Diama Old
Oint 0.05%	(13.83)	15 - 00	Diprosone OV
Oint 0.05%		15 g OP	Distagono
	(6.51) 8.97		Diprosone
		50 g OP	Distagono
Oint 0.05% in propulance ducal base	(17.11)	20 a OB	Diprosone
Oint 0.05% in propylene glycol base	(13.83)	30 g OP	Diprosone OV
	(13.65)		Diprosorie OV
BETAMETHASONE VALERATE			
* Crm 0.1%		50 g OP	✓ Beta Cream
* Oint 0.1%		50 g OP	 Beta Ointment
* Lotn 0.1%	10.05	50 ml OP	 Betnovate
CLOBETASOL PROPIONATE			
* Crm 0.05%	3.68	30 g OP	Dermol
* Oint 0.05%	3.68	30 g OP	Dermol
CLOBETASONE BUTYRATE		•	
Crm 0.05%	5.38	30 g OP	
	(7.09)	00 9 01	Eumovate
	16.13	100 g OP	Edinovato
	(22.00)	100 g 01	Eumovate
	(22.00)		Editovato
	0.07	50 × 00	
Crm 0.1%		50 g OP	Nevienne
Fatty sint 0 10/	(15.86)		Nerisone
Fatty oint 0.1%		50 g OP	Nerisone
	(15.86)		Nerisone
HYDROCORTISONE			
* Crm 1% – Only on a prescription		100 g	Pharmacy Health
	14.00	500 g	Pharmacy Health
Powder – Only in combination		25 g	✓ <u>ABM</u>
Up to 5% in a dermatological base (not proprietary galenicals. Refer, page 188	Iopical Corticosterio	od – Plain) witl	h or without other dermatological
HYDROCORTISONE BUTYRATE			
Lipocream 0.1%	2.30	30 g OP	Locoid Lipocream
•	6.85	100 g OP	 Locoid Lipocream
Oint 0.1%	6.85	100 g OP	✓ Locoid
Milky emul 0.1%		100 ml OP	✓ Locoid Crelo
		-	

	Subsidy		Fully Brand or
	(Manufacturer's \$	Price) Sui Per	osidised Generic Manufacturer
HYDROCORTISONE WITH WOOL FAT AND MINERAL OIL			
Lotn 1% with wool fat hydrous 3% and mineral oil - Only on			
a prescription	9.95	250 ml	✓ DP Lotn HC
IETHYLPREDNISOLONE ACEPONATE			
Crm 0.1%	4.95	15 g OP	Advantan
Oint 0.1%	4.95	15 g OP	Advantan
IOMETASONE FUROATE			
Crm 0.1%	1.78	15 g OP	✓ <u>m-Mometasone</u>
	3.42	45 g OP	✓ m-Mometasone
Oint 0.1%	1.78	15 g OP	m-Mometasone
	3.42	45 g OP	m-Mometasone
Lotn 0.1%	7.35	30 ml OP	Elocon
RIAMCINOLONE ACETONIDE			
Crm 0.02%	6.63	100 g OP	Aristocort
Oint 0.02%	6.69	100 g OP	✓ Aristocort
Corticosteroids - Combination			
ETAMETHASONE VALERATE WITH CLIOQUINOL - Only on a	prescription		
Crm 0.1% with clioquinol 3%		15 g OP	
	(4.90)		Betnovate-C
Oint 0.1% with clioquinol 3%		15 g OP	
·	(4.90)	0	Betnovate-C
ETAMETHASONE VALERATE WITH FUSIDIC ACID			
Crm 0.1% with fusidic acid 2%	3.49	15 g OP	
	(10.45)		Fucicort
a) Maximum of 15 g per prescription	(/		
b) Only on a prescription			
YDROCORTISONE WITH MICONAZOLE - Only on a prescript	tion		
Crm 1% with miconazole nitrate 2%		15 g OP	✓ Micreme H
YDROCORTISONE WITH NATAMYCIN AND NEOMYCIN – Or		0	· <u></u>
Crm 1% with natamycin 1% and neomycin sulphate 0.5%		15 g OP	Pimafucort
Oint 1% with natamycin 1% and neomycin sulphate 0.5%		15 g OP	 Pimatucort Pimatucort
, , ,		Ũ	
RIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCII		IIN	
Crm 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg		15 - 00	
and gramicidin 250 mcg per g – Only on a prescription		15 g OP	Viaderm KC
	(6.60)		
Disinfecting and Cleansing Agents			
HLORHEXIDINE GLUCONATE – Subsidy by endorsement			
a) No more than 500 ml per month			
b) Only if prescribed for a dialysis patient and the prescription		cordingly.	
← Handrub 1% with ethanol 70%		500 ml	✓ healthE
✓ Soln 4%	5.90	500 ml	✓ <u>Orion</u>

	Subsidy (Manufacturer's \$	Price) Sub Per	Fully Brand or sidised Generic ✓ Manufacturer
TRICLOSAN – Subsidy by endorsement a) Maximum of 500 ml per prescription b)			
 a) Only if prescribed for a patient identified with surgery in hospital and the prescription is endo b) Only if prescribed for a patient with recurrent \$ cordingly 	rsed accordingly; or		
Soln 1%	4.50 5.90	500 ml OP	 Pharmacy Health healthE
Barrier Creams and Emollients			
Barrier Creams			
ZINC AND CASTOR OIL * Oint BP		500 g	✓ Multichem
Emollients			
AQUEOUS CREAM * Crm	1.96	500 g	✓ <u>AFT</u>
CETOMACROGOL * Crm BP	3.15	500 g	✓ <u>PSM</u>
EMULSIFYING OINTMENT		500 g	✓ <u>AFT</u>
DIL IN WATER EMULSION ₭ Crm	2.63	500 g	✓ healthE Fatty Cream
JREA ₭ Crm 10%		100 g OP	✓ Nutraplus
WOOL FAT WITH MINERAL OIL – Only on a prescription * Lotn hydrous 3% with mineral oil	(3.50)	250 ml OP	Hydroderm Lotion
	5.60 (9.54) 1.40	1,000 ml 250 ml OP	Hydroderm Lotion
	(4.53) 5.60 (11.95)	1,000 ml	DP Lotion
	(11.95) (20.53) 1.40	250 ml OP	Alpha-Keri Lotion
	(7.73) 5.60	1,000 ml	BK Lotion
	(23.91)		BK Lotion

	Subsidy		Fully Prond or
	Subsidy (Manufacturer's P		Fully Brand or bsidised Generic
	\$	Per	 Manufacturer
Other Dermatological Bases			
PARAFFIN			
White soft – Only in combination	3.58	500 g	
	(7.78)		IPW
	20.20	2,500 g	V IPW
	3.58	500 g	2014
Only in combination with a dermatological galenical or as	(8.69) a diluent for a pro	nrietary Tonic	PSM pal Corticosteroid – Plain
Minor Skin Infections		prictary topic	
POVIDONE IODINE			
Oint 10%	3.27	25 g OP	 Betadine
a) Maximum of 100 g per prescription			
b) Only on a prescription	0.40		
Antiseptic soln 10%		15 ml	Datadiaa
	(4.45) 1.28	100 ml	Betadine
	(8.25)	100 111	Betadine
	6.20	500 ml	✓ Betadine
	1.28	100 ml	
	(4.20)		Riodine
	6.20	500 ml	✓ Riodine
Skin preparation, povidone iodine 10% with 30% alcohol	1.63	100 ml	
	(3.65)		Betadine Skin Prep
	10.00	500 ml	 Betadine Skin Prep
Skin preparation, povidone iodine 10% with 70% alcohol		100 ml	
	(6.04)	500 ml	Orion
	8.13	500 ml	Orion
	(18.63)		Onon
Parasiticidal Preparations			
GAMMA BENZENE HEXACHLORIDE			
Crm 1%	3.50	50 g OP	Benhex
VERMECTIN – Special Authority see SA1225 below – Retail pl			
Tab 3 mg – Up to 100 tab available on a PSO		4	 Stromectol
1) PSO for institutional use only. Must be endorsed w		e institution to	or which the PSO is required and
valid Special Authority for patient of that institution.		:	in a mationst of the institution
 2) Ivermectin available on BSO provided the BSO incomestion 3) For the purposes of subsidy of ivermectin, institution 			
facilities or penal institutions.	ullon means age i	elateu reside	initial care lacinities, disability car
►>SA1225 Special Authority for Subsidy			
itial application — (Scabies) from any relevant practitioner.	Approvals valid fo	r 1 month for	applications meeting the followin
riteria:	, pprovide valid 10		
Both:			
1 Applying clinician has discussed the diagnosis of scable	s with a dermatold	gist, infectiou	is disease physician or clinical m
crobiologist; and			
2 Either:			
2.1 Both:			
			continued

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

- 2.1.1 The patient is in the community: and
- 2.1.2 Any of the following:
 - 2.1.2.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.1.2.2 The community patient is physically or mentally unable to comply with the application instructions of topical therapy: or
 - 2.1.2.3 The patient has previously tried and failed to clear infestation using topical therapy; or
- 2.2 All of the following:
 - 2.2.1 The Patient is a resident in an institution; and
 - 2.2.2 All residents of the institution with scabies or at risk of carriage are to be treated for scabies concurrently; and
 - 2.2.3 Any of the following:
 - 2.2.3.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.2.3.2 The patient is physically or mentally unable to comply with the application instructions of topical therapy:
 - 2.2.3.3 Previous topical therapy has been tried and failed to clear the infestation.

Note: Ivermectin is no more effective than topical therapy for treatment of standard scabies infestation.

Initial application - (Other parasitic infections) only from an infectious disease specialist, clinical microbiologist or dermatologist. Approvals valid for 1 month for applications meeting the following criteria:

Any of the following:

- 1 Filaricides: or
- 2 Cutaneous larva migrans (creeping eruption); or
- 3 Strongyloidiasis.

Renewal — (Scabies) from any relevant practitioner. Approvals valid for 1 month for applications meeting the following criteria: Both:

- 1 Applying clinician has discussed the diagnosis of scabies with a dermatologist, infectious disease physician or clinical microbiologist; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 The patient is in the community; and
 - 2.1.2 Any of the following:
 - 2.1.2.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.1.2.2 The community patient is physically or mentally unable to comply with the application instructions of topical therapy; or
 - 2.1.2.3 The patient has previously tried and failed to clear infestation using topical therapy; or
 - 2.2 All of the following:
 - 2.2.1 The Patient is a resident in an institution: and
 - 2.2.2 All residents of the institution with scabies or at risk of carriage are to be treated for scabies concurrently; and
 - 2.2.3 Any of the following:
 - 2.2.3.1 Patient has a severe scabies hyperinfestation (Crusted/ Norwegian scabies); or
 - 2.2.3.2 The patient is physically or mentally unable to comply with the application instructions of topical therapy:
 - 2.2.3.3 Previous topical therapy has been tried and failed to clear the infestation.
- Note: Ivermectin is no more effective than topical therapy for treatment of standard scabies infestation.

Renewal - (Other parasitic infections) only from an infectious disease specialist, clinical microbiologist or dermatologist, Approvals valid for 1 month for applications meeting the following criteria:

- Any of the following:
 - 1 Filaricides: or
 - 2 Cutaneous larva migrans (creeping eruption): or
 - 3 Strongyloidiasis.

(1	Subsidy Manufacturer's F \$	Price) Sub Per	Fully sidised	Brand or Generic Manufacturer
MALATHION				
Liq 0.5%		200 ml OP	✓ <u>A</u>	-Lices
Shampoo 1%	2.83	30 ml OP	✓ <u>A</u>	-Lices
MALATHION WITH PERMETHRIN AND PIPERONYL BUTOXIDE				
Spray 0.25% with permethrin 0.5% and piperonyl butoxide 2%	11.15	90 g OP	🖌 Pa	ara Plus
PERMETHRIN				
Crm 5%	4.20	30 g OP	V L	/derm
Lotn 5%	3.24	30 ml OP	V A	-Scabies
Psoriasis and Eczema Preparations				
ACITRETIN - Special Authority see SA0954 below - Retail pharma	су			
Cap 10 mg	35.95	100	🖌 N	eotigason
	38.66	60	🖌 N	ovatretin
Cap 25 mg	83.11	60	🖌 N	ovatretin
	85.40	100	🖌 N	eotigason

➡SA0954 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: All of the following:

- 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
- 2 Applicant has an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and is aware of the safety issues around acitretin and is competent to prescribe acitretin; and
- 3 Either:
 - 3.1 Patient is female and has been counselled and understands the risk of teratogenicity if actiretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment; or
 - 3.2 Patient is male.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- All of the following:
 - 1 Applicant is a vocationally registered dermatologist, vocationally registered general practitioner, or nurse practitioner working in a relevant scope of practice; and
 - 2 Applicant has an up to date knowledge of the treatment options for psoriasis and of disorders of keratinisation and is aware of the safety issues around acitretin and is competent to prescribe acitretin; and
 - 3 Either:

3.1 Patient is female and has been counselled and understands the risk of teratogenicity if actiretin is used during pregnancy and the applicant has ensured that the possibility of pregnancy has been excluded prior to the commencement of the treatment and that the patient is informed that she must not become pregnant during treatment and for a period of two years after the completion of the treatment; or

3.2 Patient is male.

BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL

Oint 500 mcg with calcipotriol 50 mcg Topical gel 500 mcg with calcipotriol 50 mcg		30 g OP 30 g OP	DaivobetDaivobet
CALCIPOTRIOL			
Crm 50 mcg per g	.16.00	30 g OP	Daivonex
	45.00	100 g OP	Daivonex
Oint 50 mcg per g	.45.00	100 g OP	Daivonex
Soln 50 mcg per ml	.16.00	30 ml OP	Daivonex

DERMATOLOGICALS

	Subsidy		Fully Brand or
	(Manufacturer's F	Price) Sub Per	sidised Generic Manufacturer
	Ş	Per	Manulaclurer
COAL TAR Soln BP – Only in combination	12.05	200 ml	✓ Midwest
Up to 10 % Only in combination with a dermatological ba			
With or without other dermatological galenicals.		, ,	
COAL TAR WITH ALLANTOIN, MENTHOL, PHENOL AND SULP	HUR		
Soln 5% with sulphur 0.5%, menthol 0.75%, phenol 0.5% and			
allantoin crm 2.5%	3.43 (4.35)	30 g OP	Egopsoryl TA
	(4.33) 6.59	75 g OP	Egopsolyl IA
	(8.00)	70 g OI	Egopsoryl TA
COAL TAR WITH SALICYLIC ACID AND SULPHUR			
Soln 12% with salicylic acid 2% and sulphur 4% oint	7.95	40 g OP	✔ Coco-Scalp
SALICYLIC ACID			
Powder – Only in combination		250 g	✔ PSM
1) Only in combination with a dermatological base or p	roprietary Topica	I Corticosteroio	d – Plain or collodion flexible, refer,
page 188 2) With or without other dermatological galenicals.			
3) Maximum 20 g or 20 ml per prescription when pres	cribed with white	soft paraffin or	r collodion flexible.
SULPHUR			
Precipitated – Only in combination		100 g	✓ Midwest
 Only in combination with a dermatological base or p With or without other dermatological galenicals. 	proprietary Topic	al Corticosteroi	d – Plain, refer, page 188
TAR WITH TRIETHANOLAMINE LAURYL SULPHATE AND FLUG		nly on a proper	intion
* Soln 2.3% with triethanolamine lauryl sulphate and fluores-		niy on a presci	ιμιστ
cein sodium		500 ml	Pinetarsol
	5.82	1,000 ml	✓ Pinetarsol
Scalp Preparations			
BETAMETHASONE VALERATE * Scalp app 0.1%	7 75	100 ml OP	✓ Beta Scalp
CLOBETASOL PROPIONATE		100 111 01	
* Scalp app 0.05%	6.96	30 ml OP	V Dermol
HYDROCORTISONE BUTYRATE		00111101	V Donnor
Scalp lotn 0.1%	3.65	100 ml OP	✓ Locoid
KETOCONAZOLE			
Shampoo 2%	3.08	100 ml OP	✓ <u>Sebizole</u>
a) Maximum of 100 ml per prescription			
b) Only on a prescription			

	Subsidy (Manufacturer's \$	Price) Sub Per	Fully Brand osidised Gener	
Sunscreens				
UNSCREENS, PROPRIETARY – Subsidy by endor	sement			
Only if prescribed for a patient with severe pho		defined clinica	l condition and	the prescription i
endorsed accordingly. Crm	2 55	100 g OP		
	(5.89)	100 g 01	Hamilton	Sunscreen
Lotn	2.55	100 ml OP	Marine E SPF 30	
	5.10	200 ml OP	✓ Marine E SPF 30	
	3.19 (6.94)	125 ml OP	Aquasun	30+
Nart Preparations	(0.0.1)			
or salicylic acid preparations refer to PSORIASIS A		NS page 72		
IQUIMOD – Special Authority see SA0923 below		10, page 72		
Crm 5%		12	✓ <u>Aldara</u>	
SA0923 Special Authority for Subsidy itial application from any relevant practitioner. Application from any relevant practitioner.				
 the patient has external anogenital warts and The patient has external anogenital warts and The patient has external anogenital warts and The patient has confirmed superficial basal ce contraindicated or inappropriate. surgical excision remains first-line treatment fe and allows histological assessment of tumour Imiquimod has not been evaluated for the tre nose, mouth or ears. Imiquimod is not indicated for external genita enewal from any relevant practitioner. Approvals vary of the following: Inadequate response to initial treatment for an New confirmed superficial basal cell carcinomic cated or inappropriate; or Inadequate response to initial treatment for sub the: Every effort should be made to biopsy the lesic DDOPHYLLOTOXIN Soln 0.5% Maximum of 3.50 ml per prescription 	podophyllotoxin is unable to Il carcinoma where other sta or superficial basal cell carci- clearance. Patment of superficial basal ve, infiltrating, or nodular ba I and perianal warts (condyle lid for 4 months for applicati ogenital warts; or a where other standard treat perficial basal cell carcinom on to confirm that it is a supe 	be applied acc andard treatmer noma as it has cell carcinoma sal cell carcinon oma acuminata ons meeting the ments, includin a.	eurately to the s a higher cure r within 1 cm of ma.). e following crite g surgical excis	ite; or rigical excision, a ate than imiquimo the hairline, eye ria: ion, are contraino
b) Only on a prescription Other Skin Preparations				
Antineoplastics				
LUOROURACIL SODIUM Crm 5%	25.16	20 g OP	✓ Efudix	
 ✓ fully subsidised 4 [HP4] refer page 8 		proved medicine s dised Supply	upplied under Se	ction 29

DERMATOLOGICALS

	Subsidy (Manufacturer's Pric \$	ce) Subs Per	Fully sidised	Brand or Generic Manufacturer
Topical Analgesia				
For aspirin & chloroform application refer, page 192				
CAPSAICIN – Subsidy by endorsement Subsidised only if prescribed for post-herpetic neuralgia or accordingly.		, ,		
Crm 0.075%		45 g OP	V Zo	ostrix HP
Wound Management Products				
MAGNESIUM SULPHATE * Paste	2.98 (4.90)	80 g	P	SM

	Qubaidu		E. Ile	Durandau
	Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic
	\$	Per	~	Manufacturer
Contraceptives - Non-hormonal				
Condoms				
ONDOMS				
 49 mm – Up to 144 dev available on a PSO 	13.36	144		arquisTantiliza
				hield 49
52 mm – Up to 144 dev available on a PSO	13.36	144		arquis Selecta arquis Sensolite
				arquis Supalite
52 mm extra strength – Up to 144 dev available on a PSO		144		arquis Protecta
53 mm – Up to 144 dev available on a PSO		12		hield Blue
	13.36	144		hield Blue
	1.11	12		old Knight
	13.36	144		old Knight
	10.00	144		arquis Black
				arquis Titillata
53 mm (chocolate) – Up to 144 dev available on a PSO	1 11	12		old Knight
	13.36	144		old Knight
53 mm (strawberry) – Up to 144 dev available on a PSO		12		old Knight
	13.36	144		old Knight
E2 mm outro atronath Un to 144 day ovailable on a DCC		12		old Knight
53 mm extra strength – Up to 144 dev available on a PSC	13.36	144		old Knight
E4 mm abanad . Up to 144 day available on a DCO		144	V G	olu Kiligili
54 mm, shaped – Up to 144 dev available on a PSO		12		factulas Flored
	(1.24) 13.36	144	LI	festyles Flared
		144		factulas Eleved
EF anno 11 de 111 de constituido en e BOO	(14.84)			festyles Flared
55 mm – Up to 144 dev available on a PSO		144		arquis Conforma
56 mm – Up to 144 dev available on a PSO		12		old Knight
	13.36	144		old Knight
				urex Extra Safe
			V D	urex Select
				Flavours
56 mm, shaped – Up to 144 dev available on a PSO	1.11	12		urex Confidence
	13.36	144	🖌 D	urex Confidence
60 mm – Up to 144 dev available on a PSO	13.36	144	🖌 S	hield XL
Gold Knight 53 mm extra strength to be delisted 1 December 2	2013)			
Contraceptive Devices				
IAPHRAGM – Up to 1 dev available on a PSO				
One of each size is permitted on a PSO.				
65 mm		1	V 0	rtho All-flex
70 mm		1		rtho All-flex
75 mm		1		rtho All-flex
80 mm		1		rtho All-flex
a) Up to 40 dev available on a PSO				
b) Only on a PSO	00 50			
· IUD		1		ultiload Cu 375
			V M	ultiload Cu 375 SL

Subsidy		Fully	Bi
(Manufacturer's Price)	Su	bsidised	G
\$	Por	~	М

Brand or Generic Manufacturer

Contraceptives - Hormonal

Combined Oral Contraceptives

SA0500 Special Authority for Alternate Subsidy

Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 Either:
 - 1.1 Patient is on a Social Welfare benefit; or
 - 1.2 Patient has an income no greater than the benefit; and
- 2 Has tried at least one of the fully funded options and has been unable to tolerate it.

Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

1 Patient is on a Social Welfare benefit; or

2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999.

Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:

- on a Social Welfare benefit; or
- have an income no greater than the benefit.

The approval numbers of Special Authorities approved before 1 November 1999 are interchangeable for products within the combined oral contraceptives and progestogen-only contraceptives groups, except Loette and Microgynon 20 ED

ETHINYLOESTRADIOL WITH DESOGESTREL

*	Tab 20 mcg with desogestrel 150 mcg	6.62 (16.50)	63	Mercilon 21
	 a) Higher subsidy of \$13.80 per 63 tab with Special A b) Up to 63 tab available on a PSO 	Authority see SA0500 a	bove	
*	Tab 20 mcg with desogestrel 150 mcg and 7 inert tab	6.62	84	
		(16.50)		Mercilon 28
	 a) Higher subsidy of \$13.80 per 84 tab with Special A b) Up to 84 tab available on a PSO 	Authority see SA0500 a	bove	
*	Tab 30 mcg with desogestrel 150 mcg	6.62	63	
	5 5 5	(16.50)		Marvelon 21
	 a) Higher subsidy of \$13.80 per 63 tab with Special A b) Up to 63 tab available on a PSO 	Authority see SA0500 a	bove	
*	Tab 30 mcg with desogestrel 150 mcg and 7 inert tab	6.62	84	
	5 5 5	(16.50)		Marvelon 28
	a) Higher subsidy of \$13.80 per 84 tab with Special A	Authority see SA0500 a	bove	
	b) Up to 84 tab available on a PSO			
(M	ercilon 21 Tab 20 mcg with desogestrel 150 mcg to be de	listed 1 October 2013)		
,	arvelon 21 Tab 30 mcg with desogestrel 150 mcg to be de	/		
· · · ·	5			

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
ETHINYLOESTRADIOL WITH LEVONORGESTREL				
* Tab 50 mcg with levonorgestrel 125 mcg and 7 inert tab – Up				
to 84 tab available on a PSO		84	🗸 N	licrogynon 50 ED
* Tab 30 mcg with levonorgestrel 150 mcg		63		
a) Llichan autoidu af ¢15 00 mar 60 tab with Capacial Autom	(16.50)			licrogynon 30
 a) Higher subsidy of \$15.00 per 63 tab with Special Author b) Up to 63 tab available on a PSO 	ity see SA0500 on th	e prec	eaing page	;
 Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tab – Up 				
to 84 tab available on a PSO		84	🗸 A	va 30 ED
ETHINYLOESTRADIOL WITH NORETHISTERONE				
 Tab 35 mcg with norethisterone 1 mg – Up to 63 tab available 				
on a PSO	6.62	63	🗸 В	revinor 1/21
* Tab 35 mcg with norethisterone 1 mg and 7 inert tab - Up to				
84 tab available on a PSO		84	🖌 В	revinor 1/28
* Tab 35 mcg with norethisterone 500 mcg – Up to 63 tab avail-				
able on a PSO		63	🗸 В	revinor 21
* Tab 35 mcg with norethisterone 500 mcg and 7 inert tab -				
Up to 84 tab available on a PSO		84	V N	orimin
NORETHISTERONE WITH MESTRANOL				
* Tab 1 mg with mestranol 50 mcg and 7 inert tab	6.62 (13.80)	84	N	ariand 1/00
a) Higher subsidy of \$13.80 per 84 tab with Special Author	(/	o nroc		orinyl-1/28
b) Up to 84 tab available on a PSO		e piec	euing page	i de la constante de
Combined Oral Contraceptives - Other				
Combined Oral Contraceptives - Other				
ETHINYLOESTRADIOL WITH LEVONORGESTREL				
* Tab 20 mcg with levonorgestrel 100 mcg and 7 inert tab – Up				
to 84 tab available on a PSO	2.95	84	✓ <u>A</u>	va 20 ED
Progestogen-only Contraceptives				
SA0500 Special Authority for Alternate Subsidy Initial application from any medical practitioner. Approvals valid f	for 2 years for applica	tions	meeting the	e following criteria:

Initial application from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

1 Either:

- 1.1 Patient is on a Social Welfare benefit; or
- 1.2 Patient has an income no greater than the benefit; and

2 Has tried at least one of the fully funded options and has been unable to tolerate it.

Renewal from any medical practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

- 1 Patient is on a Social Welfare benefit; or
- 2 Patient has an income no greater than the benefit.

Notes: The approval numbers of Special Authorities approved after 1 November 1999 are interchangeable between Mercilon and Marvelon.

The additional subsidy will fund Mercilon and Marvelon up to the manufacturer's price for each of these products as identified on the Schedule at 1 November 1999.

Special Authorities approved before 1 November 1999 remain valid until the expiry date and can be renewed providing that women are still either:

• on a Social Welfare benefit; or

continued...

	Subsidy (Manufacturer's P		osidised G	rand or eneric
	\$	Per	V N	lanufacturer
continued				
• have an income no greater than the benefit. The approval numbers of Special Authorities approved before 1	November 1999 a	re interchang	eable for p	roducts within the com-
bined oral contraceptives and progestogen-only contraceptives g				
LEVONORGESTREL	0.00	04		
* Tab 30 mcg	6.62 (16.50)	84	Micro	olut
a) Higher subsidy of \$13.80 per 84 tab with Special Author	(/	on the precedi		
 b) Up to 84 tab available on a PSO * Subdermal implant (2 × 75 mg rods) 		1	🗸 Jade	elle
				<u></u>
* Inj 150 mg per ml, 1 ml syringe – Up to 5 inj available on a P	SO7.15	1	🖌 Dep	o-Provera
NORETHISTERONE				
* Tab 350 mcg – Up to 84 tab available on a PSO	6.00	84	✓ Nori	<u>day 28</u>
Emergency Contraceptives				
LEVONORGESTREL				
 * Tab 1.5 mg a) Maximum of 2 tab per prescription 	3.50	1	 Post 	inor-1
b) Up to 5 tab available on a PSO				
* Tab 750 mcg	12.50	2	🖌 Next	Choice
Antiandrogen Oral Contraceptives				
Prescribers may code prescriptions "contraceptive" (code "O") where the prescription of the prescription o	nen used as indica	ated for contra	ception. T	ne period of supply and
prescription charge will be as per other contraceptives, as follows				
 \$5.00 prescription charge (patient co-payment) will apply. prescription may be written for up to six months supply. 				
Prescriptions coded in any other way are subject to the non con		otion charges,	and the ne	on-contraceptive period
of supply. ie. Prescriptions may be written for up to three months	supply.			
CYPROTERONE ACETATE WITH ETHINYLOESTRADIOL * Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tabs	3 89	84	🖌 Gine	+ 84
Gynaecological Anti-infectives		01	<u>unit</u>	
ACETIC ACID WITH HYDROXYQUINOLINE AND RICINOLEIC				
Jelly with glacial acetic acid 0.94%, hydroxyquinoline sul phate 0.025%, glycerol 5% and ricinoleic acid 0.75% with				
applicator		100 g OP		
	(24.00)		Aci-	lel
CLOTRIMAZOLE * Vaginal crm 1% with applicators	1 20	35 g OP	🗸 Clor	nazol
 Vaginal crm 1% with applicators		20 g OP	✓ <u>Clor</u>	
MICONAZOLE NITRATE		-		_
* Vaginal crm 2% with applicator		40 g OP		
N.V/07471N	(4.10)		Micro	eme
NYSTATIN Vaginal crm 100,000 u per 5 g with applicator(s)	4.71	75 g OP	🗸 Nilst	at
· · · · · · · · · · · · · · · · · · ·				

	Subsidy (Manufacturer's \$	Price) Sub Per	Fully Brand or sidised Generic ✓ Manufacturer
Myometrial and Vaginal Hormone Preparations			
ERGOMETRINE MALEATE Inj 500 mcg per ml, 1 ml – Up to 5 inj available on a PSO	31.00	5	✓ DBL Ergometrine
OESTRIOL * Crm 1 mg per g with applicator * Pessaries 500 mcg		15 g OP 15	✓ Ovestin✓ Ovestin
OXYTOCIN – Up to 5 inj available on a PSO Inj 5 iu per ml, 1 ml Inj 10 iu per ml, 1 ml Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml	7.48	5 5 5	 ✓ Syntocinon ✓ Syntocinon ✓ Syntometrine
Pregnancy Tests - hCG Urine			
PREGNANCY TESTS - HCG URINE a) Up to 200 test available on a PSO b) Only on a PSO Cassette	22.80	40 test OP	✓ Innovacon hCG One Step Pregnancy Test
Urinary Agents			
For urinary tract Infections refer to INFECTIONS, Antibacterials, p	page 106		
5-Alpha Reductase Inhibitors			
FINASTERIDE – Special Authority see SA0928 below – Retail p * Tab 5 mg SA0928 Special Authority for Subsidy		30	✓ <u>Rex Medical</u>
Initial application from any relevant practitioner. Approvals vali the following criteria: Both: 1 Patient has symptomatic benign prostatic hyperplasia; and		renewal unless	s notified for applications meeting
 2 Either: 2.1 The patient is intolerant of non-selective alpha bloc 2.2 Symptoms are not adequately controlled with non-s Note: Patients with enlarged prostates are the appropriate candid 	kers or these are selective alpha b	lockers.	
Alpha-1A Adrenoreceptor Blockers			
TAMSULOSIN HYDROCHLORIDE – Special Authority see SA10 * Cap 400 mcg		ail pharmacy 30	✓ Tamsulosin-Rex
►SA1032 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals vali- the following criteria: Both:	d without further	renewal unless	s notified for applications meeting
1 Patient has symptomatic benign prostatic hyperplasia; and 2 The patient is intelerant of pon-selective alpha blockers or		indicated	

2 The patient is intolerant of non-selective alpha blockers or these are contraindicated.

	Subsidy (Manufacturer's Pr	rice) Sub	Fully sidised	Brand or Generic
	\$	Per	~	Manufacturer
Other Urinary Agents				
OXYBUTYNIN				
* Tab 5 mg		500		o-Oxybutynin
₭ Oral liq 5 mg per 5 ml	56.45	473 ml	V Ap	oo-Oxybutynin
POTASSIUM CITRATE				
Oral liq 3 mmol per ml – Special Authority see SA1083 below			4	
– Retail pharmacy		200 ml OP	🗸 Bi	omed
SA1083 Special Authority for Subsidy	(10 11 (
nitial application from any relevant practitioner. Approvals valid soth:	for 12 months for	applications r	neeting	the following criteria:
1 The patient has recurrent calcium oxalate urolithiasis; and				
2 The patient has had more than two renal calculi in the two	vears prior to the	application.		
tenewal from any relevant practitioner. Approvals valid for 2 ye			ins appr	opriate and the patient
enefitting from the treatment.				
ODIUM CITRO-TARTRATE				
Grans eff 4 g sachets	2.71	28	✓ Ur	al
OLIFENACIN SUCCINATE - Special Authority see SA0998 belo	ow – Retail pharn	nacy		
Tab 5 mg		30	🖌 Ve	sicare
Tab 10 mg	56.50	30	🖌 Ve	sicare
SA0998 Special Authority for Subsidy				
nitial application from any relevant practitioner. Approvals vali	id without further	renewal unle	ss notifi	ed where the patient ha
veractive bladder and a documented intolerance of oxybutynin.				
OLTERODINE – Special Authority see SA1272 below – Retail p				
Tab 1 mg		56 56		row-Tolterodine
	14.50	00	V Ar	row-rollerodine
SA1272 Special Authority for Subsidy nitial application from any relevant practitioner. Approvals valid	without further re	nowal unloca	notified y	whore patient has overa
ve bladder and a documented intolerance of oxybutynin.		newai uniess	louneu	where patient has overa
Detection of Substances in Urine				
DRTHO-TOLIDINE				
 Compound diagnostic sticks 	7.50	50 test OP		
-	(8.25)		He	emastix
ETRABROMOPHENOL				
Blue diagnostic strips	7.02	100 test OP		
	(40.00)			

(13.92)

Albustix

	Subsidy		Fully Brand or
	(Manufacturer's P \$	rice) Sub Per	osidised Generic ✔ Manufacturer
Corticosteroids and Related Agents for Systemic	c Use		
BETAMETHASONE SODIUM PHOSPHATE WITH BETAMETHAS		-	
Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1 ml		5	Celestone Chronodose
DEXAMETHASONE ≰ Tab 1 mg – Retail pharmacy-Specialist Up to 30 tab available on a PSO	5.87	100	✓ <u>Douglas</u>
Tab 4 mg – Retail pharmacy-Specialist Up to 30 tab available on a PSO	8.16	100	✓ Douglas
Oral liq 1 mg per ml – Retail pharmacy-Specialist Oral lig prescriptions:	45.00	25 ml OP	 Biomed
 Must be written by a Paediatrician or Paediatric Carc On the recommendation of a Paediatrician or Paedia 	•		
EXAMETHASONE SODIUM PHOSPHATE Dexamethasone sodium phosphate injection will not be funde	d for oral use		
 Inj 4 mg per ml, 1 ml – Up to 5 inj available on a PSO 		5	✓ Hospira
€ Inj 4 mg per ml, 2 ml – Up to 5 inj available on a PSO		5	✓ Hospira
LUDROCORTISONE ACETATE			
← Tab 100 mcg		100	Florinef
YDROCORTISONE			• • • • • • • • • • • • • • • • • • • •
Tab 5 mg	9 10	100	✓ Douglas
Tab 20 mg – For hydrocortisone oral liquid formulation refer,		100	Ubugias
page 189	20 32	100	✓ Douglas
⊱ Inj 50 mg per ml, 2 ml		1	✓ Solu-Cortef
a) Up to 5 inj available on a PSO b) Only on a PSO		·	
IETHYLPREDNISOLONE – Retail pharmacy-Specialist			
← Tab 4 mg		100	✓ Medrol
Tab 100 mg		20	Medrol
ETHYLPREDNISOLONE ACETATE			
Inj 40 mg per ml, 1 ml	6 70	1	Depo-Medrol
3 01		·	bobo moutor
IETHYLPREDNISOLONE ACETATE WITH LIGNOCAINE	7.50	1	A Dama Madral with
Inj 40 mg per ml with lignocaine 1 ml		I	 <u>Depo-Medrol with</u> Lidocaine
	nov Spooialist		LINVUITE
IETHYLPREDNISOLONE SODIUM SUCCINATE – Retail pharm Inj 40 mg per ml, 1 ml		1	✓ Solu-Medrol
Inj 62.5 mg per ml, 2 ml		1	Solu-Medrol
Inj 500 mg		1	Solu-Medrol
Inj 1 g		1	Solu-Medrol
, ,			
 REDNISOLONE SODIUM PHOSPHATE Gral liq 5 mg per ml − Up to 30 ml available on a PSO Restricted to children under 12 years of age. 		30 ml OP	Redipred

(Subsidy Manufacturer's Price) \$	S Per	Fully ubsidised	Brand or Generic Manufacturer
PREDNISONE				
* Tab 1 mg	10.68	500	🖌 A	po-Prednisone
* Tab 2.5 mg		500		po-Prednisone
* Tab 5 mg – Up to 30 tab available on a PSO		500		po-Prednisone
* Tab 20 mg	29.03	500	V A	po-Prednisone
TETRACOSACTRIN				
* Inj 250 mcg	177.18	10	✓ <u>s</u>	ynacthen
k Inj 1 mg per ml, 1 ml	29.56	1	✓ <u>s</u>	ynacthen Depot
RIAMCINOLONE ACETONIDE				
Inj 10 mg per ml, 1 ml	21.90	5	🖌 К	enacort-A
lnj 40 mg per ml, 1 ml	53.79	5	K	enacort-A40
Sex Hormones Non Contraceptive				
Androgen Agonists and Antagonists				
CYPROTERONE ACETATE – Retail pharmacy-Specialist				
Tab 50 mg	18.80	50	✓ <u>s</u>	iterone
Tab 100 mg	34.25	50	✓ <u>s</u>	iterone
ESTOSTERONE				
Transdermal patch, 2.5 mg per day	80.00	60	V A	ndroderm
ESTOSTERONE CYPIONATE – Retail pharmacy-Specialist				
Inj long-acting 100 mg per ml, 10 ml	76 50	1		epo-Testosterone
			• •	
TESTOSTERONE ESTERS – Retail pharmacy-Specialist	10.00			
Inj 250 mg per ml, 1 ml	12.98	1	VS	ustanon Ampoules
TESTOSTERONE UNDECANOATE – Retail pharmacy-Specialist				
Cap 40 mg		60		ndriol Testocaps
Inj 250 mg per ml, 4 ml	86.00	1	✓ R	eandron 1000

Hormone Replacement Therapy - Systemic

➡SA1018 Special Authority for Alternate Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 years for applications meeting the following criteria: Any of the following:

- 1 acute or significant liver disease where oral oestrogens are contraindicated as determined by a gastroenterologist or general physician. The applicant must keep written confirmation from such a specialist with the patient's record; or
- 2 oestrogen induced hypertension requiring antihypertensive therapy documented evidence must be kept on file that raised blood pressure levels or inability to control blood pressure adequately occurred post oral oestrogens; or
- 3 hypertriglyceridaemia documented evidence must be kept on file that triglyceride levels increased to at least $2 \times$ normal triglyceride levels post oral oestrogens; or
- 4 Somatropin co-therapy patient is being prescribed somatropin with subsidy provided under a valid approval issued under Special Authority.

Note: Prescriptions with a valid Special Authority (CHEM) number will be reimbursed at the level of the lowest priced TDDS product within the specified dose group.

Renewal from any relevant practitioner. Approvals valid for 5 years where the treatment remains appropriate and the patient is benefiting from treatment, or the patient remains on subsidised somatropin co-therapy.

Prescribing Guideline

HRT should be taken at the lowest dose for the shortest period of time necessary to control symptoms. Patients should be reviewed 6 monthly in line with the updated NZGG "Evidence-based Best Practice Guideline on Hormone Replacement Therapy March 2004".

	Subsidy (Manufacturer's Pr \$	rice) Su Per	Fully Brand or bsidised Generic Manufacturer
Oestrogens			
DESTRADIOL – See prescribing guideline on the preceding page	ge		
₭ Tab 1 mg	4.12	28 OP	
	(10.55)		Estrofem
₭ Tab 2 mg	4.12	28 OP	
	(10.55)		Estrofem
* TDDS 25 mcg per day		8	
	(10.86)		Estradot
a) Higher subsidy of \$10.86 per 8 patch with Special Auth	ority see SA1018	on the prece	ding page
b) No more than 2 patch per week			
c) Only on a prescription	4.40		
TDDS 3.9 mg (releases 50 mcg of oestradiol per day)		4	Olimona 50
	(13.18)		Climara 50
a) Litch an archaide a f #40.40 man 4 match ar its Or a sial Arch	(32.50)		Femtran 50
a) Higher subsidy of \$13.18 per 4 patch with Special Auth	iority see SA1018	on the prece	aing page
b) No more than 1 patch per week			
c) Only on a prescription	4.10	8	
 TDDS 50 mcg per day 	(13.18)	0	Estradat 50 mag
a) Higher subsidy of \$12.10 per 9 petch with Presial Auth	(/	on the proce	Estradot 50 mcg
 a) Higher subsidy of \$13.18 per 8 patch with Special Auth b) No more than 2 patch per week 	ionly see SATUTO	on the prece	ung page
c) Only on a prescription			
 TDDS 7.8 mg (releases 100 mcg of oestradiol per day) 	7.05	4	
	(16.14)	-	Climara 100
	(35.00)		Femtran 100
a) Higher subsidy of \$16.14 per 4 patch with Special Auth	(/	on the prece	
b) No more than 1 patch per week	,		
c) Only on a prescription			
 TDDS 100 mcg per day 	7.05	8	
	(16.14)		Estradot
a) Higher subsidy of \$16.14 per 8 patch with Special Auth	· /	on the prece	ding page
b) No more than 2 patch per week	,		31.31
c) Only on a prescription			
DESTRADIOL VALERATE - See prescribing guideline on the p	receding page		
 Tab 1 mg 	010	56	Progynova
₭ Tab 2 mg		56	Progynova
			3,
DESTROGENS – See prescribing guideline on the preceding pre- Conjugated, equine tab 300 mcg		28	
Conjugated, equine tab 300 mcg		20	Premarin
Conjugated, equine tab 625 mcg	(11.48)	28	Fieliidiiii
· Oonjugated, equine lab 020 meg	(11.48)	20	Premarin
-	(11.40)		
Progestogens			
IEDROXYPROGESTERONE ACETATE - See prescribing guid	leline on the prece	ding page	
K Tab 2.5 mg		30	Provera
k Tab 5 mg		100	Provera
₭ Tab 10 mg		30	Provera

	Subsidy (Manufacturer's Price \$	e) Per	Fully Brand or Subsidised Generic Manufacturer
Progestogen and Oestrogen Combined Prepara		rei	V Ivianulaciunen
Frogestogen and Destrogen Combined Frepara	lions		
OESTRADIOL WITH NORETHISTERONE – See prescribing gu * Tab 1 mg with 0.5 mg norethisterone acetate		28 OP	Kliovance
* Tab 2 mg with 1 mg norethisterone acetate		28 OP	
* Tab 2 mg with 1 mg norethisterone acetate (10), and 2 mg oestradiol tab (12) and 1 mg oestradiol tab (6)		28 OP	Trisequens
DESTROGENS WITH MEDROXYPROGESTERONE - See pres	00	n page 8	33
* Tab 625 mcg conjugated equine with 2.5 mg medroxyproges- terone acetate tab (28)		28 OP	Premia 2.5 Continuous
* Tab 625 mcg conjugated equine with 5 mg medroxyprogesterone acetate tab (28)		28 OP	Premia 5 Continuous
Other Oestrogen Preparations			
ETHINYLOESTRADIOL			
* Tab 10 mcg	17.60	100	✓ <u>NZ Medical and</u> <u>Scientific</u>
OESTRIOL * Tab 2 mg	7.00	30	✓ Ovestin
Other Progestogen Preparations			
LEVONORGESTREL			
 Levonorgestrel - releasing intrauterine system 20 mcg/24 hr - Special Authority see SA0782 below – Retail pharmacy 		1	 Mirena
⇒SA0782 Special Authority for Subsidy Initial application — (No previous use) only from a relevant s applications meeting the following criteria: All of the following:		practitic	oner. Approvals valid for 6 months f
 The patient has a clinical diagnosis of heavy menstrual ble The patient has failed to respond to or is unable to tolera Menstrual Bleeding Guidelines; and Either: 	ate other appropriate	e pharm	naceutical therapies as per the Hear
3.1 serum ferritin level < 16 mcg/l (within the last 12 m	onths); or		

3.2 haemoglobin level < 120 g/l.

Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria.

Initial application — (Previous use before 1 October 2002) only from a relevant specialist or general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The patient had a clinical diagnosis of heavy menstrual bleeding; and
- 2 Patient demonstrated clinical improvement of heavy menstrual bleeding; and
- 3 Applicant to state date of the previous insertion.

Note: Applications are not to be made for use in patients as contraception except where they meet the above criteria.

continued...

	Subsidy (Manufacturer's Price \$	e) (Per	Fully Subsidised	Brand or Generic Manufacturer
continued				
Renewal only from a relevant specialist or general practitioner. A	pprovals valid for 6	months	for applicat	ions meeting the following
criteria:				
Both: 1 Either:				
1.1 Patient demonstrated clinical improvement of heavy	monstrual blooding	or		
1.2 Previous insertion was removed or expelled within 3	0	,		
2 Applicant to state date of the previous insertion.		, and		
MEDROXYPROGESTERONE ACETATE				
* Tab 100 mg - Retail pharmacy-Specialist		100	🖌 Pi	rovera
* Tab 200 mg - Retail pharmacy-Specialist		30		rovera
NORETHISTERONE				
* Tab 5 mg – Up to 30 tab available on a PSO		100	🖌 Pi	rimolut N
Thyroid and Antithyroid Agents			-	
Thyroid and Antitinyroid Agents				
CARBIMAZOLE				
* Tab 5 mg	10.80	100	V N	eo-Mercazole
LEVOTHYROXINE				
* Tab 25 mcg		90	🖌 S	ynthroid
	43.24	1,000	🖌 S	ynthroid
‡ Safety cap for extemporaneously compounded oral liquid				
* Tab 50 mcg		28		ercury Pharma
	4.05 45.00	90		ynthroid ynthroid
	45.00 64.28	1,000		Itroxin
± Safety cap for extemporaneously compounded oral liquid			· Li	
* Tab 100 mcg		28	🖌 M	ercury Pharma
	4.21	90		ynthroid
	66.78	1,000	🖌 E	Itroxin
‡ Safety cap for extemporaneously compounded oral liquid	d preparations.			
PROPYLTHIOURACIL - Special Authority see SA1199 below - F	Retail pharmacy			
Tab 50 mg	35.00	100	🖌 P.	TU S29

SA1199 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

1 The patient has hyperthyroidism; and

2 The patient is intolerant of carbimazole or carbimazole is contraindicated.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefitting from the treatment.

Trophic Hormones

Growth Hormones

➡SA1279 Special Authority for Subsidy

Special Authority approved by the Growth Hormone Committee

Notes: Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

NZGHC Coordinator

PHARMAC, PO Box 10-254, WELLINGTON

Tel: 0800 808 476, Fax: (09) 929 3221, Email: growthhormone@pharmac.govt.nz

	Subsidy	.) Cut	Fully Brand or
	(Manufacturer's Price \$	Per Suc	sidised Generic Manufacturer
SOMATROPIN – Special Authority see SA1279 on the preced	ing page		
* Inj cartridge 16 iu (5.3 mg)		1	✓ Genotropin
* Inj cartridge 36 iu (12 mg)		1	Genotropin
GnRH Analogues			<u> </u>
GOSERELIN ACETATE			
Inj 3.6 mg	166.20	1	✓ Zoladex
Inj 10.8 mg		1	✓ Zoladex
Inj 3.75 mg	221.60	1	Lucrin Depot
Inj 3.75 mg prefilled syringe		1	✓ Lucrin Depot PDS
Inj 7.5 mg		1	 Eligard
lnj 11.25 mg		1	 Lucrin Depot
Inj 11.25 mg prefilled syringe		1	Lucrin Depot PDS
Inj 22.5 mg		1	Eligard
Inj 30 mg		1	 Eligard
Inj 30 mg prefilled syringe	1,109.40	1	Lucrin Depot PDS
Inj 45 mg		1	 Eligard
Vasopressin Agonists			
DESMOPRESSIN			
Nasal drops 100 mcg per ml – Retail pharmacy-Specialist	39.03 2	.5 ml OP	✓ Minirin
 Nasal spray 10 mcg per dose – Retail pharmacy-Specialis 		6 ml OP	✓ Desmopressin-
		• • • • •	PH&T
Inj 4 mcg per ml, 1 ml – Special Authority see SA0090 bel	OW		
 Retail pharmacy 	67.18	10	🖌 Minirin
Retail pharmacy SA0090 Special Authority for Subsidy	67.18	10	🖌 Minirin
SA0090 Special Authority for Subsidy			
SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals			
SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals spray or nasal drops.	valid for 2 years where	the patien	t cannot use desmopressin nasa
⇒SA0090 Special Authority for Subsidy nitial application only from a relevant specialist. Approvals spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2	valid for 2 years where	the patien	t cannot use desmopressin nasa
►SA0090 Special Authority for Subsidy nitial application only from a relevant specialist. Approvals spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment.	valid for 2 years where	the patien	t cannot use desmopressin nasa
⇒SA0090 Special Authority for Subsidy nitial application only from a relevant specialist. Approvals spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2	valid for 2 years where	the patien	t cannot use desmopressin nasa
⇒SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment. Other Endocrine Agents	valid for 2 years where	the patien	t cannot use desmopressin nasa
 SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment. Other Endocrine Agents 	valid for 2 years where 2 years where the treat	the patien	t cannot use desmopressin nasa
 SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment. Other Endocrine Agents CABERGOLINE 	valid for 2 years where 2 years where the treat be	the patien	t cannot use desmopressin nasa
⇒SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment. Other Endocrine Agents CABERGOLINE Tab 0.5 mg – Maximum of 2 tab per prescription; can	valid for 2 years where 2 years where the treat be	e the patien	t cannot use desmopressin nasa
 →SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment. Other Endocrine Agents CABERGOLINE Tab 0.5 mg – Maximum of 2 tab per prescription; can waived by Special Authority see SA1031 below 	valid for 2 years where 2 years where the treat be 	e the patien tment rema	t cannot use desmopressin nasa ins appropriate and the patient i
 ▶SA0090 Special Authority for Subsidy nitial application only from a relevant specialist. Approvals spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment. Other Endocrine Agents CABERGOLINE Tab 0.5 mg – Maximum of 2 tab per prescription; can waived by Special Authority see SA1031 below ▶SA1031 Special Authority for Waiver of Rule 	valid for 2 years where 2 years where the treat be 6.25 25.00	e the patien tment rema 2 8	t cannot use desmopressin nasa ins appropriate and the patient i <u>Dostinex</u> <u>Dostinex</u>
 →SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment. Other Endocrine Agents CABERGOLINE 	valid for 2 years where 2 years where the treat be 6.25 25.00 or gynaecologist. Ap	e the patien tment rema 2 8	t cannot use desmopressin nasa ins appropriate and the patient i <u>Dostinex</u> <u>Dostinex</u>
 ▶SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment. Other Endocrine Agents CABERGOLINE 	valid for 2 years where 2 years where the treat be 6.25 25.00 or gynaecologist. Ap ologist. Approvals valid	2 2 8 provals val without fur	t cannot use desmopressin nasa ins appropriate and the patient i <u>Dostinex</u> <u>Dostinex</u> id without further renewal unles ther renewal unless notified wher
 ⇒SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment. Other Endocrine Agents CABERGOLINE 	valid for 2 years where 2 years where the treat be 6.25 25.00 or gynaecologist. Ap ologist. Approvals valid	2 2 8 provals val without fur	t cannot use desmopressin nasa ins appropriate and the patient i <u>Dostinex</u> <u>Dostinex</u> id without further renewal unles ther renewal unless notified wher
 ▶SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment. Other Endocrine Agents CABERGOLINE Tab 0.5 mg - Maximum of 2 tab per prescription; can waived by Special Authority see SA1031 below ▶SA1031 Special Authority for Waiver of Rule Initial application only from an obstetrician, endocrinologist notified where the patient has pathological hyperprolactinemia. Renewal only from an obstetrician, endocrinologist or gynaeco the patient has previously held a valid Special Authority which is benefiting from treatment. 	valid for 2 years where 2 years where the treat be 6.25 25.00 or gynaecologist. Ap ologist. Approvals valid	2 2 8 provals val without fur	t cannot use desmopressin nasa ins appropriate and the patient i <u>Dostinex</u> <u>Dostinex</u> id without further renewal unles ther renewal unless notified wher
 SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment. Other Endocrine Agents CABERGOLINE Tab 0.5 mg – Maximum of 2 tab per prescription; can waived by Special Authority see SA1031 below SA1031 Special Authority for Waiver of Rule Initial application only from an obstetrician, endocrinologist notified where the patient has pathological hyperprolactinemia. Renewal only from an obstetrician, endocrinologist or gynaeco the patient has previously held a valid Special Authority which is benefiting from treatment. CLOMIPHENE CITRATE 	valid for 2 years where 2 years where the treat be 6.25 25.00 or gynaecologist. Ap plogist. Approvals valid has expired and the tr	2 2 8 provals val without furf eatment re	t cannot use desmopressin nasa ins appropriate and the patient i <u>Dostinex</u> <u>Dostinex</u> id without further renewal unles ther renewal unless notified wher mains appropriate and the patier
 SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment. Other Endocrine Agents CABERGOLINE Tab 0.5 mg – Maximum of 2 tab per prescription; can waived by Special Authority see SA1031 below SA1031 Special Authority for Waiver of Rule Initial application only from an obstetrician, endocrinologist notified where the patient has pathological hyperprolactinemia. Renewal only from an obstetrician, endocrinologist or gynaecc the patient has previously held a valid Special Authority which is benefiting from treatment. CLOMIPHENE CITRATE Tab 50 mg 	valid for 2 years where 2 years where the treat be 6.25 25.00 or gynaecologist. Ap plogist. Approvals valid has expired and the tr	2 2 8 provals val without fur	t cannot use desmopressin nasa ins appropriate and the patient i <u>Dostinex</u> <u>Dostinex</u> id without further renewal unles ther renewal unless notified wher
 SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment. Other Endocrine Agents CABERGOLINE Tab 0.5 mg – Maximum of 2 tab per prescription; can waived by Special Authority see SA1031 below SA1031 Special Authority for Waiver of Rule Initial application only from an obstetrician, endocrinologist notified where the patient has pathological hyperprolactinemia. Renewal only from an obstetrician, endocrinologist or gynaecc the patient has previously held a valid Special Authority which is benefiting from treatment. CLOMIPHENE CITRATE Tab 50 mg DANAZOL – Retail pharmacy-Specialist 	valid for 2 years where 2 years where the treat be 	2 8 provals val without furf eatment re	t cannot use desmopressin nasa ins appropriate and the patient i <u>Dostinex</u> <u>Dostinex</u> id without further renewal unles ther renewal unless notified wher mains appropriate and the patier <u>Serophene</u>
 ▶SA0090 Special Authority for Subsidy Initial application only from a relevant specialist. Approvals spray or nasal drops. Renewal only from a relevant specialist. Approvals valid for 2 benefiting from treatment. Other Endocrine Agents CABERGOLINE Tab 0.5 mg – Maximum of 2 tab per prescription; can waived by Special Authority see SA1031 below ▶SA1031 Special Authority for Waiver of Rule Initial application only from an obstetrician, endocrinologist notified where the patient has pathological hyperprolactinemia. Renewal only from an obstetrician, endocrinologist outified where the patient has pathological Authority which is benefiting from treatment. CLOMIPHENE CITRATE 	valid for 2 years where 2 years where the treat be 6.25 25.00 or gynaecologist. Ap ologist. Approvals valid has expired and the tr 29.84 	2 2 8 provals val without furf eatment re	t cannot use desmopressin nasa ins appropriate and the patient i <u>Dostinex</u> <u>Dostinex</u> id without further renewal unles ther renewal unless notified wher mains appropriate and the patier

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
METYRAPONE Cap 250 mg – Retail pharmacy-Specialist		50	✓ M	etopirone

	Subsidy		Fully Brand or
	(Manufacturer's P		bsidised Generic
	\$	Per	 Manufacturer
Anthelmintics			
ALBENDAZOLE – Special Authority see SA1318 below – Ret Tab 400 mg		60	Eskazole S29
►SA1318 Special Authority for Subsidy			
Initial application only from an infectious disease specialist patient has hydatids.	or clinical microbio	logist. Appro	vals valid for 6 months where the
Renewal only from an infectious disease specialist or clinical remains appropriate and the patient is benefitting from the treat		provals valid	for 6 months where the treatment
MEBENDAZOLE – Only on a prescription			4
Tab 100 mg		24	✓ <u>De-Worm</u>
Oral liq 100 mg per 5 ml	2.18 (7.17)	15 ml	Vermox
	(7.17)		Vermox
PRAZIQUANTEL Tab 600 mg		8	V Biltricide
Antibacterials		-	
a) For topical antibacterials, refer to DERMATOLOGICALS, pa			
b) For anti-infective eye preparations, refer to SENSORY ORG	ANS, page 183		
Cephalosporins and Cephamycins			
CEFACLOR MONOHYDRATE			
Cap 250 mg		100	Ranbaxy-Cefaclor
Grans for oral liq 125 mg per 5 ml	3.53	100 ml	Ranbaxy-Cefaclor
CEFAZOLIN SODIUM – Subsidy by endorsement	4h		undin all s
Only if prescribed for dialysis or cystic fibrosis patient and Inj 500 mg		5	✓ AFT
Inj 500 mg		5	✓ AFT
CEFOXITIN SODIUM – Retail pharmacy-Specialist – Subsidy			
Only if prescribed for dialysis or cystic fibrosis patient and		ndorsed acco	rdingly.
Inj 1 g		5	🖌 Mayne
(Mayne Inj 1 g to be delisted 1 October 2013)			
CEFTRIAXONE SODIUM – Subsidy by endorsement			
a) Up to 5 inj available on a PSO			
 b) Subsidised only if prescribed for a dialysis or cystic fi gonorrhoea, or the treatment of suspected meningitis in pa PSO is endorsed accordingly. 			
Inj 500 mg	2.70	1	Veracol
lnj 1 g		5	✓ <u>Aspen Ceftriaxone</u>
CEFUROXIME AXETIL – Subsidy by endorsement			
Only if prescribed for prophylaxis of endocarditis and the	prescription is endors	sed according	ıly.
Tab 250 mg		50	 Zinnat

	Subsidy		Fully	/ Brand or
	(Manufacturer's Price		Subsidised	d Generic
	\$	Per	~	Manufacturer
CEFUROXIME SODIUM				
Inj 250 mg - Maximum of 3 inj per prescription; can be				
waived by endorsement		10		Mayne
Waiver by endorsement must state that the prescription is f Inj 750 mg – Maximum of 1 inj per prescription; can be waived	or dialysis or cystic	tibrosis	patient.	
by endorsement	6.96	5	~	m-Cefuroxime
Waiver by endorsement must state that the prescription is f				
Inj 1.5 g - Retail pharmacy-Specialist - Subsidy by endorse-	· · · · · · · · · · · · · · · · · · ·			
ment		1		Mylan
	4.04			Zinacef
Only if prescribed for dialysis or cystic fibrosis patient and t (Mayne Inj 250 mg to be delisted 1 October 2013) (Mylan Inj 1.5 g to be delisted 1 October 2013) (Zinacef Inj 1.5 g to be delisted 1 October 2013)	he prescription is e	ndorsed	accordin	gly.
CEPHALEXIN MONOHYDRATE	8 00	20		Cephalexin ABM
Cap 500 mg Grans for oral lig 125 mg per 5 ml		20 100 ml		Cefalexin Sandoz
Grans for oral lig 250 mg per 5 ml		100 ml		Cefalexin Sandoz
Macrolides				
For Endorsement, patient has either: 1) Received a lung transplant and requires treatment or proph 2) Cystic fibrosis and has chronic infection with Pseudomonas Indications parked with * are Unapproved Indications Tab 250 mg Tab 500 mg – Up to 8 tab available on a PSO Grans for oral liq 200 mg per 5 ml	aeruginosa or Pseu 		as related	
CLARITHROMYCIN - Maximum of 500 mg per prescription; can	be waived by Speci	al Autho	ority see S	SA1131 below
Tab 250 mg		14		Apo-Clarithromycin
Grans for oral liq 125 mg per 5 ml		70 ml	V	Klacid
 SA1131 Special Authority for Waiver of Rule Initial application — (Mycobacterial infections) only from a rest Approvals valid for 2 years for applications meeting the following cl Either: Atypical mycobacterial infection; or Mycobacterium tuberculosis infection where there is drug-rest Renewal — (Mycobacterial infections) only from a respiratory spiratory spiratory	riteria: esistance or intolera	ince to s	standard	pharmaceutical agents.
valid for 2 years where the treatment remains appropriate and the ERYTHROMYCIN ETHYL SUCCINATE				tor paediatrician. Approvais
Tab 400 mg – Up to 30 tab available on a PSO Grans for oral lig 200 mg per 5 ml – Up to 200 ml available	16.95	100	V	E-Mycin
on a PSO	4.35	100 ml	~	E-Mycin
Grans for oral liq 400 mg per 5 ml – Up to 200 ml available on a PSO	5.85	100 ml	~	E-Mycin
ERYTHROMYCIN LACTOBIONATE				
Inj 1 g		1	~	Erythrocin IV

	Subsidy		Fully Brand or
	(Manufacturer's) \$	Price) Sul Per	bsidised Generic Manufacturer
ERYTHROMYCIN STEARATE			
Tab 250 mg – Up to 30 tab available on a PSO	14.95	100	
	(22.29)		ERA
Tab 500 mg	29.90	100	
	(44.58)		ERA
ROXITHROMYCIN			
Tab 150 mg	7.48	50	Arrow-
Tab 000 mm	44.40	50	Roxithromycin
Tab 300 mg	14.40	50	Arrow- Roxithromycin
Penicillins			Nonthioniyein
AMOXYCILLIN	10.10	F00	Alabamar
Cap 250 mg – Up to 30 cap available on a PSO		500 500	 <u>Alphamox</u> <u>Alphamox</u>
Cap 500 mg Grans for oral liq 125 mg per 5 ml – Up to 200 ml available		500	
on a PSO		100 ml	Ospamox
Grans for oral liq 250 mg per 5 ml – Up to 200 ml available		100 111	• oopamox
on a PSO		100 ml	Ospamox
Drops 125 mg per 1.25 ml		30 ml OP	 Ospamox Paediatric
			Drops
Inj 250 mg		10	✓ <u>Ibiamox</u>
Inj 500 mg		10	✓ <u>Ibiamox</u>
Inj 1 g – Up to 5 inj available on a PSO	21.94	10	✓ <u>Ibiamox</u>
AMOXYCILLIN CLAVULANATE			
Tab amoxycillin 500 mg with potassium clavulanate 125 mg		400	
- Up to 30 tab available on a PSO		100	Curam Duo
Grans for oral liq amoxycillin 125 mg with potassium clavu- lanate 31.25 mg per 5 ml – Up to 200 ml available on a			
PSO		100 ml	Augmentin
Grans for oral lig amoxycillin 250 mg with potassium clavu-			<u></u>
lanate 62.5 mg per 5 ml – Up to 200 ml available on a			
PSO	2.19	100 ml	Augmentin
BENZATHINE BENZYLPENICILLIN			
Inj 1.2 mega u per 2.3 ml – Up to 5 inj available on a PSO	315.00	10	✓ Bicillin LA
BENZYLPENICILLIN SODIUM (PENICILLIN G)			
Inj 600 mg – Up to 5 inj available on a PSO	11.50	10	✓ Sandoz
FLUCLOXACILLIN SODIUM			
Cap 250 mg – Up to 30 cap available on a PSO	22.00	250	✓ <u>Staphlex</u>
Cap 500 mg		500	✓ <u>Staphlex</u>
Grans for oral liq 125 mg per 5 ml – Up to 200 ml available			4 ·
on a PSO	2.49	100 ml	✓ <u>AFT</u>
Grans for oral liq 250 mg per 5 ml – Up to 200 ml available			✓ <u>AFT</u>
on a PSO		100 ml	🗸 AFT
	0.20	100 111	✓ AFT
Inj 250 mg		10	✓ Flucloxin
Inj 500 mg		10	✓ Flucloxin
Inj 1 g – Up to 5 inj available on a PSO	14.28	10	✓ <u>Flucloxin</u>

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist.

‡ safety cap *Three months or six months, as applicable, dispensed all-at-once

	Subsidy (Manufacturer's Price \$) Per	Fully Subsidised	Generic
PENICILLIN G BENZATHINE [BENZATHINE BENZYLPENICILLIN Inj 1.2 mega u per 2 ml – Up to 5 inj available on a PSO		10	🗸 I	Bicillin LA
PHENOXYMETHYLPENICILLIN (PENICILLIN V) Cap potassium salt 250 mg – Up to 30 cap available on a PS Cap potassium salt 500 mg Grans for oral liq 125 mg per 5 ml – Up to 200 ml available	11.70	50 50	✓ (<u>Cilicaine VK</u> Cilicaine VK
on a PSO Grans for oral liq 250 mg per 5 ml – Up to 200 ml available on a PSO		100 ml 100 ml	-	
PROCAINE PENICILLIN Inj 1.5 mega u – Up to 5 inj available on a PSO	123.50	5	v <u>(</u>	<u>Cilicaine</u>
Tetracyclines				
DOXYCYCLINE HYDROCHLORIDE * Tab 50 mg – Up to 30 tab available on a PSO	2.90 (6.00)	30	[Doxy-50
* Tab 100 mg – Up to 30 tab available on a PSO	7.95	250	✓ [Doxine
MINOCYCLINE HYDROCHLORIDE * Tab 50 mg	5.79 (12.05)	60	1	Vino-tabs
* Cap 100 mg	()	100		Minomycin
TETRACYCLINE – Special Authority see SA1332 below – Retail Cap 500 mg		30	•	Fetracyclin Wolff S29

SA1332 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 For the eradication of helicobacter pylori following unsuccessful treatment with appropriate first-line therapy; and
- 2 For use only in combination with bismuth as part of a quadruple therapy regimen.

Other Antibiotics

For topical antibiotics, refer to DERMATOLOGICALS, page 65

CIPROFLOXACIN

Recommended for patients with any of the following:

i) microbiologically confirmed and clinically significant pseudomonas infection; or

- ii) prostatitis; or
- iii) pyelonephritis; or

iv) gonorrhoea.

Tab 250 mg – Up to 5 tab available on a PSO	2.20	28	✓ Cipflox
Tab 500 mg – Up to 5 tab available on a PSO		28	✓ Cipflox
	10.71	100	✓ Cipflox
Tab 750 mg	5.15	28	✓ Cipflox
-	5.52	30	 Ciprofloxacin Rex

	Subsidy		Fully Brand or
	(Manufacturer's Price \$	e) Sul Per	bsidised Generic Manufacturer
	φ	rei	
CLINDAMYCIN			
Cap hydrochloride 150 mg – Maximum of 4 cap per prescrip- tion; can be waived by endorsement - Retail pharmacy -			
Specialist		16	Clindamycin ABM
Inj phosphate 150 mg per ml, 4 ml – Retail pharmacy-			<u>• • • • • • • • • • • • • • • • • • • </u>
Specialist		10	Dalacin C
CO-TRIMOXAZOLE			
* Tab trimethoprim 80 mg and sulphamethoxazole 400 mg -			
Up to 30 tab available on a PSO		500	🖌 Trisul
* Oral liq trimethoprim 40 mg and sulphamethoxazole 200 mg			
per 5 ml – Up to 200 ml available on a PSO		100 ml	 Deprim
COLISTIN SULPHOMETHATE - Retail pharmacy-Specialist - S	ubsidy by endorsem	nent	
Only if prescribed for dialysis or cystic fibrosis patient and the			
Inj 150 mg	65.00	1	Colistin-Link
FUSIDIC ACID			
Tab 250 mg - Retail pharmacy-Specialist		12	✓ Fucidin
Prescriptions must be written by, or on the recommendation		lisease phy	vsician or a clinical microbiologist
Inj 500 mg sodium fusidate per 10 ml – Retail pharmacy- Specialist – Subsidy by endorsement		1	
	(17.80)	'	Fucidin
Only if prescribed for a dialysis or cystic fibrosis patient an	()	endorsed	
(Fucidin Inj 500 mg sodium fusidate per 10 ml to be delisted 1 Oc			0,
GENTAMICIN SULPHATE			
Inj 10 mg per ml, 1 ml – Subsidy by endorsement	8.56	5	Mayne
Only if prescribed for a dialysis or cystic fibrosis patient o	r for prophylaxis of	endocarditi	s and the prescription is endorsed
accordingly.	175.10		(
Inj 10 mg per ml, 2 ml – Subsidy by endorsement	1/5.10	25	✓ APP Pharmaceuticals (\$29)
Only if prescribed for a dialysis or cystic fibrosis patient o	r for prophylaxis of	ondocarditi	
accordingly.	i loi propriyiaxis or	chuocarum	
Inj 40 mg per ml, 2 ml – Subsidy by endorsement	6.50	10	✓ Pfizer
Only if prescribed for a dialysis or cystic fibrosis patient o	r for prophylaxis of	endocarditi	s and the prescription is endorsed
accordingly.			
LINCOMYCIN – Retail pharmacy-Specialist			
Prescriptions must be written by, or on the recommendation of			0
Inj 300 mg per ml, 2 ml		5	 Lincocin
MOXIFLOXACIN - Special Authority see SA1065 below - Retail	pharmacy		
No patient co-payment payable	50.00	-	
Tab 400 mg		5	Avelox
■SA1065 Special Authority for Subsidy			
Initial application only from a respiratory specialist or infectiou	s disease specialis	t. Approva	Is valid for 1 year for applications
meeting the following criteria:			
Either: 1 Both:			
1.1 Active tuberculosis*; and			
1.2 Any of the following:			
1.2.1 Documented resistance to one or more first-	line medications; or		
			continued

continued...

(Subsidy Manufacturer's Price) \$	Sub Per	Fully sidised	Brand or Generic Manufacturer
continued				
1.2.2 Suspected resistance to one or more first-line r	nedications (tubero	ulosis ass	umed to	be contracted in an area
with known resistance), as part of regimen cont	taining other secon	d-line age	nts; or	
1.2.3 Impaired visual acuity (considered to preclude				
1.2.4 Significant pre-existing liver disease or hepatote				
1.2.5 Significant documented intolerance and/or side				
2 Mycobacterium avium-intracellulare complex not responding				
Note: Indications marked with * are Unapproved Indications (refer t	o Section A: Gene	ral Hules,	Part I (I	interpretations and Defini-
tions) and Part IV (Miscellaneous Provisions) rule 4.6).	aialiat Approvala	rolid for 1 y	oor wh	are the treatment remaine
Renewal only from a respiratory specialist or infectious disease spe appropriate and the patient is benefiting from treatment.	cialist. Approvais v		ear wii	
PAROMOMYCIN - Special Authority see SA1324 below - Retail ph	armacy			
Cap 250 mg	126.00	16	🖌 Hi	umatin S29
SA1324 Special Authority for Subsidy				
Initial application only from an infectious disease specialist or clinic	al microbiologist. A	opprovals v	alid for	1 month where the patient
has confirmed cryptosporidium infection.				
Renewal only from an infectious disease specialist or clinical micro	obiologist. Approv	als valid fo	or 1 moi	nth where the patient has
confirmed cryptosporidium infection.				
PYRIMETHAMINE - Special Authority see SA1328 below - Retail	oharmacy			
Tab 25 mg SA1328 Special Authority for Subsidy	26.14	30	🖌 Da	araprim S29
Initial application from any relevant practitioner. Approvals valid w the following criteria: All of the following: 1 For the treatment of toxoplasmosis in patients with HIV for a 2 For pregnant patients for the term of the pregnancy; and 3 For infants with congenital toxoplasmosis until 12 months of a	period of 3 months		s notifie	d for applications meeting
SULFADIAZINE SODIUM – Special Authority see SA1331 below –	•			
Tab 500 mg		56	✓ W	ockhardt S29
		50	• 11	OCKIIdi di 029
 SA1331 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid w the following criteria: Any of the following: For the treatment of toxoplasmosis in patients with HIV for a patients. 			s notifie	d for applications meeting
2 For pregnant patients for the term of the pregnancy; or				
3 For infants with congenital toxoplasmosis until 12 months of a	age.			
TOBRAMYCIN		_		
Inj 40 mg per ml, 2 ml – Subsidy by endorsement Only if prescribed for dialysis or cystic fibrosis patient and the		5 dorsed acc		BL Tobramycin ^{y.}
TRIMETHOPRIM				
* Tab 300 mg – Up to 30 tab available on a PSO	9.28	50	V TI	MP
VANCOMYCIN HYDROCHLORIDE – Subsidy by endorsement				
Only if prescribed for a dialysis or cystic fibrosis patient or in th endocarditis and the prescription is endorsed accordingly.	e treatment of pse	udomembr	anous (colitis or for prophylaxis of
Inj 500 mg	3.58	1	🖌 M	ylan

	0 1 1		F 11	
	Subsidy (Manufacturer's Price	e) Sub	Fully sidised	Brand or Generic
	\$	Per	V	Manufacturer
Antifungals				
a) For topical antifungals refer to DERMATOLOGICALS, page 65				
b) For topical antifungals refer to GENITO URINARY, page 79				
FLUCONAZOLE				
Cap 50 mg – Retail pharmacy-Specialist	4.77	28	✓ <u>0</u>	zole
Cap 150 mg – Subsidy by endorsement		1	✓ <u>0</u> :	
 a) Maximum of 1 cap per prescription; can be waived by e b) Patient has vaginal candida albicans and the practition 				
recommended and the prescription is endorsed according			· ·	0, 1,
Cap 200 mg – Retail pharmacy-Specialist		28	V <u>0</u>	
Powder for oral suspension 10 mg per ml - Special Authority				
see SA1148 below - Retail pharmacy		35 ml	🖌 Di	flucan
► SA1148 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid	for 6 weeks for ann	lications mo	otina th	e following criteria:
Both:	ioi o weeks ioi app			e ioliowing chiena.
1 Patient requires prophylaxis for, or treatment of systemic ca	andidiasis; and			
2 Patient is unable to swallow capsules.				
Renewal from any relevant practitioner. Approvals valid for 6 wee Both:	ks for applications r	neeting the	following	g criteria:
1 Patient requires prophylaxis for, or treatment of systemic ca	andidiasis: and			
2 Patient is unable to swallow capsules.				
ITRACONAZOLE				
Cap 100 mg – Subsidy by endorsement	4.25	15	✓ <u>Itr</u>	azole
Funded for tinea vesicolor where topical treatment has not				
or for tinea unguium where terbinafine has not been succ				
diagnosis has been confirmed by mycology and the presc Retail pharmacy - Specialist Specialist must be an infection				
or dermatologist.		n, onnioar m		
Oral liq 10 mg per ml – Special Authority see SA1322 below				
 Retail pharmacy 	141.80 1	50 ml OP	🖌 S	poranox
SA1322 Special Authority for Subsidy				
Initial application only from an infectious disease specialist, clinic	•		0	
on the recommendation of a infectious disease physician, clinic months where the patient has a congenital immune deficiency.	al microbiologist or	clinical imr	nunolog	list. Approvals valid for 6
Renewal from any relevant practitioner. Approvals valid for 6 mo	nths where the trea	atment rema	ins app	ropriate and the patient is
benefitting from the treatment.				
KETOCONAZOLE				
Tab 200 mg – Retail pharmacy-Specialist		30	🖌 Ni	
Prescriptions must be written by, or on the recommendated dermatologist, endocrinologist or oncologist	ation of, an infectio	us disease	physicia	an, clinical microbiologist,
NYSTATIN				
Tab 500,000 u		50	🖌 Ni	ilstat
Cap 500,000 u		50	V Ni	
POSACONAZOLE - Special Authority see SA1285 on the next p	age – Retail pharm	acy		
Oral liq 40 mg per ml		05 ml OP	🖌 No	oxafil

	Subsidy (Manufacturer's Price \$	e) Sul Per	Fully osidised	Brand or Generic Manufacturer
►>SA1285 Special Authority for Subsidy Initial application only from a haematologist or infectious disease the following criteria: Either:	e specialist. Approv	vals valid fo	r 6 week	s for applications meeting
 Patient has acute myeloid leukaemia and is to be treated v chemotherapy; or 	with high dose rem	ission indu	ction, re-	induction or consolidation
2 Patient has received a stem cell transplant and has graft therapy*.	versus host disea	ise and is	on signif	ficant immunosuppressive
Renewal only from a haematologist or infectious disease specia following criteria: Either:	alist. Approvals va	alid for 6 w	eeks for	applications meeting the
 Patient has acute myeloid leukaemia and is to be treated v therapy; or 	with high dose rem	ission indu	ction, re-	induction or consolidation
2 Patient has received a stem cell transplant and has graft ve requires on going posaconazole treatment.	rsus host disease a	and is on si	gnificant	immunosuppression* and
TERBINAFINE				
* Tab 250 mg - For terbinafine oral liquid formulation refer, page 189	1.78	14		<u>r Reddy's</u> Terbinafine
VORICONAZOLE - Special Authority see SA1273 below - Retail	nharmacy			Terpindinie
Tab 50 mg		56	🗸 Vi	fend
Tab 200 mg		56	🗸 Vi	
Powder for oral suspension 40 mg per ml	730.00	70 ml	🖌 Vi	fend
Initial application — (invasive fungal infection) only from a hate Approvals valid for 3 months for applications meeting the following All of the following: 1 Patient is immunocompromised; and 2 Applicant is part of a multidisciplinary team including an infe 3 Any of the following: 3.1 Patient has proven or probable invasive aspergillus i 3.2 Patient has proven or probable invasive aspergillus i 3.3 Patient has pluconazole resistant candidiasis; or 3.4 Patient has mould strain such as Fusarium spp. and Renewal — (invasive fungal infection) only from a haematolo	criteria: ectious disease spe nfection; or r Scedosporium spp	ecialist; and	l	
provals valid for 3 months for applications meeting the following or All of the following:		ease specia	alist of C	апісаї пісторіоюдія. Ар-
 Patient is immunocompromised; and Applicant is part of a multidisciplinary team including an info Any of the following: 	ectious disease spe	ecialist; and		
3.1 Patient continues to require treatment for proven or p3.2 Patient continues to require treatment for possible in				or
3.3 Patient has fluconazole resistant candidiasis; or				
3.4 Patient has mould strain such as Fusarium spp. and	Scedosporium sp).		
Antimalarials				
HYDROXYCHLOROQUINE				
* Tab 200 mg		100	✓ <u>PI</u>	laquenil
PRIMAQUINE PHOSPHATE – Special Authority see SA1326 on 1 Tab 7.5 mg		tail pharma 56		rimacin S29

		Subsidy		Fully Brand or
		(Manufacturer's Pric		Ibsidised Generic
		\$	Per	 Manufacturer
	326 Special Authority for Subsidy	aliniaal miarahialagia	+ Approvo	la valid for 1 month for applicatio
	pplication only from an infectious disease specialist or the following criteria:	clinical microbiologis	a. Approva	is valid for a month for application
Both:	the following offerta.			
	he patient has vivax or ovale malaria; and			
2 F	rimaquine is to be given for a maximum of 21 days.			
Antit	richomonal Agents			
METRO	NIDAZOLE			
	200 mg – Up to 30 tab available on a PSO	10.45	100	 Trichozole
	400 mg		100	 Trichozole
	I liq benzoate 200 mg per 5 ml		100 ml	FlagyI-S
Sup	ppos 500 mg	24.48	10	Flagyl
ORNIDA		10.50	10	Arrow-Ornidazole
	500 mg		10	Arrow-Ornidazole
Antit	uberculotics and Antileprotics			
	here is no co-payment charge for all pharmaceuticals li	isted in the Antituber	culotics an	d Antileprotics group regardless
	tion status.			
	ZIMINE – Retail pharmacy-Specialist			
	lo patient co-payment payable	allow of an infection		a han a fa fa an an Radia a fa an fa sa hafa ta a sha k
,	Prescriptions must be written by, or on the recommendation matologist.	ation of, an infectiou	s disease	pnysician, clinical microbiologist
	50 mg		100	✓ Lamprene S29
	SERINE – Retail pharmacy-Specialist			
	lo patient co-payment payable			
	Prescriptions must be written by, or on the recommend	ation of, an infectiou	s disease	physician, clinical microbiologist
	piratory physician.			
	250 mg	1,140.63	100	King S29
DAPSO	NE – Retail pharmacy-Specialist			
	lo patient co-payment payable			
	Prescriptions must be written by, or on the recommendation	ation of, an infectiou	s disease	physician, clinical microbiologist
	natologist 25 mg	95.00	100	Dapsone
	100 mg		100	✓ Dapsone
	BUTOL HYDROCHLORIDE – Retail pharmacy-Special			
	lo patient co-payment payable			
b) F	Prescriptions must be written by, or on the recommend	ation of, an infectiou	s disease	physician, clinical microbiologist
	piratory physician			
	100 mg		56	Myambutol S29
	400 mg		56	Myambutol S29
	ZID – Retail pharmacy-Specialist			
	lo patient co-payment payable Prescriptions must be written by, or on the recommendat	ion of an internal m	odioino obv	cicion poodiatricion aliniael mia
	ogist, dermatologist or public health physician	ion oi, an internal me	edicine phy	sician, paeulamcian, cimical mic
	100 mg		100	✔ PSM
* Tab	100 mg with rifampicin 150 mg 150 mg with rifampicin 300 mg	90.04	100	Rifinah

	Subsidy		Fully	Brand or
	(Manufacturer's Price \$) Sub Per	sidised ✓	Generic Manufacturer
PARA-AMINO SALICYLIC ACID – Retail pharmacy-Specialist				
 a) No patient co-payment payable b) Specialist must be an infectious disease specialist, clinica Grans for oral liq 4 g sachet 		spiratory sp 30		aser S29
PROTIONAMIDE – Retail pharmacy-Specialist				
 a) No patient co-payment payable b) Specialist must be an infectious disease specialist, clinica Tab 250 mg 		spiratory sp 100		eteha S29
PYRAZINAMIDE – Retail pharmacy-Specialist a) No patient co-payment payable b) Prescriptions must be written by, or on the recommenda	tion of, an infectious	disease pl	nysician	, clinical microbiologist or
 respiratory physician * Tab 500 mg – For pyrazinamide oral liquid formulation reference page 189 		100		FT-Pyrazinamide
RIFABUTIN – Retail pharmacy-Specialist		100	₩ A	FI-Fylazinannue
 a) No patient co-payment payable b) Prescriptions must be written by, or on the recommenda gastroenterologist * Cap 150 mg - For rifabutin oral liquid formulation refer, page 		s disease p	hysiciar	n, respiratory physician or
189		30	✓ <u>M</u>	ycobutin
 RIFAMPICIN – Subsidy by endorsement a) No patient co-payment payable b) For confirmed recurrent Staphylococcus aureus infection is based on susceptibilities and the prescription is endorsed Specialist. Specialist must be an internal medicine physici health physician. 	accordingly; can be	waived by	endorse	ment - Retail pharmacy -
* Tab 600 mg		30	🖌 Ri	
* Cap 150 mg		100 100	✓ Ri ✓ Ri	
* Cap 300 mg * Oral liq 100 mg per 5 ml		60 ml	✔ Ri	
Antivirals				
For eye preparations refer to Eye Preparations, Anti-Infective Pre	parations, page 183			
Hepatitis B Treatment				
ADEFOVIR DIPIVOXIL – Special Authority see SA0829 below – Tab 10 mg		30	V He	epsera
►SA0829 Special Authority for Subsidy Initial application only from a gastroenterologist or infectious dis the following criteria:	ease specialist. Appl	rovals valid	for 1 yea	ar for applications meeting
All of the following: 1 Patient has confirmed Hepatitis B infection (HBsAg+); and Documented resistance to lamivudine, defined as:	1			
 Patient has raised serum ALT (> 1 × ULN); and Patient has HBV DNA greater than 100,000 copies per ml Detection of M204I or M204V mutation; and 	L, or viral load $\geq 10^{\circ}$	fold over na	dir; and	
5 Either:				a anti-
				continued

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	

continued...

5.1 Both:

5.1.1 Patient is cirrhotic; and

5.1.2 adefovir dipivoxil to be used in combination with lamivudine; or

5.2 Both:

5.2.1 Patient is not cirrhotic; and

5.2.2 adefovir dipivoxil to be used as monotherapy.

Renewal only from a gastroenterologist or infectious disease specialist. Approvals valid for 2 years where in the opinion of the treating physician, treatment remains appropriate and patient is benefiting from treatment.

Notes: Lamivudine should be added to adefovir dipivoxil if a patient develops documented resistance to adefovir dipivoxil, defined as:

i) raised serum ALT (> 1 $\times\,$ ULN); and

ii) HBV DNA greater than 100,000 copies per mL, or viral load \geq 10 fold over nadir; and

iii) Detection of N236T or A181T/V mutation.

Adefovir dipivoxil should be stopped 6 months following HBeAg seroconversion for patients who were HBeAg+ prior to commencing adefovir dipivoxil.

The recommended dose of adefovir dipivoxil is no more than 10mg daily.

In patients with renal insufficiency adefovir dipivoxil dose should be reduced in accordance with the datasheet guidelines. Adefovir dipivoxil should be avoided in pregnant women and children.

ENTECAVIR - Special Authority see SA0977 below - Retail pharmacy

SA0977 Special Authority for Subsidy

Initial application only from a gastroenterologist or infectious disease specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B nucleoside analogue treatment-naive; and
- 3 Entecavir dose 0.5 mg/day; and
- 4 Either:
 - 4.1 ALT greater than upper limit of normal; or
 - 4.2 Bridging fibrosis or cirrhosis (Metavir stage 3 or greater) on liver histology; and

5 Either:

- 5.1 HBeAg positive; or
- 5.2 patient has ≥ 2,000 IU HBV DNA units per ml and fibrosis (Metavir stage 2 or greater) on liver histology; and

6 No continuing alcohol abuse or intravenous drug use; and

- 7 Not co-infected with HCV, HIV or HDV; and
- 8 Neither ALT nor AST greater than 10 times upper limit of normal; and
- 9 No history of hypersensitivity to entecavir; and
- 10 No previous documented lamivudine resistance (either clinical or genotypic).

Notes:

- Entecavir should be continued for 6 months following documentation of complete HBeAg seroconversion (defined as loss of HBeAg plus appearance of anti-HBe plus loss of serum HBV DNA) for patients who were HBeAg positive prior to commencing this agent. This period of consolidation therapy should be extended to 12 months in patients with advanced fibrosis (Metavir Stage F3 or F4).
- Entecavir should be taken on an empty stomach to improve absorption.

LAMIVUDINE - Special Authority see SA0832 on the next page - Retail pharmacy

Tab 100 mg	-	 32.50	28	Zetlam
Oral liq 5 mg per ml		 90.00	240 ml	 Zeffix

—	Subsidy	Fully	Brand or
	(Manufacturer's Price) \$	Subsidised Per 🖌	Generic Manufacturer
SA0832 Special Authority for Subsidy			
Initial application only from a gastroenterologist, infectious dis	ease specialist, paediat	rician or genera	l physician. Approvals valid
for 1 year for applications meeting the following criteria:		·	
Both:			
1 Any of the following:			
1.1 All of the following:			
1.1.1 HBsAg positive for more than 6 months; an			
1.1.2 HBeAg positive or HBV DNA positive defin	ed as $> 100,000$ copies	s per mi by quai	ntitative PCR at a reference
laboratory; and 1.1.3 ALT greater than twice upper limit of norma	or bridging fibrocic or c	virrhagig (Matavi	r stage 2 or 4 or equivalent)
on liver histology clinical/radiological evider	0 0	innosis (ivietavi	i stage 5 01 4 01 equivalent)
1.2 HBV DNA positive cirrhosis prior to liver transplan			
1.3 HBsAg positive and have had a liver, kidney, hear		ransplant: or	
1.4 Hepatitis B surface antigen positive (HbsAg) pati			a malignancy, or who has
received such treatment within the previous two m		15	0 ,
2 All of the following:			
2.1 No continuing alcohol abuse or intravenous drug u	se; and		
2.2 Not coinfected with HCV or HDV; and			
2.3 Neither ALT nor AST greater than 10 times upper	imit of normal; and		
2.4 No history of hypersensitivity to lamivudine; and			
2.5 No previous lamivudine therapy with genotypically			
Renewal only from a gastroenterologist, infectious disease spec	alist, paediatrician or ge	eneral physician	. Approvais valid for 2 years
for applications meeting the following criteria: Any of the following:			
Renewal for patients who have maintained continuous tre	atment and response to	o lamivudine	
1 All of the following:		5 Idinivadine	
1.1 Have maintained continuous treatment with lamive	dine; and		
1.2 Most recent test result shows continuing biochemi		LT); and	
1.3 HBV DNA <100,00 copies per ml by quantitative F	CR at a reference labor	ratory; or	
Renewal when given in combination with adefovir dipivox	I for patients with cirrho	sis and resistar	nce to lamivudine
2 All of the following:			
2.1 Lamivudine to be used in combination with adefov	ir dipivoxil; and		
2.2 Patient is cirrhotic; and			
Documented resistance to lamivudine, defined as:			
 2.3 Patient has raised serum ALT (> 1 × ULN); and 2.4 Patient has HBV DNA greater than 100,000 copie: 	por ml or viral load -	10 fold over pa	dir: and
2.5 Detection of M204I or M204V mutation; or	s per mi≥, or virarioau =		uii, allu
Renewal when given in combination with adefovir dipivox	I for patients with resist	ance to adefovi	r dinivoxil
3 All of the following:			diproxil
3.1 Lamivudine to be used in combination with adefor	ir dipivoxil; and		
Documented resistance to adefovir, defined as:	•		
3.2 Patient has raised serum ALT (> 1 \times ULN); and			
3.3 Patient has HBV DNA greater than 100,000 copies	s per mL, or viral load =	10 fold over na	dir; and
3.4 Detection of N236T or A181T/V mutation.			
Herpesvirus Treatments			
ACICLOVIR			
* Tab dispersible 200 mg		25	Lovir
* Tab dispersible 400 mg		•• •	<u>Lovir</u>
* Tab dispersible 800 mg		35 🖌	Lovir

	Subsidy (Manufacturer's Price) \$	S Per	Fully ubsidised	Brand or Generic Manufacturer
VALACICLOVIR – Special Authority see SA0957 below – Retail p Tab 500 mg	,	30	🖌 Va	altrex

SA0957 Special Authority for Subsidy

Initial application — (recurrent genital herpes) from any medical practitioner. Approvals valid for 12 months where the patient has genital herpes with 2 or more breakthrough episodes in any 6 month period while treated with aciclovir 400 mg twice daily.

Renewal — (recurrent genital herpes) from any medical practitioner. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (ophthalmic zoster) from any medical practitioner. Approvals valid without further renewal unless notified where the patient has previous history of ophthalmic zoster and the patient is at risk of vision impairment.

Initial application — (CMV prophylaxis) from any medical practitioner. Approvals valid for 3 months where the patient has undergone organ transplantation.

60

Valcyte

➡SA1274 Special Authority for Subsidy

Initial application — (transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 3 months where the patient has undergone a solid organ transplant and requires valganciclovir for CMV prophylaxis.

Initial application — (Lung transplant cytomegalovirus prophylaxis) only from a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 Patient has undergone a lung transplant; and
- 2 Either:
 - 2.1 The donor was cytomegalovirus positive and the patient is cytomegalovirus negative; or
 - 2.2 The recipient is cytomegalovirus positive.

Initial application — (Cytomegalovirus in immunocompromised patients) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient is immunocompromised; and
- 2 Any of the following:
 - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
 - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
 - 2.3 Patient has cytomegalovirus retinitis.

Renewal — (Cytomegalovirus in immunocompromised patients) only from a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Patient is immunocompromised; and
- 2 Any of the following:
 - 2.1 Patient has cytomegalovirus syndrome or tissue invasive disease; or
 - 2.2 Patient has rapidly rising plasma CMV DNA in absence of disease; or
 - 2.3 Patient has cytomegalovirus retinitis.

Note: for the purpose of this Special Authority "immunocompromised" includes transplant recipients, patients with immunosuppressive diseases (e.g. HIV) or those receiving immunosuppressive treatment for other conditions.

Hepatitis B/ HIV/AIDS Treatment

TENOFOVIR DISOPROXIL FUMARATE – Subsidy by endorsement; can be waived by Special Authority see SA1047 below Endorsement for treatment of HIV/AIDS: Prescription is deemed to be endorsed if tenofovir disoproxil fumarate is co-prescribed with another anti-retroviral subsidised under Special Authority SA1025 and the prescription is annotated accordingly by the

Pharmacist or endorsed by the prescriber.

Note: Tenofovir disoproxil fumarate prescribed under endorsement for the treatment of HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals for the purposes of Special Authority SA1025, page 103

Tab 300 mg	 	 531.00	30	~	Viread

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Su	bsidised	Generic	
\$	Per	~	Manufacturer	

►SA1047 Special Authority for Waiver of Rule

Initial application — (Confirmed Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria: Either:

- 1 All of the following:
 - 1.1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
 - 1.2 Patient has had previous lamivudine, adefovir or entecavir therapy; and
 - 1.3 HBV DNA greater than 20,000 IU/mL or increased $\geq~$ 10 fold over nadir; and
 - 1.4 Any of the following:
 - 1.4.1 Lamivudine resistance detection of M204I/V mutation; or
 - 1.4.2 Adefovir resistance detection of A181T/V or N236T mutation; or
 - 1.4.3 Entecavir resistance detection of relevant mutations including I169T, L180M T184S/A/I/L/G/C/M, S202C/G/I, M204V or M250I/V mutation; or
- 2 Patient is either listed or has undergone liver transplantation for HBV.

Initial application — (Pregnant) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 4 months for applications meeting the following criteria: Both:

- 1 Patient is HBsAg positive and pregnant; and
- 2 Either:
 - 2.1 HBV DNA > 20,000 IU/mL and ALT > ULN; or
 - 2.2 HBV DNA > 100 million IU/mL and ALT normal.

Renewal — (Confirmed Hepatitis B following funded tenofovir treatment for pregnancy within the previous two years) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid without further renewal unless notified for applications meeting the following criteria:

- Either:
 - 1 All of the following:
 - 1.1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
 - 1.2 Patient has had previous lamivudine, adefovir or entecavir therapy; and
 - 1.3 HBV DNA greater than 20,000 IU/mL or increased \geq 10 fold over nadir; and
 - 1.4 Any of the following:
 - 1.4.1 Lamivudine resistance detection of M204I/V mutation; or
 - 1.4.2 Adefovir resistance detection of A181T/V or N236T mutation; or
 - 1.4.3 Entecavir resistance detection of relevant mutations including I169T, L180M T184S/A/I/L/G/C/M, S202C/G/I, M204V or M250I/V mutation; or
 - 2 Patient is either listed or has undergone liver transplantation for HBV.

Renewal — (Subsequent Pregnancy) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 4 months for applications meeting the following criteria:

Both:

- 1 Patient is HBsAg positive and pregnant; and
- 2 Either:
 - 2.1 HBV DNA > 20,000 IU/mL and ALT > ULN; or
 - 2.2 HBV DNA > 100 million IU/mL and ALT normal.

Notes:

- Tenofovir disoproxil fumarate should be stopped 6 months following HBeAg seroconversion for patients who were HBeAg
 positive prior to commencing this agent and 6 months following HBsAg seroconversion for patients who were HBeAg negative
 prior to commencing this agent.
- The recommended dose of Tenofovir disoproxil fumarate for the treatment of all three indications is 300 mg once daily.
- In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Tenofovir disoproxil fumarate dose should be reduced in accordance with the approved Medsafe datasheet guidelines.
- Tenofovir disoproxil fumarate is not approved for use in children.

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	~	Manufacturer

Antiretrovirals

➡SA1025 Special Authority for Subsidy

Initial application — (Confirmed HIV/AIDS) only from a named specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Confirmed HIV infection; and
- 2 Any of the following:
 - 2.1 Symptomatic patient; or
 - 2.2 Patient aged 12 months and under; or
 - 2.3 Both:

2.3.1 Patient aged 1 to 5 years; and

- 2.3.2 Any of the following:
 - 2.3.2.1 CD4 counts $< 1000 \text{ cells/mm}^3$; or
 - 2.3.2.2 CD4 counts < 0.25 \times total lymphocyte count; or
 - 2.3.2.3 Viral load counts > 100000 copies per ml; or
- 2.4 Both:
 - 2.4.1 Patient aged 6 years and over; and
 - 2.4.2 CD4 counts < 350 cells/mm³.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (Confirmed HIV/AIDS) only from a named specialist. Approvals valid without further renewal unless notified where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Prevention of maternal transmission) only from a named specialist. Approvals valid for 1 year for applications meeting the following criteria:

Either:

1 Prevention of maternal foetal transmission; or

2 Treatment of the newborn for up to eight weeks.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Some antiretrovirals are unapproved or contraindicated for this indication. Practitioners prescribing these medications should exercise their own skill, judgement, expertise and discretion, and make their own prescribing decisions with respect to the use of a Pharmaceutical for an indication for which it is not approved or contraindicated.

Initial application — (post-exposure prophylaxis following non-occupational exposure to HIV) only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria:

- Both:
 - 1 Treatment course to be initiated within 72 hours post exposure; and
 - 2 Either:
 - 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
 - 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals.

continued...

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (second or subsequent post-exposure prophylaxis) only from a named specialist. Approvals valid for 4 weeks for applications meeting the following criteria:

Both:

1 Treatment course to be initiated within 72 hours post exposure; and

2 Either:

- 2.1 Patient has had unprotected receptive anal intercourse with a known HIV positive person; or
- 2.2 Patient has shared intravenous injecting equipment with a known HIV positive person.

Initial application — (Percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Notes: Tenofovir disoproxil fumarate prescribed under endorsement for HIV/AIDS is included in the count of up to 4 subsidised antiretrovirals.

Subsidies for a combination of up to four antiretroviral medications. The combination of a protease inhibitor and low-dose ritonavir given as a booster (either as part of a combination product or separately) will be counted as one protease inhibitor for the purpose of accessing funding to antiretrovirals.

Renewal — (Second or subsequent percutaneous exposure) only from a named specialist. Approvals valid for 6 weeks where the patient has percutaneous exposure to blood known to be HIV positive.

Non-nucleosides Reverse Transcriptase Inhibitors

EFAVIRENZ - Special Authority see SA1025 on the preceding	page - Retail pha	irmacy	
Tab 50 mg		30	Stocrin S29
Tab 200 mg		90	Stocrin
Tab 600 mg		30	Stocrin
Oral liq 30 mg per ml		180 ml OP	✓ Stocrin S29
ETRAVIRINE - Special Authority see SA1025 on the precedin	g page – Retail ph	armacy	
Tab 100 mg	770.00	120	 Intelence
Tab 200 mg	770.00	60	Intelence
(Intelence Tab 100 mg to be delisted 1 August 2013)			
NEVIRAPINE – Special Authority see SA1025 on the precedin Tab 200 mg – Brand switch fee payable (Pharmaco	01 0 1	armacy	
2433265) - see page 187 for details	95.94	60	Nevirapine Alphapharm
Oral suspension 10 mg per ml	134.55	240 ml	✓ Viramune Suspension
Nucleosides Reverse Transcriptase Inhibitors			

ABACAVIR SULPHATE – Special Authority see SA1025 on page 103 – Retail pharmacy				
Tab 300 mg		60	Ziagen	
Oral liq 20 mg per ml		240 ml OP	✓ Ziagen	
ABACAVIR SULPHATE WITH LAMIVUDINE – Special Authority see SA1025 on page 103 – Retail pharmacy				

Note: abacavir with lamivudine (combination tablets) counts as two anti-retroviral medications for the purposes of the anti-retroviral Special Authority.

	Subsidy		Fully Brand or
	(Manufacturer's Pi \$	rice) Sub: Per	sidised Generic Manufacturer
DIDANOSINE [DDI] – Special Authority see SA1025 on page 103			
Cap 125 mg		30	Videx EC
Cap 200 mg		30	Videx EC
Cap 250 mg		30	Videx EC
Cap 400 mg		30	Videx EC
 EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR DISOPR Retail pharmacy Note: Efavirenz with emtricitabine and tenofovir disoproxil furring of the anti-retroviral Special Authority 			, , , , , , , , , , , , , , , , , , , ,
Tab 600 mg with emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg		30	✔ Atripla
°			• Aulpia
EMTRICITABINE – Special Authority see SA1025 on page 103 – Cap 200 mg	, ,	30	✓ Emtriva
EMTRICITABINE WITH TENOFOVIR DISOPROXIL FUMARATE Note: Emtricitabine with tenofovir disoproxil fumarate counts retroviral Special Authority	s as two anti-retro	oviral medicati	ons for the purposes of the anti-
Tab 200 mg with tenofovir disoproxil fumarate 300 mg	838.20	30	Truvada
LAMIVUDINE – Special Authority see SA1025 on page 103 – Re			
Tab 150 mg		60	✓ <u>3TC</u>
Oral liq 10 mg per ml	50.00	240 ml OP	✓ <u>3TC</u>
STAVUDINE [D4T] – Special Authority see SA1025 on page 103 Cap 40 mg Powder for oral soln 1 mg per ml	503.80	5y 60 200 ml OP	✓ Zerit ✓ Zerit s29
ZIDOVUDINE [AZT] - Special Authority see SA1025 on page 103			
Cap 100 mg Oral liq 10 mg per ml	145.00	100 200 ml OP	 ✓ <u>Retrovir</u> ✓ <u>Retrovir</u>
ZIDOVUDINE [AZT] WITH LAMIVUDINE – Special Authority see Note: zidovudine [AZT] with lamivudine (combination tablets) anti-retroviral Special Authority.	counts as two ar	nti-retroviral me	
Tab 300 mg with lamivudine 150 mg	63.50 667.20	60	 <u>Alphapharm</u> Combivir
Protease Inhibitors			
FIOLEASE IIIIIDILOIS			
ATAZANAVIR SULPHATE - Special Authority see SA1025 on page	ge 103 – Retail p	harmacy	
Cap 150 mg		60	 Reyataz
Cap 200 mg	757.79	60	Reyataz
DARUNAVIR - Special Authority see SA1025 on page 103 - Ret	ail pharmacy		
Tab 400 mg	, ,	60	Prezista
Tab 600 mg	1,190.00	60	 Prezista
INDINAVIR – Special Authority see SA1025 on page 103 – Retai	l pharmacy		
Cap 200 mg		360	Crixivan
Cap 400 mg		180	 Crixivan
LOPINAVIR WITH RITONAVIR – Special Authority see SA1025 c		tail pharmacy	
Tab 100 mg with ritonavir 25 mg		60	✓ Kaletra
Tab 200 mg with ritonavir 50 mg		120	✓ Kaletra
Oral liq 80 mg with ritonavir 20 mg per ml		300 ml OP	✓ Kaletra
		-	

	Subsidy (Manufacturer's Pric \$	ce) Sub Per	Fully Brand or osidised Generic Manufacturer
RITONAVIR – Special Authority see SA1025 on page 103 – R Tab 100 mg Oral liq 80 mg per ml	43.31	30 90 ml OP	✓ <u>Norvir</u> ✓ Norvir
Strand Transfer Inhibitors			
RALTEGRAVIR POTASSIUM – Special Authority see SA1025 Tab 400 mg		pharmacy 60	✓ Isentress
Antiretrovirals - Additional Therapies			
HIV Fusion Inhibitors			
 ENFUVIRTIDE – Special Authority see SA0845 below – Retail Powder for inj 90 mg per ml × 60 ▶SA0845 Special Authority for Subsidy Initial application only from a named specialist. Approvals val All of the following: Confirmed HIV infection; and Enfuvirtide to be given in combination with optimized bat the patient has never previously been exposed to) for tree 3 Either: Patient has revidence of HIV replication, despite of 3.2 Patient has treatment-limiting toxicity to previous Previous treatment with 3 different antiretroviral regimen 5 All of the following:	2,380.00 id for 3 months for ap ackground therapy (in aatment failure; and ongoing therapy; or antiretroviral agents; is has failed; and e transcriptase inhibito hascriptase inhibitor ha	and and br has failed;	east 1 other antiretroviral drug tha
 5.3 Previous treatment with a protease inhibitor has f Renewal only from a named specialist. Approvals valid for 1 ye Both: 1 Evidence of at least a 10 fold reduction in viral load at 12 	ear for applications me	eeting the fo	llowing criteria:
2 The treatment remains appropriate and the patient is be Immune Modulators	1	nt.	
Guidelines for the use of interferon in the treatment of hep Physicians considering treatment of patients with hepatitis C sho physician. All subjects undergoing treatment require careful mo Patients should be otherwise fit.	ould discuss cases wi pnitoring for side effec	ets.	-

Hepatocellular carcinoma should be excluded by ultrasound examination and alpha-fetoprotein level.

Criteria for Treatment

1) Diagnosis

- Anti-HCV positive on at least two occasions with a positive PCR for HCV-RNA and preferably confirmed by a supplementary RIBA test; or
- PCR-RNA positive for HCV on at least 2 occasions if antibody negative; or
- Anti-HCV positive on at least two occasions with a positive supplementary RIBA test with a negative PCR for HCV RNA but with a liver biopsy consistent with 2(b) following.
- 2) Establishing Active Chronic Liver Disease
 - Confirmed HCV infection and serum ALT/AST levels measured on at least three occasions over six months averaging
 - > 1.5 \times upper limit of normal. (ALT is the preferable enzyme); or

continued...

continued Liver biopsy showing significant inflammatory activity (active hepatitis) with or with sary requirement for those patients with coagulopathy. (Some patients have active transaminase enzymes). Exclusion Criteria Autoimmune liver disease. (Interferon may exacerbate autoimmune liver disease as we such as thyroid disease). Pregnancy. Neutropenia (<2.0 × 10⁹) and/or thrombocytopenia. Continuing alcohol abuse and/or continuing intravenous drug users. Dosage The current recommended dosage is 3 million units of interferon alpha-2a or interferon alpha-2 times a week for 52 weeks (twelve months) Exit Criteria The patient's response to interferon treatment should be reviewed at either three or four month discontinued in patients who do not show a substantial reduction (50%) in their mean pre-treatmet INTERFERON ALPHA-2A - PCT - Retail pharmacy-Specialist	Fully Ibsidised	
sary requirement for those patients with coagulopathy. (Some patients have active transaminase enzymes). Exclusion Criteria 1) Autoimmune liver disease. (Interferon may exacerbate autoimmune liver disease as we such as thyroid disease). 2) Pregnancy. 3) Neutropenia (<2.0 × 10 ⁹) and/or thrombocytopenia. 4) Continuing alcohol abuse and/or continuing intravenous drug users. Dosage The current recommended dosage is 3 million units of interferon alpha-2a or interferon alpha-2 times a week for 52 weeks (twelve months) Exit Criteria The patient's response to interferon treatment should be reviewed at either three or four month discontinued in patients who do not show a substantial reduction (50%) in their mean pre-treatment INTERFERON ALPHA-2A - PCT - Retail pharmacy-Specialist a) See prescribing guideline on the preceding page b) Prescriptions must be written by, or on the recommendation of, an internal medicine physi Inj 3 m iu prefilled syringe		
Exclusion Criteria 1) Autoimmune liver disease. (Interferon may exacerbate autoimmune liver disease as we such as thyroid disease). 2) Pregnancy. 3) Neutropenia (<2.0 × 10 ⁹) and/or thrombocytopenia. 4) Continuing alcohol abuse and/or continuing intravenous drug users. Dosage The current recommended dosage is 3 million units of interferon alpha-2a or interferon alpha-2 times a week for 52 weeks (twelve months) Exit Criteria The patient's response to interferon treatment should be reviewed at either three or four month discontinued in patients who do not show a substantial reduction (50%) in their mean pre-treatment as pre-treatment by patient's response to meet the preceding page b) Prescriptions must be written by, or on the recommendation of, an internal medicine physiting a mit prefilled syringe 1nj 9 m in prefilled syringe a) See prescriptions must be written by, or on the recommendation of, an internal medicine physiting 3 mit prefilled syringe 1nj 9 m in prefilled syringe 1nj 9 m in prefilled syringe 1nj 12 m multidose pen 1nj 30 m up 1.2 ml multidose pen 1nj 10 m iu, 1.2 ml multidose pen 1nj 18 m iu, 1.2 ml multidose pen 1nj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 112 1135 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 112 1130 mcg prefilled syringe ×		
 1) Autoimmune liver disease. (Interferon may exacerbate autoimmune liver disease as we such as thyroid disease). 2) Pregnancy. 3) Neutropenia (<2.0 × 10°) and/or thrombocytopenia. 4) Continuing alcohol abuse and/or continuing intravenous drug users. Dosage The current recommended dosage is 3 million units of interferon alpha-2a or interferon alpha-2 times a week for 52 weeks (twelve months) Exit Criteria The patient's response to interferon treatment should be reviewed at either three or four month discontinued in patients who do not show a substantial reduction (50%) in their mean pre-treatment INTERFERON ALPHA-2A – PCT – Retail pharmacy-Specialist a) See prescribing guideline on the preceding page b) Prescriptions must be written by, or on the recommendation of, an internal medicine physis Inj 3 m iu prefilled syringe		
 such as thyroid disease). Pregnancy. Neutropenia (<2.0 × 10⁹) and/or thrombocytopenia. 4) Continuing alcohol abuse and/or continuing intravenous drug users. Dosage The current recommended dosage is 3 million units of interferon alpha-2a or interferon alpha-2 times a week for 52 weeks (twelve months) Exit Criteria The patient's response to interferon treatment should be reviewed at either three or four month discontinued in patients who do not show a substantial reduction (50%) in their mean pre-treatmet INTERFERON ALPHA-2A - PCT - Retail pharmacy-Specialist a) See prescribing guideline on the preceding page b) Prescriptions must be written by, or on the recommendation of, an internal medicine physi Inj 6 m iu prefilled syringe		
 Neutropenia (<2.0 × 10⁹) and/or thrombocytopenia. Continuing alcohol abuse and/or continuing intravenous drug users. Dosage The current recommended dosage is 3 million units of interferon alpha-2a or interferon alpha-2 times a week for 52 weeks (twelve months) Exit Criteria The patient's response to interferon treatment should be reviewed at either three or four month discontinued in patients who do not show a substantial reduction (50%) in their mean pre-treatment a) See prescribing guideline on the preceding page b) Prescriptions must be written by, or on the recommendation of, an internal medicine physis ln j 3 m iu prefilled syringe	ell as o	other autoimmune diseases
 4) Continuing alcohol abuse and/or continuing intravenous drug users. Dosage The current recommended dosage is 3 million units of interferon alpha-2a or interferon alpha-2 times a week for 52 weeks (twelve months) Exit Criteria The patient's response to interferon treatment should be reviewed at either three or four month discontinued in patients who do not show a substantial reduction (50%) in their mean pre-treatment INTERFERON ALPHA-2A - PCT - Retail pharmacy-Specialist a) See prescribing guideline on the preceding page b) Prescriptions must be written by, or on the recommendation of, an internal medicine physis Inj 6 m iu prefilled syringe 		
Dosage The current recommended dosage is 3 million units of interferon alpha-2a or interferon alpha-2 irmes a week for 52 weeks (twelve months) Exit Criteria The patient's response to interferon treatment should be reviewed at either three or four month discontinued in patients who do not show a substantial reduction (50%) in their mean pre-treatment should be reviewed at either three or four month discontinued in patients who do not show a substantial reduction (50%) in their mean pre-treatment should be reviewed at either three or four month discontinued in patients who do not show a substantial reduction (50%) in their mean pre-treatment should be reviewed at either three or four monthed dosation is a substantial reduction (50%) in their mean pre-treatment should be reviewed at either three or four monthed dosation is a substantial reduction (50%) in their mean pre-treatment should be reviewed at either three or four monthed dosation is a substantial reduction (50%) in their mean pre-treatment should be reviewed at either three or four monthed dosation is a substantial reduction (50%) in their mean pre-treatment should be reviewed at either three or four monthed dosation is a see prescribing guideline on the preceding page b) Prescriptions must be written by, or on the recommendation of, an internal medicine physic in j 18 m iu, 1.2 ml multidose pen		
The current recommended dosage is 3 million units of interferon alpha-2a or interferon alpha-2 times a week for 52 weeks (twelve months) Exit Criteria The patient's response to interferon treatment should be reviewed at either three or four month discontinued in patients who do not show a substantial reduction (50%) in their mean pre-treatment of the preceding page b) Prescriptions must be written by, or on the recommendation of, an internal medicine physis in j 3 m iu prefilled syringe		
times a week for 52 weeks (twelve months) Exit Criteria The patient's response to interferon treatment should be reviewed at either three or four month discontinued in patients who do not show a substantial reduction (50%) in their mean pre-treatme INTERFERON ALPHA-2A – PCT – Retail pharmacy-Specialist a) See prescribing guideline on the preceding page b) Prescriptions must be written by, or on the recommendation of, an internal medicine physi lnj 3 m iu prefilled syringe		
The patient's response to interferon treatment should be reviewed at either three or four month discontinued in patients who do not show a substantial reduction (50%) in their mean pre-treatmet in patients who do not show a substantial reduction (50%) in their mean pre-treatmet in the prescriptions must be written by, or on the recommendation of, an internal medicine physical states in the prescriptions must be written by, or on the recommendation of, an internal medicine physical states in the prescriptions must be written by, or on the recommendation of, an internal medicine physical states in the prescriptions must be written by, or on the recommendation of, an internal medicine physical states in the prescriptions must be written by, or on the recommendation of, an internal medicine physical states in the prescriptions must be written by, or on the recommendation of, an internal medicine physical states in the prescriptions must be written by, or on the recommendation of, an internal medicine physical states in the prescriptions must be written by, or on the recommendation of, an internal medicine physical states in the prescriptions must be written by, or on the recommendation of, an internal medicine physical states in the prescriptions must be written by, or on the recommendation of, an internal medicine physical states in the prescriptions must be written by, or on the recommendation of, an internal medicine physical states in the prescriptions must be written by, or on the recommendation of, an internal medicine physical states in the prescriptions must be written by, or on the recommendation of, an internal medicine physical states in the prescriptions must be written by, or on the recommendation of, an internal medicine physical states in the prescriptions must be written by, or on the recommendation of, an internal medicine physical states in the prescriptions must be written by, or on the recommendation of, an internal medicine physical states in the prescriptions and the prescriptions and the pre	2b adm	inistered subcutaneously 3
discontinued in patients who do not show a substantial reduction (50%) in their mean pre-treatment INTERFERON ALPHA-2A $-PCT - Retail pharmacy-Specialist$ a) See prescribing guideline on the preceding page b) Prescriptions must be written by, or on the recommendation of, an internal medicine physis Inj 3 m iu prefilled syringe		
a) See prescribing guideline on the preceding page b) Prescriptions must be written by, or on the recommendation of, an internal medicine physi Inj 3 m iu prefilled syringe		
a) See prescribing guideline on the preceding page b) Prescriptions must be written by, or on the recommendation of, an internal medicine physi Inj 3 m iu prefilled syringe		
b) Prescriptions must be written by, or on the recommendation of, an internal medicine physi Inj 3 m iu prefilled syringe		
Inj 3 m iu prefilled syringe 31.32 1Inj 6 m iu prefilled syringe 62.64 1Inj 9 m iu prefilled syringe 93.96 1INTERFERON ALPHA-2B $-PCT$ $-Retail pharmacy-Specialist$ 93.96 a) See prescribing guideline on the preceding pageb) Prescriptions must be written by, or on the recommendation of, an internal medicine physicInj 18 m iu, 1.2 ml multidose pen 187.92 1Inj 30 m iu, 1.2 ml multidose pen 626.40 1Inj 60 m iu, 1.2 ml multidose pen 626.40 1PEGYLATED INTERFERON ALPHA-2ASpecial Authority see SA1134 below - Retail pharmaSee prescribing guideline on page 106 1448.00 4Inj 135 mcg prefilled syringe 362.00 1Inj 180 mcg prefilled syringe 4 with ribavirin tab 200 mg × $1,799.68$ 112 $1,799.68$ 1 OPInj 135 mcg prefilled syringe × 4 with ribavirin tab 200 mg × $1,975.00$ 1 OPInj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × $1,975.00$ 1 OPInj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × $1,299.68$ 1 OPInj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × $1,299.68$ 1 OPInj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × $1,299.68$ 1 OPInj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × $1,299.68$ 1 OPInj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × $1,299.68$ 1 OP	sician or	or ophthalmologist
Inj 6 m iu prefilled syringe 62.64 1Inj 9 m iu prefilled syringe 93.96 1INTERFERON ALPHA-2B $-PCT$ $-Retail pharmacy-Specialist$ 93.96 1a) See prescribing guideline on the preceding pageb) Prescriptions must be written by, or on the recommendation of, an internal medicine physi 187.92 1Inj 30 m iu, 1.2 ml multidose pen 187.92 1 119.60 1Inj 60 m iu, 1.2 ml multidose pen 626.40 1PEGYLATED INTERFERON ALPHA-2A $-$ Special Authority see SA1134 below $-$ Retail pharmaSee prescribing guideline on page 106 362.00 1Inj 135 mcg prefilled syringe 362.00 1Inj 180 mcg prefilled syringe 4 with ribavirin tab 200 mg × 112 112 $1,799.68$ 1 OPInj 135 mcg prefilled syringe $\times 4$ with ribavirin tab 200 mg \times $1,975.00$ 1 OPInj 180 mcg prefilled syringe $\times 4$ with ribavirin tab 200 mg \times $1,975.00$ 1 OPInj 180 mcg prefilled syringe $\times 4$ with ribavirin tab 200 mg \times $1,975.00$ 1 OPInj 180 mcg prefilled syringe $\times 4$ with ribavirin tab 200 mg \times $1,975.00$ 1 OPInj 180 mcg prefilled syringe $\times 4$ with ribavirin tab 200 mg \times $1,975.00$ 1 OPInj 180 mcg prefilled syringe $\times 4$ with ribavirin tab 200 mg \times $1,975.00$ 1 OPInj 180 mcg prefilled syringe $\times 4$ with ribavirin tab 200 mg \times $1,975.00$ 1 OP		Roferon-A
Inj 9 m iu prefilled syringe	V F	Roferon-A
INTERFERON ALPHA-2B - PCT - Retail pharmacy-Specialist a) See prescribing guideline on the preceding page b) Prescriptions must be written by, or on the recommendation of, an internal medicine physi Inj 18 m iu, 1.2 ml multidose pen		Roferon-A
a) See prescribing guideline on the preceding page b) Prescriptions must be written by, or on the recommendation of, an internal medicine physic Inj 18 m iu, 1.2 ml multidose pen		
b) Prescriptions must be written by, or on the recommendation of, an internal medicine physi Inj 18 m iu, 1.2 ml multidose pen		
Inj 18 m iu, 1.2 ml multidose pen 187.92 1 Inj 30 m iu, 1.2 ml multidose pen 313.20 1 Inj 60 m iu, 1.2 ml multidose pen 626.40 1 PEGYLATED INTERFERON ALPHA-2A – Special Authority see SA1134 below – Retail pharma See prescribing guideline on page 106 362.00 1 Inj 135 mcg prefilled syringe 362.00 1 Inj 180 mcg prefilled syringe 450.00 1 Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1,799.68 1 OP Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1,975.00 1 OP Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1,975.00 1 OP Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1,975.00 1 OP Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1,975.00 1 OP Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1,975.00 1 OP		
Inj 30 m iu, 1.2 ml multidose pen		
Inj 60 m iu, 1.2 ml multidose pen		Intron-A
PEGYLATED INTERFERON ALPHA-2A – Special Authority see SA1134 below – Retail pharma See prescribing guideline on page 106		Intron-A
See prescribing guideline on page 106 1 Inj 135 mcg prefilled syringe 1,448.00 1 Inj 180 mcg prefilled syringe 450.00 1 Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1,800.00 4 Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1,799.68 1 OP Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1,975.00 1 OP Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1,975.00 1 OP Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1,975.00 1 OP Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1,975.00 1 OP	V	Intron-A
1,448.004Inj 180 mcg prefilled syringe11,800.0011,800.004Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1121,799.6810P1Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1681,975.0010P1Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1121,975.0010P1Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 112110P1	acy	
1,448.004Inj 180 mcg prefilled syringe11,800.0011,800.004Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1121,799.6810P1Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1681,975.0010P1Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1121,975.0010P1Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 112110P1	🖌 🖌 F	Pegasys
1,800.00 4 Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1,799.68 1 OP Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1,975.00 1 OP Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1,975.00 1 OP Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1,975.00 1 OP Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1,975.00 1 OP	🖌 F	Pegasys
1,800.00 4 Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1,799.68 1 OP Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1,975.00 1 OP Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1,975.00 1 OP Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1,975.00 1 OP Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1,975.00 1 OP		Pegasys
Inj 135 mcg prefilled syringe \times 4 with ribavirin tab 200 mg \times 112	V F	Pegasys
112 1,799.68 1 OP Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1,975.00 1 OP Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1,975.00 1 OP Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1,975.00 1 OP Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1 OP 1 OP		
Inj 135 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1,975.00 1 OP Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 112 1 OP	~	Pegasys RBV
168 1,975.00 1 OP Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 112 1 OP	• 1	Combination Pack
168 1,975.00 1 OP Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 112 1 OP		
Inj 180 mcg prefilled syringe × 4 with ribavirin tab 200 mg × 1122,059.84 1 OP		
1122,059.84 1 OP	V	Pegasys RBV Combination Pack
,		
Inj 180 mcg prefilled syringe $ imes$ 4 with ribavirin tab 200 mg $ imes$	🖌 🖌 F	Pegasys RBV
Inj 180 mcg prefilled syringe $ imes$ 4 with ribavirin tab 200 mg $ imes$		Combination Pack
1682,190.00 1 OP	V F	Pegasys RBV
	÷ 1	Combination Pack

Subsidy		Fully	Brand or	
(Manufacturer's Price)	:	Subsidised	Generic	
\$	Per	~	Manufacturer	

SA1134 Special Authority for Subsidy

Initial application — (chronic hepatitis C - genotype 1, 4, 5 or 6 infection or co-infection with HIV) from any specialist. Approvals valid for 18 months for applications meeting the following criteria:

- Both: 1 Either:
 - 1.1 Patient has chronic hepatitis C, genotype 1, 4, 5 or 6 infection; or
 - 1.2 Patient has chronic hepatitis C and is co-infected with HIV; and
 - 2 Maximum of 48 weeks therapy.

Notes:

- Consider stopping treatment if there is absence of a virological response (defined as at least a 2-log reduction in viral load) following 12 weeks of treatment since this is predictive of treatment failure.
- Consider reducing treatment to 24 weeks if serum HCV RNA level at Week 4 is undetectable by sensitive PCR assay (less than 50IU/ml) AND Baseline serum HCV RNA is less than 400,000IU/ml
- Initial application (chronic hepatitis C genotype 2 or 3 infection without co-infection with HIV) from any specialist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 Patient has chronic hepatitis C, genotype 2 or 3 infection; and
- 2 Maximum of 6 months therapy.

Initial application — (Hepatitis B) only from a gastroenterologist, infectious disease specialist or general physician. Approvals valid for 18 months for applications meeting the following criteria:

All of the following:

- 1 Patient has confirmed Hepatitis B infection (HBsAg positive for more than 6 months); and
- 2 Patient is Hepatitis B treatment-naive; and
- 3 ALT > 2 times Upper Limit of Normal; and
- 4 HBV DNA < 10 log10 IU/ml; and
- 5 Either:
 - 5.1 HBeAg positive; or
 - 5.2 serum HBV DNA \geq 2,000 units/ml and significant fibrosis (\geq Metavir Stage F2); and
- 6 Compensated liver disease; and
- 7 No continuing alcohol abuse or intravenous drug use; and
- 8 Not co-infected with HCV, HIV or HDV; and
- 9 Neither ALT nor AST > 10 times upper limit of normal; and
- 10 No history of hypersensitivity or contraindications to pegylated interferon; and
- 11 Maximum of 48 weeks therapy.

Notes:

- Approved dose is 180 mcg once weekly.
- The recommended dose of Pegylated Interferon-alpha 2a is 180 mcg once weekly.
- In patients with renal insufficiency (calculated creatinine clearance less than 50ml/min), Pegylated Interferon-alpha 2a dose should be reduced to 135 mcg once weekly.
- In patients with neutropaenia and thrombocytopaenia, dose should be reduced in accordance with the datasheet guidelines.
- Pegylated Interferon-alpha 2a is not approved for use in children.

Urinary Tract Infections

HEXAMINE HIPPURATE			
* Tab 1 g	18.40	100	
	(38.10)		Hiprex
NITROFURANTOIN			
* Tab 50 mg - For nitrofurantoin oral liquid formulation refer,			
page 189	22.20	100	Nifuran
* Tab 100 mg	37.50	100	 Nifuran

INFECTIONS - AGENTS FOR SYSTEMIC USE

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
NORFLOXACIN Tab 400 mg – Maximum of 6 tab per prescription; can be waived by endorsement - Retail pharmacy - Specialist		100		rrow-Norfloxacin

MUSCULOSKELETAL SYSTEM

	Subsidy		Fully Brand or	
	(Manufacturer's Price))	Subsidised Generic	
	\$	Per		
				1
Anticholinesterases				
NEOSTIGMINE				
Inj 2.5 mg per ml, 1 ml ampoule	140.00	50	✓ AstraZeneca	
		00	- Intransmood	
	20.00	100	1 Montinon	
▲ Tab 60 mg		100	Mestinon	
Non-Steroidal Anti-Inflammatory Drugs				
SA1038 Special Authority for Manufacturers Price				
Note: Subsidy for patients with existing approvals prior to 1 Septer	nher 2010 Approval	e valid v	without further renewal unless no	otifiad
No new approvals will be granted from 1 September 2010.		o valia v	without further reflewar unless ne	uncu.
DICLOFENAC SODIUM * Tab EC 25 mg	4.00	100	Apo-Diclo	
 * Tab EC 25 mg * Tab 50 mg dispersible – Additional subsidy by Special Au- 		100		
the so mg dispersible – Additional subsidy by Special Au- thority see SA1038 above – Retail pharmacy		20		
tionty see OA1000 above - Hetali pharmacy	(8.00)	20	Voltaren D	
* Tab EC 50 mg	()	500	✓ Apo-Diclo	
* Tab long-acting 75 mg		500	✓ Diclax SR	
* Tab long-acting 100 mg		500	✓ Diclax SR	
* Inj 25 mg per ml, 3 ml		5	✓ Voltaren	
Up to 5 inj available on a PSO				
* Suppos 12.5 mg		10	Voltaren	
* Suppos 25 mg	2.22	10	Voltaren	
* Suppos 50 mg	3.84	10	Voltaren	
Up to 10 supp available on a PSO				
* Suppos 100 mg	6.36	10	Voltaren	
IBUPROFEN - Additional subsidy by Special Authority see SA10	38 above – Retail p	harmac	Cy	
* Tab 200 mg		1,000	Arrowcare	
* Tab 400 mg	0.77	30		
	(4.56)		Brufen	
* Tab 600 mg		30		
	(6.84)		Brufen	
* Tab long-acting 800 mg		30	✓ Brufen SR	
*‡ Oral liq 20 mg per ml	2.69	200 ml	Fenpaed	
KETOPROFEN				
* Cap long-acting 100 mg		100	 Oruvail SR 	
* Cap long-acting 200 mg	43.12	100	Oruvail SR	
MEFENAMIC ACID - Additional subsidy by Special Authority see	e SA1038 above – R	letail ph	narmacy	
* Cap 250 mg	0.50	20		
	(5.60)		Ponstan	
	1.25	50	D .	
	(9.16)		Ponstan	
NAPROXEN				
* Tab 250 mg	21.25	500	Noflam 250	
* Tab 500 mg		250	Noflam 500	
* Tab long-acting 750 mg		90	✓ Naprosyn SR 750	
* Tab long-acting 1,000 mg	21.00	90	Naprosyn SR 1000	

MUSCULOSKELETAL SYSTEM

	Subsidy (Manufacturer's Pric	e) Su	Fully Brand or bsidised Generic
	\$	Per	 Manufacturer
SULINDAC – Additional subsidy by Special Authority see SA103	3 on the preceding	page – Ret	ail pharmacy
₭ Tab 100 mg		50	
h. T-h 000	(8.55)	50	Aclin
k Tab 200 mg		50	Aclin
	(15.10)		Acim
'ENOXICAM ₭ Tab 20 mg	22.75	100	✓ Tilcotil
 Inj 20 mg vial 		1	✓ AFT
IAPROFENIC ACID		•	• • • •
← Tab 300 mg	19.26	60	✓ Surgam
			· · · · · · · · · · · · · · · · · · ·
NSAIDs Other			
IELOXICAM - Special Authority see SA1034 below - Retail pha	•		
✓ Tab 7.5 mg →SA1034 Special Authority for Subsidy	11.50	30	Arrow-Meloxicam
 e following criteria: I of the following: 1 The patient has moderate to severe haemophilia with less t and 2 The patient has haemophilic arthropathy; and 	han or equal to 5%	of normal	circulating functional clotting factor
3 Pain and inflammation associated with haemophilic arthro options, or alternative funded treatment options are contrain Topical Products for Joint and Muscular Pain	ndicated.	ely controll 45 g OP	ed by alternative funded treatme
 3 Pain and inflammation associated with haemophilic arthro options, or alternative funded treatment options are contrain topical Products for Joint and Muscular Pain APSAICIN Crm 0.025% – Special Authority see SA1289 below – Retail pharmacy SA1289 Special Authority for Subsidy 	ndicated.	45 g OP	✓ Zostrix
 3 Pain and inflammation associated with haemophilic arthrooptions, or alternative funded treatment options are contrain topical Products for Joint and Muscular Pain APSAICIN Crm 0.025% – Special Authority see SA1289 below – Retail pharmacy >>SA1289 Special Authority for Subsidy itial application from any relevant practitioner. Approvals val 	ndicated. 9.95 id without further r	45 g OP enewal unl	✓ Zostrix ess notified where the patient h
 3 Pain and inflammation associated with haemophilic arthropoptions, or alternative funded treatment options are contrain to provide the second second	ndicated. 9.95 id without further r	45 g OP enewal unl	✓ Zostrix ess notified where the patient h
 Pain and inflammation associated with haemophilic arthropoptions, or alternative funded treatment options are contrained to the contrained treatment option. 	ndicated. 9.95 id without further r	45 g OP enewal unl	✓ Zostrix ess notified where the patient h
 3 Pain and inflammation associated with haemophilic arthrooptions, or alternative funded treatment options are contrain Topical Products for Joint and Muscular Pain APSAICIN Crm 0.025% – Special Authority see SA1289 below – Retail pharmacy SA1289 Special Authority for Subsidy itial application from any relevant practitioner. Approvals val steoarthritis that is not responsive to paracetamol and oral non-stantirheumatoid Agents 	ndicated. 9.95 id without further r	45 g OP enewal unl	✓ Zostrix ess notified where the patient h.
 3 Pain and inflammation associated with haemophilic arthropoptions, or alternative funded treatment options are contrained to a structure options, or alternative funded treatment options are contrained to a structure option optingenetic option option option option option option option opti	ndicated. 9.95 id without further r teroidal anti-inflam	45 g OP enewal unl	✓ Zostrix ess notified where the patient h
 3 Pain and inflammation associated with haemophilic arthrooptions, or alternative funded treatment options are contrain topical Products for Joint and Muscular Pain APSAICIN Crm 0.025% – Special Authority see SA1289 below – Retail pharmacy SA1289 Special Authority for Subsidy itial application from any relevant practitioner. Approvals val steoarthritis that is not responsive to paracetamol and oral non-se Antirheumatoid Agents URANOFIN Tab 3 mg 	ndicated. 9.95 id without further r teroidal anti-inflam	45 g OP enewal unl matories al	✓ Zostrix ess notified where the patient h re contraindicated.
 3 Pain and inflammation associated with haemophilic arthrooptions, or alternative funded treatment options are contrain topical Products for Joint and Muscular Pain APSAICIN Crm 0.025% – Special Authority see SA1289 below – Retail pharmacy SA1289 Special Authority for Subsidy itial application from any relevant practitioner. Approvals val steoarthritis that is not responsive to paracetamol and oral non-se Antirheumatoid Agents URANOFIN Tab 3 mg 	ndicated. 9.95 id without further r teroidal anti-inflam 68.99	45 g OP enewal unl matories al	✓ Zostrix ess notified where the patient h re contraindicated.
 3 Pain and inflammation associated with haemophilic arthrooptions, or alternative funded treatment options are contrain topical Products for Joint and Muscular Pain APSAICIN Crm 0.025% – Special Authority see SA1289 below – Retail pharmacy Special Authority for Subsidy itial application from any relevant practitioner. Approvals val steoarthritis that is not responsive to paracetamol and oral non-se Antirheumatoid Agents JRANOFIN Tab 3 mg EFLUNOMIDE 	ndicated. 9.95 id without further r teroidal anti-inflam 68.99	45 g OP enewal unl matories au 60	✓ Zostrix ess notified where the patient h re contraindicated. ✓ Ridaura s29 s29
 3 Pain and inflammation associated with haemophilic arthrooptions, or alternative funded treatment options are contrain topical Products for Joint and Muscular Pain APSAICIN Crm 0.025% – Special Authority see SA1289 below – Retail pharmacy >>SA1289 Special Authority for Subsidy itial application from any relevant practitioner. Approvals val steoarthritis that is not responsive to paracetamol and oral non-secont the second s	ndicated. 9.95 id without further r teroidal anti-inflam 68.99 	45 g OP enewal unl matories at 60 30	 Zostrix ess notified where the patient has a contraindicated. Ridaura s29 s29 Arava
 3 Pain and inflammation associated with haemophilic arthrooptions, or alternative funded treatment options are contrain topical Products for Joint and Muscular Pain APSAICIN Crm 0.025% - Special Authority see SA1289 below - Retail pharmacy >>SA1289 Special Authority for Subsidy itial application from any relevant practitioner. Approvals val steoarthritis that is not responsive to paracetamol and oral non-seantirheumatoid Agents URANOFIN Tab 3 mg Tab 20 mg Tab 100 mg Tab 100 mg 	ndicated. 9.95 id without further r teroidal anti-inflam 68.99 	45 g OP enewal unl matories au 60 30 30	 ✓ Zostrix ess notified where the patient has a contraindicated. ✓ Ridaura s29 s29 ✓ Arava ✓ Arava ✓ Arava
 3 Pain and inflammation associated with haemophilic arthrooptions, or alternative funded treatment options are contrain topical Products for Joint and Muscular Pain APSAICIN Crm 0.025% - Special Authority see SA1289 below - Retail pharmacy >>SA1289 Special Authority for Subsidy itial application from any relevant practitioner. Approvals val steoarthritis that is not responsive to paracetamol and oral non-se Antirheumatoid Agents URANOFIN Tab 3 mg Tab 10 mg Tab 100 mg ENICILLAMINE Tab 125 mg 	ndicated. 9.95 id without further r steroidal anti-inflam 68.99 	45 g OP enewal unl matories an 60 30 30 3 3 3 100	 ✓ Zostrix ess notified where the patient has a contraindicated. ✓ Ridaura s29 s29 ✓ Arava
3 Pain and inflammation associated with haemophilic arthro options, or alternative funded treatment options are contrain Topical Products for Joint and Muscular Pain APSAICIN Crm 0.025% - Special Authority see SA1289 below - Retail pharmacy	ndicated. 9.95 id without further r steroidal anti-inflam 68.99 	45 g OP enewal unl matories au 60 30 30 30 3	 ✓ Zostrix ess notified where the patient has a contraindicated. ✓ Ridaura s29 s29 ✓ Arava ✓ Arava ✓ Arava ✓ Arava ✓ Arava ✓ Arava
3 Pain and inflammation associated with haemophilic arthro options, or alternative funded treatment options are contrai Topical Products for Joint and Muscular Pain XAPSAICIN Crm 0.025% - Special Authority see SA1289 below - Retail pharmacy	ndicated. 9.95 id without further r steroidal anti-inflam 68.99 68.99 68.99 	45 g OP enewal unl matories au 60 30 30 3 3 100 100	 ✓ Zostrix ess notified where the patient h re contraindicated. ✓ Ridaura s29 s29 ✓ Arava ✓ Arava ✓ Arava ✓ Arava ✓ D-Penamine ✓ D-Penamine
 3 Pain and inflammation associated with haemophilic arthrooptions, or alternative funded treatment options are contrain Topical Products for Joint and Muscular Pain CAPSAICIN Crm 0.025% - Special Authority see SA1289 below - Retail pharmacy SA1289 Special Authority for Subsidy Ditial application from any relevant practitioner. Approvals val steoarthritis that is not responsive to paracetamol and oral non-se Antirheumatoid Agents URANOFIN Tab 3 mg EFLUNOMIDE Tab 10 mg Tab 100 mg ENICILLAMINE Tab 125 mg Tab 250 mg CODIUM AUROTHIOMALATE Inj 10 mg in 0.5 ml ampoule 	ndicated. 9.95 id without further r steroidal anti-inflam 68.99 	45 g OP enewal unl matories au 60 30 30 3 100 100 10	 Zostrix ess notified where the patient h re contraindicated. Ridaura s29 s29 Arava Arava Arava Arava D-Penamine D-Penamine Myocrisin
3 Pain and inflammation associated with haemophilic arthro options, or alternative funded treatment options are contrai Topical Products for Joint and Muscular Pain CAPSAICIN Crm 0.025% – Special Authority see SA1289 below – Retail pharmacy	ndicated. 9.95 id without further r steroidal anti-inflam 68.99 68.99 	45 g OP enewal unl matories au 60 30 30 3 3 100 100	 ✓ Zostrix ess notified where the patient have contraindicated. ✓ Ridaura s29 s29 ✓ Arava ✓ Arava ✓ Arava ✓ Arava ✓ Arava ✓ D-Penamine ✓ D-Penamine

Subsidy		Fully	Brar
(Manufacturer's Price)	9	Subsidised	Gen
\$	Per	~	Man

Brand or Generic Manufacturer

Drugs Affecting Bone Metabolism

Alendronate for Osteoporosis

SA1039 Special Authority for Subsidy

Initial application — (Underlying cause – Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) \geq 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -2.5) (see Note); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score \leq -3.0 (see Note); or
- 5 A 10-year risk of hip fracture ≥ 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
- 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause Osteoporosis) or raloxifene.

Initial application — (Underlying cause – glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is receiving systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
- 2 Any of the following:
 - 2.1 The patient has documented BMD $\geq~$ 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score $\leq~$ -1.5) (see Note); or
 - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
 - 2.3 The patient has had a Special Authority approval for zoledronic acid (Underlying cause glucocorticosteroid therapy) or raloxifene.

Renewal — (Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year where the patient is continuing systemic glucocorticosteriod therapy (\geq 5 mg per day prednisone equivalents).

Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause - osteoporosis' criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) \geq 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -2.5) (see Note); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score $\leq~$ -3.0 (see Note); or
- 5 A 10-year risk of hip fracture \geq 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
- 6 Patient has had a Special Authority approval for zoledronic acid (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause Osteoporosis' criteria) or raloxifene.

Notes:

a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.

MUSCULOSKELETAL SYSTEM

Subsidy (Manufacturer's Pr		Brand or Generic	
(Manuaculers Fi	Per	Manufacturer	

continued...

- b) Evidence used by National Institute for Health and Clinical Excellence (NICE) guidance indicates that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) In line with the Australian guidelines for funding alendronate, a vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

ALE	ENDRONATE SODIUM	 Special Authority s 	ee SA1039 on the prece	eding page – Ret	tail pharmacy	/
*	Tab 70 mg			22.90	4 🖌	' Fosamax

Alendronate for Paget's Disease

SA0949 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: Both:

- 1 Paget's disease; and
- 2 Any of the following:
 - 2.1 Bone or articular pain; or
 - 2.2 Bone deformity; or
 - 2.3 Bone, articular or neurological complications; or
 - 2.4 Asymptomatic disease, but risk of complications due to site (base of skull, spine, long bones of lower limbs); or
 - 2.5 Preparation for orthopaedic surgery.

Renewal from any relevant practitioner. Approvals valid for 6 months where the treatment remains appropriate and the patient is benefiting from treatment.

* Tab 40 mg		30	Fosamax	
Other Treatments				
CALCITONIN X Inj 100 iu per ml, 1 ml	110.00	5	✓ <u>Miacalcic</u>	
ETIDRONATE DISODIUM – See prescribing guideline below * Tab 200 mg		100	✓ Arrow-Etidronate	

Prescribing Guidelines

Etidronate for osteoporosis should be prescribed for 14 days (400 mg in the morning) and repeated every three months. It should not be taken at the same time of the day as any calcium supplementation (minimum dose – 500 mg per day of elemental calcium). Etidronate should be taken at least 2 hours before or after any food or fluid, except water.

PAMIDRONATE DISODIUM Pamisol 1 1 Pamidronate BNM Pamidronate BNM 1 1 Pamidronate BNM RALOXIFENE HYDROCHLORIDE - Special Authority see SA1138 on the next page - Retail pharmacy Evista Tab 60 mg53.76 28

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	

SA1138 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) \geq 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -2.5) (see Notes); or
- 2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
- 3 History of two significant osteoporotic fractures demonstrated radiologically; or
- 4 Documented T-Score \leq -3.0 (see Notes); or
- 5 A 10-year risk of hip fracture \geq 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Notes); or
- 6 Patient has had a prior Special Authority approval for zoledronic acid (Underlying cause Osteoporosis) or alendronate (Underlying cause Osteoporosis).

Notes:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence used by the UK National Institute for Health and Clinical Excellence (NICE) in developing its guidance indicates that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for raloxifene funding.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis, and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

TERIPARATIDE - Special Authority see SA1139 below - Retail pharmacy

Inj 250 mcg per ml, 2.4 ml		1	Forteo
----------------------------	--	---	--------

➡SA1139 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 18 months for applications meeting the following criteria: All of the following:

- 1 The patient has severe, established osteoporosis; and
- 2 The patient has a documented T-score less than or equal to -3.0 (see Notes); and
- 3 The patient has had two or more fractures due to minimal trauma; and
- 4 The patient has experienced at least one symptomatic new fracture after at least 12 months' continuous therapy with a funded antiresorptive agent at adequate doses (see Notes).

Notes:

- a) The bone mineral density (BMD) measurement used to derive the T-score must be made using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable
- b) Antiresorptive agents and their adequate doses for the purposes of this Special Authority are defined as: alendronate sodium tab 70 mg or tab 70 mg with cholecalciferol 5,600 iu once weekly; raloxifene hydrochloride tab 60 mg once daily; zoledronic acid 5 mg per year. If an intolerance of a severity necessitating permanent treatment withdrawal develops during the use of one antiresorptive agent, an alternate antiresorptive agent must be trialled so that the patient achieves the minimum requirement of 12 months' continuous therapy.
- c) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.
- d) A maximum of 18 months of treatment (18 cartridges) will be subsidised.

MUSCULOSKELETAL SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
ZOLEDRONIC ACID – Special Authority see SA1187 below – Re Soln for infusion 5 mg in 100 ml		100 ml	🗸 A	clasta

SA1187 Special Authority for Subsidy

Initial application — (Paget's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- All of the following:
 - 1 Paget's disease; and
 - 2 Any of the following:
 - 2.1 Bone or articular pain; or
 - 2.2 Bone deformity; or
 - 2.3 Bone, articular or neurological complications; or
 - 2.4 Asymptomatic disease, but risk of complications; or
 - 2.5 Preparation for orthopaedic surgery; and
 - 3 The patient will not be prescribed more than one infusion in the 12-month approval period.

Initial application — (Underlying cause - Osteoporosis) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density (BMD) \geq 2.5 standard deviations below the mean normal value in young adults (i.e. T-Score \leq -2.5) (see Note); or
 - 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 1.4 Documented T-Score ≤ -3.0 (see Note); or
 - 1.5 A 10-year risk of hip fracture \geq 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause Osteoporosis) or raloxifene; and
- 2 The patient will not be prescribed more than one infusion in a 12-month period.

Initial application — (Underlying cause - glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- All of the following:
 - 1 The patient is receiving systemic glucocorticosteroid therapy (≥ 5 mg per day prednisone equivalents) and has already received or is expected to receive therapy for at least three months; and
 - 2 Any of the following:
 - The patient has documented BMD ≥ 1.5 standard deviations below the mean normal value in young adults (i.e. T-Score ≤ -1.5) (see Note); or
 - 2.2 The patient has a history of one significant osteoporotic fracture demonstrated radiologically; or
 - 2.3 The patient has had a Special Authority approval for alendronate (Underlying cause glucocorticosteroid therapy) or raloxifene; and
 - 3 The patient will not be prescribed more than one infusion in the 12-month approval period.

Renewal — (Paget's disease) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 The patient has relapsed (based on increases in serum alkaline phosphatase); or
 - 1.2 The patient's serum alkaline phosphatase has not normalised following previous treatment with zoledronic acid; or
 - 1.3 Symptomatic disease (prescriber determined); and

Subsidy (Manufacturer's Price)	Si	Fully ubsidised	Brand or Generic
\$	Per	~	Manufacturer

continued...

2 The patient will not be prescribed more than one infusion in the 12-month approval period.

The patient must not have had more than 1 prior approval in the last 12 months.

Renewal — (Underlying cause was, and remains, glucocorticosteroid therapy) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

1 The patient is continuing systemic glucocorticosteriod therapy (≥ 5 mg per day prednisone equivalents); and

2 The patient will not be prescribed more than one infusion in the 12-month approval period.

The patient must not have had more than 1 prior approval in the last 12 months.

Renewal — (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause - osteoporosis' criteria) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 Any of the following:
 - 1.1 History of one significant osteoporotic fracture demonstrated radiologically and documented bone mineral density $(BMD) \ge 2.5$ standard deviations below the mean normal value in young adults (i.e. T-Score \le -2.5) (see Note); or
 - 1.2 History of one significant osteoporotic fracture demonstrated radiologically, and either the patient is elderly, or densitometry scanning cannot be performed because of major logistical, technical or pathophysiological reasons. It is unlikely that this provision would apply to many patients under 75 years of age; or
 - 1.3 History of two significant osteoporotic fractures demonstrated radiologically; or
 - 1.4 Documented T-Score $\leq~$ -3.0 (see Note); or
 - 1.5 A 10-year risk of hip fracture \geq 3%, calculated using a published risk assessment algorithm (e.g. FRAX or Garvan) which incorporates BMD measurements (see Note); or
 - 1.6 Patient has had a Special Authority approval for alendronate (Underlying cause was glucocorticosteroid therapy but patient now meets the 'Underlying cause Osteoporosis' criteria) or raloxifene; and
- 2 The patient will not be prescribed more than one infusion in a 12-month period.

Notes:

- a) BMD (including BMD used to derive T-Score) must be measured using dual-energy x-ray absorptiometry (DXA). Quantitative ultrasound and quantitative computed tomography (QCT) are not acceptable.
- b) Evidence used by National Institute for Health and Clinical Excellence (NICE) guidance indicates that patients aged 75 years and over who have a history of significant osteoporotic fracture demonstrated radiologically are very likely to have a T-Score ≤ -2.5 and, therefore, do not require BMD measurement for treatment with bisphosphonates.
- c) Osteoporotic fractures are the incident events for severe (established) osteoporosis and can be defined using the WHO definitions of osteoporosis and fragility fracture. The WHO defines severe (established) osteoporosis as a T-score below -2.5 with one or more associated fragility fractures. Fragility fractures are fractures that occur as a result of mechanical forces that would not ordinarily cause fracture (minimal trauma). The WHO has quantified this as forces equivalent to a fall from a standing height or less.
- d) A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

Hyperuricaemia and Antigout

ALLOPURINOL		
* Tab 100 mg15.90	1,000	Apo-Allopurinol
* Tab 300 mg - For allopurinol oral liquid formulation refer,		
page 189	500	Apo-Allopurinol
BENZBROMARONE – Special Authority see SA1319 on the next page – Reta	il pharmacy	
Tab 100 mg45.00	100	Benzbromaron S29

MUSCULOSKELETAL SYSTEM

	Subsidy		Fully	Brand or
(Manufacturer's Pr \$	ice) S Per	Subsidised	Generic Manufacturer
	ą	Fei	6	Manulaciurei
►SA1319 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valid fo	r 6 months for a	nnlications	meetina tl	ne following criteria:
Both:		phications	meening u	te tottowing chiena.
1 Any of the following:				
1.1 The patient has a serum urate level greater than 0.36 600 mg/day and appropriate doses of probenecid; or	3 mmol/l despite	e treatment	t with allop	urinol at doses of at least
1.2 The patient has experienced intolerable side effects f and serum urate remains greater than 0.36 mmol/l de				
1.3 Both:			00	
1.3.1 The patient has renal impairment and serum ur with allopurinol (see Note); and	Ũ			
1.3.2 The patient has a rate of creatinine clearance g	greater than or e	equal to 20	ml/min; or	
 1.4 All of the following: 1.4.1 The patient is taking azathioprine and requires 	urate-lowering	therapy; an	ıd	
1.4.2 Allopurinol is contraindicated; and1.4.3 Appropriate doses of probenecid are ineffective and	e or probenecid	cannot be	used due	to reduced renal function;
2 The patient is receiving monthly liver function tests.				
Renewal from any relevant practitioner. Approvals valid for 2 years Both:	for applications	meeting th	e following	criteria:
1 The treatment remains appropriate and the patient is benefit	ting from the tre	atment; an	d	
 There is no evidence of liver toxicity and patient is continuin tests. 	•			ree months) liver function
Notes: Benzbromarone has been associated with potentially fatal he	epatotoxicity.			
Optimal treatment with allopurinol in patients with renal impairment				
dose of allopurinol then, if serum urate remains greater than 0.36 m	mol/l, a gradual	increase o	f the dose	of allopurinol to 600 mg or
the maximum tolerated dose.				
COLCHICINE * Tab 500 mcg	9 60	100		olgout
PROBENECID		100	• •	olgout
* Tab 500 mg	55.00	100	🖌 Pi	robenecid-AFT
Muscle Relaxants				
BACLOFEN				
* Tab 10 mg – For baclofen oral liquid formulation refer, page 189	2.95	100		acifen
		100	V F	achen
DANTROLENE	00.00	100		
* Cap 25 mg	32.96 (65.00)	100	D	antrium
* Cap 50 mg	()	100		annun
	(77.00)	100	D	antrium
ORPHENADRINE CITRATE	/		_	
Tab 100 mg		100	🖌 N	orflex
QUININE SULPHATE				
* Tab 300 mg	54.06	500	VQ	300
‡ Safety cap for extemporaneously compounded oral liquid p		500	÷ Q	
$_{\pm}$ -siev, explicit entertiperarioodory composition of the inquire p				

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Agents for Parkinsonism and Related Disorders				
Dopamine Agonists and Related Agents				
AMANTADINE HYDROCHLORIDE				
▲ Cap 100 mg		60	✓ <u>S</u>	ymmetrel
APOMORPHINE HYDROCHLORIDE ▲ Inj 10 mg per ml, 2 ml	110.00	5		pomine
BROMOCRIPTINE MESYLATE		0	• 4	ponnine
* Tab 2.5 mg		100	V A	po-Bromocriptine
* Cap 5 mg		100		po-Bromocriptine
ENTACAPONE				
▲ Tab 200 mg		100	🖌 <u>E</u>	ntapone
LEVODOPA WITH BENSERAZIDE				
* Tab dispersible 50 mg with benserazide 12.5 mg		100		adopar
				Dispersible
 Cap 50 mg with benserazide 12.5 mg Cap 100 mg with benserazide 25 mg 		100		adopar 62.5
 Cap 100 mg with benserazide 25 mg Cap long-acting 100 mg with benserazide 25 mg 		100 100		adopar 125 adopar HBS
* Cap 200 mg with benserazide 50 mg		100		adopar 250
LEVODOPA WITH CARBIDOPA			•	
* Tab 100 mg with carbidopa 25 mg - For levodopa with car-				
bidopa oral liquid formulation refer, page 189		50	🖌 Si	ndopa
	20.00	100	🖌 Si	nemet
* Tab long-acting 200 mg with carbidopa 50 mg	47.50	100	🖌 Si	nemet CR
* Tab 250 mg with carbidopa 25 mg	40.00	100	🖌 Si	nemet
LISURIDE HYDROGEN MALEATE				
▲ Tab 200 mcg	25.00	30	V D	opergin
PERGOLIDE				
▲ Tab 0.25 mg		100		ermax
▲ Tab 1 mg		100	✓ <u>Pe</u>	ermax
PRAMIPEXOLE HYDROCHLORIDE	= 00	~~	4.5	5.11.6
▲ Tab 1 mg		30		r Reddy's Pramipexole
▲ Tab 0.125 mg	1 95	30		r Reddy's
		00		Pramipexole
▲ Tab 0.25 mg	2.40	30		r Reddy's
				Pramipexole
▲ Tab 0.5 mg	4.20	30		r Reddy's Prominovolo
				Pramipexole
	6.00	04		anin
▲ Tab 0.25 mg ▲ Tab 1 mg		84 84	✓ <u>R</u>	
Tab 1 mg		04 84		
▲ Tab 5 mg		84	✓ R	

	Subsidy		Fully Brand or
	(Manufacturer's Price		Subsidised Generic
	\$	Per	 Manufacturer
SELEGILINE HYDROCHLORIDE			
* Tab 5 mg		100	✓ Apo-Selegiline
3			✓ Apo-Selegiline
			S29 S29
TOLCAPONE			
▲ Tab 100 mg	126.20	100	✓ Tasmar
		100	
Anticholinergics			
BENZTROPINE MESYLATE			
Tab 2 mg	7.00	60	Benztrop
Inj 1 mg per ml, 2 ml		5	Cogentin
		5	Cogentin
a) Up to 5 inj available on a PSO b) Only on a PSO			
, ,			
	05.45	050	
Tab 50 mg		250	Disipal
PROCYCLIDINE HYDROCHLORIDE			
Tab 5 mg	7.40	100	 Kemadrin
Agents for Essential Tremor, Chorea and Relate	d Disorders		
	170.00	112	Matatia
Tab 25 mg	178.00	112	✓ Motetis
Anaesthetics			
Local			
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE			4 × · · · · ·
Viscous soln 2%		200 ml	Xylocaine Viscous
Inj 1%, 5 ml – Up to 5 inj available on a PSO		50	Xylocaine
Inj 2%, 5 ml – Up to 5 inj available on a PSO		25	✓ Lidocaine-Claris
lai 10/ 00 ml	23.00	50	✓ Xylocaine
Inj 1%, 20 ml – Up to 5 inj available on a PSO		5	✓ <u>Xylocaine</u>
Inj 2%, 20 ml – Up to 5 inj available on a PSO		1 5	Lidocaine-Claris
	15.00	э	 Xylocaine
IGNOCAINE			
Gel 2%, 10 ml urethral syringe – Subsidy by endorsement	43.26	10	Pfizer
a) Up to 5 each available on a PSO			
 b) Subsidised only if prescribed for urethral or cervical adr 	ministration and the p	orescrip	tion is endorsed accordingly.
IGNOCAINE WITH CHLORHEXIDINE			
Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringes -			
Subsidy by endorsement		10	Pfizer
a) Up to 5 each available on a PSO			
b) Subsidised only if prescribed for urethral or cervical ad	ministration and the	orescrip	tion is endorsed accordingly.
IGNOCAINE WITH PRILOCAINE - Special Authority see SA09	06 on the next page	- Retai	il pharmacy
Crm 2.5% with prilocaine 2.5%	1 0	30 g OF	
Crm 2.5% with prilocaine 2.5% (5 g tubes)		5	
······································		-	· · · · · · · · · · · · · · · · · · ·

	Subsidy (Manufacturer's F \$	Price) Sul Per	Fully Brand or bsidised Generic Manufacturer
SA0906 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals val condition requiring frequent injections or venepuncture. Renewal from any relevant practitioner. Approvals valid for 2 y benefiting from treatment.	2		
Analgesics			
For Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, page 2010	age 110		
Non-opioid Analgesics			
ASPIRIN			
* Tab EC 300 mg	2.00 (8.10)	100	Aspec 300
* Tab dispersible 300 mg - Up to 30 tab available on a PSO.		100	✓ <u>Ethics Aspirin</u>
NEFOPAM HYDROCHLORIDE Tab 30 mg	23.40	90	 Acupan
PARACETAMOL			
 Tab 500 mg - Up to 30 tab available on a PSO toral liq 120 mg per 5 ml a) Up to 200 ml available on a PSO 		1,000 500 ml	 ✓ <u>Parafast</u> ✓ <u>Ethics Paracetamol</u>
b) Not in combination *‡ Oral liq 250 mg per 5 ml	6.70	1,000 ml	✓ Paracare Double Strength
a) Up to 100 ml available on a PSO b) Not in combination			ouengui
* Suppos 125 mg	7.49	20	Panadol
* Suppos 250 mg	14.40	20	Panadol
* Suppos 500 mg	20.70	50	✓ Paracare
TRAMADOL HYDROCHLORIDE			
Tab sustained-release 100 mg		20	Tramal SR 100
Tab sustained-release 150 mg		20	Tramal SR 150
Tab sustained-release 200 mg Cap 50 mg		20 100	 Tramal SR 200 Arrow-Tramadol
Opioid Analgesics		100	<u>Anon Handdor</u>
	armina dianancia	froqueses	
CODEINE PHOSPHATE – Safety medicine; prescriber may dete Tab 15 mg		100 trequency	V PSM
Tab 30 mg		100	✓ PSM
Tab 60 mg		100	✓ PSM
Tab long-acting 60 mg	07.07	60	DHC Continus

	Subsidy (Manufacturer's Price \$	e) Per	Fully Subsidised	Brand or Generic Manufacturer
FENTANYL				
a) Only on a controlled drug form				
b) No patient co-payment payable	,			
c) Safety medicine; prescriber may determine d		F	. / M	lulan Fantanul
Transdermal patch 12.5 mcg per hour	8.90	5	<u>IV</u>	i <u>ylan Fentanyl</u> Patch
Transdermal patch 25 mcg per hour		5	V M	ylan Fentanyl
			_	Patch
Transdermal patch 50 mcg per hour	11.50	5	✓ <u>M</u>	ylan Fentanyl
		_		Patch
Transdermal patch 75 mcg per hour		5	✓ <u>M</u>	lylan Fentanyl
Transdermal patch 100 mcg per hour	14 50	5	V M	<u>Patch</u> Iylan Fentanyl
nansoonnai paten roo meg per nour		5	•	Patch
FENTANYL CITRATE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine d	ispensing frequency			
Inj 50 mcg per ml, 2 ml		10		oucher and Muir
Inj 50 mcg per ml, 10 ml	11.77	10	✓ <u>B</u>	oucher and Muir
METHADONE HYDROCHLORIDE				
 a) Only on a controlled drug form 				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine d				
 d) Extemporaneously compounded methadone powder, not methadone tablets). 	will only be reimbursed at the rat	e of the	e cheapest 1	form available (methadone
e) For methadone hydrochloride oral liquid refer	nage 102			
Tab 5 mg		10	V M	lethatabs
Oral liq 2 mg per ml		200 ml	-	iodone
t Oral liq 5 mg per ml	5.55	200 ml	✓ B	iodone Forte
the second	6.55	200 ml	✓ <u>B</u>	iodone Extra Forte
Inj 10 mg per ml, 1 ml	61.00	10	🗸 A	FT
MORPHINE HYDROCHLORIDE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine d		000		A . M
Oral liq 1 mg per ml		200 ml		A-Morph
Oral liq 2 mg per ml Oral liq 5 mg per ml		200 ml 200 ml		<u>A-Morph</u> A-Morph
training of this por this training of this por this training of this por this		200 ml		A-Morph

	Subsidy (Manufacturer's Price)	Fully Subsidised	Brand or Generic
	(Manulacturer's Frice \$	Per		Manufacturer
/ORPHINE SULPHATE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing freq	nuency			
Tab immediate-release 10 mg		10	V S	evredol
Tab long-acting 10 mg		10		rrow-Morphine LA
Tab immediate-release 20 mg		10		evredol
Tab long-acting 30 mg		10		rrow-Morphine LA
Tab long-acting 60 mg		10		rrow-Morphine LA
Tab long-acting 100 mg		10		rrow-Morphine LA
Cap long-acting 10 mg		10		-Eslon
Cap long-acting 30 mg		10		<u>i-Eslon</u>
Cap long-acting 60 mg		10		-Eslon
Cap long-acting 100 mg		10		-Eslon
Inj 5 mg per ml, 1 ml – Up to 5 inj available on a PSO	5.51	5	<u>v</u> <u>b</u>	BL Morphine
	. ==	_		Sulphate
Inj 10 mg per ml, 1 ml – Up to 5 inj available on a PSO	4.79	5	✓ <u>D</u>	BL Morphine
		_		Sulphate
Inj 15 mg per ml, 1 ml – Up to 5 inj available on a PSO	5.01	5	✓ <u>D</u>	BL Morphine
				Sulphate
Inj 30 mg per ml, 1 ml – Up to 5 inj available on a PSO	5.30	5	✓ <u>D</u>	BL Morphine
				Sulphate
MORPHINE TARTRATE				
a) Only on a controlled drug form				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing freq	nuency			
Inj 80 mg per ml, 1.5 ml		5	🖌 Н	ospira
Inj 80 mg per ml, 5 ml		5		ospira
		•	•	
DXYCODONE HYDROCHLORIDE				
a) Only on a controlled drug form				
b) See prescribing guideline below				
c) No patient co-payment payable				
d) Safety medicine; prescriber may determine dispensing free				
Tab controlled-release 5 mg	7.51	20		xyContin
Tab controlled-release 10 mg		20		xyContin
Tab controlled-release 20 mg		20		xyContin
Tab controlled-release 40 mg		20	V 0	xyContin
Tab controlled-release 80 mg		20	V 0	xyContin
Cap 5 mg	2.83	20	V 0	xyNorm
Cap 10 mg	5.58	20	V 0	xyNorm
Cap 20 mg	9.77	20	V 0	xyNorm
Oral lig 5 mg per 5 ml		250 ml	V 0	xyNorm
Inj 10 mg per ml, 1 ml		5		xycodone Orion
Inj 10 mg per ml, 2 ml		5		xycodone Orion
Inj 50 mg per ml, 1 ml		5		xyNorm
		Ũ	• •	
rescriping Guideline			arabiaa au	Inhoto and alinical ad
Prescribing Guideline Prescribers should note that oxycodone is significantly more ex	nensive than long-a	ctina n		
Prescribers should note that oxycodone is significantly more ex				ipnale and clinical ad
Prescribers should note that oxycodone is significantly more ex uggests that it is reasonable to consider this as a second-line ag	ent to be used after	morphi	ne.	iiphale and clinical ad
Prescribers should note that oxycodone is significantly more ex	ent to be used after may determine dispe	morphi	ne. requency	aracetamol +

<u>Codeine (Relieve)</u>

	Subsidy		Fully	Brand or
	(Manufacturer's Price)		Subsidised	Generic
	\$	Per	~	Manufacturer
PETHIDINE HYDROCHLORIDE				
a) Only on a controlled drug form				
, ,				
b) No patient co-payment payable				
c) Safety medicine; prescriber may determine dispensing free				~~~
Tab 50 mg		10	<u> </u>	
Tab 100 mg		10	<u> </u>	
Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO	5.51	5	✓ <u>D</u>	BL Pethidine
		_	4 -	Hydrochloride
Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO	5.83	5	✓ <u>D</u>	BL Pethidine
				Hydrochloride
Antidepressants				
Cyclic and Related Agents				
-)				
AMITRIPTYLINE - Safety medicine; prescriber may determine d	ispensing frequency			
Tab 10 mg		100	✓ A	rrow Amitriptyline
Tab 25 mg	1.85	100	V A	mitrip
Tab 50 mg	3.60	100	🖌 🖌	mitrip
CLOMIPRAMINE HYDROCHLORIDE – Safety medicine; prescri	har may datarmina di	cnonc	ina froquon	01/
Tab 10 mg		100		po-Clomipramine
Tab 25 mg		100		po-Clomipramine
•				po-ciomprannie
DOTHIEPIN HYDROCHLORIDE - Safety medicine; prescriber m	, ,	sing fre		
Tab 75 mg	10.50	100		opress
Cap 25 mg	6.17	100	V D	opress
DOXEPIN HYDROCHLORIDE - Safety medicine; prescriber may	v determine dispensin	na frea	uencv	
Cap 10 mg	, i	100	🗸 🗸	nten
Cap 25 mg		100	✓ A	
Cap 50 mg		100	✓ A	
IMIPRAMINE HYDROCHLORIDE – Safety medicine; prescriber		-		
Tab 10 mg		50		ofranil
Tab 25 mg	8.80	50	V T	ofranil
MAPROTILINE HYDROCHLORIDE - Safety medicine; prescribe	er may determine disp	ensind	frequency	
Tab 25 mg		100		udiomil
Tab 75 mg		30	V L	udiomil
-				
MIANSERIN HYDROCHLORIDE – Special Authority see SA104				alvan
Tab 30 mg		30		olvon

➡SA1048 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

1 Both:

- 1.1 Depression; and
- 1.2 Either:
 - 1.2.1 Co-existent bladder neck obstruction; or
 - 1.2.2 Cardiovascular disease; or

2 Both:

- 2.1 The patient has a severe major depressive episode; and
- 2.2 Either:

	Subsidy		Fully	Brand or
	(Manufacturer's Price \$) Subs Per	sidised	Generic Manufacturer
continued	·	-		
2.2.1 The patient must have had a trial of two dif	ferent antidepressants	and was ur	hable to	tolerate the treatments or
failed to respond to an adequate dose over				
2.2.2 Both: 2.2.2.1 The patient is currently a hospital in	nationt as a result of	an acuta da	orocciv	vo opicada: and
2.2.2.2 The patient is currently a hospital in 2.2.2.2 The patient must have had a trial of				
respond to an adequate dose over a	an adequate period of	time.		
Renewal from any relevant practitioner. Approvals valid for 2 benefiting from treatment.				
NORTRIPTYLINE HYDROCHLORIDE – Safety medicine; pres Tab 10 mg		dispensing 1 100		ncy Iorpress
Tab 25 mg		180		orpress
Monoamine-Oxidase Inhibitors (MAOIs) - Non S				
. ,	Selective			
PHENELZINE SULPHATE	05.00	100	V N	avalil
* Tab 15 mg		100	V N	ardii
TRANYLCYPROMINE SULPHATE * Tab 10 mg	22.94	50	✓ P	arnate
Monoamine-Oxidase Type A Inhibitors			• 1	
Monoannine-Oxidase Type A minibitors				
MOCLOBEMIDE Note: There is a significant cost differential between moclol expensive). For depressive syndromes it is therefore more ing prescribing moclobemide.	cost-effective to start to		th fluox	etine first before consider-
* Tab 150 mg		500 100		po-Moclobemide
* Tab 300 mg	29.51	100	• <u>A</u>	po-Moclobemide
Selective Serotonin Reuptake Inhibitors				
CITALOPRAM HYDROBROMIDE				
* Tab 20 mg	2.34	84	✓ <u>A</u>	rrow-Citalopram
ESCITALOPRAM * Tab 10 mg	2.65	28		oxalate
* Tab 20 mg		28		oxalate
FLUOXETINE HYDROCHLORIDE			_	
* Tab dispersible 20 mg, scored – Subsidy by endorsement	2.50	30	✓ <u>F</u>	luox
Subsidised by endorsement 1) When prescribed for a patient who cannot swallow	whole teblete or early	uloo and the	nrooo	ription is anderead accord
ingly; or	whole tablets of caps		; piesc	ription is endorsed accord-
2) When prescribed in a daily dose that is not a m				
endorsed. Note: Tablets should be combined with		ncremental 84	10 mg	
* Cap 20 mg PAROXETINE HYDROCHLORIDE	2.10	04	₩ <u>Γ</u>	
* Tab 20 mg	2.38	30	V L	oxamine
SERTRALINE				<u></u>
* Tab 50 mg		90		rrow-Sertraline
* Tab 100 mg	9.60	90	✓ <u>A</u>	rrow-Sertraline

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Other Antidepressants				
MIRTAZAPINE – Special Authority see SA0994 below – Reta	il pharmacy			
Tab 30 mg	8.78	30	✓ <u>A</u>	vanza
Tab 45 mg	13.95	30	✓ <u>A</u>	vanza
SA0994 Special Authority for Subsidy				
itial application from any relevant practitioner. Approvals va	alid for 2 years for applica	ations	meeting the	e following criteria:
1 The patient has a severe major depressive episode; an 2 Either:	d			
2.1 The patient must have had a trial of two differen	t antidepresents and wa	s una	ble to tolera	ate the treatments or faile
to respond to an adequate dose over an adequa				ks); or
to respond to an adequate dose over an adequa 2.2 Both: 2.2.1 The patient is currently a hospital in-patie 2.2.2 The patient must have had a trial of one of	ate period of time (usually ent as a result of an acute ther antidepressant and e	at lea	ast four wee essive episo	ode; and
to respond to an adequate dose over an adequa 2.2 Both: 2.2.1 The patient is currently a hospital in-patie	ate period of time (usually ent as a result of an acute ther antidepressant and e eriod of time.	at lea depre	essive episo could not tol	ode; and lerate it or failed to respon
to respond to an adequate dose over an adequa 2.2 Both: 2.2.1 The patient is currently a hospital in-patie 2.2.2 The patient must have had a trial of one of to an adequate dose over an adequate p tenewal from any relevant practitioner. Approvals valid for 2 nined).	the period of time (usually ent as a result of an acute ther antidepressant and e eriod of time. years where the patient	at lea depre	essive episo could not tol	ode; and lerate it or failed to respon
to respond to an adequate dose over an adequa 2.2 Both: 2.2.1 The patient is currently a hospital in-patie 2.2.2 The patient must have had a trial of one of to an adequate dose over an adequate per tenewal from any relevant practitioner. Approvals valid for 2	the period of time (usually ent as a result of an acute ther antidepressant and e eriod of time. years where the patient ail pharmacy	at lea depre	ast four wee essive episo could not tol high risk of	ode; and lerate it or failed to respon
to respond to an adequate dose over an adequa 2.2 Both: 2.2.1 The patient is currently a hospital in-patie 2.2.2 The patient must have had a trial of one or to an adequate dose over an adequate p tenewal from any relevant practitioner. Approvals valid for 2 nined). ENLAFAXINE – Special Authority see SA1061 below – Reta	ate period of time (usually ent as a result of an acute ther antidepressant and e eriod of time. years where the patient ail pharmacy 	at lea depre either o has a	ast four wee essive episo could not tol high risk of ✓ A	ode; and erate it or failed to respon relapse (prescriber dete rrow-Venlafaxine
to respond to an adequate dose over an adequa 2.2 Both: 2.2.1 The patient is currently a hospital in-patie 2.2.2 The patient must have had a trial of one of to an adequate dose over an adequate per tenewal from any relevant practitioner. Approvals valid for 2 lined). ENLAFAXINE – Special Authority see SA1061 below – Reta Tab 37.5 mg	the period of time (usually ent as a result of an acute ther antidepressant and e eriod of time. years where the patient ail pharmacy 	at lea depre either o has a 28	ast four wee essive episo could not tol high risk of ✓ A ✓ A	ode; and erate it or failed to respon relapse (prescriber dete rrow-Venlafaxine XR rrow-Venlafaxine
to respond to an adequate dose over an adequa 2.2 Both: 2.2.1 The patient is currently a hospital in-patie 2.2.2 The patient must have had a trial of one of to an adequate dose over an adequate po- tenewal from any relevant practitioner. Approvals valid for 2 nined). IENLAFAXINE – Special Authority see SA1061 below – Reta Tab 37.5 mg Tab 75 mg	the period of time (usually ent as a result of an acute ther antidepressant and e eriod of time. years where the patient ail pharmacy 	at lea depre either o has a 28 28	ast four wee essive episo could not tol high risk of ✓ A ✓ A	ode; and erate it or failed to respon- relapse (prescriber dete rrow-Venlafaxine XR rrow-Venlafaxine XR rrow-Venlafaxine XR
to respond to an adequate dose over an adequa 2.2 Both: 2.2.1 The patient is currently a hospital in-patie 2.2.2 The patient must have had a trial of one or to an adequate dose over an adequate pe enewal from any relevant practitioner. Approvals valid for 2 ined). ENLAFAXINE – Special Authority see SA1061 below – Reta Tab 37.5 mg Tab 75 mg Tab 150 mg	the period of time (usually ent as a result of an acute ther antidepressant and e eriod of time. years where the patient ail pharmacy 	at lea depre ither o has a 28 28 28 28	ast four wee essive episo could not tol high risk of A A A A A A	ode; and erate it or failed to respon- relapse (prescriber dete rrow-Venlafaxine XR rrow-Venlafaxine XR rrow-Venlafaxine XR rrow-Venlafaxine
to respond to an adequate dose over an adequa 2.2 Both: 2.2.1 The patient is currently a hospital in-patie 2.2.2 The patient must have had a trial of one of to an adequate dose over an adequate po- tenewal from any relevant practitioner. Approvals valid for 2 nined). IENLAFAXINE – Special Authority see SA1061 below – Reta Tab 37.5 mg Tab 75 mg Tab 150 mg	te period of time (usually ent as a result of an acute ther antidepressant and e eriod of time. years where the patient ail pharmacy 	at lea depre ither of has a 28 28 28 28 28 28	ast four wee essive episo could not tol high risk of A A A A A A A A A A A A A A	ode; and erate it or failed to respon relapse (prescriber dete XR rrow-Venlafaxine XR rrow-Venlafaxine XR rrow-Venlafaxine XR rrow-Venlafaxine XR

Initial application only from a relevant specialist or vocationally registered general practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 The patient has 'treatment-resistant' depression; and
- 2 Either:
 - 2.1 The patient must have had a trial of two different antidepressants and have had an inadequate response from an adequate dose over an adequate period of time (usually at least four weeks); or

2.2 Both:

- 2.2.1 The patient is currently a hospital in-patient as a result of an acute depressive episode; and
- 2.2.2 The patient must have had a trial of one other antidepressant and have had an inadequate response from an adequate dose over an adequate period of time.

Renewal from any medical practitioner. Approvals valid for 2 years where the patient has a high risk of relapse (prescriber determined).

	Subsidy (Manufacturer's Price \$	e) Subs Per	Fully sidised	Brand or Generic Manufacturer
Antiepilepsy Drugs				
Agents for Control of Status Epilepticus				
CLONAZEPAM – Safety medicine; prescriber may determine disp Inj 1 mg per ml, 1 ml		5	🖌 R	ivotril
DIAZEPAM – Safety medicine; prescriber may determine dispens Inj 5 mg per ml, 2 ml – Subsidy by endorsement a) Up to 5 inj available on a PSO b) Only on a PSO c) PSO must be endorsed "not for anaesthetic procedures"	9.24	5	✔ M	ayne
Rectal tubes 5 mg - Up to 5 tube available on a PSO	25.05	5		tesolid
Rectal tubes 10 mg – Up to 5 tube available on a PSO		5	✓ Si	tesolid
PARALDEHYDE * Inj 5 ml	1.500.00	5	🗸 A	FT
PHENYTOIN SODIUM		0	• //	
 * Inj 50 mg per ml, 2 ml – Up to 5 inj available on a PSO * Inj 50 mg per ml, 5 ml – Up to 5 inj available on a PSO 		5 5	✔ M ✔ M	
Control of Epilepsy				
CARBAMAZEPINE * Tab 200 mg Tab long-acting 200 mg * Tab 400 mg * Tab long-acting 400 mg * Tab long-acting 400 mg * ‡ Oral liq 100 mg per 5 ml	16.98 34.58 39.17	100 100 100 100 250 ml	✓ Te ✓ Te	egretol egretol CR egretol egretol CR egretol
CLOBAZAM – Safety medicine; prescriber may determine dispen Tab 10 mg ‡ Safety cap for extemporaneously compounded oral liquic CLONAZEPAM – Safety medicine; prescriber may determine disp	sing frequency 9.12 I preparations.	50	🖌 Fi	risium
CLONAZEPANI – Salety medicine, prescriber may determine disp Oral drops 2.5 mg per ml	0 1 7	10 ml OP	🗸 R	ivotril
ETHOSUXIMIDE * Cap 250 mg *‡ Oral liq 250 mg per 5 ml		200 200 ml		arontin arontin
GABAPENTIN – Special Authority see SA1071 below – Retail ph ▲ Cap 100 mg		100	🗸 N	upentin
 ▲ Cap 300 mg - For gabapentin oral liquid formulation refer, page 189 ▲ Cap 400 mg 	11.50	100 100	🗸 N	upentin upentin

SA1071 Special Authority for Subsidy

Initial application — (Epilepsy) from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria:

Either:

- 1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
- 2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents.

Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

continued...

Note: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Initial application — (Neuropathic pain) from any relevant practitioner. Approvals valid for 3 months where the patient has tried and failed, or has been unable to tolerate, treatment with a tricyclic antidepressant.

Renewal — (Epilepsy) from any relevant practitioner. Approvals valid without further renewal unless notified where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life.

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

Renewal — (Neuropathic pain) from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria:

Either:

- 1 The patient has demonstrated a marked improvement in their control of pain (prescriber determined); or
- 2 The patient has previously demonstrated clinical responsiveness to gabapentin and has now developed neuropathic pain in a new site.

GABAPENTIN (NEURONTIN) - Special Authority see SA0973 below - Retail pharmacy

A ⁻	Tab 600 mg	67.50	100	Neurontin
	Cap 100 mg		100	Neurontin
	Cap 300 mg - For gabapentin (neurontin) oral liquid formu-			
	lation refer, page 189		100	Neurontin
A (Cap 400 mg		100	Neurontin

SA0973 Special Authority for Subsidy

Notes: Subsidy for patients pre-approved by PHARMAC on 1 August 2009. Approvals valid without further renewal unless notified. No new approvals will be granted from 1 August 2009.

LACOSAMIDE - Special Authority see SA1125 below - Retail pharmacy

Tab 50 mg		14	Vimpat
Tab 100 mg		14	Vimpat
C C	200.24	56	Vimpat
Tab 150 mg	75.10	14	Vimpat
C C	300.40	56	Vimpat
Tab 200 mg		56	Vimpat

➡SA1125 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both:

- 1 Patient has partial-onset epilepsy; and
- 2 Seizures are not adequately controlled by, or patient has experienced unacceptable side effects from, optimal treatment with all of the following: sodium valproate, topiramate, levetiracetam and any two of carbamazepine, lamotrigine and phenytoin sodium (see Note).

Note: "Optimal treatment" is defined as treatment which is indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight and other features affecting the pharmacokinetics of the drug with good evidence of compliance. Women of childbearing age are not required to have a trial of sodium valproate.

Renewal from any relevant practitioner. Approvals valid for 24 months where the patient has demonstrated a significant and sustained improvement in seizure rate or severity and/or quality of life compared with that prior to starting lacosamide treatment (see Note).

Note: As a guideline, clinical trials have referred to a notional 50% reduction in seizure frequency as an indicator of success with anticonvulsant therapy and have assessed quality of life from the patient's perspective.

	Subsidy (Manufacturer's Price)	c	Fully Brand or Subsidised Generic
	(Manufacturer's Price) \$	Per	Manufacturer
MOTRIGINE			
Tab dispersible 2 mg	6.74	30	 Lamictal
Tab dispersible 5 mg	9.64	30	 Lamictal
	15.00	56	Arrow-Lamotrigine
Tab dispersible 25 mg	19.38	56	Logem
	20.40		 Arrow-Lamotrigine Mogine
	29.09		
Tab dispersible 50 mg		56	✓ Logem
	34.70		✓ Arrow-Lamotrigine
			✓ Mogine
	47.89		Lamictal
Tab dispersible 100 mg	56.91	56	Logem
	59.90		Arrow-Lamotrigine
			 Mogine
	79.16		Lamictal
VETIRACETAM			
Tab 250 mg	24.03	60	 Levetiracetam-Rex
Tab 500 mg - For levetiracetam oral liquid formulation refer,			
page 189		60	 Levetiracetam-Rex
Tab 750 mg	45.23	60	Levetiracetam-Rex
ENOBARBITONE			
For phenobarbitone oral liquid refer, page 192			
Tab 15 mg		500	✔ PSM
Tab 30 mg		500	V PSM
ENYTOIN SODIUM			
Tab 50 mg	42 09	200	Dilantin Infatab
Cap 30 mg		200	✓ Dilantin
Cap 100 mg		200	✓ Dilantin
: Oral liq 30 mg per 5 ml		500 ml	✓ Dilantin
IMIDONE			
Tab 250 mg	17.05	100	✓ Apo-Primidone
ő		100	V Apo-Fillindone
DDIUM VALPROATE			4 - 111 - 11 - 11
Tab 100 mg		100	Epilim Crushable
Tab 200 mg EC		100	Epilim
Tab 500 mg EC		100	✓ Epilim
Cral liq 200 mg per 5 ml		300 ml	Epilim S/F Liquid
Inj 100 mg per ml, 4 ml	41.50	1	 Epilim Syrup Epilim IV
IRIPENTOL - Special Authority see SA1330 on the next page			
Cap 250 mg		60	V Diacomit S29
Powder for oral liq 250 mg sachet		60	✓ Diacomit s29
1 0 main 101 01 at 119 200 119 3a01161		00	

Subsidy		Fully	Brand or	
(Manufacturer's Price)		Subsidised	Generic	
\$	Per	~	Manufacturer	

SA1330 Special Authority for Subsidy

Initial application only from a paediatric neurologist or Practitioner on the recommendation of a paediatric neurologist. Approvals valid for 6 months for applications meeting the following criteria:

- Both:
 - 1 Patient has confirmed diagnosis of Dravet syndrome; and
 - 2 Seizures have been inadequately controlled by appropriate courses of sodium valproate, clobazam and at least two of the following: topiramate, levetiracetam, ketogenic diet.

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified where the patient continues to benefit from treatment as measured by reduced seizure frequency from baseline.

TOPIRAMATE

▲ Tab 25 mg		60	Arrow-Topiramate
-	26.04		Topamax
▲ Tab 50 mg		60	Arrow-Topiramate
	44.26		Topamax
▲ Tab 100 mg		60	Arrow-Topiramate
-	75.25		Topamax
▲ Tab 200 mg		60	Arrow-Topiramate
-	129.85		Topamax
Sprinkle cap 15 mg		60	Topamax
Sprinkle cap 25 mg		60	Topamax
VIGABATRIN – Special Authority see SA1072 below	 Retail pharmacy 		
▲ Tab 500 mg		100	 Sabril

➡SA1072 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 15 months for applications meeting the following criteria: Both:

1 Either:

- 1.1 Patient has infantile spasms; or
- 1.2 Both:
 - 1.2.1 Patient has epilepsy; and
 - 1.2.2 Either:
 - 1.2.2.1 Seizures are not adequately controlled with optimal treatment with other antiepilepsy agents; or
 - 1.2.2.2 Seizures are controlled adequately but the patient has experienced unacceptable side effects from optimal treatment with other antiepilepsy agents; and

2 Either:

- Patient is, or will be, receiving regular automated visual field testing (ideally before starting therapy and on a 6-monthly basis thereafter); or
- 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

Notes: "Optimal treatment with other antiepilepsy agents" is defined as treatment with other antiepilepsy agents which are indicated and clinically appropriate for the patient, given in adequate doses for the patient's age, weight, and other features affecting the pharmacokinetics of the drug with good evidence of compliance.

Vigabatrin is associated with a risk of irreversible visual field defects, which may be asymptomatic in the early stages.

Renewal from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Both:

- 1 The patient has demonstrated a significant and sustained improvement in seizure rate or severity and or quality of life; and
- 2 Either:
 - 2.1 Patient is receiving regular automated visual field testing (ideally every 6 months) on an ongoing basis for duration of treatment with vigabatrin; or
 - 2.2 It is impractical or impossible (due to comorbid conditions) to monitor the patient's visual fields.

	Subsidy (Manufacturer's Price \$	e) Su Per	Fully Ibsidised	Brand or Generic Manufacturer
continued Notes: As a guideline, clinical trials have referred to a notional 50% anticonvulsant therapy and have assessed quality of life from the p Vigabatrin is associated with a risk of irreversible visual field defect	atient's perspective	e.		
Antimigraine Preparations				
For Anti-inflammatory NSAIDS refer to MUSCULOSKELETAL, pag	je 110			
Acute Migraine Treatment				
ERGOTAMINE TARTRATE WITH CAFFEINE Tab 1 mg with caffeine 100 mg	31.00	100	✔ C	afergot
METOCLOPRAMIDE HYDROCHLORIDE WITH PARACETAMOL Tab 5 mg with paracetamol 500 mg	6.77	60	V P	aramax
RIZATRIPTAN Tab orodispersible 10 mg	18.00	30	✓ <u>R</u>	izamelt
SUMATRIPTAN Tab 50 mg		4 100		rrow-Sumatriptan
Tab 100 mg	38.83 1.55 77.66	2 100	✓ A	rrow-Sumatriptan rrow-Sumatriptan rrow-Sumatriptan
Inj 12 mg per ml, 0.5 ml - Maximum of 10 inj per prescription		2 OP	✓ <u>A</u>	rrow-Sumatriptan
Prophylaxis of Migraine				
For Beta Adrenoceptor Blockers refer to CARDIOVASCULAR SYS	TEM, page 55			
PIZOTIFEN * Tab 500 mcg	23.21	100	✓ <u>s</u>	andomigran_
Antinausea and Vertigo Agents				
For Antispasmodics refer to ALIMENTARY TRACT, page 26				
APREPITANT – Special Authority see SA0987 below – Retail pha Cap 2 × 80 mg and 1 × 125 mg		3 OP		mend Tri-Pack
►SA0987 Special Authority for Subsidy		3 OF	V L	Inenu III-rack
Initial application from any relevant practitioner. Approvals valid for chemotherapy and/or anthracycline-based chemotherapy for the tr Renewal from any relevant practitioner. Approvals valid for 12 mont apy and/or anthracycline-based chemotherapy for the treatment of	eatment of maligna	ancy.		
BETAHISTINE DIHYDROCHLORIDE * Tab 16 mg		84	V V	ergo 16
CYCLIZINE HYDROCHLORIDE Tab 50 mg	0.59	10	✓ <u>N</u>	ausicalm
CYCLIZINE LACTATE Inj 50 mg per ml, 1 ml	14.95	5	🗸 N	ausicalm
DOMPERIDONE * Tab 10 mg – For domperidone oral liquid formulation refer,	2.05	100	<u>م</u> ا	rokinov
page 189 HYOSCINE (SCOPOLAMINE) – Special Authority see SA0939 or				<u>rokinex</u>

✓ Scopoderm TTS

2

	Subsidy (Manufacturer's Pr \$	ice) Si Per	Fully Brand or ubsidised Generic ✓ Manufacturer
■SA0939 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals value All of the following: 1 Control of intractable nausea, vomiting, or inability to swa 2 Patient cannot tolerate or does not adequately respond to	llow saliva in the tre	eatment of r	
3 The applicant must specify the underlying malignancy or	chronic disease.		a ta a su a su a ta a su a ta ta a su a ta a ta
Renewal from any relevant practitioner. Approvals valid for 1 benefiting from treatment.	year where the tre	atment rem	ains appropriate and the patient is
HYOSCINE HYDROBROMIDE			
* Inj 400 mcg per ml, 1 ml	6.66	5	Mayne
METOCLOPRAMIDE HYDROCHLORIDE			-
* Tab 10 mg - For metoclopramide hydrochloride oral liqui	d		
formulation refer, page 189		100	✓ Metamide
* Inj 5 mg per ml, 2 ml - Up to 5 inj available on a PSO		10	✓ Pfizer
ONDANSETRON			
* Tab 4 mg	5.10	30	✓ Dr Reddy's
5			Ondansetron
* Tab disp 4 mg	0.68	4	✓ Dr Reddy's
			Ondansetron
	1.70	10	✓ Dr Reddy's
			Ondansetron
	17.18		✓ Zofran Zydis
* Tab 8 mg	1.70	10	✓ <u>Dr Reddy's</u>
* Tab disp 8 mg	2.00	10	Ondansetron ✓ Dr Reddy's
	2.00	10	Ondansetron
PROCHLORPERAZINE			endenooren
* Tab 3 mg buccal	5 97	50	
	(15.00)	00	Buccastem
* Tab 5 mg – Up to 30 tab available on a PSO	()	500	✓ Antinaus
* Inj 12.5 mg per ml, 1 ml - Up to 5 inj available on a PSO		10	✓ Stemetil
* Suppos 25 mg	23.87	5	 Stemetil
PROMETHAZINE THEOCLATE			
* Tab 25 mg	1.20	10	
	(6.24)		Avomine
TROPISETRON			
a) Maximum of 6 cap per prescription			
b) Maximum of 3 cap per dispensing			
c) Not more than one prescription per month.			
Cap 5 mg	77.41	5	Navoban

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	I Generic
\$	Per 🖌	Manufacturer

Antipsychotics

Guidelines for the use of atypical antipsychotic agents

Diagnosis: Schizophrenia and related psychoses when positive symptoms (delusions, hallucinations and thought disorder) are prominent and/or disabling or when both positive symptoms and negative symptoms (flattened affect, emotional and social withdrawal and poverty of speech) are present. Treatment: Before initiating atypical antipsychotic therapy, physicians should consider whether the patient is likely to respond to and/or tolerate conventional antipsychotic therapy and, where appropriate, trial one or more conventional agent prior to use of an atypical agent.

General

AMISULPRIDE - Safety medicine; prescriber may determ	ine dispensing frequency	y	
Tab 100 mg	6.22	30	Solian
Tab 200 mg	21.92	60	Solian
Tab 400 mg		60	Solian
Oral liq 100 mg per ml		60 ml	Solian
ARIPIPRAZOLE – Special Authority see SA0920 below – Safety medicine; prescriber may determine dispensing			
Tab 10 mg		30	Abilify
Tab 15 mg	175.28	30	Abilify
Tab 20 mg	213.42	30	🖌 Abilify
Tab 30 mg		30	🖌 Abilify

➡SA0920 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

- 1 Patient is suffering from schizophrenia or related psychoses; and
- 2 Either:
 - 2.1 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of unacceptable side effects; or
 - 2.2 An effective dose of risperidone or quetiapine has been trialled and has been discontinued, or is in the process of being discontinued, because of inadequate clinical response.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

CHLORPROMAZINE HYDROCHLORIDE – Safety medicine; prescriber may determine dispensing frequency

0 V Largactil	100		Tab 10 mg – Up to 30 tab available on a PSO
0 V Largactil	100		Tab 25 mg - Up to 30 tab available on a PSO
0 V Largactil	100		Tab 100 mg - Up to 30 tab available on a PSO
0 V Largactil	10	a PSO25.66	Inj 25 mg per ml, 2 ml - Up to 5 inj available on a PS

	Subsidy (Manufacturer's Price) S		Fully Brand or Subsidised Generic
	\$	Per	Manufacturer
CLOZAPINE – Hospital pharmacy [HP4]			
Safety medicine; prescriber may determine dispensing freq	uency		
Tab 25 mg		50	Clozaril
	26.74	100	Clozaril
	6.69	50	Clopine
	13.37	100	✓ Clopine
Tab 50 mg		50	✓ Clopine
0	17.33	100	✓ Clopine
Tab 100 mg		50	Clozaril
-	69.30	100	Clozaril
	17.33	50	Clopine
	34.65	100	✓ Clopine
Tab 200 mg		50	Clopine
•	69.30	100	Clopine
Suspension 50 mg per ml	17.33	100 ml	Clopine
ALOPERIDOL - Safety medicine; prescriber may determine (dispensing frequenc	cv	
Tab 500 mcg – Up to 30 tab available on a PSO		100	Serenace
Tab 1.5 mg – Up to 30 tab available on a PSO		100	✓ Serenace
Tab 5 mg – Up to 30 tab available on a PSO		100	✓ Serenace
Oral lig 2 mg per ml – Up to 200 ml available on a PSO		100 ml	✓ Serenace
Inj 5 mg per ml, 1 ml – Up to 5 inj available on a PSO		10	✓ Serenace
EVOMEPROMAZINE - Safety medicine; prescriber may dete		oguopov	
, , , , , , , , , , , , , , , , , , ,	1 0	, ,	A Norinon
Tab 25 mg		100 100	 Nozinan Nozinan
Tab 100 mg		100	✓ Nozinan
Inj 25 mg per ml, 1 ml			Nozinan
THIUM CARBONATE – Safety medicine; prescriber may dete	1 0	, ,	
Tab 250 mg		500	Lithicarb FC
Tab 400 mg		100	Lithicarb FC
Tab long-acting 400 mg		100	Priadel
Cap 250 mg	9.42	100	Douglas
LANZAPINE - Safety medicine; prescriber may determine dis	spensing frequency		
Tab 2.5 mg	2.00	28	Dr Reddy's
			Olanzapine
			Olanzine
	(51.07)		Zyprexa
Tab 5 mg	3.85	28	Dr Reddy's
			Olanzapine
			Olanzine
	(101.21)		Zyprexa
Tab 10 mg	6.35	28	Dr Reddy's
			Olanzapine
			 Olanzine
	(204.49)		Zyprexa
ERICYAZINE - Safety medicine; prescriber may determine di	spensing frequency	/	
Tab 2.5 mg		, 100	Neulactil
Tab 10 mg		100	V Neulactil
	UP.177	100	• Houldotti

	Subsidy (Manufacturer's Price) \$	Per	Fully Brand or Subsidised Generic Manufacturer
ETIAPINE - Safety medicine; prescriber may determine d	ispensing frequency		
Tab 25 mg	7.00	60	 Dr Reddy's Quetiapine
			✓ Seroquel
	10.50	90	Quetapel
Tab 100 mg	14.00	60	Dr Reddy's
			Quetiapine
			 Seroquel
T 000	21.00	90	V Quetapel
Tab 200 mg		60	✓ Dr Reddy's
			Quetiapine
	36.00	90	 Seroquel Quetapel
Tab 300 mg		90 60	✓ Dr Reddy's
		00	Quetiapine
			✓ Seroquel
	60.00	90	V Quetapel
PERIDONE - Safety medicine; prescriber may determine	dispensing frequency		·
Tab 0.5 mg	1 0 1 7	60	Apo-Risperidone
		00	✓ Dr Reddy's
			Risperidone
			✓ Ridal
	1.17	20	
	(2.86)		Risperdal
Tab 1 mg	6.00	60	Apo-Risperidone
			 Dr Reddy's Risperidone
			Ridal
	(16.92)		Risperdal
Tab 2 mg	11.00	60	Apo-Risperidone
			✓ Dr Reddy's
			Risperidone
	(33.84)		Ridal Risperdal
Tab 3 mg	(/	60	✓ Apo-Risperidone
		00	✓ Dr Reddy's
			Risperidone
			•
	(50.78)		Risperidone
Tab 4 mg	(/	60	Risperidone Ridal Risperdal Apo-Risperidone
Tab 4 mg	(/	60	Risperidone ✓ Ridal Risperdal ✓ Apo-Risperidone ✓ Dr Reddy's
Tab 4 mg	(/	60	Risperidone Ridal Risperdal Apo-Risperidone Dr Reddy's Risperidone
Tab 4 mg		60	Risperidone Ridal Risperdal Apo-Risperidone Dr Reddy's Risperidone Kisperidone
-			Risperidone Ridal Risperdal Apo-Risperidone Dr Reddy's Risperidone Kidal Risperdal
Tab 4 mg Oral liq 1 mg per ml		60 30 ml	Risperidone Ridal Risperdal Apo-Risperidone Dr Reddy's Risperidone Kisperidone

	Subsidy (Manufacturer's Price) \$	Subs Per	Fully sidised	Brand or Generic Manufacturer
TRIFLUOPERAZINE HYDROCHLORIDE – Safety medicine; preso Tab 1 mg Tab 2 mg Tab 5 mg	9.83 14.64	e dispensir 100 100 100	✓ 9 ✓ 9	juency Stelazine Stelazine Stelazine
ZIPRASIDONE – Subsidy by endorsement a) Safety medicine; prescriber may determine dispensing frequ b) Ziprasidone is subsidised for patients suffering from schizop risperidone or quetiapine that has been discontinued, or is in the effects or inadequate response, and the prescription is endorse Cap 20 mg	ohrenia or related p le process of being ed accordingly. 87.88		ed, bed ✓ Z	
Cap 60 mg Cap 80 mg	247.17 329.56	60 60	✔ Z	čeldox čeldox
ZUCLOPENTHIXOL HYDROCHLORIDE – Safety medicine; presc Tab 10 mg	,	e dispensin 100		uency Clopixol
Depot Injections				
FLUPENTHIXOL DECANOATE – Safety medicine; prescriber may Inj 20 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 20 mg per ml, 2 ml – Up to 5 inj available on a PSO Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO		ing frequer 5 5 5	V F	Fluanxol Fluanxol Fluanxol
FLUPHENAZINE DECANOATE – Safety medicine; prescriber may Inj 12.5 mg per 0.5 ml, 0.5 ml – Up to 5 inj available on a PSO Inj 25 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO		ing frequer 5 5 5		Nodecate Nodecate Nodecate
HALOPERIDOL DECANOATE – Safety medicine; prescriber may Inj 50 mg per ml, 1 ml – Up to 5 inj available on a PSO Inj 100 mg per ml, 1 ml – Up to 5 inj available on a PSO	28.39	ng frequend 5 5	Í 🖌 F	laldol laldol Concentrate
OLANZAPINE PAMOATE MONOHYDRATE – Special Authority se Safety medicine; prescriber may determine dispensing frequen		Retail phar	macy	
Inj 210 mg Inj 300 mg Inj 405 mg SA1146 Special Authority for Subsidy	280.00 460.00	1 1 1	🗸 Z	Zyprexa Relprevv Zyprexa Relprevv Zyprexa Relprevv

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 The patient has schizophrenia; and
- 2 The patient has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
- 3 The patient has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in the last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had less than 12 months' treatment with olanzapine depot injection; and
- 1.2 There is no clinical reason to discontinue treatment; or
- 2 The initiation of olanzapine depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of olanzapine depot injection.

Note: The patient should be monitored for post-injection syndrome for at least two hours after each injection.

135

(Subsidy Manufacturer's Price) \$	Sub Per	Fully sidised	Brand or Generic Manufacturer
PIPOTHIAZINE PALMITATE - Safety medicine; prescriber may deter	ermine dispensing f	requency		
Inj 50 mg per ml, 1 ml - Up to 5 inj available on a PSO	178.48	10	🖌 Pi	iportil
Inj 50 mg per ml, 2 ml - Up to 5 inj available on a PSO	353.32	10	🖌 Pi	iportil
RISPERIDONE – Special Authority see SA0926 below – Retail pha Safety medicine; prescriber may determine dispensing frequence				
Inj 25 mg per 2 ml	175.00	1	🖌 R	isperdal Consta
Inj 37.5 mg per 2 ml	230.00	1	🖌 R	isperdal Consta
Inj 50 mg per 2 ml	280.00	1	🖌 R	isperdal Consta

►SA0926 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 The patient has schizophrenia or other psychotic disorder; and
- 2 Has tried but failed to comply with treatment using oral atypical antipsychotic agents; and
- 3 Has been admitted to hospital or treated in respite care, or intensive outpatient or home-based treatment for 30 days or more in last 12 months.

Renewal from any relevant practitioner. Approvals valid for 12 months for applications meeting the following criteria: Either:

1 Both:

- 1.1 The patient has had less than 12 months treatment with risperidone depot injection; and
- 1.2 There is no clinical reason to discontinue treatment; or
- 2 The initiation of risperidone depot injection has been associated with fewer days of intensive intervention than was the case during a corresponding period of time prior to the initiation of risperidone depot injection.

Note: Risperidone depot injection should ideally be used as monotherapy (i.e. without concurrent use of any other antipsychotic medication). In some cases, it may be clinically appropriate to attempt to treat a patient with typical antipsychotic agents in depot injectable form before trialing risperidone depot injection.

ZUCLOPENTHIXOL DECANOATE - Safety medicine; prescriber may determine dispensing frequency

Inj 200 mg per ml, 1 ml – Up to 5 inj available on a PSO	5	
Orodispersible Antipsychotics		
OLANZAPINE – Safety medicine; prescriber may determine dispensing frequency Orodispersible tab 5 mg6.36	28	 Dr Reddy's Olanzapine Olanzine-D
Orodispersible tab 10 mg8.76	28	 ✓ Dr Reddy's Olanzapine ✓ Olanzine-D
Wafer 5 mg6.36 (102.19)	28	Zyprexa Zydis
Wafer 10 mg8.76 (204.37)	28	Zyprexa Zydis
RISPERIDONE – Special Authority see SA0927 on the next page – Retail pharmacy Safety medicine; prescriber may determine dispensing frequency		
Orally-disintegrating tablets 0.5 mg	28 28 28	 Risperdal Quicklet Risperdal Quicklet Risperdal Quicklet

Subsidy (Manufacturer's Price)	Fully Subsidised		Brand or Generic	
\$	Per	~	Manufacturer	

➡SA0927 Special Authority for Subsidy

Initial application — (Acute situations) from any relevant practitioner. Approvals valid for 6 weeks for applications meeting the following criteria:

- Both:
 - 1 For a non-adherent patient on oral therapy with standard risperidone tablets or risperidone oral liquid; and
 - 2 The patient is under direct supervision for administration of medicine.

Initial application — (Chronic situations) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.

Renewal from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The patient is unable to take standard risperidone tablets or oral liquid, or once stabilized refuses to take risperidone tablets or oral liquid; and
- 2 The patient is under direct supervision for administration of medicine.

Note: Risperdal Quicklets cost significantly more than risperidone tablets and should only be used where necessary.

Anxiolytics

LPRAZOLAM – Safety medicine; prescriber may determine dispensing frequency	ı	
Tab 250 mcg	50	Arrow-Alprazolam
‡ Safety cap for extemporaneously compounded oral liquid preparations.		
Tab 500 mcg4.10	50	Arrow-Alprazolam
‡ Safety cap for extemporaneously compounded oral liquid preparations.		
Tab 1 mg7.25	50	Arrow-Alprazolam
‡ Safety cap for extemporaneously compounded oral liquid preparations.		
USPIRONE HYDROCHLORIDE – Special Authority see SA0863 below – Retail p	harmacy	
Tab 5 mg	100	Pacific Buspirone
Tab 10 mg17.00	100	Pacific Buspirone
		•

➡SA0863 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Both:

1 For use only as an anxiolytic; and

2 Other agents are contraindicated or have failed.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

CLONAZEPAM - Safety medicine; prescriber may determine dispensing frequency		
Tab 500 mcg6.68	100	Paxam
Tab 2 mg12.75	100	Paxam
DIAZEPAM – Safety medicine; prescriber may determine dispensing frequency		
Tab 2 mg11.44	500	Arrow-Diazepam
‡ Safety cap for extemporaneously compounded oral liquid preparations.		
Tab 5 mg13.71	500	Arrow-Diazepam
‡ Safety cap for extemporaneously compounded oral liquid preparations.		
LORAZEPAM – Safety medicine; prescriber may determine dispensing frequency		
Tab 1 mg16.42	250	Ativan
‡ Safety cap for extemporaneously compounded oral liquid preparations.		
Tab 2.5 mg11.17	100	Ativan
‡ Safety cap for extemporaneously compounded oral liquid preparations.		

(Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
OXAZEPAM – Safety medicine; prescriber may determine dispensi	ing frequency			
Tab 10 mg		100	✓ 0	<u>x-Pam</u>
‡ Safety cap for extemporaneously compounded oral liquid p	preparations.			
Tab 15 mg		100	✓ 0	<u>x-Pam</u>
± Safety cap for extemporaneously compounded oral liquid r	preparations.			

Multiple Sclerosis Treatments

SA1062 Special Authority for Subsidy

Special Authority approved by the Multiple Sclerosis Treatment Committee

Notes: Budget managed by appointed clinicians on the Multiple Sclerosis Treatment Assessments Committee (MSTAC).

Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria (below).

Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz or:

The coordinator	Phone: 04 460 4990
Multiple Sclerosis Treatment Assessment Committee	Facsimile: 04 916 7571
PHARMAC PO Box 10 254	Email: mstaccoordinator@pharmac.govt.nz
147 H ² ·	

Wellington

Completed application forms must be sent to the coordinator for MSTAC and will be considered by MSTAC at the next practicable opportunity.

Notification of MSTAC's decision will be sent to the patient, the applying clinician and the patient's GP (if specified).

These agents will NOT be subsidised if dispensed from a community or hospital pharmacy. Regular supplies will be distributed to all approved patients or their clinicians by courier.

Prescribers must send quarterly prescriptions for approved patients to the MSTAC coordinator.

Only prescriptions for 6 million iu of interferon beta-1-alpha per week, or 8 million iu of interferon beta-1-beta every other day, or 20 mg glatiramer acetate daily will be subsidised.

Appeals against MSTAC's decision and/or the processing of any application may be lodged with the MSTAC coordinator. Concerns that cannot be or have not been adequately addressed by MSTAC will be forwarded to a separate Appeal Committee if necessary. Switching between treatments is permitted within the 12 month approval period without reapproval by MSTAC. The MSTAC coordinator should be notified of the change and a new prescription provided.

Entry Criteria

- Diagnosis of multiple sclerosis (MS) must be confirmed by a neurologist. Diagnosis should as a rule include MRI confirmation. For patients diagnosed before MRI was widely utilised in New Zealand, confirmation of diagnosis via clinical assessment and laboratory/ancillary data must be provided; and
- 2) patients must have active relapsing MS (confirmed by MR scan where necessary) with or without underlying progression; and
- 3) patients must have either:
 - a) EDSS score 2.5 5.5 with 2+ relapses:
 - experienced at least 2 significant relapses of MS in the previous 12 months, and
 - an EDSS score of between 2.5 and 5.5 inclusive; or
 - b) EDSS score 2.0 with 3+ relapses:
 - experienced at least 3 significant relapses of MS in the previous 12 months, and
 - an EDSS score of 2.0; and
- 4) Each relapse must:
 - a) be confirmed by a neurologist or general physician (the patient may not necessarily have been seen during the relapse but the neurologist/physician must be satisfied that the clinical features were characteristic and met the specified criteria);
 - b) be associated with characteristic new symptom(s)/sign(s) or substantial worsening of previously experienced symptom(s)/sign(s);

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	~	Manufacturer

continued...

- c) last at least one week;
- d) follow a period of stability of at least one month;
- e) be severe enough to change either the EDSS or at least one of the Kurtzke functional systems scores by at least 1 point;
- f) be distinguishable from the effects of general fatigue; and
- g) not be associated with a fever (T>37.5 $^{\circ}$ C); and
- 5) applications must be made at least four weeks after the date of the onset of the last known relapse; and
- 6) patients must have no previous history of lack of response to beta-interferon or glatiramer acetate (see criteria for stopping).
- applications must be submitted to the Multiple Sclerosis Treatment Assessment Committee (MSTAC) by the patient's neurologist or a general physician; and
- 8) patients must agree (via informed consent) to co-operate if as a result of their meeting the stopping criteria, funding is withdrawn. Patients must agree to the collection of clinical data relating to their MS and use of those data by PHARMAC; and
- 9) patients must agree to allow clinical data to be collected and reviewed by MSTAC annually for each year in which they receive funding for beta-interferon or glatiramer acetate.

Stopping Criteria

- 1) Confirmed progression of disability that is sustained for six months during a minimum of one year of treatment. Progression of disability is defined as any of:
 - a) an increase of 2 EDSS points where starting EDSS was 2.0; or
 - b) an increase of 1.5 EDSS points where starting EDSS was 2.5 or 3.0; or
 - c) an increase of 1 EDSS point where starting EDSS 3.5 or greater; or
 - d) an increase in EDSS score to 6.0 or more; or
- 2) stable or increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment)(see note); or
- 3) pregnancy and/or lactation; or
- within the 12 month approval year, intolerance to interferon beta-1-alpha, and/or interferon beta-1-beta and/or glatiramer acetate; or
- 5) non-compliance with treatment, including refusal to undergo annual assessment or refusal to allow the results of the assessment to be submitted to MSTAC; or
- 6) patients may, subject to conclusions drawn from published evidence available at the time, be excluded if they develop a high titre of neutralising anti-bodies to beta-interferon or glatiramer acetate.

Note: Patients who have a stable or increasing relapse rate over 12 months of treatment (compared with the relapse rate on starting treatment) and who do not meet any of the other Stopping Criteria at annual review may switch to a different class of funded treatment (i.e. patients may switch from either of the beta-interferons [interferon beta-1-beta or interferon beta-1-alpha] to glatiramer acetate or vice versa). Patients may switch classes of treatment for this reason only once, after which they will be required to stop funded treatment if they meet any of the Stopping Criteria at annual review (including the criterion relating to stable or increasing relapse rate over 12 months of treatment).

GLATIRAMER ACETATE – Special Authority see SA1062 Inj 20 mg prefilled syringe		28	 Copaxone
INTERFERON BETA-1-ALPHA - Special Authority see SA	A1062 on the preceding pa	ige	
Inj 6 million iu prefilled syringe		4	Avonex
Injection 6 million iu per 0.5 ml pen injector	1,425.10	4	Avonex Pen
Inj 6 million iu per vial	1,425.10	4	Avonex
INTERFERON BETA-1-BETA - Special Authority see SA1	062 on the preceding pag	е	
Inj 8 million iu per 1 ml	1,322.89	15	 Betaferon

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Sedatives and Hypnotics				
LORMETAZEPAM – Safety medicine; prescriber may determine di Tab 1 mg		30	Ν	Voctamid
‡ Safety cap for extemporaneously compounded oral liquid	preparations.			
MIDAZOLAM – Safety medicine; prescriber may determine dispen Inj 1 mg per ml, 5 ml		10	V H	Pfizer łypnovel
Inj 5 mg per ml, 3 ml	11.90	5		lypnovel Pfizer
NITRAZEPAM – Safety medicine; prescriber may determine dispe Tab 5 mg ‡ Safety cap for extemporaneously compounded oral liquid	2.00 (4.98)	100	Ν	litrados
 TEMAZEPAM – Safety medicine; prescriber may determine disper Tab 10 mg	nsing frequency	25	✓ <u>N</u>	<u>lormison</u>
TRIAZOLAM – Safety medicine; prescriber may determine dispensive Tab 125 mcg	0 1 2	100	F	lypam
‡ Safety cap for extemporaneously compounded oral liquid Tab 250 mcg	preparations.	100		lypam
\ddagger Safety cap for extemporaneously compounded oral liquid <code>ZOPICLONE</code>			·	
Tab 7.5 mg		30 500		Apo-Zopiclone Apo-Zopiclone

Stimulants/ADHD Treatments

Stimulants/ADHD treatments

ATOMOXETINE - Special Authority see SA0951 below - Reta	il pharmacy		
Cap 10 mg		28	 Strattera
Cap 18 mg	107.03	28	Strattera
Cap 25 mg	107.03	28	Strattera
Cap 40 mg	107.03	28	 Strattera
Cap 60 mg	107.03	28	 Strattera
Cap 80 mg	139.11	28	 Strattera
Cap 100 mg	139.11	28	 Strattera

►SA0951 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Patient has ADHD (Attention Deficit and Hyperactivity Disorder) diagnosed according to DSM-IV or ICD 10 criteria; and
- 2 Once-daily dosing; and
- 3 Any of the following:

Subsidy	Ful	ly Brand or
(Manufacturer's	s Price) Subsidise	d Generic
\$	Per	 Manufacturer

continued...

- 3.1 Treatment with a subsidised formulation of a stimulant has resulted in the development or worsening of serious adverse reactions or where the combination of subsidised stimulant treatment with another agent would pose an unacceptable medical risk; or
- 3.2 Treatment with a subsidised formulation of a stimulant has resulted in worsening of co-morbid substance abuse or there is a significant risk of diversion with subsidised stimulant therapy; or
- 3.3 An effective dose of a subsidised formulation of a stimulant has been trialled and has been discontinued because of inadequate clinical response; and
- 4 The patient will not be receiving treatment with atomoxetine in combination with a subsidised formulation of a stimulant, except for the purposes of transitioning from subsidised stimulant therapy to atomoxetine.

Renewal from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Note: A "subsidised formulation of a stimulant" refers to currently subsidised methylphenidate hydrochloride tablet formulations (immediate-release, sustained-release and extended-release) or dexamphetamine sulphate tablets.

DEXAMPHETAMINE SULPHATE - Special Authority see SA1149 below - Retail pharmacy

- a) Only on a controlled drug form
- b) Safety medicine; prescriber may determine dispensing frequency

Tab 5 mg16.50 100 🗸 <u>PSM</u>

➡SA1149 Special Authority for Subsidy

Initial application — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient.

Initial application — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:

Both:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria.

Initial application — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient.

Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

	Subsidy (Manufacturer's Price) \$	Per	Full Subsidise	,
METHYLPHENIDATE HYDROCHLORIDE - Special Authority see	e SA1150 below – Re	tail pł	narmacy	
 a) Only on a controlled drug form 				
b) Safety medicine; prescriber may determine dispensing freq	uency			
Tab immediate-release 5 mg		30	~	Rubifen
Tab immediate-release 10 mg		30	~	Ritalin
U U			V	Rubifen
Tab immediate-release 20 mg		30	~	Rubifen
Tab sustained-release 20 mg		30	~	Rubifen SR
	50.00	100	V	Ritalin SR

➡SA1150 Special Authority for Subsidy

Initial application — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients aged 5 years or over; and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient.

Initial application — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months for applications meeting the following criteria:

- Both:
 - 1 ADHD (Attention Deficit and Hyperactivity Disorder) patients under 5 years of age; and
 - 2 Diagnosed according to DSM-IV or ICD 10 criteria.

Initial application — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the patient suffers from narcolepsy.

Renewal — (ADHD in patients 5 or over) only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient.

Renewal — (ADHD in patients under 5) only from a paediatrician or psychiatrist. Approvals valid for 12 months where the treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (Narcolepsy) only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE - Special Authority see SA1151 on the next page - Retail pharmacy

- a) Only on a controlled drug form
- b) Safety medicine; prescriber may determine dispensing frequency

Tab extended-release 18 mg	 30	Concerta
Tab extended-release 27 mg	 30	Concerta
Tab extended-release 36 mg	30	Concerta
Tab extended-release 54 mg	30	Concerta
Cap modified-release 10 mg	30	Ritalin LA
Cap modified-release 20 mg	30	Ritalin LA
Cap modified-release 30 mg	30	Ritalin LA
Cap modified-release 40 mg	30	Ritalin LA
· · · · · · · · · · · · · · · · · · ·		

Subsidy	Fu	Illy Brand or	
(Manufacturer's Price)	Subsidise	ed Generic	
\$	Per	 Manufacturer 	

SA1151 Special Authority for Subsidy

Initial application only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 ADHD (Attention Deficit and Hyperactivity Disorder); and
- 2 Diagnosed according to DSM-IV or ICD 10 criteria; and
- 3 Either:
 - 3.1 Applicant is a paediatrician or psychiatrist; or
 - 3.2 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient; and
- 4 Either:
 - 4.1 Patient is taking a currently subsidised formulation of methylphenidate hydrochloride (immediate-release or sustained-release) which has not been effective due to significant administration and/or compliance difficulties; or
 - 4.2 There is significant concern regarding the risk of diversion or abuse of immediate-release methylphenidate hydrochloride.

Renewal only from a paediatrician, psychiatrist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 24 months for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 Either:
 - 2.1 Applicant is a paediatrician or psychiatrist; or
 - 2.2 Applicant is a medical practitioner and confirms that a relevant specialist has been consulted within the last 2 years and has recommended treatment for the patient.

MODAFINIL - Special Authority see SA1126 below - Retail pharmacy

➡SA1126 Special Authority for Subsidy

Initial application only from a neurologist or respiratory specialist. Approvals valid for 24 months for applications meeting the following criteria:

All of the following:

- 1 The patient has a diagnosis of narcolepsy and has excessive daytime sleepiness associated with narcolepsy occurring almost daily for three months or more; and
- 2 Either:
 - 2.1 The patient has a multiple sleep latency test with a mean sleep latency of less than or equal to 10 minutes and 2 or more sleep onset rapid eye movement periods; or
 - 2.2 The patient has at least one of: cataplexy, sleep paralysis or hypnagogic hallucinations; and

3 Either:

- 3.1 An effective dose of a subsidised formulation of methylphenidate or dexamphetamine has been trialled and discontinued because of intolerable side effects; or
- 3.2 Methylphenidate and dexamphetamine are contraindicated.

Renewal only from a neurologist or respiratory specialist. Approvals valid for 24 months where the treatment remains appropriate and the patient is benefiting from treatment.

Treatments for Dementia

DONEPEZIL HYDROCHLORIDE

*	Tab 5 mg7.71	90	Donepezil-Rex
*	Tab 10 mg14.06	90	 Donepezil-Rex

	Subsidy (Manufacturer's Price) \$	S Per	Fully ubsidised	Brand or Generic Manufacturer
Treatments for Opioid Overdose				
NALOXONE HYDROCHLORIDE a) Up to 5 inj available on a PSO b) Only on a PSO * Inj 400 mcg per ml, 1 ml		5	✔ M	layne
Treatments for Substance Dependence				
BUPRENORPHRINE WITH NALOXONE – Special Authority se a) No patient co-payment payable b) Safety medicine; prescriber may determine dispensing fre Tab sublingual 2 mg with naloxone 0.5 mg Tab sublingual 8 mg with naloxone 2 mg	equency 57.40	ail phari 28 28	✓ S	uboxone uboxone
►SA1203 Special Authority for Subsidy Initial application — (Detoxification) from any medical pract following criteria: All of the following: 1 Patient is opioid dependent; and 2 Patient is currently engaged with an opioid treatment server	titioner. Approvals val	linistry c		
 3 Applicant works in an opioid treatment service approved I Initial application — (Maintenance treatment) from any me meeting the following criteria: All of the following: 1 Patient is opioid dependent; and 2 Patient will not be receiving methadone; and 			valid for 1	2 months for applications
 Patient winner be receiving includence, and Patient is currently enrolled in an opioid substitution treatr Applicant works in an opioid treatment service approved I Renewal — (Detoxification) from any medical practitioner. A 	by the Ministry of Healt	th.		

Renewal — (Detoxification) from any medical practitioner. Approvals valid for 1 month for applications meeting the following criteria:

All of the following:

- 1 Patient is opioid dependent; and
- 2 Patient has previously trialled but failed detoxification with buprenorphine with naloxone with relapse back to opioid use and another attempt is planned; and
- 3 Patient is currently engaged with an opioid treatment service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

Renewal — (Maintenance treatment) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient is or has been receiving maintenance therapy with buprenorphine with naloxone (and is not receiving methadone); and
- 2 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and
- 3 Applicant works in an opioid treatment service approved by the Ministry of Health or is a medical practitioner authorised by the service to manage treatment in this patient.

Renewal — (Maintenance treatment where the patient has previously had an initial application for detoxification) from any medical practitioner. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 Patient received but failed detoxification with buprenorphine with naloxone; and
- 2 Maintenance therapy with buprenorphine with naloxone is planned (and patient will not be receiving methadone); and
- 3 Patient is currently enrolled in an opioid substitution program in a service approved by the Ministry of Health; and
- 4 Applicant works in an opioid treatment service approved by the Ministry of Health.

NERVOUS SYSTEM

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
BUPROPION HYDROCHLORIDE Tab modified-release 150 mg	65.00	30	🗸 Z	yban
DISULFIRAM Tab 200 mg	24.30	100	🗸 A	ntabuse
NALTREXONE HYDROCHLORIDE – Special Authority see SA090 Tab 50 mg		narmac 30	y ✔ <u>N</u>	altraccord

■SA0909 Special Authority for Subsidy

Initial application from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria: Both:

1 Patient is currently enrolled in a recognised comprehensive treatment programme for alcohol dependence; and

2 Applicant works in or with a community Alcohol and Drug Service contracted to one of the District Health Boards or accredited

against the New Zealand Alcohol and Other Drug Sector Standard or the National Mental Health Sector Standard. Renewal from any medical practitioner. Approvals valid for 3 months for applications meeting the following criteria:

Both:

- 1 Compliance with the medication (prescriber determined); and
- 2 Any of the following:
 - 2.1 Patient is still unstable and requires further treatment; or
 - 2.2 Patient achieved significant improvement but requires further treatment; or
 - 2.3 Patient is well controlled but requires maintenance therapy.

The patient must not have had more than 1 prior approval in the last 12 months.

NICOTINE

Nicotine will not be funded under the Dispensing Frequency Rule in amounts less than 4 weeks of treatment.

F	Patch 7 mg – Up to 28 patch available on a PSO	28	Habitrol
F	Patch 14 mg – Up to 28 patch available on a PSO	28	Habitrol
F	Patch 21 mg – Up to 28 patch available on a PSO19.14	28	Habitrol
L	ozenge 1 mg - Up to 216 loz available on a PSO19.94	216	Habitrol
L	ozenge 2 mg - Up to 216 loz available on a PSO	216	Habitrol
Ģ	Gum 2 mg (Classic) – Up to 384 piece available on a PSO	384	Habitrol
Ģ	Gum 2 mg (Fruit) - Up to 384 piece available on a PSO	384	Habitrol
Ģ	Gum 2 mg (Mint) - Up to 384 piece available on a PSO	384	Habitrol
C	Gum 4 mg (Classic) - Up to 384 piece available on a PSO	384	Habitrol
C	Sum 4 mg (Fruit) - Up to 384 piece available on a PSO42.04	384	Habitrol
Ģ	Gum 4 mg (Mint) - Up to 384 piece available on a PSO42.04	384	✓ Habitrol

VARENICLINE TARTRATE - Special Authority see SA1161 below - Retail pharmacy

a) Varenicline will not be funded under the Dispensing Frequency Rule in amounts less than 2 weeks of treatment.

b) A maximum of 3 months' varenicline will be subsidised on each Special Authority approval.

Tab 1 mg	28	Champix
135.48	56	Champix
Tab 0.5 mg \times 11 and 1 mg \times 1460.48	25 OP	Champix

➡SA1161 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria: All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 Either:

Subsidy (Manufacturer's Price)	Fully Subsidised	Brand or Generic	
\$	Per 🖌	Manufacturer	

continued...

- 3.1 The patient has tried but failed to quit smoking after at least two separate trials of nicotine replacement therapy, at least one of which included the patient receiving comprehensive advice on the optimal use of nicotine replacement therapy; or
- 3.2 The patient has tried but failed to quit smoking using bupropion or nortriptyline; and
- 4 The patient has not used funded varenicline in the last 12 months; and
- 5 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 6 The patient is not pregnant; and
- 7 The patient will not be prescribed more than 3 months' funded varenicline (see note).

Renewal from any relevant practitioner. Approvals valid for 5 months for applications meeting the following criteria:

All of the following:

- 1 Short-term therapy as an aid to achieving abstinence in a patient who has indicated that they are ready to cease smoking; and
- 2 The patient is part of, or is about to enrol in, a comprehensive support and counselling smoking cessation programme, which includes prescriber or nurse monitoring; and
- 3 The patient has not used funded varenicline in the last 12 months; and
- 4 Varenicline is not to be used in combination with other pharmacological smoking cessation treatments and the patient has agreed to this; and
- 5 The patient is not pregnant; and
- 6 The patient will not be prescribed more than 3 months' funded varenicline (see note).

The patient must not have had an approval in the past 12 months.

Note: a maximum of 3 months' varenicline will be subsidised on each Special Authority approval.

	Subsidy (Manufacturer's \$	Price) Sub Per	sidised Ge	and or eneric anufacturer
Chemotherapeutic Agents				
Alkylating Agents				
BUSULPHAN – PCT – Retail pharmacy-Specialist Tab 2 mg		100	🖌 Myler	an
CARBOPLATIN – PCT only – Specialist Inj 10 mg per ml, 5 ml	20.00	1	A Carbo	anlatin Ebowa
Inj 10 mg per ml, 15 ml		1	Carbo	oplatin Ebewe
	22.50	I		oplatin Ebewe
Inj 10 mg per ml, 45 ml		1	✓ Carba	
	50.00	·		oplatin Ebewe
				Carboplatin
Inj 10 mg per ml, 100 ml		1	🖌 Carbo	oplatin Ebewe
Inj 1 mg for ECP	0.13	1 mg	🖌 Baxte	er
CARMUSTINE – PCT only – Specialist				
Inj 100 mg	204.13	1	🖌 BiCN	U
Inj 100 mg for ECP	204.13	100 mg OP	🖌 Baxte	er
CHLORAMBUCIL – PCT – Retail pharmacy-Specialist				
Tab 2 mg		25	🖌 Leuk	eran FC
CISPLATIN – PCT only – Specialist				
Inj 1 mg per ml, 50 ml	15.00	1	Cispl	atin Ebewe
··· j · ··· 3 · ··· ·· ·· ···				Cisplatin
Inj 1 mg per ml, 100 ml	21.00	1	🗸 Cispl	atin Ebewe
			🖌 DBL	Cisplatin
Inj 1 mg for ECP	0.27	1 mg	 Baxte 	er
CYCLOPHOSPHAMIDE				
Tab 50 mg – PCT – Retail pharmacy-Specialist	25.71	50	Cyclo	<u>blastin</u>
Inj 1 g – PCT – Retail pharmacy-Specialist		1	🖌 Endo	xan
	127.80	6	Cyto	
Inj 2 g – PCT only – Specialist		1	Endo	
Inj 1 mg for ECP – PCT only – Specialist	0.03	1 mg	V Baxte	er
IFOSFAMIDE – PCT only – Specialist				
lnj 1 g		1	Holo>	
Inj 2 g		1	Holo	
Inj 1 mg for ECP	0.10	1 mg	V Baxte	<u> </u>
LOMUSTINE – PCT only – Specialist	(a a a c			
Cap 10 mg		20	CeeN	
Cap 40 mg		20	CeeN	U
MELPHALAN		<i>c</i> -		
Tab 2 mg – PCT – Retail pharmacy-Specialist		25	 Alker 	
Inj 50 mg – PCT only – Specialist		1	 Alker 	an

	Subsidy (Manufacturer's Price	e)	Fully Brand or Subsidised Generic
	(Manulacturer 31 no) \$	Per	Manufacturer
DXALIPLATIN – PCT only – Specialist			
Inj 50 mg	15.32	1	 Oxaliplatin Actavis 50
	55.00		 Oxaliplatin Ebewe
	200.00		 Eloxatin
Inj 100 mg	25.01	1	 Oxaliplatin Actavis 100
	110.00		Oxaliplatin Ebewe
	400.00		 Eloxatin
Inj 1 mg for ECP	0.28	1 mg	Baxter
THIOTEPA – PCT only – Specialist			
Inj 15 mg	CBS	1	 Bedford S29 THIO-TEPA S29
Antimetabolites			
CALCIUM FOLINATE			
Tab 15 mg - PCT - Retail pharmacy-Specialist	82.45	10	✓ <u>DBL Leucovorin</u> Calcium
Inj 3 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist	17.10	5	✓ Mayne
Inj 50 mg - PCT - Retail pharmacy-Specialist	24.50	5	 Calcium Folinate Ebewe
Inj 100 mg – PCT only – Specialist	9.75	1	 Calcium Folinate Ebewe
Inj 300 mg – PCT only – Specialist		1	 Calcium Folinate Ebewe
Inj 1 g – PCT only – Specialist	90.00	1	 Calcium Folinate Ebewe
Inj 1 mg for ECP – PCT only – Specialist	0.10	1 mg	Baxter
CAPECITABINE – Retail pharmacy-Specialist		-	
Tab 150 mg		60	✓ Xeloda
Tab 500 mg		120	Xeloda
CLADRIBINE – PCT only – Specialist			
Inj 1 mg per ml, 10 ml	5,249.72	7	Leustatin
Inj 10 mg for ECP	749.96 1	10 mg Ol	P 🖌 Baxter
CYTARABINE			
Inj 100 mg – PCT – Retail pharmacy-Specialist	76.00	5	Pfizer
	80.00		Mayne
Inj 500 mg – PCT – Retail pharmacy-Specialist		1	✓ Pfizer
	95.36	5	Mayne
Inj 1 g – PCT – Retail pharmacy-Specialist		1	✓ Pfizer
Ini 0 a DCT Datail pharmany Crasiclist	42.65	4	Mayne
Inj 2 g – PCT – Retail pharmacy-Specialist		1	 Pfizer Mayne
Inj 1 mg for ECP – PCT only – Specialist	• • • • •	10 mg	✓ Mayne

	Subsidy			and or
(M:	anufacturer's \$	Price) Subs Per		eneric anufacturer
UDARABINE PHOSPHATE – PCT only – Specialist				
Tab 10 mg	433.50	20	🖌 Fluda	ara Oral
Inj 50 mg		5		arabine Ebewe
, .	.430.00	0	✓ Flud	
Inj 50 mg for ECP	,	50 mg OP	✓ Baxt	
, ,		00 mg 01		
JOROURACIL SODIUM	00.05	-		
Inj 50 mg per ml, 10 ml – PCT only – Specialist		5		rouracil Ebewe
Inj 50 mg per ml, 20 ml – PCT only – Specialist		1		rouracil Ebewe
Inj 25 mg per ml, 100 ml – PCT only – Specialist		•	Mayr	rouracil Ebewe
Inj 50 mg per ml, 50 ml – PCT only – Specialist		1		
Inj 50 mg per ml, 100 ml – PCT only – Specialist		1		rouracil Ebewe
Inj 1 mg for ECP – PCT only – Specialist	0.77	100 mg	 Baxt 	er
MCITABINE HYDROCHLORIDE – PCT only – Specialist				
Inj 1 g	62.50	1	🖌 DBL	Gemcitabine
			✔ Gem Ac	citabine tavis 1000
			🖌 Gem	citabine Ebewe
	349.20		🖌 Gem	zar
Inj 200 mg	12.50	1	🖌 Gem	citabine
			Ac	tavis 200
			🖌 Gem	citabine Ebewe
	78.00		🗸 Gem	zar
Inj 1 mg for ECP	0.07	1 mg	Baxt	er
VOTECAN – PCT only – Specialist		0		
	0.24	1	1 Irino	tooon Actovia
Inj 20 mg per ml, 2 ml	9.34	I	✓ Inno 40	tecan Actavis
	41.00			
	41.00		Cam	
	00.04	1		tecan-Rex tecan Actavis
Inj 20 mg per ml, 5 ml	23.34	I		
	100.00		100	
	100.00		Cam	
	0.04	4	· · · ·	tecan-Rex
Inj 1 mg for ECP	0.24	1 mg	 Baxt 	er
RCAPTOPURINE – PCT – Retail pharmacy-Specialist				
Tab 50 mg	47.06	25	Purir	nethol
THOTREXATE				
Tab 2.5 mg – PCT – Retail pharmacy-Specialist	5 22	30	🖌 Meth	oblastin
Tab 10 mg – PCT – Retail pharmacy-Specialist		50		oblastin
Inj 2.5 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist		5	✓ Mayr	
Inj 25 mg per ml, 2 ml – PCT – Retail pharmacy Specialist		5	✓ Hosp	
Inj 25 mg per ml, 20 ml – PCT – Retail pharmacy-Specialist		1	✓ Hosp	
Inj 100 mg per ml, 10 ml – PCT – Retail pharmacy-Specialist		1	4	otrexate Ebewe
Inj 25 mg per ml, 40 ml – PCT – Retail pharmacy-Specialist		1	✓ DBL	
				thotrexate S29
Inj 100 mg per ml, 50 ml – PCT – Retail pharmacy-Specialist	125.00	1		otrexate Ebewe
Inj 1 mg for ECP – PCT only – Specialist		1 mg	✓ Baxt	
Inj 5 mg intrathecal syringe for ECP – PCT only – Specialist		5 mg OP	✓ Baxt	
		Uning Of		
OGUANINE – PCT – Retail pharmacy-Specialist		_		
Tab 40 mg		25	Lanv	

▲Three months supply may be dispensed at one time if endorsed "certified exemption" by the prescriber or pharmacist. 149

	Subsidy (Manufacturer's Price) \$	Su Per	Fully Ibsidised	Brand or Generic Manufacturer
Other Cytotoxic Agents				
AMSACRINE – PCT only – Specialist Inj 75 mg	CBS	6	🗸 A	msidine S29
ANAGRELIDE HYDROCHLORIDE – PCT only – Specialist Cap 0.5 mg	CBS	100		grylin S29 eva S29
ARSENIC TRIOXIDE – PCT only – Specialist Inj 10 mg	4,817.00	10	🖌 A	FT (\$29)
BLEOMYCIN SULPHATE – PCT only – Specialist Inj 15,000 iu		1	🗸 D	BL Bleomycin Sulfate
Inj 1,000 iu for ECP		,000 iu	🗸 В	axter
BORTEZOMIB – PCT only – Specialist – Special Authority see Inj 1 mg Inj 3.5 mg Inj 1 mg for ECP	540.70 1,892.50	1 1 1 mg	V V	elcade elcade axter

SA1127 Special Authority for Subsidy

Initial application — (Treatment naive multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 15 months for applications meeting the following criteria: Both:

1 Either:

1.1 The patient has treatment-naive symptomatic multiple myeloma; or

- 1.2 The patient has treatment-naive symptomatic systemic AL amyloidosis *; and
- 2 Maximum of 9 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

Initial application — (Relapsed/refractory multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 The patient has relapsed or refractory multiple myeloma; or
 - 1.2 The patient has relapsed or refractory systemic AL amyloidosis *; and
- 2 The patient has received only one prior front line chemotherapy for multiple myeloma or amyloidosis; and
- 3 The patient has not had prior publicly funded treatment with bortezomib; and
- 4 Maximum of 4 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

Renewal — (Relapsed/refractory multiple myeloma/amyloidosis) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 8 months for applications meeting the following criteria: Both:

- 1 The patient's disease obtained at least a partial response from treatment with bortezomib at the completion of cycle 4; and
- 2 Maximum of 4 further treatment cycles (making a total maximum of 8 consecutive treatment cycles).

Notes: Responding relapsed/refractory multiple myeloma patients should receive no more than 2 additional cycles of treatment beyond the cycle at which a confirmed complete response was first achieved. A line of therapy is considered to comprise either:

a) a known therapeutic chemotherapy regimen and supportive treatments; or

b) a transplant induction chemotherapy regimen, stem cell transplantation and supportive treatments.

Refer to datasheet for recommended dosage and number of doses of bortezomib per treatment cycle.

COLASPASE [L-ASPARAGINASE] - PCT only - Specialist

Inj 10,000 iu	 1	Leunase
Inj 10,000 iu for ECP	 10,000 iu OP	 Baxter

	fully subsidised
150	[HP4] refer page 8

	Subsidy		Fully Brand or
	(Manufacturer's \$	Price) Sub Per	sidised Generic ✓ Manufacturer
DACARBAZINE – PCT only – Specialist			
Inj 200 mg	48.00	1	Hospira
Inj 200 mg for ECP		200 mg OP	✓ Baxter
, 0		200 mg Of	• Burter
DACTINOMYCIN [ACTINOMYCIN D] - PCT only - Specialist	10.50	4	(Coomeren
Inj 0.5 mg		1	Cosmegen
Inj 0.5 mg for ECP		0.5 mg OP	Baxter
DAUNORUBICIN – PCT only – Specialist			
Inj 2 mg per ml, 10 ml	118.72	1	✓ Pfizer
Inj 20 mg for ECP	118.72	20 mg OP	 Baxter
DOCETAXEL – PCT only – Specialist			
Inj 20 mg		1	Docetaxel Ebewe
j - 0			Docetaxel Sandoz
Inj 20 mg per ml, 1 ml		1	✓ Taxotere
Inj 20 mg per ml, 4 ml		1	✓ Taxotere
Inj 80 mg		1	Docetaxel Ebewe
)			Docetaxel Sandoz
Inj 1 mg for ECP		1 mg	✓ Baxter
DOXORUBICIN – PCT only – Specialist		0	
, ,	10.00	1	Doxorubicin Ebewe
Inj 10 mg Inj 50 mg		1	 Arrow-Doxorubicin
IIIJ 50 IIIg	40.00	I	 Allow-Doxorubicin DBL Doxorubicin
	40.00		 DBL Doxorubicin DBL Doxorubicin
			S29 S29
			✓ Doxorubicin Ebewe
Ini 100 mg	00.00	1	Doxorubicin Ebewe Doxorubicin Ebewe
Inj 100 mg		1	 Arrow-Doxorubicin
Inj 200 mg		I	
	150.00		 Adriamycin Doxorubicin Ebewe
Inj 1 mg for ECP	0.27	1 ma	Baxter
, ,	0.37	1 mg	Baxter
EPIRUBICIN – PCT only – Specialist			
Inj 2 mg per ml, 5 ml		1	Epirubicin Ebewe
Inj 2 mg per ml, 25 ml		1	DBL Epirubicin
			Hydrochloride
	87.50		 Epirubicin Ebewe
Inj 2 mg per ml, 50 ml		1	DBL Epirubicin
			Hydrochloride
	125.00		Epirubicin Ebewe
Inj 2 mg per ml, 100 ml		1	DBL Epirubicin
			Hydrochloride
	210.00		Epirubicin Ebewe
Inj 1 mg for ECP	0.82	1 mg	✓ Baxter
ETOPOSIDE		č	
Cap 50 mg – PCT – Retail pharmacy-Specialist	340 72	20	✓ Vepesid
Cap 100 mg – PCT – Retail pharmacy-Specialist		10	Vepesid
Inj 20 mg per ml, 5 ml – PCT – Retail pharmacy-Specialist		10	Mayne
	25.00 612.20	10	Vepesid
Inj 1 mg for ECP – PCT only – Specialist	• • = • = •	1 mg	Baxter
	0.00	i ing	

	Subsidy (Manufacturer's Price) \$ Per		Fully Brand or ubsidised Generic Manufacturer
	2	Per	 Manufacturer
TOPOSIDE PHOSPHATE – PCT only – Specialist	40.00		
Inj 100 mg (of etoposide base)		1	Etopophos
Inj 1 mg (of etoposide base) for ECP	0.47	1 mg	Baxter
YDROXYUREA – PCT – Retail pharmacy-Specialist			
Cap 500 mg		100	Hydrea
ARUBICIN HYDROCHLORIDE – PCT only – Specialist			
Cap 5 mg	115.00	1	Zavedos
Cap 10 mg	144.50	1	Zavedos
Inj 5 mg		1	Zavedos
Inj 10 mg		1	Zavedos
Inj 1 mg for ECP	22.20	1 mg	Baxter
ESNA – PCT only – Specialist			
Tab 400 mg	210.65	50	Uromitexan
Tab 600 mg		50	Uromitexan
Inj 100 mg per ml, 4 ml	137.04	15	Uromitexan
Inj 100 mg per ml, 10 ml		15	 Uromitexan
Inj 1 mg for ECP	2.29	100 mg	Baxter
ITOMYCIN C – PCT only – Specialist			
lnj 5 mg	72.75	1	Arrow
Inj 1 mg for ECP		1 mg	Baxter
ITOZANTRONE – PCT only – Specialist			
Inj 2 mg per ml, 5 ml	110.00	1	Mitozantrone Ebewe
Inj 2 mg per ml, 10 ml		1	✓ Mitozantrone Ebewe
Inj 2 mg per ml, 12.5 ml		1	Onkotrone
Inj 1 mg for ECP		1 mg	Baxter
ACLITAXEL – PCT only – Specialist		0	
Inj 30 mg	137 50	5	Paclitaxel Ebewe
Inj 100 mg		1	Paclitaxel Actavis
		•	Paclitaxel Ebewe
Inj 150 mg		1	Anzatax
, ,			Paclitaxel Actavis
			Paclitaxel Ebewe
Inj 300 mg	275.00	1	Anzatax
			Paclitaxel Actavis
			Paclitaxel Ebewe
Inj 600 mg		1	Paclitaxel Ebewe
Inj 1 mg for ECP	1.02	1 mg	Baxter
EGASPARGASE – PCT only – Special Authority see SA132	5 below		
Inj 3,750 IU per 5 ml		1	Oncaspar S29

SA1325 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has newly diagnosed acute lymphoblastic leukaemia; and
- 2 Pegaspargase to be used with a contemporary intensive multi-agent chemotherapy treatment protocol; and
- 3 Treatment is with curative intent.

	Subsidy (Manufacturer's Price) \$	S Per	Fully Subsidised	Brand or Generic Manufacturer
continued				
Renewal only from a relevant specialist or medical practitioner	on the recommendation	n of a re	elevant spe	ecialist. Approvals valid for
12 months for applications meeting the following criteria:				
All of the following: 1 The patient has relapsed acute lymphoblastic leukaemia;	and			
2 Pegaspargase to be used with a contemporary intensive		anv trea	atment pro	tocol: and
3 Treatment is with curative intent.	maia agent enemetrie	upy lice		
PENTOSTATIN [DEOXYCOFORMYCIN] - PCT only - Special	ist			
Inj 10 mg		1	🖌 N	ipent S29
PROCARBAZINE HYDROCHLORIDE - PCT only - Specialist				
Cap 50 mg		50	🖌 N	atulan S29
TEMOZOLOMIDE – Special Authority see SA1063 below – Re	tail pharmacy			
Cap 5 mg		5	🖌 T	emaccord
Cap 20 mg		5		emaccord
Cap 100 mg		5		emaccord
Cap 250 mg		5	<u> </u>	emaccord
SA1063 Special Authority for Subsidy				
Initial application only from a relevant specialist. Approvals val	id for 10 months for ap	plicatior	ns meeting	the following criteria:
All of the following:				
1 Either:				
1.1 Patient has newly diagnosed glioblastoma multifor	,			
1.2 Patient has newly diagnosed anaplastic astrocytor				
2 Temozolomide is to be (or has been) given concomitantly3 Following concomitant treatment temozolomide is to be u	1.77		o of E dow	a tractment at a maximum
dose of 200 mg/m ² .		SIX CYCIE	5 01 5 uay	
Notes: Indication marked with a * is an Unapproved Indicatio	n. Temozolomide is n	ot subsi	idised for	the treatment of relapsed
glioblastoma multiforme. Reapplications will not be approved.				
Studios of tomozolomido about that its honofit is prodominantly	in these notionts with a			a status (MILIO susada O su

Studies of temozolomide show that its benefit is predominantly in those patients with a good performance status (WHO grade 0 or 1 or Karnofsky score >80), and in patients who have had at least a partial resection of the tumour.

THALIDOMIDE - PCT only - Specialist - Special Authority see SA1124 below

Cap 50 mg	· · ·		28	Thalomid
Cap 100 mg		1,008.00	28	 Thalomid

➡SA1124 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either:

The patient has multiple myeloma; or
 The patient has systemic AL amyloidosis*.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified where the patient has obtained a response from treatment during the initial approval period. Notes: Prescription must be written by a registered prescriber in the thalidomide risk management programme operated by the supplier.

Maximum dose of 400 mg daily as monotherapy or in a combination therapy regimen.

Indication marked with * is an Unapproved Indication.

TRETINOIN

Cap 10 mg	- PCT - Retail pharmacy-Specialist		Vesanoid
-----------	------------------------------------	--	----------

	Subsidy Icturer's Price) \$	Per	Fully Subsidised	
VINBLASTINE SULPHATE				
Inj 10 mg – PCT – Retail pharmacy-Specialist2	7.50	1		Mayne
	7.50	5		Mayne
Inj 1 mg for ECP – PCT only – Specialist	3.05 1	mg	~	Baxter
VINCRISTINE SULPHATE				
Inj 1 mg per ml, 1 ml – PCT – Retail pharmacy-Specialist	3.00	5	~	Hospira
Inj 1 mg per ml, 2 ml – PCT – Retail pharmacy-Specialist	6.00	5	~	Hospira
Inj 1 mg for ECP – PCT only – Specialist1	5.77 1	mg	~	Baxter
/INORELBINE - PCT only - Specialist				
Inj 10 mg per ml, 1 ml	2.85	1	V	Navelbine
42	2.00		~	Vinorelbine Ebewe
Inj 10 mg per ml, 5 ml64	4.25	1	~	Navelbine
	0.00		~	Vinorelbine Ebewe
Inj 1 mg for ECP	1.45 1	mg	~	Baxter
Protein-tyrosine Kinase Inhibitors				
DASATINIB – Special Authority see SA0976 below				
Tab 20 mg	4.06	60	~	Sprycel
Tab 50 mg		60	V	Sprycel
Tab 70 mg7,692		60	~	Sprycel
Tab 100 mg6,214		30	~	Sprycel

SA0976 Special Authority for Subsidy

Special Authority approved by the CML/GIST Co-ordinator

Notes: Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz, and prescriptions should be sent to:

The CML/GIST Co-ordinator	Phone: (04) 460 4990
PHARMAC	Facsimile: (04) 916 7571
PO Box 10 254	Email: mary.chesterfield@pharmac.govt.nz
MATE III was a set of a	

Wellington

Special Authority criteria for CML - access by application

- a) Funded for patients with diagnosis (confirmed by a haematologist) of a chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase.
- b) Maximum dose of 140 mg/day for accelerated or blast phase, and 100 mg/day for chronic phase CML.
- c) Subsidised for use as monotherapy only.
- d) Initial approvals valid seven months.
- e) Subsequent approval(s) are granted on application and are valid for six months. The first reapplication (after seven months) should provide details of the haematological response. The third reapplication should provide details of the cytogenetic response after 14-18 months from initiating therapy. All other reapplications should provide details of haematological response, and cytogenetic response if such data is available. Applications to be made and subsequent prescriptions can be written by a haematologist or an oncologist.

Note: Dasatinib is indicated for the treatment of adults with chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib.

Guideline on discontinuation of treatment for patients with CML

- a) Prescribers should consider discontinuation of treatment if, after 6 months from initiating therapy, a patient did not obtain a haematological response as defined as any one of the following three levels of response:
 - complete haematologic response (as characterised by an absolute neutrophil count (ANC) > 1.5 × 10⁹/L, platelets > 100 × 10⁹/L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or

Subsidy (Manufacturer's Price)	Subs	Fully	Brand or Generic	
 \$	Per	~	Manufacturer	

continued...

- 2) no evidence of leukaemia (as characterised by an absolute neutrophil count (ANC) > 1.0×10^{9} /L, platelets > 20×10^{9} /L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
- return to chronic phase (as characterised by BM and PB blasts < 15%, BM and PB blasts and promyelocytes < 30%, PB basophils < 20% and absence of extramedullary disease other than spleen and liver).
- b) Prescribers should consider discontinuation of treatment if, after 18 months from initiating therapy, a patient did not obtain a major cytogenetic response defined as 0-35% Ph+ metaphases.

ERLOTINIB HYDROCHLORIDE - Retail pharmacy-Specialist - Special Authority see SA1044 below

Tab 100 mg	30	 Tarceva
Tab 150 mg3,950.00	30	Tarceva

➡SA1044 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 Patient has advanced, unresectable, Non Small Cell Lung Cancer (NSCLC); and
- 2 Patient has documented disease progression following treatment with first line platinum based chemotherapy; and
- 3 Erlotinib is to be given for a maximum of 3 months.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

GEFITINIB - Retail pharmacy-Specialist

Tab 250 mg − Special Authority see SA1226 below......1,700.00 30 🖌 Iressa

SA1226 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 4 months for applications meeting the following criteria: Either:

- 1 All of the following:
 - 1.1 Patient has treatment naive locally advanced, or metastatic, unresectable, non-squamous Non Small Cell Lung Cancer (NSCLC); and
 - 1.2 There is documentation confirming that disease expresses activating mutations of EGFR tyrosine kinase; and
 - 1.3 Gefitinib is to be given for a maximum of 3 months; or
- 2 The patient received gefitinib treatment prior to 1 August 2012 and radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

Renewal only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months where radiological assessment (preferably including CT scan) indicates NSCLC has not progressed.

IMATINIB MESYLATE - Special Authority see SA0643 below

Tab 100 mg2,400.00 60 🗸 Glivec

➡SA0643 Special Authority for Subsidy

Special Authority approved by the CML/GIST Co-ordinator

Notes: Application details may be obtained from PHARMAC's website http://www.pharmac.govt.nz, and prescriptions should be sent to:

The CML/GIST Co-ordinator	Phone: (04) 460 4990
PHARMAC	Facsimile: (04) 916 7571
PO Box 10 254	Email: mary.chesterfield@pharmac.govt.nz
Wellington	

Special Authority criteria for CML - access by application

a) Funded for patients with diagnosis (confirmed by a haematologist) of a chronic myeloid leukaemia (CML) in blast crisis, accelerated phase, or in chronic phase.

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

- b) Maximum dose of 600 mg/day for accelerated or blast phase, and 400 mg/day for chronic phase CML.
- c) Subsidised for use as monotherapy only.
- d) Initial approvals valid seven months.
- e) Subsequent approval(s) are granted on application and are valid for six months. The first reapplication (after seven months) should provide details of the haematological response. The third reapplication should provide details of the cytogenetic response after 14-18 months from initiating therapy. All other reapplications should provide details of haematological response, and cytogenetic response if such data is available. Applications to be made and subsequent prescriptions can be written by a haematologist or an oncologist.

Guideline on discontinuation of treatment for patients with CML

- a) Prescribers should consider discontinuation of treatment if after 6 months from initiating therapy a patient did not obtain a haematological response as defined as any one of the following three levels of response:
 - 1) complete haematologic response (as characterised by an absolute neutrophil count (ANC) > 1.5×10^{9} /L, platelets > 100×10^{9} /L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
 - 2) no evidence of leukaemia (as characterised by an absolute neutrophil count (ANC) > 1.0×10^9 /L, platelets > 20×10^9 /L, absence of peripheral blood (PB) blasts, bone marrow (BM) blasts < 5% (or FISH Ph+ 0-35% metaphases), and absence of extramedullary disease); or
 - return to chronic phase (as characterised by BM and PB blasts < 15%, BM and PB blasts and promyelocytes < 30%, PB basophils < 20% and absence of extramedullary disease other than spleen and liver).
- b) Prescribers should consider discontinuation of treatment if after 18 months from initiating therapy a patient did not obtain a major cytogenetic response defined as 0-35% Ph+ metaphases.

Special Authority criteria for GIST – access by application

- a) Funded for patients:
 - 1) with a diagnosis (confirmed by an oncologist) of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST); and
 - 2) who have immunohistochemical documentation of c-kit (CD117) expression by the tumour.
- b) Maximum dose of 400 mg/day.
- c) Applications to be made and subsequent prescriptions can be written by an oncologist.
- d) Initial and subsequent applications are valid for one year. The re-application criterion is an adequate clinical response to the treatment with imatinib (prescriber determined).

LAPATINIB DITOSYLATE - Special Authority see SA1191 below - Retail pharmacy

Tab 250 mg	 	1,899.00	70	🖌 🖌 T	ykerb

➡SA1191 Special Authority for Subsidy

Initial application — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

Either:

- 1 All of the following:
 - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 1.2 The patient has not previously received trastuzumab treatment for HER 2 positive metastatic breast cancer; and
 - 1.3 Lapatinib not to be given in combination with trastuzumab; and
 - 1.4 Lapatinib to be discontinued at disease progression; or
- 2 All of the following:
 - The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2.2 The patient started trastuzumab for metastatic breast cancer but discontinued trastuzumab within 3 months of starting treatment due to intolerance; and
 - 2.3 The cancer did not progress whilst on trastuzumab; and

	Subsidy (Manufacturer's Price) \$	Su Per	Fully Ibsidised	Brand or Generic Manufacturer
continued 2.4 Lapatinib not to be given in combination with tras 2.5 Lapatinib to be discontinued at disease progress Renewal — (metastatic breast cancer) only from a relevant s	on.	titioner o	n the rec	nmendation of a relevan
specialist. Approvals valid for 12 months for applications meeting All of the following:				
 The patient has metastatic breast cancer expressing H and 	ER-2 IHC 3+ or ISH+ (ii	ncluding	FISH or	other current technology)
 The cancer has not progressed at any time point during Lapatinib not to be given in combination with trastuzuma Lapatinib to be discontinued at disease progression. 		whilst o	n lapatinil	o; and
PAZOPANIB – Special Authority see SA1190 below – Retail pl	armaou			
Tab 200 mg		30	V Ve	otrient
Tab 400 mg		30		otrient
►SA1190 Special Authority for Subsidy				
Initial application only from a relevant specialist or medical pr valid for 3 months for applications meeting the following criteria All of the following:		nendation	n of a rele	evant specialist. Approval
1 The patient has metastatic renal cell carcinoma; and				
2 Any of the following:				
2.1 The patient is treatment naive; or				
2.2 The patient has only received prior cytokine treat	ment; or			
2.3 Both:				
2.3.1 The patient has discontinued sunitinib with	nin 3 months of starting	treatmen	t due to i	ntolerance; and
2.3.2 The cancer did not progress whilst on sun				
3 The patient has good performance status (WHO/ECOG	grade 0-2); and			
4 The disease is of predominant clear cell histology; and				
The patient has intermediate or poor prognosis defined 5 Any of the following:	as:			
5.1 Lactate dehydrogenase level > 1.5 times upper li	mit of normal: or			
5.2 Haemoglobin level < lower limit of normal; or	The of Horman, of			
5.3 Corrected serum calcium level > 10 mg/dL (2.5 n	nmol/L): or			
5.4 Interval of < 1 year from original diagnosis to the		y; or		
5.5 Karnofsky performance score of \leq 70; or				
5.6 \geq 2 sites of organ metastasis; and				
6 Pazopanib to be used for a maximum of 3 months.				
Renewal only from a relevant specialist or medical practitioner	on the recommendation	n of a rel	evant spe	cialist. Approvals valid fo
3 months for applications meeting the following criteria:				
Both:				
 No evidence of disease progression; and The treatment remains appropriate and the patient is be 	nefiting from treatment			
Notes: Pazopanib treatment should be stopped if disease prog				
Poor prognosis patients are defined as having at least 3 of crite		e proana	sis patien	ts are defined as having
or 2 of criteria 5.1-5.6.		progrie	olo pallon	le ale demied de namig
SUNITINIB – Special Authority see SA1266 on the next page	- Retail pharmacy			
Cap 12.5 mg		28	🖌 S	utent
Cap 25 mg		28	🖌 Si	utent

Subsidy (Manufacturer's Pric	ce)	Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

➡SA1266 Special Authority for Subsidy

Initial application — (RCC) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic renal cell carcinoma; and
- 2 Any of the following:
 - 2.1 The patient is treatment naive; or
 - 2.2 The patient has only received prior cytokine treatment; or
 - 2.3 The patient has only received prior treatment with an investigational agent within the confines of a bona fide clinical trial which has Ethics Committee approval; or
 - 2.4 Both:
 - 2.4.1 The patient has discontinued pazopanib within 3 months of starting treatment due to intolerance; and
 - 2.4.2 The cancer did not progress whilst on pazopanib; and
- 3 The patient has good performance status (WHO/ECOG grade 0-2); and
- 4 The disease is of predominant clear cell histology; and
- The patient has intermediate or poor prognosis defined as:
- 5 Any of the following:
 - 5.1 Lactate dehydrogenase level > 1.5 times upper limit of normal; or
 - 5.2 Haemoglobin level < lower limit of normal; or
 - 5.3 Corrected serum calcium level > 10 mg/dL (2.5 mmol/L); or
 - 5.4 Interval of < 1 year from original diagnosis to the start of systemic therapy; or
 - 5.5 Karnofsky performance score of \leq 70; or
 - 5.6 \geq 2 sites of organ metastasis; and
- 6 Sunitinib to be used for a maximum of 2 cycles.

Initial application — (GIST) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 The patient has unresectable or metastatic malignant gastrointestinal stromal tumour (GIST); and
- 2 Either:
 - 2.1 The patient's disease has progressed following treatment with imatinib; or
 - 2.2 The patient has documented treatment-limiting intolerance, or toxicity to, imatinib.

Renewal — (RCC) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria:

- Both:
 - 1 No evidence of disease progression; and
 - 2 The treatment remains appropriate and the patient is benefiting from treatment.

Renewal — (GIST) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 6 months for applications meeting the following criteria:

Both:

The patient has responded to treatment or has stable disease as determined by Choi's modified CT response evaluation criteria as follows:

- 1 Any of the following:
 - 1.1 The patient has had a complete response (disappearance of all lesions and no new lesions); or
 - 1.2 The patient has had a partial response (a decrease in size of ≥ 10% or decrease in tumour density in Hounsfield Units (HU) of ≥ 15% on CT and no new lesions and no obvious progression of non measurable disease); or
 - 1.3 The patient has stable disease (does not meet criteria the two above) and does not have progressive disease and no symptomatic deterioration attributed to tumour progression; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.
- Notes: RCC Sunitinib treatment should be stopped if disease progresses.

	Subsidy (Manufacturer's Price \$) Si Per	Fully ubsidised	Brand or Generic Manufacturer
continued				
Poor prognosis patients are defined as having at least 3 of criteria	5.1-5.6. Intermediat	e progno	sis patien	ts are defined as having 1
or 2 of criteria 5.1-5.6				eveluation eritoria (1 Olia
GIST - It is recommended that response to treatment be assess Oncol, 2007, 25:1753-1759). Progressive disease is defined as				
criteria of partial response (PR) by tumour density (HU) on CT; or				•
of the existing intratumoral nodules.		minutation		
Endocrine Therapy				
For GnRH ANALOGUES – refer to HORMONE PREPARATIONS,		page 86		
BICALUTAMIDE – Special Authority see SA0941 below – Retail	pharmacy			
Tab 50 mg	10.00	28	✓ <u>B</u>	icalaccord
SA0941 Special Authority for Subsidy				
Initial application from any medical practitioner. Approvals val advanced prostate cancer.	id without further re	newal un	less notifi	ied where the patient has
, , , , , , , , , , , , , , , , , ,	id without further rea	newal un		
advanced prostate cancer.		30	🖌 Fl	utamin S29 S29
advanced prostate cancer. FLUTAMIDE – Retail pharmacy-Specialist			🖌 Fl	
advanced prostate cancer. FLUTAMIDE – Retail pharmacy-Specialist Tab 250 mg		30	🖌 Fl	utamin S29 S29
advanced prostate cancer. FLUTAMIDE – Retail pharmacy-Specialist	16.50 55.00	30	✓ FI ✓ <u>FI</u>	utamin S29 S29
advanced prostate cancer. FLUTAMIDE – Retail pharmacy-Specialist Tab 250 mg MEGESTROL ACETATE – Retail pharmacy-Specialist Tab 160 mg	16.50 55.00	30 100	✓ FI ✓ <u>FI</u>	lutamin S29 s29 lutamin
advanced prostate cancer. FLUTAMIDE – Retail pharmacy-Specialist Tab 250 mg MEGESTROL ACETATE – Retail pharmacy-Specialist Tab 160 mg OCTREOTIDE (SOMATOSTATIN ANALOGUE) Inj 50 mcg per ml, 1 ml		30 100	✓ FI ✓ <u>FI</u> ✓ <u>A</u>	lutamin S29 s29 lutamin
advanced prostate cancer. FLUTAMIDE – Retail pharmacy-Specialist Tab 250 mg MEGESTROL ACETATE – Retail pharmacy-Specialist Tab 160 mg OCTREOTIDE (SOMATOSTATIN ANALOGUE) Inj 50 mcg per ml, 1 ml Inj 100 mcg per ml, 1 ml		30 100 30 5 5		lutamin S29 s29 lutamin po-Megestrol ctreotide MaxRx ctreotide MaxRx
advanced prostate cancer. FLUTAMIDE – Retail pharmacy-Specialist Tab 250 mg MEGESTROL ACETATE – Retail pharmacy-Specialist Tab 160 mg OCTREOTIDE (SOMATOSTATIN ANALOGUE) Inj 50 mcg per ml, 1 ml		30 100 30 5		lutamin S29 s29 lutamin po-Megestrol ctreotide MaxRx
advanced prostate cancer. FLUTAMIDE – Retail pharmacy-Specialist Tab 250 mg MEGESTROL ACETATE – Retail pharmacy-Specialist Tab 160 mg OCTREOTIDE (SOMATOSTATIN ANALOGUE) Inj 50 mcg per ml, 1 ml Inj 100 mcg per ml, 1 ml Inj 500 mcg per ml, 1 ml		30 100 30 5 5 5 5		lutamin S29 s29 lutamin po-Megestrol ctreotide MaxRx ctreotide MaxRx ctreotide MaxRx
advanced prostate cancer. FLUTAMIDE – Retail pharmacy-Specialist Tab 250 mg MEGESTROL ACETATE – Retail pharmacy-Specialist Tab 160 mg OCTREOTIDE (SOMATOSTATIN ANALOGUE) Inj 50 mcg per ml, 1 ml Inj 100 mcg per ml, 1 ml Inj 500 mcg per ml, 1 ml		30 100 30 5 5 5 5	✓ FI ✓ <u>FI</u> ✓ <u>A</u> ✓ <u>O</u> ✓ <u>O</u> Retail pha	lutamin S29 s29 lutamin po-Megestrol ctreotide MaxRx ctreotide MaxRx ctreotide MaxRx
advanced prostate cancer. FLUTAMIDE – Retail pharmacy-Specialist Tab 250 mg MEGESTROL ACETATE – Retail pharmacy-Specialist Tab 160 mg OCTREOTIDE (SOMATOSTATIN ANALOGUE) Inj 50 mcg per ml, 1 ml Inj 100 mcg per ml, 1 ml Inj 500 mcg per ml, 1 ml Inj 500 mcg per ml, 1 ml COTREOTIDE LAR (SOMATOSTATIN ANALOGUE) – Special Au		30 100 30 5 5 5 5 5	✓ FI ✓ <u>FI</u> ✓ <u>A</u> ✓ <u>O</u> ✓ <u>O</u> Retail pha ✓ Sa	lutamin S29 s29 lutamin po-Megestrol ctreotide MaxRx ctreotide MaxRx ctreotide MaxRx armacy

➡SA1016 Special Authority for Subsidy

Initial application — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 2 months for applications meeting the following criteria:

All of the following:

- 1 The patient has nausea* and vomiting* due to malignant bowel obstruction*; and
- 2 Treatment with antiemetics, rehydration, antimuscarinic agents, corticosteroids and analgesics for at least 48 hours has failed; and
- 3 Octreotide to be given at a maximum dose 1500 mcg daily for up to 4 weeks.
- Note: Indications marked with * are Unapproved Indications.

Renewal — (Malignant Bowel Obstruction) from any relevant practitioner. Approvals valid for 3 months where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 3 months for applications meeting the following criteria: Both:

- 1 The patient has acromegaly; and
- 2 Any of the following:
 - 2.1 Treatment with surgery, radiotherapy and a dopamine agonist has failed; or
 - 2.2 Treatment with octreotide is for an interim period while awaiting the effects of radiotherapy and a dopamine agonist has failed; or

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🖌	Manufacturer	

continued...

2.3 The patient is unwilling, or unable, to undergo surgery and/or radiotherapy.

Renewal — (Acromegaly) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Both:

- 1 IGF1 levels have decreased since starting octreotide; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment.

Note: In patients with Acromegaly octreotide treatment should be discontinued if IGF1 levels have not decreased after 3 months treatment. In patients treated with radiotherapy octreotide treatment should be withdrawn every 2 years, for 1 month, for assessment of remission. Octreotide treatment should be stopped where there is biochemical evidence of remission (normal IGF1 levels) following octreotide treatment withdrawal for at least 4 weeks

Initial application — (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

Any of the following:

- 1 VIPomas and Glucagonomas for patients who are seriously ill in order to improve their clinical state prior to definitive surgery; or
- 2 Both:
 - 2.1 Gastrinoma; and
 - 2.2 Either:
 - 2.2.1 Patient has failed surgery; or
 - 2.2.2 Patient in metastatic disease after H2 antagonists (or proton pump inhibitors) have failed; or
- 3 Both:
 - 3.1 Insulinomas; and
 - 3.2 Surgery is contraindicated or has failed; or
- 4 For pre-operative control of hypoglycaemia and for maintenance therapy; or
- 5 Both:
 - 5.1 Carcinoid syndrome (diagnosed by tissue pathology and/or urinary 5HIAA analysis); and
 - 5.2 Disabling symptoms not controlled by maximal medical therapy.

Note: The use of octreotide in patients with fistulae, oesophageal varices, miscellaneous diarrhoea and hypotension will not be funded as a Special Authority item

Renewal — (Other Indications) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

TAMOXIFEN CITRATE

* Tab 10 mg17.50 * Tab 20 mg	100 100	 ✓ Genox ✓ Genox
Aromatase Inhibitors		
ANASTROZOLE * Tab 1 mg26.55	30	 ✓ Aremed ✓ Arimidex ✓ DP-Anastrozole
EXEMESTANE * Tab 25 mg22.57	30	✓ <u>Aromasin</u>
LETROZOLE * Tab 2.5 mg	30	Letraccord

	Subsidy (Manufacturer's Pric \$	ce) Per	Fully Subsidised	Brand or Generic Manufacturer
Immunosuppressants				
Cytotoxic Immunosuppressants				
AZATHIOPRINE – Retail pharmacy-Specialist				
* Tab 50 mg - For azathioprine oral liquid formulation refer	3			
page 189		100	V <u>I</u>	muprine
				muran
* Inj 50 mg	60.00	1	✓ <u> </u>	muran
MYCOPHENOLATE MOFETIL - Special Authority see SA1041 I	below – Retail pharı	macy		
Dispensing pharmacy should check which brand to dispense	with the prescriber	if prescr	ibed gene	rically.
Tab 500 mg	60.00	50	V (Ceptolate
				Ayaccord .
	70.00			Cellcept
Cap 250 mg		50		Ceptolate
	60.00	100		lyaccord
	70.00			Cellcept
Powder for oral liq 1 g per 5 ml – Subsidy by endorsement Mycophenolate powder for oral liquid is subsidised only for		165 ml O o swallov		Cellcept nd capsules. and when the

prescription is endorsed accordingly. SA1041 Special Authority for Subsidy

Initial application only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid without further renewal unless notified for applications meeting the following criteria: Fither

- 1 Transplant recipient: or
- 2 Both:
 - Patients with diseases where
 - 2.1 Steroids and azathioprine have been trialled and discontinued because of unacceptable side effects or inadequate clinical response; and
 - 2.2 Either:
 - Patients with diseases where
 - 2.2.1 Cyclophosphamide has been trialled and discontinued because of unacceptable side effects or inadequate clinical response; or
 - 2.2.2 Cyclophosphamide treatment is contraindicated.

Fusion Proteins

ETANERCEPT - Special Authority see SA1157 below - Retail p	oharmacy		
Inj 25 mg	949.96	4	Enbrel
Inj 50 mg autoinjector	1,899.92	4	 Enbrel
Inj 50 mg prefilled syringe	1,899.92	4	Enbrel

SA1157 Special Authority for Subsidy

Initial application — (juvenile idiopathic arthritis) only from a named specialist or rheumatologist. Approvals valid for 4 months for applications meeting the following criteria:

All of the following:

- 1 To be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 2 Patient diagnosed with Juvenile Idiopathic Arthritis (JIA); and
- 3 Patient has had severe active polyarticular course JIA for 6 months duration or longer; and

Subsidy	Fully	Brand or	
(Manufacturer's Price)	Subsidised	Generic	
\$	Per 🖌	Manufacturer	

continued...

- 4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate (at a dose of 10-20 mg/m² weekly or at the maximum tolerated dose) in combination with either oral corticosteroids (prednisone 0.25 mg/kg or at the maximum tolerated dose) or a full trial of serial intra-articular corticosteroid injections; and
- 5 Both:
 - 5.1 Either:
 - 5.1.1 Patient has persistent symptoms of poorly-controlled and active disease in at least 20 swollen, tender joints; or
 - 5.1.2 Patient has persistent symptoms of poorly-controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, shoulder, cervical spine, hip; and
 - 5.2 Physician's global assessment indicating severe disease.

Initial application — (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for rheumatoid arthritis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
 - 2.5 Any of the following:
 - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and
 - 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following:
 - wrist, elbow, knee, ankle, and either shoulder or hip; and

2.7 Either:

- 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
- 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for adalimumab for severe chronic plaque psoriasis; and
 - 1.2 Either:

 Subsidy	Fully	Brand or
nufacturer's Price)	Subsidised	Generic
	Per 🖌	

continued...

- 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
- 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for severe chronic plaque psoriasis; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
 - 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and
 - 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
 - 2.4 The most recent PASI assessment is no more than 1 month old at the time of application.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Initial application — (ankylosing spondylitis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for ankylosing spondylitis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis present for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
 - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal antiinflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the average normal values corrected for age and gender (see Notes); and
 - 2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application. Average normal chest expansion corrected for age and gender:

|--|

continued...

18-24 years - Male: 7.0 cm; Female: 5.5 cm 25-34 years - Male: 7.5 cm; Female: 5.5 cm 35-44 years - Male: 6.5 cm; Female: 4.5 cm

45-54 years - Male: 6.0 cm; Female: 5.0 cm

55-64 years - Male: 5.5 cm; Female: 4.0 cm

65-74 years - Male: 4.0 cm; Female: 4.0 cm

75+ years - Male: 3.0 cm; Female: 2.5 cm

Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for adalimumab for psoriatic arthritis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from adalimumab; or
 - 1.2.2 The patient has received insufficient benefit from adalimumab to meet the renewal criteria for adalimumab for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
 - 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
 - 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (juvenile idiopathic arthritis) only from a named specialist, rheumatologist or Practitioner on the recommendation of a named specialist or rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 Either:
 - 1.1 Applicant is a named specialist or rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a named specialist or rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Subsidised as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:
 - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count and an improvement in physician's global assessment from baseline; or
 - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count and continued improvement in physician's global assessment from baseline.

Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

osidy F urer's Price) Subsid		rand or leneric
\$ Per	✔ M	lanufacturer

continued...

- 1 Either: 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and

3 Either:

- 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
- 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 4 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Renewal — (severe chronic plaque psoriasis) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a dermatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 2.1.2 Following each prior etanercept treatment course the patient has a PASI score which is reduced by 75% or more, or is sustained at this level, when compared with the pre-treatment baseline value; or
 - 2.2 Both:
 - 2.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
 - 2.2.2 Either:
 - 2.2.2.1 Following each prior etanercept treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 2.2.2.2 Following each prior etanercept treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-treatment baseline value; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Note: A treatment course is defined as a minimum of 12 weeks of etanercept treatment

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Following 12 weeks of etanercept treatment, BASDAI has improved by 4 or more points from pre-treatment baseline on a 10 point scale, or by 50%, whichever is less; and
- 3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
- 4 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

1 Either:

- 1.1 Applicant is a rheumatologist; or
- 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with etanercept treatment; and
- 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior etanercept treatment in the opinion of the treating physician; and
- 3 Etanercept to be administered at doses no greater than 50 mg every 7 days.

Immune Modulators

ANTITHYMOCYTE GLOBULIN (EQUINE) – PCT only – Specialist Inj 50 mg per ml, 5 ml2,137.50	5	🗸 ATGAM
BACILLUS CALMETTE-GUERIN (BCG) VACCINE – PCT only – Specialist Subsidised only for bladder cancer. Inj 2-8 × 100 million CFU	1	✔ OncoTICE
Monoclonal Antibodies		
ADALIMUMAB – Special Authority see SA1156 below – Retail pharmacy Inj 40 mg per 0.8 ml prefilled pen	2	🖌 HumiraPen
	-	
Inj 40 mg per 0.8 ml prefilled syringe1,799.92	2	Humira

SA1156 Special Authority for Subsidy

Initial application — (rheumatoid arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for rheumatoid arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for rheumatoid arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe and active erosive rheumatoid arthritis for six months duration or longer; and
 - 2.2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
 - 2.3 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and
 - 2.4 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with sulphasalazine and hydroxychloroquine sulphate (at maximum tolerated doses); and
 - 2.5 Any of the following:
 - 2.5.1 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with the maximum tolerated dose of cyclosporin; or
 - 2.5.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate in combination with intramuscular gold; or
 - 2.5.3 Patient has tried and not responded to at least three months of therapy at the maximum tolerated dose of leflunomide alone or in combination with oral or parenteral methotrexate; and

		Subsidy (Manufacturer's Price) \$	Fully Subsidised Per 🖌	Brand or Generic Manufacturer	
--	--	---	------------------------------	-------------------------------------	--

continued...

- 2.6 Either:
 - 2.6.1 Patient has persistent symptoms of poorly controlled and active disease in at least 20 swollen, tender joints; or
 - 2.6.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following:
 - wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2.7 Either:
 - 2.7.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.7.2 C-reactive protein levels not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Initial application — (Crohn's disease) only from a gastroenterologist. Approvals valid for 3 months for applications meeting the following criteria:

All of the following:

- 1 Patient has severe active Crohn's disease; and
- 2 Any of the following:
 - 2.1 Patient has a Crohn's Disease Activity Index (CDAI) score of greater than or equal to 300; or
 - 2.2 Patient has extensive small intestine disease affecting more than 50 cm of the small intestine; or
 - 2.3 Patient has evidence of short gut syndrome or would be at risk of short gut syndrome with further bowel resection; or
 - 2.4 Patient has an ileostomy or colostomy, and has intestinal inflammation; and
- 3 Patient has tried but had an inadequate response to, or has experienced intolerable side effects from, prior systemic therapy with immunomodulators at maximum tolerated doses (unless contraindicated) and corticosteroids; and
- 4 Surgery (or further surgery) is considered to be clinically inappropriate.

Initial application — (severe chronic plaque psoriasis) only from a dermatologist. Approvals valid for 4 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for etanercept for severe chronic plaque psoriasis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for severe chronic plaque psoriasis; or
- 2 All of the following:
 - 2.1 Either:
 - 2.1.1 Patient has "whole body" severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 15, where lesions have been present for at least 6 months from the time of initial diagnosis; or
 - 2.1.2 Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis; and
 - 2.2 Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following (at maximum tolerated doses unless contraindicated): phototherapy, methotrexate, cyclosporin, or acitretin; and
 - 2.3 A PASI assessment has been completed for at least the most recent prior treatment course (but preferably all prior treatment courses), preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course; and
 - 2.4 The most recent PASI assessment is no more than 1 month old at the time of application.

Note: "Inadequate response" is defined as: for whole body severe chronic plaque psoriasis, a PASI score of greater than 15, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment; for severe chronic plaque psoriasis of the face, hand or foot, at least 2 of the 3 PASI symptom subscores for erythema, thickness and scaling are rated as severe or very severe, and the skin area affected is 30% or more of the face, palm of a hand or sole of a foot, as assessed preferably while still on treatment but no longer than 1 month following cessation of the most recent prior treatment.

Subsidy (Manufacturer's Price)	Full Subsidise		
\$	Per •	Manufacturer	

continued...

Initial application — (ankylosing spondylitis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

1 Both:

- 1.1 The patient has had an initial Special Authority approval for etanercept for ankylosing spondylitis; and
- 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for ankylosing spondylitis; or
- 2 All of the following:
 - 2.1 Patient has a confirmed diagnosis of ankylosing spondylitis for more than six months; and
 - 2.2 Patient has low back pain and stiffness that is relieved by exercise but not by rest; and
 - 2.3 Patient has bilateral sacroiliitis demonstrated by plain radiographs, CT or MRI scan; and
 - 2.4 Patient's ankylosing spondylitis has not responded adequately to treatment with two or more non-steroidal antiinflammatory drugs (NSAIDs), in combination with anti-ulcer therapy if indicated, while patient was undergoing at least 3 months of an exercise regime supervised by a physiotherapist; and
 - 2.5 Either:
 - 2.5.1 Patient has limitation of motion of the lumbar spine in the sagittal and the frontal planes as determined by the following Bath Ankylosing Spondylitis Metrology Index (BASMI) measures: a modified Schober's test of less than or equal to 4 cm and lumbar side flexion measurement of less than or equal to 10 cm (mean of left and right); or
 - 2.5.2 Patient has limitation of chest expansion by at least 2.5 cm below the following average normal values corrected for age and gender (see Notes); and
 - 2.6 A Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) of at least 6 on a 0-10 scale.

Notes: The BASDAI must have been determined at the completion of the 3 month exercise trial, but prior to ceasing NSAID treatment. The BASDAI measure must be no more than 1 month old at the time of initial application.

Average normal chest expansion corrected for age and gender:

- 18-24 years Male: 7.0 cm; Female: 5.5 cm
- 25-34 years Male: 7.5 cm; Female: 5.5 cm
- 35-44 years Male: 6.5 cm; Female: 4.5 cm
- 45-54 years Male: 6.0 cm; Female: 5.0 cm
- 55-64 years Male: 5.5 cm; Female: 4.0 cm
- 65-74 years Male: 4.0 cm; Female: 4.0 cm

75+ years - Male: 3.0 cm; Female: 2.5 cm

Initial application — (psoriatic arthritis) only from a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

Either:

- 1 Both:
 - 1.1 The patient has had an initial Special Authority approval for etanercept for psoriatic arthritis; and
 - 1.2 Either:
 - 1.2.1 The patient has experienced intolerable side effects from etanercept; or
 - 1.2.2 The patient has received insufficient benefit from etanercept to meet the renewal criteria for etanercept for psoriatic arthritis; or
- 2 All of the following:
 - 2.1 Patient has had severe active psoriatic arthritis for six months duration or longer; and
 - 2.2 Patient has tried and not responded to at least three months of oral or parenteral methotrexate at a dose of at least 20 mg weekly or a maximum tolerated dose; and

Subsidy		Fully	Brand or
(Manufacturer's Price)		Subsidised	Generic
\$	Per	~	Manufacturer

continued...

- 2.3 Patient has tried and not responded to at least three months of sulphasalazine at a dose of at least 2 g per day or leflunomide at a dose of up to 20 mg daily (or maximum tolerated doses); and
- 2.4 Either:
 - 2.4.1 Patient has persistent symptoms of poorly controlled and active disease in at least 15 swollen, tender joints; or
 - 2.4.2 Patient has persistent symptoms of poorly controlled and active disease in at least four joints from the following: wrist, elbow, knee, ankle, and either shoulder or hip; and
- 2.5 Any of the following:
 - 2.5.1 Patient has a C-reactive protein level greater than 15 mg/L measured no more than one month prior to the date of this application; or
 - 2.5.2 Patient has an elevated erythrocyte sedimentation rate (ESR) greater than 25 mm per hour; or
 - 2.5.3 ESR and CRP not measured as patient is currently receiving prednisone therapy at a dose of greater than 5 mg per day and has done so for more than three months.

Renewal — (rheumatoid arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Treatment is to be used as an adjunct to methotrexate therapy or monotherapy where use of methotrexate is limited by toxicity or intolerance; and
- 3 Either:
 - 3.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 3.2 On subsequent reapplications, the patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; and
- 4 Either:
 - 4.1 Adalimumab to be administered at doses no greater than 40 mg every 14 days; or
 - 4.2 Patient cannot take concomitant methotrexate and requires doses of adalimumab higher than 40 mg every 14 days to maintain an adequate response.

Renewal — (Crohn's disease) only from a gastroenterologist or Practitioner on the recommendation of a gastroenterologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 Either:
 - 1.1 Applicant is a gastroenterologist; or
 - 1.2 Applicant is a Practitioner and confirms that a gastroenterologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Either:
 - 2.1 Either:
 - 2.1.1 CDAI score has reduced by 100 points from the CDAI score when the patient was initiated on adalimumab; or 2.1.2 CDAI score is 150 or less; or
 - 2.2 Both:
 - 2.2.1 The patient has demonstrated an adequate response to treatment but CDAI score cannot be assessed; and
 - 2.2.2 Applicant to indicate the reason that CDAI score cannot be assessed; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (severe chronic plaque psoriasis) only from a dermatologist or Practitioner on the recommendation of a dermatologist. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 Either:

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

continued...

- 1.1 Applicant is a dermatologist; or
- 1.2 Applicant is a Practitioner and confirms that a dermatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
- 2 Either:
 - 2.1 Both:
 - 2.1.1 Patient had "whole body" severe chronic plaque psoriasis at the start of treatment; and
 - 2.1.2 Following each prior adalimumab treatment course the patient has a PASI score which is reduced by 75% or
 - more, or is sustained at this level, when compared with the pre-adalimumab treatment baseline value; or

2.2 Both:

- 2.2.1 Patient had severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot at the start of treatment; and
- 2.2.2 Either:
 - 2.2.2.1 Following each prior adalimumab treatment course the patient has a reduction in the PASI symptom subscores for all 3 of erythema, thickness and scaling, to slight or better, or sustained at this level, as compared to the treatment course baseline values; or
 - 2.2.2.2 Following each prior adalimumab treatment course the patient has a reduction of 75% or more in the skin area affected, or sustained at this level, as compared to the pre-adalimumab treatment baseline value; and
- 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.
- Note: A treatment course is defined as a minimum of 12 weeks adalimumab treatment

Renewal — (ankylosing spondylitis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
 - 2 Following 12 weeks of adalimumab treatment, BASDAI has improved by 4 or more points from pre-adalimumab baseline on a 10 point scale, or by 50%, whichever is less; and
 - 3 Physician considers that the patient has benefited from treatment and that continued treatment is appropriate; and
 - 4 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

Renewal — (psoriatic arthritis) only from a rheumatologist or Practitioner on the recommendation of a rheumatologist. Approvals valid for 6 months for applications meeting the following criteria:

- All of the following:
 - 1 Either:
 - 1.1 Applicant is a rheumatologist; or
 - 1.2 Applicant is a Practitioner and confirms that a rheumatologist has provided a letter, email or fax recommending that the patient continues with adalimumab treatment; and
 - 2 Either:
 - 2.1 Following 3 to 4 months' initial treatment, the patient has at least a 50% decrease in active joint count from baseline and a clinically significant response to treatment in the opinion of the physician; or
 - 2.2 The patient demonstrates at least a continuing 30% improvement in active joint count from baseline and a clinically significant response to prior adalimumab treatment in the opinion of the treating physician; and
 - 3 Adalimumab to be administered at doses no greater than 40 mg every 14 days.

RITUXIMAB - PCT only - Specialist - Special Authority see SA1152 on the next page

Inj 100 mg per 10 ml vial1,075	.50 2	Mabthera
Inj 500 mg per 50 ml vial2,688	.30 1	Mabthera
Inj 1 mg for ECP5	.64 1 mg	 Baxter

 Subsidy (Manufacturer's Price) \$ Pe	Fully Subsidised er 🖌	Brand or Generic Manufacturer	

➡SA1152 Special Authority for Subsidy

Initial application — (Post-transplant) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Both:

- 1 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 2 To be used for a maximum of 8 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

Initial application — (Indolent, Low-grade lymphomas) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria: Either:

1 Both:

- 1.1 The patient has indolent low grade NHL with relapsed disease following prior chemotherapy; and
- 1.2 To be used for a maximum of 6 treatment cycles; or
- 2 Both:
 - 2.1 The patient has indolent, low grade lymphoma requiring first-line systemic chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia.

Initial application — (Aggressive CD20 positive NHL) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 All of the following:
 - 1.1 The patient has treatment naive aggressive CD20 positive NHL; and
 - 1.2 To be used with a multi-agent chemotherapy regimen given with curative intent; and
 - 1.3 To be used for a maximum of 8 treatment cycles; or
- 2 Both:
 - 2.1 The patient has aggressive CD20 positive NHL with relapsed disease following prior chemotherapy; and
 - 2.2 To be used for a maximum of 6 treatment cycles.
- Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

Initial application — (Chronic Lymphocytic Leukaemia) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

- All of the following:
 - 1 The patient has progressive Binet stage A, B or C chronic lymphocytic leukaemia (CLL) requiring treatment; and
 - 2 The patient is rituximab treatment naive; and
 - 3 Either:
 - 3.1 The patient is chemotherapy treatment naive; or

3.2 Both:

- 3.2.1 The patient's disease has relapsed following no more than three prior lines of chemotherapy treatment; and
- 3.2.2 The patient has had a treatment-free interval of 12 months or more if previously treated with fludarabine and cyclophosphamide chemotherapy; and
- 4 The patient has good performance status; and
- 5 The patient has good renal function (creatinine clearance \geq 30 ml/min); and
- 6 The patient does not have chromosome 17p deletion CLL; and
- 7 Rituximab to be administered in combination with fludarabine and cyclophosphamide for a maximum of 6 treatment cycles; and
- 8 It is planned that the patient receives full dose fludarabine and cyclophosphamide (orally or dose equivalent intravenous administration).

Note: 'Chronic lymphocytic leukaemia (CLL)' includes small lymphocytic lymphoma. A line of chemotherapy treatment is considered to comprise a known standard therapeutic chemotherapy regimen and supportive treatments. 'Good performance status' means

Subsidy (Manufacturer's Price) Sul	Fully bsidised	Brand or Generic	
\$	Per	~	Manufacturer	

continued...

ECOG score of 0-1, however, in patients temporarily debilitated by their CLL disease symptoms a higher ECOG (2 or 3) is acceptable where treatment with rituximab is expected to improve symptoms and improve ECOG score to <2.

Renewal — (Post-transplant) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has B-cell post-transplant lymphoproliferative disorder*; and
- 3 To be used for no more than 6 treatment cycles.

Note: Indications marked with * are Unapproved Indications.

Renewal — (Indolent, Low-grade lymphomas) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 9 months for applications meeting the following criteria:

All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has indolent, low-grade NHL with relapsed disease following prior chemotherapy; and
- 3 To be used for no more than 6 treatment cycles.

Note: 'Indolent, low-grade lymphomas' includes follicular, mantle, marginal zone and lymphoplasmacytic/Waldenstrom macroglobulinaemia.

Renewal — (Aggressive CD20 positive NHL) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: All of the following:

- 1 The patient has had a rituximab treatment-free interval of 12 months or more; and
- 2 The patient has relapsed refractory/aggressive CD20 positive NHL; and
- 3 To be used with a multi-agent chemotherapy regimen given with curative intent; and
- 4 To be used for a maximum of 4 treatment cycles.

Note: 'Aggressive CD20 positive NHL' includes large B-cell lymphoma and Burkitt's lymphoma/leukaemia

TRASTUZUMAB - PCT only - Specialist - Special Authority see SA1192 below

Inj 150 mg vial1,350.00	1	 Herceptin
Inj 440 mg vial	1	 Herceptin
Inj 1 mg for ECP9.36	1 mg	 Baxter

➡SA1192 Special Authority for Subsidy

Initial application — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria: Either:

- 1 All of the following:
 - 1.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 1.2 The patient has not previously received lapatinib treatment for HER 2 positive metastatic breast cancer; and
 - 1.3 Trastuzumab not to be given in combination with lapatinib; and
 - 1.4 Trastuzumab to be discontinued at disease progression; or
- 2 All of the following:
 - 2.1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
 - 2.2 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
 - 2.3 The cancer did not progress whilst on lapatinib; and
 - 2.4 Trastuzumab not to be given in combination with lapatinib; and
 - 2.5 Trastuzumab to be discontinued at disease progression.

Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	

continued...

Renewal — (metastatic breast cancer) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
- 3 Trastuzumab not to be given in combination with lapatinib; and
- 4 Trastuzumab to be discontinued at disease progression.

Initial application — (early breast cancer*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 15 months for applications meeting the following criteria:

All of the following:

- 1 The patient has early breast cancer expressing HER 2 IHC 3+ or ISH + (including FISH or other current technology); and
- 2 Maximum cumulative dose of 106 mg/kg (12 months' treatment); and
- 3 Any of the following:
 - 3.1 9 weeks' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.2 12 months' concurrent treatment with adjuvant chemotherapy is planned; or
 - 3.3 12 months' sequential treatment following adjuvant chemotherapy is planned; or
 - 3.4 Other treatment regimen, in association with adjuvant chemotherapy, is planned.

Renewal — (early breast cancer*) only from a relevant specialist or medical practitioner on the recommendation of a relevant specialist. Approvals valid for 12 months for applications meeting the following criteria:

All of the following:

- 1 The patient has metastatic breast cancer expressing HER-2 IHC 3+ or ISH+ (including FISH or other current technology); and
- 2 The patient received prior adjuvant trastuzumab treatment for early breast cancer; and
- 3 Any of the following:
 - 3.1 All of the following:
 - 3.1.1 The patient has not previously received lapatinib treatment for metastatic breast cancer; and
 - 3.1.2 Trastuzumab not to be given in combination with lapatinib; and
 - 3.1.3 Trastuzumab to be discontinued at disease progression; or
 - 3.2 All of the following:
 - 3.2.1 The patient started lapatinib treatment for metastatic breast cancer but discontinued lapatinib within 3 months of starting treatment due to intolerance; and
 - 3.2.2 The cancer did not progress whilst on lapatinib; and
 - 3.2.3 Trastuzumab not to be given in combination with lapatinib; and
 - 3.2.4 Trastuzumab to be discontinued at disease progression; or
 - 3.3 All of the following:
 - 3.3.1 The cancer has not progressed at any time point during the previous 12 months whilst on trastuzumab; and
 - 3.3.2 Trastuzumab not to be given in combination with lapatinib; and
 - 3.3.3 Trastuzumab to be discontinued at disease progression.

Note: * For patients with relapsed HER-2 positive disease who have previously received adjuvant trastuzumab for early breast cancer.

Other Immunosuppressants

CYCLOSPORIN

Cap 25 mg	50	Neoral
Cap 50 mg	50	Neoral
Cap 100 mg	50	Neoral
Oral liq 100 mg per ml	50 ml OP	✓ Neoral

	Subsidy (Manufacturer's Price) \$		Fully Subsidised	Brand or Generic Manufacturer
SIROLIMUS - Special Authority see SA0866 below - Retail pharm	acy			
Tab 1 mg	813.00	100	🖌 R	lapamune
Tab 2 mg	1,626.00	100	🖌 R	lapamune
Oral lig 1 mg per ml	487.80 60) ml O	P 🖌 🖌 🖪	lapamune

SA0866 Special Authority for Subsidy

Initial application from any medical practitioner. Approvals valid without further renewal unless notified where the drug is to be used for rescue therapy for an organ transplant recipient.

Notes: Rescue therapy defined as unresponsive to calcineurin inhibitor treatment as defined by refractory rejection; or intolerant to calcineurin inhibitor treatment due to any of the following:

- GFR<30 ml/min; or
- Rapidly progressive transplant vasculopathy; or
- Rapidly progressive obstructive bronchiolitis; or
- . HUS or TTP; or
- Leukoencepthalopathy; or
- Significant malignant disease

	TACROLIMUS	 Special Authorit 	v see SA0669 below -	Retail pharmacv
--	------------	--------------------------------------	----------------------	-----------------

Cap 0.5 mg	100	Prograf
Cap 1 mg	100	Prograf
Cap 5 mg - For tacrolimus oral liquid formulation refer, page		-
189	50	 Prograf

➡SA0669 Special Authority for Subsidy

Initial application only from a relevant specialist. Approvals valid without further renewal unless notified where the patient is an organ transplant recipient.

Note: Subsidy applies for either primary or rescue therapy.

	Subsidy		Fully Brand or
	(Manufacturer's P		osidised Generic
	\$	Per	 Manufacturer
Antiallergy Preparations			
BEE VENOM ALLERGY TREATMENT – Special Authority see S	A0053 below – R	etail pharmac	у
Maintenance kit - 6 vials 120 mcg freeze dried venom, 6 dilu-			•
ent 1.8 ml		1 OP	Albay
Treatment kit - 1 vial 550 mcg freeze dried venom, 1 diluent 9 ml, 3 diluent 1.8 ml		1 OP	✔ Albay
SA0053 Special Authority for Subsidy			
Initial application only from a relevant specialist. Approvals valid Both:	for 2 years for a	oplications me	eting the following criteria:
1 RAST or skin test positive; and			
2 Patient has had severe generalised reaction to the sensitis Renewal only from a relevant specialist. Approvals valid for 2 ye benefiting from treatment.		eatment rema	ins appropriate and the patient is
0	SA0053 bolow	Rotail pharm	
WASP VENOM ALLERGY TREATMENT – Special Authority see Treatment kit (Paper wasp venom) - 1 vial 550 mcg freeze		netali priarma	acy
dried polister venom, 1 diluent 9 ml, 1 diluent 1.8 ml		1 OP	✓ Albay
Treatment kit (Yellow jacket venom) - 1 vial 550 mcg freeze			• • • • • • • • • • • • • • • • • • • •
dried vespula venom, 1 diluent 9 ml, 1 diluent 1.8 ml		1 OP	✓ Albay
SA0053 Special Authority for Subsidy			
Initial application only from a relevant specialist. Approvals valid	for 2 years for a	oplications me	eting the following criteria:
Both:			
 RAST or skin test positive; and Patient has had severe generalised reaction to the sensitis 	ing agont		
Renewal only from a relevant specialist. Approvals valid for 2 ye		eatment rema	ins appropriate and the patient is
benefiting from treatment.			
Antihistamines			
CETIRIZINE HYDROCHLORIDE			
* Tab 10 mg	1.59	100	✓ <u>Zetop</u>
*‡ Oral liq 1 mg per ml	3.52	200 ml	Cetirizine - AFT
CHLORPHENIRAMINE MALEATE			
*‡ Oral liq 2 mg per 5 ml	8.06	500 ml	 Histafen
DEXTROCHLORPHENIRAMINE MALEATE			
* Tab 2 mg		20	
	(5.99)	40	Polaramine
	2.02 (8.40)	40	Polaramine
*‡ Oral liq 2 mg per 5 ml		100 ml	Folaramine
	(10.29)	100 111	Polaramine
FEXOFENADINE HYDROCHLORIDE	(
* Tab 60 mg	4.34	20	
	(11.53)	-	Telfast
* Tab 120 mg		10	
	(11.53)		Telfast
	14.22	30	Tolfact
	(29.81)		Telfast

	Subsidy		Fully Brand or
	(Manufacturer's \$	Price) Sub Per	sidised Generic Manufacturer
LORATADINE			
* Tab 10 mg	2.09	100	 Loraclear Hayfever Relief
* Oral liq 1 mg per ml	3.10	100 ml	✓ Lorapaed
PROMETHAZINE HYDROCHLORIDE			
* Tab 10 mg		50	Allersoothe
* Tab 25 mg		50	Allersoothe
st_{\ddagger} Oral liq 5 mg per 5 ml		100 ml	✓ <u>Allersoothe</u>
Inj 25 mg per ml, 2 ml – Up to 5 inj available on a PSO	11.00	5	Mayne
TRIMEPRAZINE TARTRATE			
Oral liq 30 mg per 5 ml	2.79	100 ml OP	
	(8.06)		Vallergan Forte
Inhaled Corticosteroids			
BECLOMETHASONE DIPROPIONATE			
Aerosol inhaler, 100 mcg per dose CFC-free	12 50	200 dose OP	Beclazone 100
Aerosol inhaler, 250 mcg per dose CFC-free		200 dose OP	✓ Beclazone 250
Aerosol inhaler, 50 mcg per dose CFC-free		200 dose OP	✓ Beclazone 50
BUDESONIDE			
Powder for inhalation, 100 mcg per dose	17.00	200 dose OP	V Pulmicort
		200 0030 01	Turbuhaler
Powder for inhalation, 200 mcg per dose	15 20	200 dose OP	✓ Budenocort
	19.00	200 0000 01	✓ Pulmicort
	10.00		Turbuhaler
Powder for inhalation, 400 mcg per dose	25.60	200 dose OP	✓ Budenocort
	32.00	200 0000 01	✓ Pulmicort
			Turbuhaler
FLUTICASONE			
Aerosol inhaler, 50 mcg per dose CFC-free		120 dose OP	Flixotide
Powder for inhalation, 50 mcg per dose		60 dose OP	 Flixotide Accuhaler
Powder for inhalation, 100 mcg per dose		60 dose OP	 Flixotide Accuhaler
Aerosol inhaler, 125 mcg per dose CFC-free		120 dose OP	 Flixotide
Aerosol inhaler, 250 mcg per dose CFC-free	27.20	120 dose OP	Flixotide
Powder for inhalation, 250 mcg per dose	13.60	60 dose OP	Flixotide Accuhaler

Inhaled Long-acting Beta-adrenoceptor Agonists

Prescribing Guideline for Inhaled Long-Acting Beta-Adrenoceptor Agonists

The addition of inhaled long-acting beta-adrenoceptor agonists (LABAs) to inhaled corticosteroids is recommended:

• For younger children (aged under 12 years) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 200 mcg beclomethasone or budesonide (or 100 mcg fluticasone).

 For adults and older children (aged 12 years and over) where asthma is poorly controlled despite using inhaled corticosteroids for at least three months at total daily doses of 400 mcg beclomethasone or budesonide (or 200 mcg fluticasone).
 Note:

Further information on the place of inhaled corticosteroids and inhaled LABAs in the management of asthma can be found in the New Zealand guidelines for asthma in adults (www.nzgg.org.nz) and in the New Zealand guidelines for asthma in children aged 1-15 (www.paediatrics.org.nz).

	Subsidy (Manufacturer's		Fully Brand or sidised Generic
	\$	Per	 Manufacturer
EFORMOTEROL FUMARATE – See prescribing guideline on th Powder for inhalation, 6 mcg per dose, breath activated		e 60 dose OP	Oxis Turbuhaler
Powder for inhalation, 12 mcg per dose, and monodose de vice		60 dose	Foradil
SALMETEROL – See prescribing guideline on the preceding pa Aerosol inhaler CFC-free, 25 mcg per dose Powder for inhalation, 50 mcg per dose, breath activated		120 dose OP 60 dose OP	 ✓ Serevent ✓ Serevent Accuhaler
Inhaled Corticosteroids with Long-Acting Beta-	Adrenocept	or Agonists	
 SA1179 Special Authority for Subsidy Initial application from any relevant practitioner. Approvals valic Either: All of the following: 	d for 2 years for a	applications mee	ting the following criteria:
1.1 Patient is a child under the age of 12; and1.2 Has been treated with inhaled corticosteroids of at per day fluticasone; and1.3 The prescriber considers that the patient would reproduct; or		-	-
 2 All of the following: 2.1 Patient is over the age of 12; and 2.2 Has been treated with inhaled corticosteroids of at per day fluticasone; and 2.3 The prescriber considers that the patient would reproduct. 	eceive additiona	I clinical benefit	from switching to a combination
Renewal from any relevant practitioner. Approvals valid for 2 y benefiting from treatment.	ears where the	treatment remain	ns appropriate and the patient is
BUDESONIDE WITH EFORMOTEROL – Special Authority see Aerosol inhaler 100 mcg with eformoterol fumarate 6 mcg Powder for inhalation 100 mcg with eformoterol fumarate		- Retail pharmac 120 dose OP	y 🗸 Vannair
6 mcg		120 dose OP	 Symbicort Turbuhaler 100/6
Aerosol inhaler 200 mcg with eformoterol fumarate 6 mcg Powder for inhalation 200 mcg with eformoterol fumarat		120 dose OP	✓ Vannair
6 mcg	60.00	120 dose OP	 Symbicort Turbuhaler 200/6
Powder for inhalation 400 mcg with eformoterol fumarate 12 mcg – No more than 2 dose per day		60 dose OP	✓ Symbicort Turbuhaler 400/12
FLUTICASONE WITH SALMETEROL – Special Authority see S Aerosol inhaler 50 mcg with salmeterol 25 mcg Aerosol inhaler 125 mcg with salmeterol 25 mcg		Retail pharmacy 120 dose OP 120 dose OP	✓ Seretide ✓ Seretide
Powder for inhalation 100 mcg with salmeterol 50 mcg – N more than 2 dose per day	0	60 dose OP	 Seretide Accuhaler
Powder for inhalation 250 mcg with salmeterol 50 mcg - N more than 2 dose per day		60 dose OP	✓ Seretide Accuhaler

	Subsidy (Manufacturer's \$		Fully Brand or sidised Generic ✔ Manufacturer
Beta-Adrenoceptor Agonists			
SALBUTAMOL ‡ Oral liq 2 mg per 5 ml	1.20 1.99	90 ml 150 ml	✓ Broncolin s₂9 ✓ Salapin ✓ Ventolin
Infusion 1 mg per ml, 5 ml		10	Ventolin
Inj 500 mcg per ml, 1 ml – Up to 5 inj available on a PSO (Broncolin see Oral liq 2 mg per 5 ml to be delisted 1 August 201 (Ventolin Oral liq 2 mg per 5 ml to be delisted 1 August 2013)		5	Ventolin
Inhaled Beta-Adrenoceptor Agonists			
SALBUTAMOL Aerosol inhaler, 100 mcg per dose CFC free – Up to 1000 dose available on a PSO		200 dose OP	 ✓ Respigen ✓ Salamol Ventolin
Nebuliser soln, 1 mg per ml, 2.5 ml – Up to 30 neb available on a PSO Nebuliser soln, 2 mg per ml, 2.5 ml – Up to 30 neb available	3.25	20	✓ <u>Asthalin</u>
on a PSO	3.44	20	✓ <u>Asthalin</u>
TERBUTALINE SULPHATE Powder for inhalation, 250 mcg per dose, breath activated		200 dose OP	 Bricanyl Turbuhaler
Inhaled Anticholinergic Agents			
PRATROPIUM BROMIDE Aerosol inhaler, 20 mcg per dose CFC-free Nebuliser soln, 250 mcg per ml, 1 ml – Up to 40 neb available		200 dose OP	✓ Atrovent
on a PSO	3.79	20 20	 ✓ <u>Univent</u> ✓ Univent
TIOTROPIUM BROMIDE – Special Authority see SA1193 below Powder for inhalation, 18 mcg per dose	– Retail pharm		 ✓ Spiriva

➡SA1193 Special Authority for Subsidy

Initial application only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 To be used for the long-term maintenance treatment of bronchospasm and dyspnoea associated with COPD; and
- 2 In addition to standard treatment, the patient has trialled a short acting bronchodilator of at least 40 mcg ipratropium q.i.d for one month; and

3 Either:

- The patient's breathlessness according to the Medical Research Council (UK) dyspnoea scale is:
- 3.1 Grade 4 (stops for breath after walking about 100 meters or after a few minutes on the level); or
- 3.2 Grade 5 (too breathless to leave the house, or breathless when dressing or undressing); and
- Applicant must state recent measurement of:
- 4 All of the following:

Subsidy (Manufacturer's Price) \$	Subs Per	Fully sidised	Brand or Generic Manufacturer	

continued...

- 4.1 Actual FEV₁ (litres); and
- 4.2 Predicted FEV₁ (litres); and
- 4.3 Actual FEV₁ as a % of predicted (must be below 60%); and

5 Either:

- 5.1 Patient is not a smoker (for reporting purposes only); or
- 5.2 Patient is a smoker and has been offered smoking cessation counselling; and
- 6 The patient has been offered annual influenza immunisation.

Renewal only from a general practitioner or relevant specialist. Approvals valid for 2 years for applications meeting the following criteria:

All of the following:

- 1 Patient is compliant with the medication; and
- 2 Patient has experienced improved COPD symptom control (prescriber determined); and Applicant must state recent measurement of:
- 3 All of the following:
 - 3.1 Actual FEV_1 (litres); and
 - 3.2 Predicted FEV1 (litres); and
 - 3.3 Actual FEV1 as a % of predicted.

Inhaled Beta-Adrenoceptor Agonists with Anticholinergic Agents

SALBUTAMOL WITH IPRATROPIUM BROMIDE

Aerosol inhaler, 100 mcg with ipratropium bromide, 20 mcg per dose CFC-free	.12.19	200 dose OP	🖌 Duolin HFA
Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml – Up to 20 neb available on a PSO		20	✔ Duolin

Leukotriene Receptor Antagonists

MONTELUKAST - Special Authority see SA1227 below - Retail pharmacy

Prescribing Guideline: Clinical evidence indicates that the effectiveness of montelukast is strongest when montelukast is used in short treatment courses.

lab 4 mg18.48	28	Singulair
Tab 5 mg	28	Singulair
Tab 10 mg18.48	28	Singulair

SA1227 Special Authority for Subsidy

Initial application — (Pre-school wheeze) from any relevant practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 To be used for the treatment of intermittent severe wheezing (possibly viral) in children under 5 years; and
- 2 The patient has trialled inhaled corticosteroids at a dose of up to 400 mcg per day beclomethasone or budesonide, or 200 mcg per day fluticasone for at least one month; and
- 3 The patient continues to have at least three severe exacerbations at least one of which required hospitalisation (defined as in-patient stay or prolonged Emergency Department treatment) in the past 12 months.

Renewal — (Pre-school wheeze) from any relevant practitioner. Approvals valid for 1 year where the treatment remains appropriate and the patient is benefiting from treatment.

Initial application — (exercise-induced asthma) from any relevant practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria: Both:

	Subsidy (Manufacturer's \$	Price) Sub	Fully Brand or sidised Generic ✓ Manufacturer
continued	Ŷ		
1 Patient is being treated with maximal asthr	na therapy, including inhaled o	corticosteroids a	nd long-acting beta-adrenoceptor
agonists; and			
2 Patient continues to experience frequent ep Initial application — (aspirin desensitisation)			
applications meeting the following criteria:	only norn a chinear infinunoi	ogist of allergis	. Approvais valid for 1 year for
All of the following:			
1 Patient is undergoing aspirin desensitisation			
2 Patient has moderate to severe aspirin-example		r Samter's triad;	and
 3 Nasal polyposis, confirmed radiologically or 4 Documented aspirin or NSAID allergy con 		a alinical histor	w of action to contrin or
NSAID where challenge would be consider		a chinical histor	y of severe reaction to aspirit of
Mast Cell Stabilisers			
NEDOCROMIL			
Aerosol inhaler, 2 mg per dose CFC-free		112 dose OP	✓ Tilade
SODIUM CROMOGLYCATE			
Powder for inhalation, 20 mg per dose		50 dose	Intal Spincaps
Aerosol inhaler, 5 mg per dose CFC-free		112 dose OP	Intal Forte CFC Free
Methylxanthines			
AMINOPHYLLINE			
* Inj 25 mg per ml, 10 ml - Up to 5 inj available	on a PSO53.75	5	DBL Aminophylline
THEOPHYLLINE			
* Tab long-acting 250 mg		100	Nuelin-SR
*‡ Oral liq 80 mg per 15 ml		500 ml	Nuelin
Mucolytics			
DORNASE ALFA – Special Authority see SA0611	below – Retail pharmacy		
Nebuliser soln, 2.5 mg per 2.5 ml ampoule		6	 Pulmozyme
SA0611 Special Authority for Subsidy			
Special Authority approved by the Cystic Fibrosis			
Notes: Application details may be obtained from P		v.pharmac.govt.r	nz or:
The Co-ordinator, Cystic Fibrosis Advisory Pane			
PHARMAC, PO Box 10 254	Facsimile: (04) 916 7571	a sout an	
Wellington	Email: CFPanel@pharma		odiatriaiana who have avertices
Prescriptions for patients approved for treatment r and expertise in treating cystic fibrosis.	nust be written by respiratory p	onysicians of par	ediatriciaris who have experience
SODIUM CHLORIDE			
Not funded for use as a nasal drop.	00.50	00	Diamod
Soln 7%		90 ml OP	Biomed

RESPIRATORY SYSTEM AND ALLERGIES

	Subsidy		- Fully Brand or
	(Manufacturer's \$	Price) Sub Per	sidised Generic Manufacturer
lasal Preparations			
Allergy Prophylactics			
ECLOMETHASONE DIPROPIONATE			
Metered aqueous nasal spray, 50 mcg per dose	2.35	200 dose OP	
	(4.85)		Alanase
Metered aqueous nasal spray, 100 mcg per dose		200 dose OP	A1
	(5.75)		Alanase
JDESONIDE	0.05		
Metered aqueous nasal spray, 50 mcg per dose		200 dose OP	Butacort Aqueous
Metered aqueous nasal spray, 100 mcg per dose	(4.85) 2.61	200 dose OP	Bulacon Aqueous
	(5.75)	200 0000 01	Butacort Aqueous
UTICASONE PROPIONATE	· · · ·		
Metered aqueous nasal spray, 50 mcg per dose	2.30	120 dose OP	Flixonase Hayfever
			& Allergy
RATROPIUM BROMIDE			
Aqueous nasal spray, 0.03%	4.03	15 ml OP	✓ Univent
DDIUM CROMOGLYCATE			
Nasal spray, 4%		22 ml OP	✓ Rex
Rex Nasal spray, 4% to be delisted 1 November 2013)			
Respiratory Devices			
ASK FOR SPACER DEVICE			
a) Up to 20 dev available on a PSO			
b) Only on a PSO			
c) Only for children aged six years and under			
Size 2	2.99	1	EZ-fit Paediatric
			Mask
EAK FLOW METER			
a) Up to 10 dev available on a PSO b) Only on a PSO			
Low range	11 44	1	Breath-Alert
Normal range		1	✓ Breath-Alert
PACER DEVICE			·
a) Up to 20 dev available on a PSO			
b) Only on a PSO			
230 ml (single patient)	4.72	1	✓ Space Chamber
			Plus
800 ml	8.50	1	Volumatic
PACER DEVICE AUTOCLAVABLE			
 a) Up to 5 dev available on a PSO 			
b) Only on a PSO	11 00	4	Chamber
		1 of starilisation	✓ Space Chamber

RESPIRATORY SYSTEM AND ALLERGIES

	Subsidy (Manufacturer's Price) \$	Per	Fully Subsidised	Brand or Generic Manufacturer
Respiratory Stimulants				
CAFFEINE CITRATE Oral liq 20 mg per ml (10 mg base per ml)		5 ml OF	Bi	iomed

	Out-side		Fully Desired an
	Subsidy (Manufacturer's I	Price) Sub	Fully Brand or osidised Generic
	\$	Per	 Manufacturer
Ear Preparations			
ACETIC ACID WITH 1, 2- PROPANEDIOL DIACETATE AND BEN For Vosol ear drops with hydrocortisone powder refer, page 1 Ear drops 2% with 1, 2-Propanediol diacetate 3% and benzethonium chloride 0.02%	92	35 ml OP	✔ Vosol
CHLORAMPHENICOL			
Ear drops 0.5%	2.20	5 ml OP	 Chloromycetin
Ear drops 0.02% with clioquinol 1%	4.46	7.5 ml OP	 Locacorten-Viaform ED's
			 Locorten-Vioform
TRIAMCINOLONE ACETONIDE WITH GRAMICIDIN, NEOMYCII		IN	
Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g		7.5 ml OP	✓ Kenacomb
		7.5 111 01	 Renacomb
Ear/Eye Preparations			
DEXAMETHASONE WITH FRAMYCETIN AND GRAMICIDIN			
Ear/Eye drops 500 mcg with framycetin sulphate 5 mg and			
gramicidin 50 mcg per ml	4.50 (9.27)	8 ml OP	Sofradex
FRAMYCETIN SULPHATE			
Ear/Eye drops 0.5%	4.13 (8.65)	8 ml OP	Soframycin
Eye Preparations			
	the stated athem	viaa	
Eye preparations are only funded for use in the eye, unless explic	illy stated other	wise.	
Anti-Infective Preparations			
ACICLOVIR			
* Eye oint 3%		4.5 g OP	Zovirax
CHLORAMPHENICOL			
Eye oint 1%		4 g OP 10 ml OP	✓ <u>Chlorsig</u>
Eye drops 0.5% Funded for use in the ear.	1.20	10 IIII OF	Chlorafast
CIPROFLOXACIN			
Eye Drops 0.3%		5 ml OP	Ciloxan
For treatment of bacterial keratitis or severe bacterial conju	unctivitis resistar	nt to chloramph	ienicol.
FUSIDIC ACID Eye drops 1%	4.50	5 g OP	 Fucithalmic
GENTAMICIN SULPHATE			
Eye drops 0.3%	11.40	5 ml OP	 Genoptic
PROPAMIDINE ISETHIONATE			
* Eye drops 0.1%		10 ml OP	
	(7.99)		Brolene

183

	Subsidy	Deitere) Out	Fully Brand or
	(Manufacturer's I \$	Price) Sur Per	osidised Generic Manufacturer
FOBRAMYCIN			
Eye oint 0.3%		3.5 g OP	✓ <u>Tobrex</u>
Eye drops 0.3%	11.48	5 ml OP	✓ <u>Tobrex</u>
Corticosteroids and Other Anti-Inflammatory Pro	eparations		
DEXAMETHASONE	5.00		
 ₭ Eye oint 0.1% ₭ Eye drops 0.1% 		3.5 g OP 5 ml OP	 ✓ <u>Maxidex</u> ✓ Maxidex
DEXAMETHASONE WITH NEOMYCIN AND POLYMYXIN B SUL			
E Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin			
B sulphate 6,000 u per g		3.5 g OP	✓ Maxitrol
₭ Eye drops 0.1% with neomycin sulphate 0.35% and polymy-		-	
xin B sulphate 6,000 u per ml	4.50	5 ml OP	Maxitrol
DICLOFENAC SODIUM			4 M M
₭ Eye drops 1 mg per ml	13.80	5 ml OP	Voltaren Ophtha
EUOROMETHOLONE	0.00		
₭ Eye drops 0.1%		5 ml OP	✓ <u>Flucon</u>
EVOCABASTINE Eye drops 0.5 mg per ml	9 71	4 ml OP	
	(10.34)	4 IIII OF	Livostin
ODOXAMIDE TROMETAMOL	(10101)		
Eye drops 0.1%	8.71	10 ml OP	✓ Lomide
REDNISOLONE ACETATE			
₭ Eye drops 0.12%	4.50	5 ml OP	Pred Mild
₭ Eye drops 1%	4.50	5 ml OP	Pred Forte
SODIUM CROMOGLYCATE			
Eye drops 2%	1.18	5 ml OP	✓ <u>Rexacrom</u>
Glaucoma Preparations - Beta Blockers			
BETAXOLOL HYDROCHLORIDE			
₭ Eye drops 0.25%		5 ml OP	Betoptic S
< Eye drops 0.5%		5 ml OP	Betoptic
EVOBUNOLOL ← Eye drops 0.25%	7 00	5 ml OP	✓ Betagan
 Eye drops 0.25% Eye drops 0.5% 		5 ml OP	✓ Betagan
			-
 ✓ Eye drops 0.25% 	2.08	5 ml OP	✓ <u>Arrow-Timolol</u>
₭ Eye drops 0.25%, gel forming		2.5 ml OP	✓ Timoptol XE
k Eye drops 0.5%		5 ml OP	Arrow-Timolol
Eye drops 0.5%, gel forming Glaucoma Preparations - Carbonic Anhydrase Ir		2.5 ml OP	Timoptol XE
ACETAZOLAMIDE K Tab 250 mg – For acetazolamide oral liquid formulation refer,			
page 189		100	Diamox
BRINZOLAMIDE			
₭ Eye Drops 1%	9.77	5 ml OP	Azopt
✓ fully subsidised	coo Unonn	round modiaina a	upplied under Section 29

	Subsidy (Manufacturer's I \$	Price) Sub Per	Fully Brand or osidised Generic Manufacturer
OORZOLAMIDE HYDROCHLORIDE ₭ Eye drops 2%		5 ml OP	
	(13.95)		Trusopt
ORZOLAMIDE HYDROCHLORIDE WITH TIMOLOL MALEATE Eve drops 2% with timolol maleate 0.5%	-	5 ml OP	✔ Cosopt
Glaucoma Preparations - Prostaglandin Analog	jues		
BIMATOPROST – Retail pharmacy-Specialist k Eye drops 0.03%		3 ml OP	🗸 Lumigan
ATANOPROST – Retail pharmacy-Specialist ₭ Eye drops 50 mcg per ml, 2.5 ml	1.99	2.5 ml OP	✓ <u>Hysite</u>
RAVOPROST – Retail pharmacy-Specialist ₭ Eye drops 0.004%		2.5 ml OP	🗸 Travatan
Glaucoma Preparations - Other			
BRIMONIDINE TARTRATE			
₭ Eye Drops 0.2%	6.45	5 ml OP	Arrow-Brimonidine
RIMONIDINE TARTRATE WITH TIMOLOL MALEATE	40.50	E will OD	1 O militaria
Eye drops 0.2% with timolol maleate 0.5%		5 ml OP	 Combigan
ILOCARPINE ₭ Eve drops 1%	4 26	15 ml OP	Isopto Carpine
 ► Eye drops 2% 		15 ml OP	 Isopto Carpine
 Eye drops 4% Subsidised for oral use pursuant to the Standard Formula 	7.99 ae.	15 ml OP	 Isopto Carpine
Eye drops 2% single dose – Special Authority see SA089			
below – Retail pharmacy	31.95 (32.72)	20 dose	Minims

SA0895 Special Authority for Subsidy

Initial application from any relevant practitioner. Approvals valid for 2 years for applications meeting the following criteria: Either:

1 Patient has to use an unpreserved solution due to an allergy to the preservative; or

2 Patient wears soft contact lenses.

Note: Minims for a general practice are considered to be "tools of trade" and are not approved as special authority items. **Renewal** from any relevant practitioner. Approvals valid for 2 years where the treatment remains appropriate and the patient is benefiting from treatment.

Mydriatics and Cycloplegics

ATROPINE SULPHATE * Eye drops 1%	15 ml OP	✓ Atropt
CYCLOPENTOLATE HYDROCHLORIDE * Eye drops 1%	15 ml OP	✓ Cyclogyl
HOMATROPINE HYDROBROMIDE * Eye drops 2%	15 ml OP	✓ Isopto Homatropine
(Isopto Homatropine Eye drops 2% to be delisted 1 October 2013) TROPICAMIDE		
* Eye drops 0.5%	15 ml OP 15 ml OP	 ✓ <u>Mydriacyl</u> ✓ <u>Mydriacyl</u>

▲Three months supply may be dispensed at one time

if endorsed "certified exemption" by the prescriber or pharmacist. 185

	Subsidy (Manufacturer's Pr \$	rice) Subs Per	Fully sidised	Brand or Generic Manufacturer
Preparations for Tear Deficiency				
For acetylcysteine eye drops refer, page 192				
HYPROMELLOSE	0.00	45 ml 00		.
* Eye drops 0.3% * Eye drops 0.5%		15 ml OP 15 ml OP	V PC	oly-Tears
	(3.92)		Me	ethopt
POLYVINYL ALCOHOL				
* Eye drops 1.4%		15 ml OP	Vi Vi	••••
* Eye drops 3%		15 ml OP	V VI	stil Forte
Other Eye Preparations				
NAPHAZOLINE HYDROCHLORIDE				
* Eye drops 0.1%	4.15	15 ml OP	✓ <u>Na</u>	aphcon Forte
OLOPATADINE	17.00	- 100		
Eye drops 0.1%	17.00	5 ml OP	🗸 Pa	itanol
PARAFFIN LIQUID WITH SOFT WHITE PARAFFIN * Eye oint with soft white paraffin	3 63	3.5 g OP	v 1a	cri-Lube
PARAFFIN LIQUID WITH WOOL FAT LIQUID		0.0 y OI	₩ <u>La</u>	
* Eye oint 3% with wool fat liq 3%		3.5 g OP	🖌 Po	oly-Visc

VARIOUS

	Subsidy (Manufacturer's Price) \$	Su Per	Fully ubsidised	Brand or Generic Manufacturer	
Various					
May only be claimed once per patient.					
PHARMACY SERVICES					
* Brand switch fee	4.33	1 fee	✓ B ✓ B ✓ B ✓ B	SF Alphapharm SF Apo-Diltiazem CD SF CareSens II SF CareSens N SF CareSens N POP SF Nevirapine Alphapharm	
 a) The Pharmacode for BSF CareSens N is 2423138 - see b) The Pharmacode for BSF CareSens II is 2423146 - see c) The Pharmacode for BSF CareSens N POP is 2423154 d) The Pharmacode for BSF Alphapharm is 2433494 - see e) The Pharmacode for BSF Nevirapine Alphapharm is 2433 f) The Pharmacode for BSF Apo-Diltiazem CD is 2437775 - (BSF Alphapharm Brand switch fee to be delisted 1 July 2013) (BSF CareSens II Brand switch fee to be delisted 1 July 2013) (BSF CareSens N Brand switch fee to be delisted 1 July 2013) (BSF CareSens N POP Brand switch fee to be delisted 1 July 2013) (BSF CareSens N POP Brand switch fee to be delisted 1 July 2013) (BSF CareSens N POP Brand switch fee to be delisted 1 July 2013) (BSF Nevirapine Alphapharm Brand switch fee to be delisted 1 July 2013) 	also page 30 - see also page 30 also page ?? 33265 - see also page - see also page 57 2013) 3)	je 104			

INTRODUCTION

The following extemporaneously compounded products are eligible for subsidy:

- The "Standard Formulae".
- Oral liquid mixtures for patients unable to swallow subsidised solid dose oral formulations.
- The preparation of syringe drivers when prescribed by a general practitioner.
- Dermatological preparations
 - a) One or more subsidised dermatological galenical(s) in a subsidised dermatological base.
 - b) Dilution of proprietary Topical Corticosteroid-Plain preparations with a dermatological base (Retail pharmacy-specialist).
 - c) Menthol crystals only in the following bases: Aqueous cream

Urea cream 10% Wool fat with mineral oil lotion Hydrocortisone 1% with wool fat and mineral oil lotion Glycerol, paraffin and cetyl alcohol lotion.

Glossary

Dermatological base: The products listed in the Barrier creams and Emollients section and the Topical Corticosteroids-Plain section of the Pharmaceutical Schedule are classified as dermatological bases for the purposes of extemporaneous compounding and are the bases to which the dermatological galenicals can be added. Also the dermatological bases in the Barrier Creams and Emollients section of the Pharmaceutical Schedule can be used for diluting proprietary Topical Corticosteroid-Plain preparations. The following products are dermatological bases:

- Aqueous cream
- Cetomacrogol cream BP
- Collodion flexible
- Emulsifying ointment BP
- Hydrocortisone with wool fat and mineral oil lotion
- · Oil in water emulsion
- Urea cream 10%
- White soft paraffin
- Wool fat with mineral oil lotion
- Zinc and castor oil ointment BP
- Proprietary Topical Corticosteroid-Plain preparations

Dermatological galenical: Dermatological galenicals will only be subsidised when added to a dermatological base. More than one dermatological galenical can be added to a dermatological base.

The following are dermatological galenicals:

- Coal tar solution BP up to 10%
- Hydrocortisone powder up to 5%
- Menthol crystals
- · Salicylic acid powder
- Sulphur precipitated powder

Standard formulae: Standard formulae are a list of fomulae for ECPs that are subsidised. Their ingredients are listed under the appropriate therapeutic heading in Section B of the Pharmaceutical Schedule and also in Section C.

Explanatory notes

Oral liquid mixtures

Oral liquid mixtures are subsidised for patients unable to swallow subsidised solid oral dose forms where no suitable alternative proprietary formulation is subsidised. Suitable alternatives include dispersible and sublingual formulations, oral liquid formulations or rectal formulations. Before extemporaneously compounding an oral liquid mixture, other alternatives such as dispersing the solid dose form (if appropriate) or crushing the solid dose form in jam, honey or soft foods such as yoghurt should be explored.

The Emixt website **www.pharminfotech.co.nz** has evidence-based formulations which are intended to standardise compounded oral liguids within New Zealand.

Pharmaceuticals with standardised formula for compounding in Ora products

Acetazolamide 25 mg/ml	Flecainide 20 mg/ml	Rifabutin 20 mg/ml
Allopurinol 20 mg/ml	Gabapentin 100 mg/ml	Sildenafil 2 mg/ml
Amlodipine 1 mg/ml	Gabapentin (Neurontin) 100 mg/ml	Sotalol 5 mg/ml
Azathioprine 50 mg/ml	Hydrocortisone 1 mg/ml	Sulphasalazine 100 mg/ml
Baclofen 10 mg/ml	Labetolol 10 mg/ml	Tacrolimus 1 mg/ml
Carvedilol 1 mg/ml	Levetiracetam 100 mg/ml	Terbinafine 25 mg/ml
Clopidogrel 5 mg/ml	Levodopa with carbidopa (5 mg lev-	Ursodeoxycholic acid 50 mg/ml
Diazoxide 10 mg/ml	odopa + 1.25 mg carbidopa)/ml	Valganciclovir 60 mg/ml*
Diltiazem hydrochloride 12 mg/ml	Metoclopramide 1 mg/ml	Verapamil hydrochloride 50 mg/ml
Dipyridamole 10 mg/ml	Metoprolol tartrate 10 mg/ml	
Domperidone 1 mg/ml	Nitrofurantoin 10 mg/ml	
Enalapril 1 mg/ml	Pyrazinamide 100 mg/ml	

*Note this is a DCS formulation

PHARMAC endorses the recommendations of the Emixt website and encourages New Zealand pharmacists to use these formulations when compounding is appropriate. The Emixt website also provides stability and expiry data for compounded products. For the majority of products compounded with Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet or Ora-Sweet SF a four week expiry is appropriate.

Please note that no oral liquid mixture will be eligible for Subsidy unless all the requirements of Section B and C of the Schedule applicable to that pharmaceutical are met.

Some community pharmacies may not have appropriate equipment to compound all of the listed products, please use appropriate clinical judgement.

Subsidy for extemporaneously compounded oral liquid mixtures is based on:

Solid dose form	qs
Preservative	qs
Suspending agent	qs
Water	to 100%

or

Solid dose form

Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and/or Ora-Sweet SF

Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients such as flavouring and colouring agents, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.

to 100%

The majority of extemporaneously compounded oral liquid mixtures should contain a preservative and suspending agent.

- Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and Ora-Sweet SF when used correctly are an appropriate preservative and suspending agent.
- Methylcellulose 3% is considered a suitable suspending agent and compound hydroxybenzoate solution or methyl hydroxybenzoate 10% solution are considered to be suitable preservatives. Usually 1 ml of these preservative solutions is added to 100 ml of oral liquid mixture.

Some solid oral dose forms are not appropriate for compounding into oral liquid mixtures and should therefore not be used/considered for extemporaneously compounded oral liquid mixtures. This includes long-acting solid dose formulations, enteric coated tablets or capsules, sugar coated tablets, hard gelatin capsules and chemotherapeutic agents.

The following practices will not be subsidised:

- Where a Standard Formula exists in the Pharmaceutical Schedule for a solid dose form, compounding the solid dose form in Ora-Blend, Ora-Blend SF, Ora-Plus, Ora-Sweet and/or Ora-Sweet SF.
- Mixing one or more proprietary oral liquids (eg an antihistamine with pholcodine linctus).
- Extemporaneously compounding an oral liquid with more than one solid dose chemical.
- Mixing more than one extemporaneously compounded oral liquid mixture.
- Mixing one or more extemporaneously compounded oral liquid mixtures with one or more proprietary oral liquids.
- The addition of a chemical/powder/agent/solution to a proprietary oral liquid or extemporaneously compounded oral mixture.

Standard formulae

A list of standard formulae is contained in this section. All ingredients associated with a standard formula will be subsidised and an appropriate compounding fee paid.

Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.


Dermatological Preparations

Proprietary topical corticosteroid preparations may be diluted with a dermatological base (see page 188) from the Barrier Creams and Emollients section of the Pharmaceutical Schedule (Retail pharmacy-Specialist). Dilution of proprietary topical corticosteroid preparations should only be prescribed for withdrawing patients off higher strength proprietary topical corticosteroid products where there is no suitable proprietary product of a lower strength available or an extemporaneously compounded product with up to 5% hydrocortisone is not appropriate. (In general proprietary topical corticosteroid preparations should not be diluted because dilution effects can be unpredictable and may not be linear, and usually there is no stability data available for diluted products).

One or more dermatological galenicals may be added to a dermatological base (including proprietary topical corticosteroid preparations). Prescribers may prescribe or pharmacists may add extra non-subsidised ingredients, but these extra ingredients will not be reimbursed. The subsidised ingredients in the formula will be reimbursed and a compounding fee paid.

The addition of dermatological galenicals to diluted proprietary Topical Corticosteroids-Plain will not be subsidised.

The flow diagram on the next page may assist you in deciding whether or not a dermatological ECP is subsidised.



EXTEMPORANEOUSLY COMPOUNDED PRODUCTS & GALENICALS

Standard Formulae

••••••	
ACETYLCYSTEINE EYE DROPS Acetylcysteine inj 200 mg per ml, 10 ml Suitable eye drop base	qs qs
ASPIRIN AND CHLOROFORM APPLICATI Aspirin Soluble tabs 300 mg Chloroform	ON 12 tabs to 100 ml
CODEINE LINCTUS PAEDIATRIC (3 mg pe Codeine phosphate Glycerol Preservative Water	er 5 ml) 60 mg 40 ml qs to 100 ml
CODEINE LINCTUS DIABETIC (15 mg per Codeine phosphate Glycerol Preservative Water	5 ml) 300 mg 40 ml qs to 100 ml
FOLINIC MOUTHWASH Calcium folinate 15 mg tab Preservative Water (Preservative should be used if quantity sup more than 5 days. Maximum 500 ml per pre	
MAGNESIUM HYDROXIDE MIXTURE Magnesium hydroxide paste Methyl hydroxybenzoate Water METHADONE MIXTURE Methadone powder	275 g 1.5 g 770 ml qs
Glycerol Water	qs qs to 100 ml
METHYL HYDROXYBENZOATE 10% SOL Methyl hydroxybenzoate Propylene glycol (Use 1 ml of the 10% solution per 100 ml of mixture)	10 g to 100 ml

OMEPRAZOLE SUSPENSION Omeprazole capules or powder Sodium bicarbonate powder BP Water	qs 8.4 g to 100 ml
PHENOBARBITONE ORAL LIQUID Phenobarbitone Sodium Glycerol BP Water	1 g 70 ml to 100 ml
PHENOBARBITONE SODIUM PAEDIATRI LIQUID (10 mg per ml) Phenobarbitone Sodium Glycerol BP Water	C ORAL 400 mg 4 ml to 40 ml
PILOCARPINE ORAL LIQUID Pilocarpine 4% eye drops Preservative Water (Preservative should be used if quantity su more than 5 days.)	qs qs to 500 ml pplied is for
SALIVA SUBSTITUTE FORMULA Methylcellulose Preservative Water (Preservative should be used if quantity su more than 5 days. Maximum 500 ml per pr	
SODIUM CHLORIDE ORAL LIQUID Sodium chloride inj 23.4%, 20 ml Water (Only funded if prescribed for treatment of	qs qs hyponatraemia)
VOSOL EAR DROPS WITH HYDROCORTISONE POWDER 1% Hydrocortisone powder	1%

Vosol Ear Drops to 35 ml

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

	Subsidy (Manufacturer's F \$	Price) Su Per	Fully Brand or bsidised Generic ✔ Manufacturer
Extemporaneously Compounded Preparations a	and Galenica	lls	
ACETYLCYSTEINE – Retail pharmacy-Specialist Inj 200 mg per ml, 10 ml	178.00	10	✓ <u>Martindale</u> Acetylcysteine
Inj 200 mg per ml, 30 ml BENZOIN	219.00	4	✓ Acetadote
Tincture compound BP	(5.10)	50 ml	PSM
CHLOROFORM – Only in combination	24.42 (38.00)	500 ml	PSM
Only in aspirin and chloroform application. Chloroform BP	25.50	500 ml	✔ PSM
CODEINE PHOSPHATE – Safety medicine; prescriber may dete Powder – Only in combination		g frequency 5 g	
	(25.46) 63.09 (90.09)	25 g	Douglas Douglas
a) Only in extemporaneously compounded codeine linctus b) ‡ Safety cap for extemporaneously compounded oral line	diabetic or code		0
COLLODION FLEXIBLE Collodion flexible COMPOUND HYDROXYBENZOATE – Only in combination	19.30	100 ml	✔ PSM
Only in extemporaneously compounded oral mixtures. Soln		100 ml	✓ David Craig
GLYCERIN WITH SODIUM SACCHARIN – Only in combination Only in combination with Ora-Plus. Suspension	35 50	473 ml	✔ Ora-Sweet SF
GLYCERIN WITH SUCROSE – Only in combination Only in combination with Ora-Plus.			
Suspension		473 ml	✓ Ora-Sweet
 Liquid – Only in combination Only in extemporaneously compounded oral liquid prepara MAGNESIUM HYDROXIDE 		2,000 ml	✓ <u>healthE</u>
Paste METHADONE HYDROCHLORIDE	22.61	500 g	🗸 PSM
 a) Only on a controlled drug form b) No patient co-payment payable c) Safety medicine; prescriber may determine dispensing free d) Extemporaneously compounded methadone will only be r powder, not methadone tablets). 	quency eimbursed at the	e rate of the ch	eapest form available (methadone
Powder ‡ Safety cap for extemporaneously compounded oral liqui		1 g	🗸 AFT
METHYL HYDROXYBENZOATE Powder	8.00 8.98	25 g	✓ PSM✓ Midwest

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS

	Subsidy (Manufacturer's F \$	Price) Sul Per	Fully Brand or osidised Generic ✓ Manufacturer
ETHYLCELLULOSE			
Powder		100 g	✓ ABM
Suspension - Only in combination	36.95 35.50	473 ml	✓ MidWest ✓ Ora-Plus
BM Powder to be delisted 1 December 2013)		470 mi	
ETHYLCELLULOSE WITH GLYCERIN AND SODIUM SACCH	ARIN – Only in c	combination	
Suspension		473 ml	Ora-Blend SF
ETHYLCELLULOSE WITH GLYCERIN AND SUCROSE - On	y in combination		
Suspension	35.50	473 ml	 Ora-Blend
IENOBARBITONE SODIUM			
Powder – Only in combination		10 g	MidWest
a) Only in children up to 12 years	325.00	100 g	 MidWest
b) ± Safety cap for extemporaneously compounded oral li	quid preparations	3.	
ROPYLENE GLYCOL	quiù propulatione		
Only in extemporaneously compounded methyl hydroxybenz	oate 10% solutio	n.	
Liq		500 ml	V PSM
	11.25		 Midwest
DDIUM BICARBONATE			
Powder BP – Only in combination	8.95 9.80	500 g	 Midwest
	9.80 (29.50)		David Craig
Only in extemporaneously compounded omeprazole and	()	pension.	Dana oralg
(RUP (PHARMACEUTICAL GRADE) – Only in combination	·		
Only in extemporaneously compounded oral liquid preparation			
Liq	21.75	2,000 ml	 Midwest
ATER			
Tap – Only in combination	0.00	1 ml	Tap water

EXPLANATORY NOTES

The list of special foods to which Subsidies apply is contained in this section. The list of available products, guidelines for use, subsidies and charges is reviewed as required. Applications for new listings and changes to subsidies and access criteria will be considered by the special foods sub-committee of PTAC which meets as and when required. In all cases, subsidies are available by Special Authority only. This means that, unless a patient has a valid Special Authority number for their special food requirements, they must pay the full cost of the products themselves.

Eligibility for Special Authority

Special Authorities will be approved for patients meeting conditions specified under the *Conditions and Guidelines* for each product. In some cases there are also limits to how products can be prescribed (for example quantity, use or duration). Only those brands, presentations and flavours of special foods listed in this section are subsidised.

Who can apply for Special Authority?

Initial Applications:	Only from a dietitian, relevant specialist or a vocationally registered general
	practitioner.
Reapplications:	Only from a dietitian, relevant specialist or a vocationally registered general
	practitioner or general practitioner on the recommendation of a dietitian, rele-
	vant specialist or a vocationally registered general practitioner. Other general
	practitioners must include the name of the dietitian, relevant specialist or voca-
	tionally registered general practitioner and the date contacted.

All applications must be made on an official form available from the PHARMAC website www.pharmac.govt.nz. All applications must include specific details as requested on the form relating to the application. Applications must be forwarded to:

Ministry of Health Sector Services Private Bag 3015 WHANGANUI 4540 Freefax 0800 100 131

Subsidies and manufacturer's surcharges

The Subsidies for some special foods are based on the lowest priced product within each group. Where this is so, or where special foods are otherwise not fully subsidised, a manufacturer's surcharge may be payable by the patient. The manufacturer's surcharge is the difference between the price of the product and the subsidy attached to it and may be subject to mark-ups applied at a pharmacy level. As a result the manufacturer's surcharge may vary. Fully subsidised alternatives are available in most cases (as indicated by a tick in the left hand column). Patients should only have to pay a co-payment on these products.

Where are special foods available from?

Distribution arrangements for special foods vary from region to region. Special foods are available from hospital pharmacies providing an outpatient dispensing service as well as retail pharmacies in the Northern, Midland and Central (including Nelson and Blenheim) regions.

Definitions

 Failure to thrive
 An inability to gain or maintain weight resulting in physiological impairment.

 Growth deficiency
 Where the weight of the child is less than the fifth or possibly third percentile for their age, with evidence of malnutrition

Dietitian Prescribing

Prescriptions from Dietitians will be only valid for subsidy where they are for special foods, as listed in this section, or where they are for the following products:

ASCORBIC ACID Tab 100 mg

CALCIUM CARBONATE

- Tab eff 1.75 g (1 g elemental)
 Tab 1.25 g (500 mg elemental)
- COMPOUND ELECTROLYTES

✓ Powder for soln for oral use 4.4 g

DEXTROSE WITH ELECTROLYTES ✓ Soln with electrolytes

FERROUS FUMARATE

✓ Tab 200 mg (65 mg elemental)

FERROUS FUMARATE WITH FOLIC ACID

✓ Tab 310 mg (100 mg elemental) with folic acid 350 mcg

FERROUS SULPHATE

Tab long-acting 325 mg (105 mg elemental) ✓ Oral liq 30 mg per 1 ml (6 mg elemental per 1 ml)

FERROUS SULPHATE WITH FOLIC ACID

Tab long-acting 325 mg (105 mg elemental) with folic acid 350 mcg

FOLIC ACID Tab 0.8 mg

MULTIVITAMINS

PANCREATIC ENZYME

✓ Cap EC 10,000 BP u lipase, 9,000 BP u amylase and 210 BP u protease

POTASSIUM BICARBONATE

✓ Tab eff 315 mg with sodium acid phosphate 1.937 g and sodium bicarbonate 350 mg

POTASSIUM CHLORIDE

Tab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq)

✔ Tab long-acting 600 mg

POTASSIUM IODATE

✓ Tab 256 mcg (150 mcg elemental iodine)

PYRIDOXINE HYDROCHLORIDE

- 🖌 Tab 25 mg
- ✔ Tab 50 mg

SODIUM CHLORIDE

🖌 lnj 23.4%, 20 ml

SODIUM FLUORIDE

Tab 1.1 mg (0.5 mg elemental)

THIAMINE HYDROCHLORIDE

✔ Tab 50 mg

VITAMIN A WITH VITAMINS D AND C

Soln 1000 u with Vitamin D 400 u and ascorbic acid 30 mg per 10 drops

VITAMIN B COMPLEX

Tab, strong, BPC

VITAMINS

- Tab (BPC cap strength)
- Cap (fat soluble vitamins A, D, E, K)

SPECIAL FOODS

Subsidy		Fully	Bra
(Manufacturer's Price)	Su	bsidised	Ge
\$	Per	~	Ma

Brand or Generic Manufacturer

Nutrient Modules

Carbohydrate

➡SA1090 Special Authority for Subsidy

Initial application — (Cystic fibrosis or renal failure) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Either:

- 1 cystic fibrosis; or
- 2 chronic renal failure or continuous ambulatory peritoneal dialysis (CAPD) patient.

Initial application — (Indications other than cystic fibrosis or renal failure) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Any of the following:

1 cancer in children: or

- 2 cancers affecting alimentary tract where there are malabsorption problems in patients over the age of 20 years; or
- 3 failure to thrive; or
- 4 growth deficiency; or
- 5 bronchopulmonary dysplasia; or
- 6 premature and post premature infant; or
- 7 inborn errors of metabolism.

Renewal — (Cystic fibrosis or renal failure) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis or renal failure) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Both:
 - 1 The treatment remains appropriate and the patient is benefiting from treatment; and
 - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CARBOHYDRATE SUPPLEMENT – Special Authority see SA1090 above – Hospital pharmacy [HP3]

Powder	 5.29 1.30	400 g OP 368 g OP	Polycal
	(12.00)	Ũ	Moducal

Carbohydrate And Fat

SA1091 Special Authority for Subsidy

Initial application — (Cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

1 infant aged four years or under; and

2 cystic fibrosis.

Initial application — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

continued...

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

- 1 infant aged four years or under; and
- 2 Any of the following:
 - 2.1 cancer in children; or
 - 2.2 failure to thrive; or
 - 2.3 growth deficiency; or
 - 2.4 bronchopulmonary dysplasia; or
 - 2.5 premature and post premature infants.

Renewal — (Cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CARBOHYDRATE AND F	AT SUPPLEMENT -	- Special Authority s	ee SA1091 c	on the preceding	page ·	- Hospital pharmacy [HP3]
Powder (neutral)			60.31	400 g OP	V	Duocal Super
						Soluble Powder

Fat

➡SA1092 Special Authority for Subsidy

Initial application — (Inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has inborn errors of metabolism.

Initial application — (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 failure to thrive where other high calorie products are inappropriate or inadequate; or
- 2 growth deficiency; or
- 3 bronchopulmonary dysplasia; or
- 4 fat malabsorption; or
- 5 lymphangiectasia; or
- 6 short bowel syndrome; or
- 7 infants with necrotising enterocolitis; or
- 8 biliary atresia.

Renewal — (Inborn errors of metabolism) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

continued...

Subsidy	Fully	Brand or
(Manufacturer's Price)	Subsidised	Generic
\$	Per 🖌	Manufacturer

Renewal - (Indications other than inborn errors of metabolism) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FAI	SUPPLEMENT – Special Auth	prity see SA1092 on the preceding page -	Hospital pharmacy	/ [HP3]
	Emulsion (neutral)		200 ml OP	Calogen
		30.75	500 ml OP	Calogen
	Emulsion (strawberry)		200 ml OP	Calogen
	Oil		250 ml OP	Liquigen
		30.00	500 ml OP	 MCT oil (Nutricia)

Protein

SA1093 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Fither:
 - 1 protein losing enteropathy; or
 - 2 high protein needs (eg burns).

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

PROTEIN SUPPLEMENT – Special Authority see SA1093 above – Hospital pha	rmacy [HP3]	
Powder7.90	225 g OP	Protifar
8.95	227 g OP	 Resource Beneprotein
Powder (vanilla)12.90	275 g OP	Promod
Oral Supplements/Complete Dist (Necessatria/Costractory	Tube Feed	N N

Oral Supplements/Complete Diet (Nasogastric/Gastrostomy Tube Feed)

Respiratory Products

SA1094 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient has CORD and hypercapnia.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

CORD	ORAL FEE	ED 1.5KCAL/ML	- Special	Authority	see SA1094	above -	 Hospita 	l phari	nacy	[HP3]	

Pulmocare 237 ml OP

	Subsidy (Manufacturer's Pr \$	rice) Sub Per	Fully sidised	Brand or Generic Manufacturer
Diabetic Products				
 SA1095 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or voc where the patient is a type I or and II diabetic who is suffering we Renewal only from a dietitian, relevant specialist, vocationally register mendation of a dietitian, relevant specialist or vocationally register meeting the following criteria: Both: The treatment remains appropriate and the patient is benu? General Practitioners must include the name of the dietitia and date contacted. DIABETIC ENTERAL FEED 1KCAL/ML – Special Authority see Liquid	eight loss and malr egistered general p ered general practi efiting from treatmen, relevant special SA1095 above – I	nutrition that re ractitioner or g tioner. Approva ent; and ist or vocationa	equires general als valic ally regi hacy [H	nutritional support. practitioner on the recom- d for 1 year for applications
DIABETIC ORAL FEED 1KCAL/ML – Special Authority see SA1 Liquid (strawberry) Liquid (vanilla)		oital pharmacy 200 ml OP 200 ml OP 250 ml OP 237 ml OP	✓ D ✓ D ✓ G	iasip iasip Iucerna Select esource Diabetic
Fat Modified Products				

➡SA1096 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Either:

- 1 Patient has metabolic disorders of fat metabolism; or
- 2 Patient has chylothorax.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

FAT MODIFIED FEED - Special Authority see SA1096 above - Hospital pharmacy [HP3]

Po	wder	 	60.48	400 g OP	~

High Protein Products

SA1097 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Anorexia and weight loss; and
- 2 Either:
 - 2.1 decompensating liver disease without encephalopathy; or
 - 2.2 protein losing gastro-enteropathy.

continued...

Monogen

Subsidy		Fully	Brand or	
(Manufacturer's Price		Subsidised	Generic	
\$	Per	~	Manufacturer	

Liquid

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

ŀ

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

	HIGH PROTEIN ORAL FEED 1KCAL/ML	- Special Authority see SA1097	on the preceding page - Hospital p	harmacy [HP3]
--	---------------------------------	--------------------------------	------------------------------------	---------------

	200 ml OP	V	Fortimel Regular
--	-----------	---	------------------

Paediatric Products For Children Awaiting Liver Transplant

SA1098 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) who requires a liver transplant.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL FEED 1KCAL/M	 – Special Authority see SA1098 above 	e – Hospital pharmacy [HP3]
---------------------------	--	-----------------------------

Powder	400 g OP	Generaid Plus
Powder (unflavoured)78.97	400 g OP	Heparon Junior
(Generaid Plus Powder to be delisted 1 August 2013)	÷	

Paediatric Products For Children With Chronic Renal Failure

SA1099 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient is a child (up to 18 years) with chronic renal failure.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment: and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL FEED 1KCAL/ML	- Special Authority see SA1099 above -	Hospital pharmacy	/ [HP3]
Liquid		400 a OP	Kindergen

Paediatric Products

SA1224 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Child is aged one to ten years; and
- 2 Any of the following:

continued.

	Subsidy (Manufacturer's \$	Price) Sub Per	Fully osidised	Brand or Generic Manufacturer
continued 2.1 the child is being fed via a tube or a tube is to be in	nserted for the pu	irposes of feedi	ng; or	
2.2 any condition causing malabsorption; or2.3 failure to thrive; or2.4 increased nutritional requirements.				
Renewal only from a dietitian, relevant specialist, vocationally re mendation of a dietitian, relevant specialist or vocationally registe meeting the following criteria: Both:				
 The treatment remains appropriate and the patient is benular General Practitioners must include the name of the dietitia and date contacted. 	n, relevant speci	alist or vocation	, ,	0
PAEDIATRIC ENTERAL FEED 1KCAL/ML – Special Authority s Liquid	ee SA1224 on th 2.68	e preceding pa 500 ml OP	🖌 N	spital pharmacy [HP3] utrini RTH ediasure RTH
PAEDIATRIC ENTERAL FEED WITH FIBRE 1.5KCAL/ML – S pharmacy [HP3]	Special Authority	see SA1224 c	on the p	preceding page - Hospital
Liquid	6.00	500 ml OP		utrini Energy Multi Fibre
PAEDIATRIC ORAL FEED – Special Authority see SA1224 on tl	ho proceding par	na Hacaital ak		utrini Energy RTH
Powder (vanilla)		900 g OP		ediasure
PAEDIATRIC ORAL FEED 1.5KCAL/ML – Special Authority see Liquid (strawberry) Liquid (vanilla)	1.60	preceding page 200 ml OP 200 ml OP	✓ F	ital pharmacy [HP3] ortini ortini
PAEDIATRIC ORAL FEED 1KCAL/ML – Special Authority see S Liquid (chocolate)		eceding page – 200 ml OP		al pharmacy [HP3] ediasure
Liquid (strawberry)	1.07	200 ml OP	V P	ediasure
Liquid (vanilla)	1.07 1.27	200 ml OP 237 ml OP		ediasure ediasure
PAEDIATRIC ORAL FEED WITH FIBRE 1.5KCAL/ML – Special	Authority see SA	1224 on the pre	eceding	page – Hospital pharmacy
[HP3] Liquid (chocolate) Liquid (strawberry)		200 ml OP 200 ml OP		ortini Multi Fibre ortini Multi Fibre
Liquid (vanilla)	1.60	200 ml OP	✔ Fe	ortini Multi Fibre
Renal Products				
SA1101 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or voca where the patient has acute or chronic renal failure.	ationally register	ed general prac	titioner.	Approvals valid for 3 years
Renewal only from a dietitian, relevant specialist, vocationally re mendation of a dietitian, relevant specialist or vocationally registe meeting the following criteria: Both:				
 The treatment remains appropriate and the patient is benular General Practitioners must include the name of the dietitia and date contacted. 			ally regi	stered general practitioner
RENAL ENTERAL FEED 2 KCAL/ML – Special Authority see S. Liquid		lospital pharma 500 ml OP		^{3]} epro RTH

SPECIAL FOODS

	Subsidy (Manufacturer's P \$	rice) Sub Per	Fully sidised	Brand or Generic Manufacturer
RENAL ORAL FEED 2KCAL/ML – Special Authority see SA1101 Liquid			🖌 N	rmacy [HP3] epro (strawberry) epro (vanilla)
	2.88 (3.31)	237 ml OP	N	ovaSource Renal
Liquid (apricot) Liquid (caramel)		125 ml OP 125 ml OP		enilon 7.5 enilon 7.5

Specialised And Elemental Products

➡SA1102 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

- Any of the following:
 - 1 malabsorption; or
 - 2 short bowel syndrome; or
 - 3 enterocutaneous fistulas; or
 - 4 pancreatitis.

Notes: Each of these products is highly specialised and would be prescribed only by an expert for a specific disorder. The alternative is hospitalisation.

Elemental 028 Extra is more expensive than other products listed in this section and should only be used where the alternatives have been tried first and/or are unsuitable.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL/ORAL ELEMENTAL FEED 1KCAL/ML – Special Authority see SA1102 above – Hospital pharmacy [HP3]

Powder	4.40	79 g OP	Vital HN
	7.50	76 g OP	✓ Alitraq
ORAL ELEMENTAL FEED 0.8KCAL/ML - Special Authority see SA	A1102 above -	 Hospital pharm 	
Liquid (grapefruit)	9.50	250 ml OP	Elemental 028 Extra
Liquid (pineapple & orange)	9.50	250 ml OP	Elemental 028 Extra
Liquid (summer fruit)	9.50	250 ml OP	 Elemental 028 Extra
ORAL ELEMENTAL FEED 1KCAL/ML - Special Authority see SA1	102 above – I	Hospital pharma	acy [HP3]
Powder (unflavoured)	4.50	80.4 g OP	Vivonex TEN
SEMI-ELEMENTAL ENTERAL FEED 1KCAL/ML – Special Authorit Liquid			

Undyalised End Stage Renal Failure

➡SA1103 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years where the patient has undialysed end stage renal failure.

Note: Where possible, the requirements for oral supplementation should be established in conjunction with assessment by a dietitian.

continued...

Subsidy		Fully	Brand or	
(Manufacturer's Price)	Subs	sidised	Generic	
\$	Per	V	Manufacturer	

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

RENAL ORAL FEED 1KCAL/ML - Special Authority see SA1103 on the preceding page - Hospital pharmacy [HP3]

Paediatric Products For Children With Low Energy Requirements

➡SA1196 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 Child aged one to eight years; and
- 2 The child has a low energy requirement but normal protein and micronutrient requirements.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Standard Supplements

➡SA1228 Special Authority for Subsidy

Initial application — (Children) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 Any of the following:
 - 2.1 The patient has a condition causing malabsorption; or
 - 2.2 The patient has failure to thrive; or
 - 2.3 The patient has increased nutritional requirements; and
- 3 Nutrition goal has been set (eg reach a specific weight or BMI).

Renewal — (Children) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 The patient is under 18 years of age; and
- 2 The treatment remains appropriate and the patient is benefiting from treatment; and
- 3 A nutrition goal has been set (eg reach a specific weight or BMI).

Initial application — (Adults) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 months for applications meeting the following criteria:

continued...

Multi Fibre

Subsidy (Manufacturer's Price)		Fully Subsidised	Brand or Generic	
\$	Per	~	Manufacturer	
				<u> </u>

All of the following:

- 1 Any of the following:
 - Patient is Malnourished
 - 1.1 Patient has a body mass index (BMI) of less than 18.5 kg/m2; or
 - 1.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
 - 1.3 Patient has a BMI of less than 20 kg/m2 and unintentional weight loss greater than 5% within the last 3-6 months; and
- 2 Any of the following:
 - Patient has not responded to first-line dietary measures over a 4 week period by:
 - 2.1 Increasing their food intake frequency (eg snacks between meals); or
 - 2.2 Using high-energy foods (e.g. milkshakes, full fat milk, butter, cream, cheese, sugar etc); or
 - 2.3 Using over the counter supplements (e.g. Complan); and
- 3 A nutrition goal has been set (e.g. to reach a specific weight or BMI).

Renewal — (Adults) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 A nutrition goal has been set (eg reach a specific weight or BMI); and
- 2 Any of the following:
 - Patient is Malnourished
 - 2.1 Patient has a body mass index (BMI) of less than 18.5 kg/m2; or
 - 2.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
 - 2.3 Patient has a BMI of less than 20 kg/m2 and unintentional weight loss greater than 5% within the last 3-6 months.

Initial application — (Adults transitioning from hospital Discretionary Community Supply) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria: All of the following:

- 1 The patient has had up to a 30 day supply of a 1.0 or a 1.5 kcal/ml Standard Oral Supplement; and
- 2 A nutrition goal has been set (eg reach a specific weight or BMI); and
- 3 Any of the following:
 - Patient is Malnourished
 - 3.1 Patient has a body mass index (BMI) of less than 18.5 kg/m2; or
 - 3.2 Patient has unintentional weight loss greater than 10% within the last 3-6 months; or
 - 3.3 Patient has a BMI of less than 20 kg/m2 and unintentional weight loss greater than 5% within the last 3-6 months.

Initial application — (Short-term medical condition) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Is being feed via a nasogastric tube or a nasogastric tube is to be inserted for feeding; or
- 2 Malignancy and is considered likely to develop malnutrition as a result; or
- 3 Is undergoing a bone marrow transplant; or
- 4 Tempomandibular surgery; or
- 5 Both:
 - 5.1 Pregnant; and
 - 5.2 Any of the following:
 - 5.2.1 Patient is in early pregnancy (<13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or
 - 5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine's (1990) recommended weight gain guidelines for pregnancy or the patient's weight has not increased past her booking/pre-pregnancy weight; or

continued...

Subsidy (Manufacturer's Price)	Per	Fully Subsidised	Brand or Generic Manufacturer	
Ŷ	rei		Manulaclurei	

5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being meet.

Renewal — (Short-term medical condition) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a nasogastric tube; or
- 2 Malignancy and is considered likely to develop malnutrition as a result; or
- 3 Has undergone a bone marrow transplant; or
- 4 Tempomandibular surgery; or
- 5 Both:
 - 5.1 Pregnant; and
 - 5.2 Any of the following:
 - 5.2.1 Patient is in early pregnancy (<13 weeks) and has severe clinical hyperemesis gravidarum requiring admission to hospital and is unlikely to meet her nutritional requirements due to continuing hyperemesis gravidarum; or
 - 5.2.2 Patient has clinical hyperemesis gravidarum continuing past 13 weeks and either there is concern that the patient is unlikely to meet the Institute of Medicine's (1990) recommended weight gain guidelines for pregnancy or the patient's weight has not increased past her booking/pre-pregnancy weight; or
 - 5.2.3 Patient is having multiple births and is under the care of an obstetric team who consider the nutritional needs of the patient are not being meet.

Initial application — (Long-term medical condition) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

- Any of the following:
 - 1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube refer to specific medical condition criteria); or
 - 2 Cystic Fibrosis; or
 - 3 Liver disease; or
 - 4 Chronic Renal failure; or
 - 5 Inflammatory bowel disease; or
 - 6 Chronic obstructive pulmonary disease with hypercapnia; or
 - 7 Short bowel syndrome; or
 - 8 Bowel fistula; or
 - 9 Severe chronic neurological conditions; or
 - 10 Epidermolysis bullosa; or
 - 11 AIDS (CD4 count < 200 cells/mm³); or
 - 12 Chronic pancreatitis.

Renewal — (Chronic disease OR tube feeding for patients who have previously been funded under Special Authority forms

SA0702 or SA0583) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Is being fed via a tube or a tube is to be inserted for the purpose of feeding (not nasogastric tube refer to specific medical condition criteria); or
- 2 Cystic Fibrosis; or
- 3 Liver disease; or
- 4 Chronic Renal failure; or
- 5 Inflammatory bowel disease; or
- 6 Chronic obstructive pulmonary disease with hypercapnia; or
- 7 Short bowel syndrome; or
- 8 Bowel fistula; or
- 9 Severe chronic neurological conditions.

SPECIAL FOODS

	Subsidy (Manufacturer's \$		Fully Brand or sidised Generic ✔ Manufacturer
ENTERAL FEED 1.5KCAL/ML – Special Authority see SA1228 (Liquid		Hospital pharmad 1,000 ml	cy [HP3] ✔ Nutrison Energy
ENTERAL FEED 1KCAL/ML – Special Authority see SA1228 on Liquid	1 0	ospital pharmacy 250 ml OP	[HP3] ✓ Isosource Standard ✓ Osmolite
	2.65	500 ml OP	 Nutrison Standard RTH
	5.29	1,000 ml OP	 ✓ Nutrison Standard RTH ✓ Isosource Standard RTH
	2.65 5.29	500 ml OP 1,000 ml OP	 Osmolite RTH Osmolite RTH
ENTERAL FEED WITH FIBRE 1 KCAL/ML – Special Authority s Liquid		page 204 – Hos 237 ml OP 500 ml OP 1,000 ml OP 500 ml OP 1,000 ml OP	 bital pharmacy [HP3] Jevity Nutrison Multi Fibre Nutrison Multi Fibre Jevity RTH Jevity RTH
ENTERAL FEED WITH FIBRE 1.5KCAL/ML – Special Authority Liquid		n page 204 – Ho: 250 ml OP 1,000 ml OP	spital pharmacy [HP3]
ORAL FEED (POWDER) - Special Authority see SA1228 on par Powder (chocolate)		tal pharmacy [HI 900 g OP	P3] ✔ Sustagen Hospital Formula
Powder (vanilla)	13.00 9.50 10.22	900 g OP	 ✓ Ensure ✓ Fortisip ✓ Sustagen Hospital Formula
	13.00		✓ Ensure

SPECIAL FOODS

PRAL FEED 1.5KCAL/ML - Special Authority see SA1228 on page 204 - Hospital pharmacy [HP3] Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, or who have severe epider molysis bulosa. The prescription must be endorsed accordingly. Liquid (banana) - Higher subsidy of \$1.26 per 200 ml with Endorsement. 0.72 200 ml OP (1.26) Ensure Plus (1.26) Ensure Plus (1.26) Ensure Plus (1.26) Ensure Plus (1.26) Contained to the forestime of the fore		Subsidy (Manufacturer's \$		Fully Brand or dised Generic ✔ Manufacturer
(1.26) Ensure Plus Liquid (chocolate) - Higher subsidy of up to \$1.33 per 237 ml 0.72 200 ml OP (1.26) Ensure Plus 0.85 237 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.26) Fortisip Liquid (fruit of the forest) - Higher subsidy of \$1.26 per 200 ml (1.26) with Endorsement. 0.72 200 ml OP (1.26) Ensure Plus Liquid (strawberry) - Higher subsidy of up to \$1.33 per 237 ml with Endorsement. 0.72 200 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.26) Fortisip Liquid (toffee) - Higher subsidy of \$1.26 per 200 ml with Endorsement 0.72 200 ml OP (1.26) Fortisip Liquid (Additional subsidy by endorsement is available for patients be molysis bullosa. The prescription must be endorsed according	ing bolus fed th		-
(1.26) Fortisip Liquid (chocolate) – Higher subsidy of up to \$1.33 per 237 ml 0.72 200 ml OP (1.26) Ensure Plus 0.85 237 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.31) Cast Ensure Plus 0.72 200 ml OP Liquid (truit of the forest) – Higher subsidy of \$1.26 per 200 ml (1.26) Ensure Plus 0.72 Liquid (strawberry) – Higher subsidy of up to \$1.33 per 2.72 200 ml OP Ensure Plus Liquid (toffee) – Higher subsidy of \$1.26 per 200 ml with Endorsement. 0.72 200 ml OP Ensure Plus (1.26) Fortisip (1.26) Fortisip Ensure Plus Liquid (toffee) – Higher subsidy of \$1.26 per 200 ml with Endorsement. 0.72 200 ml OP 1.26) Liquid (tropical fruit) – Higher subsidy of \$1.26 per 200 ml 0.72 200 ml OP 1.26) Fortisip Liquid (tranilla) – Higher subsidy of \$1.26 per 200 ml 0.72 200 ml OP 1.26) Fortisip Liquid (tranilla) – Higher subsidy of \$1.26 per 200 ml 0.72 200 ml OP 1.26) Forti		0.72	200 ml OP	
Liquid (chocolate) – Higher subsidy of up to \$1.33 per 237 ml with Endorsement				Ensure Plus
with Endorsement. 0.72 200 ml OP (1.26) Ensure Plus 0.85 237 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.26) Fortisip Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 ml 0.72 200 ml OP (1.26) Ensure Plus 0.72 200 ml OP (1.26) Fortisip 0.72 200 ml OP Liquid (troficel fruit) – Higher subsidy of \$1.26 per 200 ml 0.72 200 ml OP Liquid (troficel fruit) – Higher subsidy of \$1.26 per 200 ml 0.72 200 ml OP (1.26) Fortisip E		(1.26)		Fortisip
(1.26) Ensure Plus 0.85 237 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.26) Fortisip Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 ml (1.26) with Endorsement. 0.72 200 ml OP (1.26) Ensure Plus Liquid (strawberry) – Higher subsidy of up to \$1.33 per 200 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.26) Fortisip Liquid (toffee) – Higher subsidy of \$1.26 per 200 ml with Endorsement. 0.72 0.72 200 ml OP (1.26) Fortisip Liquid (toffee) – Higher subsidy of \$1.26 per 200 ml with Endorsement. 0.72 200 ml OP (1.26) Fortisip Liquid (tropical fruit) – Higher subsidy of \$1.26 per 200 ml with Endorsement. 0.72 200 ml OP (1.26) Liquid (torosement. 0.72 200 ml OP (1.26) Fortisip Ensure Plus 0.85 237 ml OP (1	Liquid (chocolate) – Higher subsidy of up to \$1.33 per 237 ml			
⁰ .86 ² ²³⁷ ml OP ^(1,33) ^{Ensure Plus ^{0.72} ²⁰⁰ ml OP ^(1,26) ^{Fortisip Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 ml with Endorsement}}	with Endorsement	0.72	200 ml OP	
(1.33) Ensure Plus 0.72 200 ml OP (1.26) Fortisip Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 ml with Endorsement		(1.26)		Ensure Plus
0.72 200 ml OP (1.26) Fortisip Liquid (truit of the forest) – Higher subsidy of \$1.26 per 200 ml 0.72 200 ml OP (1.26) Ensure Plus Liquid (strawberry) – Higher subsidy of up to \$1.33 per 237 ml with Endorsement. 0.72 200 ml OP (1.26) Ensure Plus 0.72 200 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.26) Fortisip 1.33 Ensure Plus 0.72 200 ml OP (1.26) Fortisip Liquid (toffee) – Higher subsidy of \$1.26 per 200 ml with Endorsement. 0.72 200 ml OP (1.26) Fortisip Ensure Plus 0.72 200 ml OP (1.26) Fortisip 1.26 Fortisip 1.26 Liquid (tropical fruit) – Higher subsidy of \$1.26 per 200 ml 0.72 200 ml OP 1.26 Liquid (vanilla) – Higher subsidy of up to \$1.33 per 237 ml 0.72 200 ml OP 1.33 Ensure Plus 0.72 200 ml OP (1.26) Fortisip 0.72 200 ml OP (1.26) <t< td=""><td></td><td>0.85</td><td>237 ml OP</td><td></td></t<>		0.85	237 ml OP	
(1.26) Fortisip Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 ml (1.26) Ensure Plus (1.26) Ensure Plus (1.26) Ensure Plus Liquid (strawberry) – Higher subsidy of up to \$1.33 per 200 ml OP (1.26) Ensure Plus (1.26) Ensure Plus 0.72 200 ml OP (1.33) Ensure Plus 0.85 237 ml or OP (1.26) Fortisip (1.26) Fortisip Liquid (toffee) – Higher subsidy of \$1.26 per 200 ml with Endorsement. 0.72 200 ml OP (1.26) Fortisip Liquid (tropical fruit) – Higher subsidy of \$1.26 per 200 ml (1.26) Fortisip Fortisip Liquid (tropical fruit) – Higher subsidy of \$1.26 per 200 ml (1.26) Fortisip Ensure Plus Liquid (vanilla) – Higher subsidy of up to \$1.33 per 237 ml 0.72 200 ml OP (1.26) Fortisip Liquid (vanilla) – Higher subsidy of up to \$1.33 per 237 ml 0.72 200 ml OP (1.26) Fortisip RAL FEED WITH FIBRE 1.5 KCAL/ML – Special Authority see SA1228 on page 204 – Hospital pharmacy [HP3] Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, or who have severe epider 0.72 200 ml OP <t< td=""><td></td><td>(1.33)</td><td></td><td>Ensure Plus</td></t<>		(1.33)		Ensure Plus
Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 ml with Endorsement		0.72	200 ml OP	
with Endorsement. 0.72 200 ml OP (1.26) Ensure Plus Liquid (strawberry) - Higher subsidy of up to \$1.33 per 237 ml with Endorsement. 0.72 200 ml OP (1.26) Ensure Plus 0.85 237 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.26) Fortisip Liquid (toffee) - Higher subsidy of \$1.26 per 200 ml with En- 0.72 200 ml OP (1.26) Fortisip Liquid (tropical fruit) - Higher subsidy of \$1.26 per 200 ml (1.26) Fortisip Liquid (tropical fruit) - Higher subsidy of \$1.26 per 200 ml 0.72 200 ml OP (1.26) Fortisip Fortisip Liquid (tropical fruit) - Higher subsidy of \$1.33 per 237 ml 0.72 200 ml OP (1.26) Ensure Plus 0.85 237 ml OP (1.30) Ensure Plus 0.72 200 ml OP (1.26) Fortisip 1.33 Ensure Plus 0.72 200 ml OP (1.26) Fortisip Vith Endorsement 0.72 200 ml OP (1.26) Vitage Common page 204 - Hospital pharmacy [HP3] Addi		(1.26)		Fortisip
with Endorsement. 0.72 200 ml OP (1.26) Ensure Plus Liquid (strawberry) – Higher subsidy of up to \$1.33 per 0.72 200 ml OP (1.26) Ensure Plus 0.85 237 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.26) Fortisip 1.26 Fortisip Liquid (toffee) – Higher subsidy of \$1.26 per 200 ml with En- 0.72 200 ml OP (1.26) Fortisip 1.26 Fortisip Liquid (tropical fruit) – Higher subsidy of \$1.26 per 200 ml 0.72 200 ml OP (1.26) Fortisip 1.26 Fortisip Liquid (vanilla) – Higher subsidy of up to \$1.33 per 237 ml 0.72 200 ml OP (1.26) Ensure Plus 0.85 237 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.26) Fortisip 1.33 Ensure Plus 0.72 200 ml OP (1.26) Fortisip 0.72 200 ml OP (1.26) Fortisip 0.72 200 ml OP (1.26) Fort	Liquid (fruit of the forest) – Higher subsidy of \$1.26 per 200 ml	()		
Liquid (strawberry) – Higher subsidy of up to \$1.33 per 237 ml with Endorsement			200 ml OP	
237 ml with Endorsement. 0.72 200 ml OP (1.26) Ensure Plus 0.85 237 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.26) Fortisip Liquid (toffee) – Higher subsidy of \$1.26 per 200 ml with Endorsement. 0.72 200 ml OP (1.26) Fortisip Liquid (tropical fruit) – Higher subsidy of \$1.26 per 200 ml (1.26) Fortisip Liquid (vanilla) – Higher subsidy of \$1.26 per 200 ml 0.72 200 ml OP (1.26) Fortisip Ensure Plus 0.72 200 ml OP (1.26) Fortisip Liquid (vanilla) – Higher subsidy of up to \$1.33 per 237 ml 0.72 200 ml OP (1.26) Ensure Plus 0.85 237 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.26) Fortisip 0.72 200 ml OP <		(1.26)		Ensure Plus
237 ml with Endorsement. 0.72 200 ml OP (1.26) Ensure Plus 0.85 237 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.26) Fortisip Liquid (toffee) – Higher subsidy of \$1.26 per 200 ml with Endorsement. 0.72 200 ml OP (1.26) Fortisip Liquid (tropical fruit) – Higher subsidy of \$1.26 per 200 ml (1.26) Fortisip Liquid (vanilla) – Higher subsidy of \$1.26 per 200 ml 0.72 200 ml OP (1.26) Fortisip Ensure Plus 0.72 200 ml OP (1.26) Fortisip Liquid (vanilla) – Higher subsidy of up to \$1.33 per 237 ml 0.72 200 ml OP (1.26) Ensure Plus 0.85 237 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.26) Fortisip 0.72 200 ml OP <	Liquid (strawberry) - Higher subsidy of up to \$1.33 per	(<i>'</i>		
(1.26) Ensure Plus 0.85 237 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.26) Fortisip Liquid (toffee) – Higher subsidy of \$1.26 per 200 ml with En- 0.72 200 ml OP (1.26) Fortisip Liquid (tropical fruit) – Higher subsidy of \$1.26 per 200 ml (1.26) Fortisip uith Endorsement 0.72 200 ml OP (1.26) Liquid (vanilla) – Higher subsidy of up to \$1.33 per 237 ml 0.72 200 ml OP (1.26) Ensure Plus 0.85 237 ml OP (1.26) Ensure Plus 0.85 237 ml OP (1.26) Ensure Plus 0.85 237 ml OP (1.33) Ensure Plus 0.85 237 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.26) Fortisip 0.72 200 ml O			200 ml OP	
0.85 237 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.26) Fortisip Liquid (toffee) – Higher subsidy of \$1.26 per 200 ml with En- 0.72 200 ml OP (1.26) Fortisip Liquid (tropical fruit) – Higher subsidy of \$1.26 per 200 ml (1.26) Fortisip uith Endorsement. 0.72 200 ml OP (1.26) Fortisip Liquid (vanilla) – Higher subsidy of \$1.26 per 200 ml (1.26) Fortisip uith Endorsement. 0.72 200 ml OP (1.26) uith Endorsement. 0.72 200 ml OP (1.26) Uiquid (vanilla) – Higher subsidy of up to \$1.33 per 237 ml Ensure Plus 0.85 237 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.26) Fortisip 0.72 200 ml OP (1.26) Fortisip Uitauto (tocolate) - Higher subsidy of \$1.26 per 200 ml with Endorsement 0.72 200 ml OP Liquid (chocolate) – Higher subsidy of \$1.26 per 200 ml with Endorsement 0.72 200 ml OP C1.26) Fortisi				Ensure Plus
0.72 200 ml OP (1.26) Fortisip Liquid (toffee) – Higher subsidy of \$1.26 per 200 ml with Endorsement. 0.72 200 ml OP (1.26) Fortisip Liquid (tropical fruit) – Higher subsidy of \$1.26 per 200 ml (1.26) Fortisip with Endorsement. 0.72 200 ml OP (1.26) Fortisip Liquid (vanilla) – Higher subsidy of up to \$1.33 per 237 ml 0.72 200 ml OP (1.26) Ensure Plus 0.85 237 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.26) Fortisip 0.72 200 ml OP (1.26) Fortisip 0.85 237 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.26) Fortisip 0.72 200 ml OP (1.26) Fortisip 0.72 200 ml OP (1.26) Fortisip 0.72 200 ml OP (1.26) Fortisip 0.72 200 ml OP (1.26) Fortisip 0.72 200 ml OP (1.26) Fortisip 0.72 1.26 Fortisip 0.72 200 ml OP (1.26) Fortisip Mutti Fibre		· · ·	237 ml OP	
0.72 200 ml OP (1.26) Fortisip Liquid (toffee) – Higher subsidy of \$1.26 per 200 ml with En- dorsement		(1.33)		Ensure Plus
Liquid (toffee) – Higher subsidy of \$1.26 per 200 ml with En- dorsement		```	200 ml OP	
Liquid (toffee) – Higher subsidy of \$1.26 per 200 ml with En- dorsement		(1.26)		Fortisip
dorsement	Liquid (toffee) - Higher subsidy of \$1.26 per 200 ml with En-			
(1.26) Fortisip Liquid (tropical fruit) – Higher subsidy of \$1.26 per 200 ml with Endorsement		0.72	200 ml OP	
Liquid (tropical fruit) – Higher subsidy of \$1.26 per 200 ml with Endorsement				Fortisip
with Endorsement. 0.72 200 ml OP (1.26) Fortisip Liquid (vanilla) – Higher subsidy of up to \$1.33 per 237 ml 0.72 200 ml OP (1.26) Ensure Plus 0.85 237 ml OP (1.26) Ensure Plus 0.85 237 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.26) Fortisip VRAL FEED WITH FIBRE 1.5 KCAL/ML – Special Authority see SA1228 on page 204 – Hospital pharmacy [HP3] Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, or who have severe epidel molysis bullosa. The prescription must be endorsed accordingly. Liquid (chocolate) – Higher subsidy of \$1.26 per 200 ml with Endorsement 0.72 200 ml OP (1.26) Fortisip Multi Fibre Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml with Endorsement Endorsement 0.72 200 ml OP (1.26) Fortisip Multi Fibre Liquid (vanilla) – Higher subsidy of \$1.26 per 200 ml with Endorsement Endorsement 0.72 200 ml OP (1.26) Fortisip Multi F	Liquid (tropical fruit) - Higher subsidy of \$1.26 per 200 ml	```		·
(1.26) Fortisip Liquid (vanilla) – Higher subsidy of up to \$1.33 per 237 ml with Endorsement			200 ml OP	
Liquid (vanilla) – Higher subsidy of up to \$1.33 per 237 ml with Endorsement				Fortisip
with Endorsement	Liquid (vanilla) – Higher subsidy of up to \$1.33 per 237 ml	()		
(1.26) Ensure Plus 0.85 237 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.26) Fortisip ORAL FEED WITH FIBRE 1.5 KCAL/ML – Special Authority see SA1228 on page 204 – Hospital pharmacy [HP3] Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, or who have severe epider molysis bullosa. The prescription must be endorsed accordingly. Liquid (chocolate) – Higher subsidy of \$1.26 per 200 ml with Endorsement			200 ml OP	
0.85 237 ml OP (1.33) Ensure Plus 0.72 200 ml OP (1.26) Fortisip ORAL FEED WITH FIBRE 1.5 KCAL/ML – Special Authority see SA1228 on page 204 – Hospital pharmacy [HP3] Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, or who have severe epider molysis bullosa. The prescription must be endorsed accordingly. Liquid (chocolate) – Higher subsidy of \$1.26 per 200 ml with Endorsement			200 0.	Ensure Plus
(1.33) Ensure Plus 0.72 200 ml OP (1.26) Fortisip ORAL FEED WITH FIBRE 1.5 KCAL/ML – Special Authority see SA1228 on page 204 – Hospital pharmacy [HP3] Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, or who have severe epider molysis bullosa. The prescription must be endorsed accordingly. Liquid (chocolate) – Higher subsidy of \$1.26 per 200 ml with Endorsement		· · · ·	237 ml OP	
0.72 200 ml OP (1.26) Fortisip PRAL FEED WITH FIBRE 1.5 KCAL/ML – Special Authority see SA1228 on page 204 – Hospital pharmacy [HP3] Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, or who have severe epider molysis bullosa. The prescription must be endorsed accordingly. Liquid (chocolate) – Higher subsidy of \$1.26 per 200 ml with Endorsement				Ensure Plus
IRAL FEED WITH FIBRE 1.5 KCAL/ML - Special Authority see SA1228 on page 204 - Hospital pharmacy [HP3] Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, or who have severe epider molysis bullosa. The prescription must be endorsed accordingly. Liquid (chocolate) - Higher subsidy of \$1.26 per 200 ml with Endorsement 0.72 200 ml OP (1.26) Fortisip Multi Fibre Liquid (strawberry) - Higher subsidy of \$1.26 per 200 ml with 0.72 200 ml OP (1.26) Fortisip Multi Fibre Liquid (vanilla) - Higher subsidy of \$1.26 per 200 ml with 0.72 200 ml OP (1.26) Fortisip Multi Fibre Liquid (vanilla) - Higher subsidy of \$1.26 per 200 ml with 0.72 200 ml OP (1.26) Fortisip Multi Fibre Liquid (vanilla) - Higher subsidy of \$1.26 per 200 ml with Endorsement 0.72 200 ml OP		· · ·	200 ml OP	
PRAL FEED WITH FIBRE 1.5 KCAL/ML - Special Authority see SA1228 on page 204 - Hospital pharmacy [HP3] Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, or who have severe epider molysis bullosa. The prescription must be endorsed accordingly. Liquid (chocolate) - Higher subsidy of \$1.26 per 200 ml with Endorsement 0.72 200 ml OP (1.26) Fortisip Multi Fibre Liquid (strawberry) - Higher subsidy of \$1.26 per 200 ml with 0.72 200 ml OP (1.26) Fortisip Multi Fibre Liquid (vanilla) - Higher subsidy of \$1.26 per 200 ml with 0.72 200 ml OP (1.26) Fortisip Multi Fibre Liquid (vanilla) - Higher subsidy of \$1.26 per 200 ml with 0.72 200 ml OP (1.26) Fortisip Multi Fibre Liquid (vanilla) - Higher subsidy of \$1.26 per 200 ml with Endorsement 0.72 200 ml OP				Fortisip
Additional subsidy by endorsement is available for patients being bolus fed through a feeding tube, or who have severe epider molysis bullosa. The prescription must be endorsed accordingly. Liquid (chocolate) – Higher subsidy of \$1.26 per 200 ml with Endorsement	NRAL FEED WITH FIRRE 1.5 KCAL/ML - Special Authority see	SA1228 on nac	a 204 – Hospital	nbarmacy [HP3]
Endorsement 0.72 200 ml OP (1.26) Fortisip Multi Fibre Liquid (strawberry) – Higher subsidy of \$1.26 per 200 ml with 0.72 200 ml OP (1.26) Fortisip Multi Fibre Liquid (vanilla) – Higher subsidy of \$1.26 per 200 ml with Endorsement 0.72 200 ml OP Liquid (vanilla) – Higher subsidy of \$1.26 per 200 ml with Endorsement 0.72 200 ml OP	Additional subsidy by endorsement is available for patients be molysis bullosa. The prescription must be endorsed according	ing bolus fed th gly.	•	
Endorsement		0.72	200 ml OP	Fortisip Multi Fibre
Endorsement	Liquid (strawberry) - Higher subsidy of \$1.26 per 200 ml with	. ,		•
Liquid (vanilla) – Higher subsidy of \$1.26 per 200 ml with Endorsement0.72 200 ml OP		0.72	200 ml OP	
Liquid (vanilla) – Higher subsidy of \$1.26 per 200 ml with Endorsement0.72 200 ml OP		(1.26)		Fortisip Multi Fibre
Endorsement	Liquid (vanilla) - Higher subsidy of \$1.26 per 200 ml with	()		
			200 ml OP	
		(1.26)		Fortisip Multi Fibre

Subsidy	Fu	illy	Brand or
(Manufacturer's Price)	Subsidis	ed	Generic
\$	Per	~	Manufacturer

Adult Products High Calorie

SA1195 Special Authority for Subsidy

Initial application — (Cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

- All of the following:
 - 1 Cystic fibrosis; and
 - 2 other lower calorie products have been tried; and
 - 3 patient has substantially increased metabolic requirements.

Initial application — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

All of the following:

- 1 Any of the following:
 - 1.1 any condition causing malabsorption; or
 - 1.2 failure to thrive; or
 - 1.3 increased nutritional requirements; or
 - 1.4 fluid restricted; and
- 2 other lower calorie products have been tried; and
- 3 patient has substantially increased metabolic requirements or is fluid restricted.

Renewal — (Cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 3 years for applications meeting the following criteria:

- Both:
 - 1 The treatment remains appropriate and the patient is benefiting from treatment; and
 - 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Indications other than cystic fibrosis) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria: Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

ENTERAL FEED 2 KCAL/ML - Special Authority see SA1195 above - Hos	pital p	pharmacy [HP3]	
Liquid5.	50	500 ml OP	 Nutrison Concentrated
11.	00	1,000 ml OP	Two Cal HN RTH
ORAL FEED 2 KCAL/ML – Special Authority see SA1195 above – Hospital Additional subsidy by endorsement is available for patients being bolus molysis bullosa. The prescription must be endorsed accordingly. Liquid (vanilla) – Higher subsidy of \$2.25 per 237 ml with			tube, or who have severe epider-
Endorsement1.	4	237 ml OP	
(2.)	25)		Two Cal HN

	Subsidy (Manufacturer's Price) \$	Subsi Per	Fully idised	Brand or Generic Manufacturer
Food Thickeners				
►SA1106 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or voc where the patient has motor neurone disease with swallowing dis Renewal only from a dietitian, relevant specialist, vocationally re mendation of a dietitian, relevant specialist or vocationally registe meeting the following criteria: Both:	sorder. gistered general pract	titioner or ge	eneral	practitioner on the recom-
 The treatment remains appropriate and the patient is benu General Practitioners must include the name of the dietitia and date contacted. 			lly regi	stered general practitione
FOOD THICKENER – Special Authority see SA1106 above – He Powder		3] 80 g OP		ptamil Feed Thickener
Gluten Free Foods				
The funding of gluten free foods is no longer being actively mana longer considering the listing of new products, or making subsidy that the range of funded items will reduce over time. Manageme outcomes. A range of gluten free options are available through re	or other changes to t nt of Coeliac disease	he existing l	listings	. As a result we anticipate
► SA1107 Special Authority for Subsidy Initial application only from a dietitian, relevant specialist or vo further renewal unless notified for applications meeting the follow Either:		general prac	ctitione	r. Approvals valid withou
1 Gluten enteropathy has been diagnosed by biopsy; or 2 Patient suffers from dermatitis herpetiformis.				
GLUTEN FREE BAKING MIX – Special Authority see SA1107 a Powder		nacy [HP3] 00 g OP		
	(5.15)	-	H	ealtheries Simple

	(0.10)		Baking Mix
GLUTEN FREE BREAD MIX – Special Authority see SA1107 abov Powder		pharmacy [HP3] 1,000 g OP	
	(7.32)	.,	NZB Low Gluten Bread Mix
	4.77		
	(8.71)		Bakels Gluten Free Health Bread Mix
	3.51		
	(10.87)		Horleys Bread Mix
GLUTEN FREE FLOUR – Special Authority see SA1107 above – Powder		macy [HP3] 2,000 g OP	
	(18.10)	,	Horleys Flour

	Subsidy (Manufacturer's Pri \$		Fully Brand or dised Generic Manufacturer
GLUTEN FREE PASTA - Special Authority see SA1107 on the p	receding page – H	lospital pharma	cy [HP3]
Buckwheat Spirals	2.00	250 g OP	
	(3.11)		Orgran
Corn and Vegetable Shells	2.00	250 g OP	
	(2.92)		Orgran
Corn and Vegetable Spirals	2.00	250 g OP	
	(2.92)		Orgran
Rice and Corn Lasagne Sheets	1.60	200 g OP	
	(3.82)		Orgran
Rice and Corn Macaroni	2.00	250 g OP	
	(2.92)		Orgran
Rice and Corn Penne	2.00	250 g OP	
	(2.92)		Orgran
Rice and Maize Pasta Spirals	2.00	250 g OP	
	(2.92)		Orgran
Rice and Millet Spirals	2.00	250 g OP	
	(3.11)		Orgran
Rice and corn spaghetti noodles	2.00	375 g OP	
	(2.92)		Orgran
Vegetable and Rice Spirals	2.00	250 g OP	
	(2.92)		Orgran
Italian long style spaghetti	2.00	220 g OP	
	(3.11)		Orgran

Foods And Supplements For Inborn Errors Of Metabolism

SA1108 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid without further renewal unless notified for applications meeting the following criteria:

Any of the following:

- 1 Dietary management of homocystinuria; or
- 2 Dietary management of maple syrup urine disease; or
- 3 Dietary management of phenylketonuria (PKU); or
- 4 For use as a supplement to the Ketogenic diet in patients diagnosed with epilepsy.

Supplements For Homocystinuria

AMINOACID FORMULA WITHOUT METHIONINE - Spe Powder	,	bital pharmacy [HP3] XMET Maxamum
Supplements For MSUD		
AMINOACID FORMULA WITHOUT VALINE, LEUCINE pharmacy [HP3]	AND ISOLEUCINE -	 y see SA1108 above - Hospital

Powder	500 g OP	MSUD Maxamaid
437.22		MSUD Maxamum

	Subsidy (Manufacturer's	Price) Sub	Fully	Brand or Generic
	(Manulacturer 3) \$	Per	V	Manufacturer
Supplements For PKU				
MINOACID FORMULA WITHOUT PHENYLALANINE - Spec	cial Authority see	SA1108 on the	precedi	ng page – Hospital pha
acy [HP3]				
Tabs		75 OP		lexy 10
Powder (unflavoured) 29 g sachets		30		U Anamix Junior
Sachets (tropical)		30		lexy 10
Infant formula	174.72	400 g OP		U Anamix Infant
Powder (orange)	221.00	500 g OP		Maxamaid
	320.00		🖌 XP	Maxamum
Powder (unflavoured)	221.00	500 g OP	🖌 XP	Maxamaid
	320.00		🖌 XP	Maxamum
Liquid (berry)	13.10	125 ml OP	🖌 PK	U Anamix Junior
			L	_Q
Liquid (citrus)		62.5 ml OP	🖌 PK	U Lophlex LQ 10
	31.20	125 ml OP	🖌 PK	U Lophlex LQ 20
Liquid (forest berries)		250 ml OP		siphen Liquid
Liquid (juicy berries)		62.5 ml OP	🖌 PK	U Lophlex LQ 10
1 6 9 /	31.20	125 ml OP		U Lophlex LQ 20
Liquid (juicy orange)		62.5 ml OP		U Lophlex LQ 10
	31.20	125 ml OP		U Lophlex LQ 20
Liquid (orange)		125 ml OP	🖌 PK	U Anamix Junior
Liquid (unflavoured)	13.10	125 ml OP	🖌 PK	U Anamix Junior
Phlexy 10 Sachets (tropical) to be delisted 1 November 2013)			L	_Q
Foods				
				(1) (De)
OW PROTEIN BAKING MIX – Special Authority see SA1108 Powder		bage – Hospital 500 g OP		cy [HP3] profin Mix
		0		•
OW PROTEIN PASTA – Special Authority see SA1108 on the				•
Animal shapes		500 g OP		profin
Lasagne		250 g OP	✓ Lo	•
Low protein rice pasta		500 g OP		profin
Macaroni		250 g OP	✔ Lo	
Penne		500 g OP		profin
Spaghetti		500 g OP		profin
Spirals	11.91	500 g OP	V Lo	profin
nfant Formulae				
For Premature Infants				
RETERM POST-DISCHARGE INFANT FORMULA - Special	Authority see SA1	198 on the nex	t page -	Hospital pharmacy [HP
Powder		400 g OP		26 Gold Premgro
		3 -		

SPECIAL FOODS

Locasol

Subsidy	Full	/ Brand or
(Manufacturer's Price)	Subsidise	d Generic
\$	Per 🖌	 Manufacturer

➡SA1198 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Both:

- 1 The infant was born before 33 weeks gestation or weighed less than 1.5 kg at birth; and
- 2 Either:
 - 2.1 The infant has faltering growth (downward crossing of percentiles); or
 - 2.2 The infant is not maintaining, or is considered unlikely to maintain, adequate growth on standard infant formula.

For Williams Syndrome

SA1110 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year where the patient is an infant suffering from Williams Syndrome and associated hypercalcaemia.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 1 year for applications meeting the following criteria:

Both:

- 1 The treatment remains appropriate and the patient is benefiting from treatment; and
- 2 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

LOW CALCIUM INFANT FORMULA - Special Authority see SA1110 above - Hospital pharmacy [HP3]

400 a OP

Gastrointestinal and Other Malabsorptive Problems

AMINO ACID FORMULA - Special Authority see SA1219 below - Hospital pl	harmacy [HP3]	
Powder	48.5 g OP	Vivonex Pediatric
53.00	400 g OP	Neocate
	-	Neocate LCP
Powder (unflavoured)53.00	400 g OP	Elecare
	0	Elecare LCP
		Neocate Advance
		Neocate Gold
Powder (vanilla)53.00	400 g OP	Elecare
	0	Neocate Advance

(Neocate Powder to be delisted 1 July 2013)

SA1219 Special Authority for Subsidy

Initial application only from a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

Any of the following:

- 1 Extensively hydrolysed formula has been reasonably trialled and is inappropriate due to documented severe intolerance or allergy or malabsorption: or
- 2 History of anaphylaxis to cows milk protein formula or dairy products; or
- 3 Eosinophilic oesophagitis.

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

1 An assessment as to whether the infant can be transitioned to a cows milk protein, soy, or extensively hydrolysed infant formula has been undertaken: and

continued...

	0.1.11		
	Subsidy (Manufacturer's Price)	Fully Subsidised	Brand or Generic
		Per 🗸	Manufacturer
continued			
2 The outcome of the assessment is that the infant continu	es to require an amino ad	cid infant formul	a; and
3 General Practitioners must include the name of the dietitia and date contacted.	an, relevant specialist or v	ocationally regi	stered general practitioner
EXTENSIVELY HYDROLYSED FORMULA - Special Authority	see SA1220 below – Hos	pital pharmacy	[HP3]
Powder			ptamil Gold Pepti
		-	Junior
►SA1220 Special Authority for Subsidy			
Initial application only from a dietitian, relevant specialist or	vocationally registered g	eneral practitio	ner. Approvals valid for 6
months for applications meeting the following criteria:	voodalonally rogiotorod g	onoral praotition	
Any of the following:			
1 Both:			
1.1 Cows milk formula is inappropriate due to severe i	ntolerance or allergy to it	s protein conter	nt: and
1.2 Either:	5,		,
1.2.1 Soy milk formula has been trialled without r	esolution of symptoms; c	or	
1.2.2 Soy milk formula is considered clinically ina			
2 Severe malabsorption; or			
3 Short bowel syndrome; or			
4 Intractable diarrhea; or			
5 Biliary atresia; or			
6 Cholestatic liver diseases causing malsorption; or			
7 Chylous ascite; or			
8 Chylothorax; or			
9 Cystic fibrosis; or			
10 Proven fat malabsorption; or			
11 Severe intestinal motility disorders causing significant ma	labsorption; or		
12 Intestinal failure.			

Renewal only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 An assessment as to whether the infant can be transitioned to a cows milk protein or soy infant formula has been undertaken; and
- 2 The outcome of the assessment is that the infant continues to require an extensively hydrolysed infant formula; and
- 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and date contacted.

Renewal — (Step Down from Amino Acid Formula) only from a dietitian, relevant specialist, vocationally registered general practitioner or general practitioner on the recommendation of a dietitian, relevant specialist or vocationally registered general practitioner. Approvals valid for 6 months for applications meeting the following criteria:

All of the following:

- 1 The infant is currently receiving funded amino acid formula; and
- 2 The infant is to be trialled on, or transitioned to, an extensively hydrolysed formula; and
- 3 General Practitioners must include the name of the dietitian, relevant specialist or vocationally registered general practitioner and the date contacted.

SPECIAL FOODS

	Subsidy (Manufacturer's Price) \$	Fully Subsidised Per 🖌	Brand or Generic Manufacturer
Ketogenic Diet			
►SA1197 Special Authority for Subsidy Initial application only from a metabolic physician or paediatric intractable epilepsy, pyruvate dehydrogenase deficiency or gluco ketogenic diet. Renewal only from a metabolic physician or paediatric neurologi diet and the patient is benefiting from the diet.	ose transported type-1	deficiency and o	ther conditions requiring a
HIGH FAT LOW CARBOHYDRATE FORMULA – Special Author Powder (unflavoured)) g OP 🧴 🖌 K	cy (etoCal 4:1 (etocal 3:1

		Ketocal 3:1
Powder (vanilla)	 300 g OP	KetoCal 4:1

Pharmaceuticals and quantities that may be obtained on a Practitioner's Supply Order

ADRENALINE ✓ Inj 1 in 1,000, 1 ml ampoule
AMINOPHYLLINE ✔ Inj 25 mg per ml, 10 ml5
AMIODARONE HYDROCHLORIDE Inj 50 mg per ml, 3 ml ampoule6
AMOXYCILLIN ✓ Cap 250 mg
AMOXYCILLIN CLAVULANATE ✓ Tab amoxycillin 500 mg with potassium clavulanate 125 mg
ASPIRIN ✔ Tab dispersible 300 mg
ATROPINE SULPHATE Inj 600 mcg per ml, 1 ml ampoule5
AZITHROMYCIN V Tab 500 mg – See note on page 908
BENDROFLUMETHIAZIDE [BENDROFLUAZIDE] V Tab 2.5 mg – See note on page 59
BENZATHINE BENZYLPENICILLIN ✓ Inj 1.2 mega u per 2.3 ml
BENZTROPINE MESYLATE ✔ Inj 1 mg per ml, 2 ml
BENZYLPENICILLIN SODIUM (PENICILLIN G) ✔ Inj 600 mg
 CEFTRIAXONE SODIUM ✓ Inj 500 mg – Subsidy by endorsement – See note on page 89
CHARCOAL ✔ Oral liq 50 g per 250 ml 250 ml

ned on a Practitioner's Supply Order
CHLORPROMAZINE HYDROCHLORIDE ✓ Tab 10 mg
CIPROFLOXACIN ✓ Tab 250 mg – See note on page 925 ✓ Tab 500 mg – See note on page 925
 CO-TRIMOXAZOLE ✓ Tab trimethoprim 80 mg and sulphamethoxazole 400 mg30 ✓ Oral liq trimethoprim 40 mg and sulphamethoxazole 200 mg per 5 ml
COMPOUND ELECTROLYTES Powder for soln for oral use 4.4 g
CONDOMS 144 49 mm
► Hab + Hig Flottal pharmacy operation DEXAMETHASONE SODIUM PHOSPHATE ✓ Inj 4 mg per ml, 1 ml – See note on page 82
DEXTROSE ✔ Inj 50%, 10 ml5 ✔ Inj 50%, 90 ml5
DIAPHRAGM ✓ 65 mm – See note on page 76

PRACTITIONER'S SUPPLY ORDERS

(continued)

 DIAZEPAM ✓ Inj 5 mg per ml, 2 ml – Subsidy by endorsement – See note on page 126
DICLOFENAC SODIUM ✓ Inj 25 mg per ml, 3 ml ✓ Suppos 50 mg 10
DIGOXIN ✔ Tab 62.5 mcg
DOXYCYCLINE HYDROCHLORIDE Tab 50 mg
ERGOMETRINE MALEATE Inj 500 mcg per ml, 1 ml
ERYTHROMYCIN ETHYL SUCCINATE ✓ Tab 400 mg
ERYTHROMYCIN STEARATE Tab 250 mg
ETHINYLOESTRADIOL WITH DESOGESTREL Tab 20 mcg with desogestrel 150 mcg63 Tab 20 mcg with desogestrel 150 mcg and 7 inert tab
ETHINYLOESTRADIOL WITH LEVONORGESTREL Tab 50 mcg with levonorgestrel 125 mcg and 7 inert tab Tab 30 mcg with levonorgestrel 150 mcg. 63 Tab 30 mcg with levonorgestrel 150 mcg and 7 inert tab 84
 ETHINYLOESTRADIOL WITH NORETHISTERONE ✓ Tab 35 mcg with norethisterone 1 mg and 7 inert tab

FLUCLOXACILLIN SODIUM
 ✓ Cap 250 mg
✓ Grans for oral liq 250 mg per 5 ml
✓ Inj 1 g5
FLUPENTHIXOL DECANOATE
 ✓ Inj 20 mg per ml, 1 ml
✓ Inj 20 mg per ml, 2 ml
FLUPHENAZINE DECANOATE ✓ Inj 12.5 mg per 0.5 ml, 0.5 ml
✓ Inj 25 mg per ml, 1 ml
✓ Inj 100 mg per ml, 1 ml
FUROSEMIDE [FRUSEMIDE]
✓ Tab 40 mg
✓ Inj 10 mg per ml, 2 ml ampoule5
GLUCAGON HYDROCHLORIDE
✓ Inj 1 mg syringe kit5
GLYCERYL TRINITRATE
✓ Tab 600 mcg 100
✓ Oral spray, 400 mcg per dose 250 dose
HALOPERIDOL
✓ Tab 500 mcg
✓ Tab 1.5 mg
✓ Oral liq 2 mg per ml
✓ Inj 5 mg per ml, 1 ml
HALOPERIDOL DECANOATE
✓ Inj 50 mg per ml, 1 ml5
✓ Inj 100 mg per ml, 1 ml5
HYDROCORTISONE
✓ Inj 50 mg per ml, 2 ml5
HYDROXOCOBALAMIN
✓ Inj 1 mg per ml, 1 ml6
HYOSCINE N-BUTYLBROMIDE
✓ lnj 20 mg, 1 ml5
INTRA-UTERINE DEVICE
✓ IUD
IPRATROPIUM BROMIDE
✓ Nebuliser soln, 250 mcg per ml, 1 ml
✓ Nebuliser soln, 250 mcg per ml, 2 ml
IVERMECTIN
✓ Tab 3 mg – See note on page 70 100

continued...

✓ fully subsidised brand available

Please refer to Section A for a definition, and conditions of supply, of Practitioner's Supply Orders.

(continued)

LEVONORGESTREL Tab 30 mcg
LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE ✓ Inj 1%, 5 ml
LIGNOCAINE ✓ Gel 2%, 10 ml urethral syringe – Subsidy by endorsement – See note on page 1195
LIGNOCAINE WITH CHLORHEXIDINE Gel 2% with chlorhexidine 0.05%, 10 ml urethral syringes – Subsidy by endorsement – See note on page 1195
LOPERAMIDE HYDROCHLORIDE ✓ Tab 2 mg
MASK FOR SPACER DEVICE ✓ Size 2 – See note on page 18120
MEDROXYPROGESTERONE ACETATE ✓ Inj 150 mg per ml, 1 ml syringe5
METOCLOPRAMIDE HYDROCHLORIDE ✓ Inj 5 mg per ml, 2 ml
METRONIDAZOLE
✔ Tab 200 mg30
 Tab 200 mg
 MORPHINE SULPHATE ✓ Inj 5 mg per ml, 1 ml – Only on a controlled drug form

 ✓ Gum 2 mg (Mint) – See note on page 145
NORETHISTERONE ✔ Tab 350 mcg84 ✔ Tab 5 mg
NORETHISTERONE WITH MESTRANOL Tab 1 mg with mestranol 50 mcg and 7 inert tab
OXYTOCIN ✓ Inj 5 iu per ml, 1 ml
PARACETAMOL ✓ Tab 500 mg
PEAK FLOW METER ✓ Low range
PENICILLIN G BENZATHINE [BENZATHINE BENZYLPENICILLIN] ✔ Inj 1.2 mega u per 2 ml
 PETHIDINE HYDROCHLORIDE ✓ Inj 50 mg per ml, 1 ml – Only on a controlled drug form
PHENOXYMETHYLPENICILLIN (PENICILLIN V) ✓ Cap potassium salt 250 mg
PHENYTOIN SODIUM ✔ Inj 50 mg per ml, 2 ml5 ✔ Inj 50 mg per ml, 5 ml5
PHYTOMENADIONE ✔ Inj 2 mg per 0.2 ml
PIPOTHIAZINE PALMITATE ✓ Inj 50 mg per ml, 1 ml

PREDNISOLONE SODIUM PHOSPHATE ✓ Oral liq 5 mg per ml – See note on page 82
PREDNISONE ✔ Tab 5 mg
PREGNANCY TESTS - HCG URINE Cassette
PROCAINE PENICILLIN ✓ Inj 1.5 mega u5
PROCHLORPERAZINE ✓ Tab 5 mg
PROMETHAZINE HYDROCHLORIDE ✓ Inj 25 mg per ml, 2 ml
SALBUTAMOL ✓ Inj 500 mcg per ml, 1 ml
✓ Nebuliser soln, 2 mg per ml, 2.5 ml
 Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml
SILVER SULPHADIAZINE ✓ Crm 1%250 g

SODIUM BICARBONATE ✓ Inj 8.4%, 50 ml
SODIUM CHLORIDE ✓ Inf 0.9% - See note on page 50
SPACER DEVICE ✓ 230 ml (single patient)
SPACER DEVICE AUTOCLAVABLE ✓ 230 ml (autoclavable) – Subsidy by endorsement – See note on page 1815
TRIMETHOPRIM ✓ Tab 300 mg
VERAPAMIL HYDROCHLORIDE V Inj 2.5 mg per ml, 2 ml ampoule
WATER ✓ Purified for inj, 5 ml – See note on page 505 ✓ Purified for inj, 10 ml – See note on page 505 ✓ Purified for inj, 20 ml – See note on page 505
ZUCLOPENTHIXOL DECANOATE

~	Inj	200	mg	per	ml,	1	ml5
•		-00	····9	por	,		

Rural Areas for Practitioner's Supply Orders

NORTH ISLAND

Northland DHB Dargaville Hikurangi Kaeo Kaikohe Kaitaia Kawakawa Kerikeri Mangonui Maungaturoto Moerewa Naunauru Paihia Rawene **Ruakaka** Russell Tutukaka Waipu Whangaroa

Waitemata DHB

Helensville Huapai Kumeu Snells Beach Waimauku Warkworth Wellsford

Auckland DHB

Great Barrier Island Oneroa Ostend

Counties Manukau DHB

Tuakau Waiuku

Waikato DHB

Coromandel Huntly Kawhia Matamata Morrinsville Ngatea Otorohanga Paeroa Pauanui Beach Putaruru Raglan

Tairua Taumarunui Te Aroha Te Kauwhata Te Kuiti Tokoroa Waihi Whangamata Whitianga

Bay of Plenty DHB

Edaecumbe Katikati Kawerau Murupara Opotiki Taneatua Te Kaha Waihi Beach Whakatane

Lakes DHB Mangakino

Turangi

Tairawhiti DHB

Ruatoria Te Araroa Te Karaka Te Puia Springs Tikitiki Tokomaru Bay Tolaga Bay

Taranaki DHB

Eltham Inglewood Manaia Oakura Okato Opunake Patea Stratford Waverley

Hawkes Bav DHB

Chatham Islands Waipawa Waipukurau Wairoa Whanganui DHB Bulls

Waiouru MidCentral DHB Dannevirke Foxton Levin Otaki Pahiatua Shannon Woodville Wairarapa DHB Carteron

Marton

Raetihi

Taihape

Ohakune

Featherston Grevtown Martinborough

SOUTH ISLAND

Nelson/Marlborough DHB

Havelock Mapua Motueka Murchison Picton Takaka Wakefield

West Coast DHB

Dobson Grevmouth Hokitika Karamea Reefton South Westland Westport Whataroa

Canterbury DHB

Akaroa Amberlev Amuri Cheviot Darfield Diamond Harbour Hanmer Springs Kaikoura

Leeston I incoln Methven Oxford Rakaia Rolleston Rotherham Templeton Waikari

South Canterbury DHB

Fairlie Geraldine Pleasant Point Temuka Twizel Waimate

Southern DHB

Alexandra Balclutha Cromwell Gore Kurow I awrence Lumsden Mataura Milton Oamaru Oban Otautau Outram Owaka Palmerston Queenstown Ranfurly Riverton Roxburgh Tapanui Te Anau Tokonui Tuatapere Wanaka Winton

✓ fully subsidised brand available

SECTION F: PART I

A Community Pharmaceutical identified with a * within the other sections of the Pharmaceutical Schedule:

a) is exempt from any requirement to dispense in Monthly Lots;

b) will only be subsidised if it is dispensed in a 90 Day Lot unless it is under the Dispensing Frequency Rule.

A Community Pharmaceutical that is an oral contraceptive and that is identified with a * within the other sections of the Pharmaceutical Schedule:

a) is exempt from any requirement to dispense in Monthly Lots;

b) will only be subsidised if it is dispensed in a 180 Day Lot unless it is is under the Dispensing Frequency Rule.

SECTION F: PART II: CERTIFIED EXEMPTIONS AND ACCESS EXEMPTIONS TO MONTHLY DISPENSING

A Community Pharmaceutical, other than a Community Pharmaceutical identified with a * within the other sections of the Pharmaceutical Schedule, may be dispensed in a 90 Day Lot if:

a) the Community Pharmaceutical is identified with a **A** within the other sections of the Pharmaceutical Schedule and the prescriber/pharmacist has endorsed/annotated the Prescription item(s) on the Prescription to which the exemption applies "certified exemption".

In endorsing/annotating the Prescription items for a certified exemption, the prescriber/pharmacist is certifying that:

- i) the patient wished to have the medicine dispensed in a quantity greater than a Monthly Lot; and
- ii) the patient has been stabilised on the same medicine for a reasonable period of time; and
- iii) the prescriber/pharmacist has reason to believe the patient will continue on the medicine and is compliant.
- b) a patient, who has difficulty getting to and from a pharmacy, signs the back of the Prescription to qualify for an Access Exemption. In signing the Prescription, the patient or his or her nominated representative must also certify which of the following criteria they meet:

i) have limited physical mobility;

- ii) live and work more than 30 minutes from the nearest pharmacy by their normal form of transport;
- iii) are relocating to another area;
- iv) are travelling extensively and will be out of town when the repeat prescriptions are due.

SECTION F: PART III: FLEXIBLE AND VARIABLE DISPENSING PERIODS FOR PHARMACY

A Community Pharmaceutical, other than a Community Pharmaceutical identified with a * within the other sections of the Pharmaceutical Schedule, may be dispensed in variable dispensing periods under the following conditions:

- a) for stock management where the original pack(s) result in dispensing greater than 30 days supply,
- b) to synchronise a patients medication where multiple medicines result in uneven supply periods, note if dispensing a medicine other than a Pharmaceutical identified with a * please refer to Section F; Part II

Note - the total quantity and dispensing period can not exceed the total quantity and period prescribed on the prescription.

The following Community Pharmaceuticals are identified with a A within the other sections of the Pharmaceutical Schedule and may be dispensed in a 90 Day Lot if endorsed as a certified exemption in accordance with paragraph (a) in Section F Part II above.

ALIMENTARY TRACT AND METABOLISM

INSULIN ASPART

INSULIN ASPART WITH INSULIN ASPART PROTAMINE

INSULIN GLARGINE

INSULIN GLULISINE

INSULIN ISOPHANE

INSULIN ISOPHANE WITH INSULIN NEUTRAL

INSULIN LISPRO

INSULIN LISPRO WITH INSULIN LISPRO PROTAMINE

INSULIN NEUTRAL

CARDIOVASCULAR SYSTEM

AMIODARONE HYDROCHLORIDE					
Tab 100 mg	Cordarone-X				
Tab 200 mg	Cordarone-X				

DISOPYRAMIDE PHOSPHATE

FLECAINIDE ACETATE

Tab 50 mg	Tambocor
Tab 100 mg	Tambocor
Cap long-acting 100 mg	Tambocor CR
Cap long-acting 200 mg	Tambocor CR

MEXILETINE HYDROCHLORIDE

MINOXIDIL

NICORANDIL

PROPAFENONE HYDROCHLORIDE

HORMONE PREPARATIONS - SYSTEMIC EXCLUDING CONTRACEPTIVE HORMONES

DESMOPRESSIN Nasal drops 100 mcg Minirin per ml Nasal spray 10 mcg per Desmopressin-PH&T dose

MUSCULOSKELETAL SYSTEM PYRIDOSTIGMINE BROMIDE

NERVOUS SYSTEM

AMANTADINE HYDROCHLORIDE

APOMORPHINE HYDROCHLORIDE

ENTACAPONE

GABAPENTIN

GABAPENTIN (NEURONTIN)

LACOSAMIDE

LAMOTRIGINE

LISURIDE HYDROGEN MALEATE

PERGOLIDE

PRAMIPEXOLE HYDROCHLORIDE

ROPINIROLE HYDROCHLORIDE

TOLCAPONE

TOPIRAMATE

VIGABATRIN

SECTION G: SAFETY CAP MEDICINES

Pharmacists are required, under the Code of Ethics of the Pharmacy Council of New Zealand, to endeavour to use safety caps when dispensing any of the medicines listed in Section G in an oral liquid formulation pursuant to a prescription or Practitioner's Supply Order. This includes all proprietary and extemporaneously compounded oral liquid preparations of those pharmaceuticals listed in Section G of the Pharmaceutical Schedule. These medicines will be identified throughout Section B of the Pharmaceutical Schedule with the symbol '‡'.

Exemptions

Oral liquid preparations of the pharmaceuticals listed in Section G of the Pharmaceutical Schedule will be dispensed in a container with a safety cap unless:

- the practitioner has endorsed the Prescription or Practitioner's Supply Order, stating that, the Pharmaceutical is not to be dispensed in a container with a safety cap; or
- the Contractor has annotated the Prescription or Practitioner's Supply Order stating that, because of infirmity of the particular
 person, the Pharmaceutical to be used by that person should not be dispensed in a container with a safety cap; or
- the Pharmaceutical is packaged in an Original Pack so designed that on the professional judgement of the Contractor, transfer to a container with a safety cap would be inadvisable or a retrograde procedure.

Reimbursment

Pharmacists will be reimbursed according to their agreement. Where an additional fee is paid on safety caps it will be paid on all dispensings of oral liquid preparations for those pharmaceuticals listed in Section G of the Pharmaceutical Schedule unless the practitioner has endorsed or the contractor has annotated the Prescription or Practitioner's Supply Order that a safety cap has not been supplied.

Safety Caps (NZS 5825:1991)

20 mm	. Clic-Loc, United Closures & Plastics PLC, England
	Kerr, Cormack Packaging, Sydney, under licence to Kerr USA
24 mm	.Clic-Loc, United Closures & Plastics PLC, England
	Clic-Loc, ACI Closures under license to Owens-Illinois
	Kerr, Cormack Packaging, Sydney, under licence to Kerr USA
28 mm	.Clic-Loc, United Closures & Plastics PLC, England
	Clic-Loc, ACI Closures under license to Owens-Illinois
	Kerr, Cormack Packaging, Sydney, under licence to Kerr USA
	PDL Squeezlok
	PDL FG

SAFETY CAP MEDICINES

ALIMENTARY TRACT AND M FERROUS SULPHATE Oral liq 30 mg per 1 ml		CLOBAZAM Tab 10 mg Frisium (Extemporaneously compounded oral liquid preparations)		
(6 mg elemental per 1 ml) CARDIOVASCULAR SYSTEM AMILORIDE HYDROCHLOF Oral lig 1 mg per ml		CLONAZEPAM Oral drops 2.5 mg per ml DIAZEPAM	Rivotril	
CAPTOPRIL Oral liq 5 mg per ml	Capoten	Tab 2 mg Tab 5 mg (Extemporaneously compound)	Arrow-Diazepam Arrow-Diazepam ed oral liquid preparations)	
CHLOROTHIAZIDE Oral liq 50 mg per ml	Biomed	ETHOSUXIMIDE Oral lig 250 mg per 5 ml		
DIGOXIN Oral liq 50 mcg per ml FUROSEMIDE (FRUSEMID	Lanoxin	LORAZEPAM Tab 1 mg	Ativan	
Oral liq 10 mg per ml	⊑j Lasix	Tab 2.5 mg Ativan (Extemporaneously compounded oral liquid preparation		
SPIRONOLACTONE Oral liq 5 mg per ml	Biomed	LORMETAZEPAM Tab 1 mg	Noctamid	
HORMONE PREPARATIONS - CONTRACEPTIVE HORMONE LEVOTHYROXINE		(Extemporaneously compounded oral liquid preparations)		
Tab 25 mcg Tab 50 mcg	Synthroid Eltroxin Mercury Pharma	Oral liq 2 mg per ml Oral liq 5 mg per ml Oral liq 10 mg per ml	Biodone Biodone Forte Biodone Extra Forte	
Tab 100 mcg	Synthroid Eltroxin Mercury Pharma Synthroid	MORPHINE HYDROCHLOF Oral liq 1 mg per ml Oral liq 2 mg per ml	RA-Morph RA-Morph	
(Extemporaneously compound	ed oral liquid preparations)	Oral liq 5 mg per ml Oral liq 10 mg per ml	RA-Morph RA-Morph	
MUSCULOSKELETAL SYSTE IBUPROFEN Oral liq 20 mg per ml	M Fenpaed	NITRAZEPAM Tab 5 mg (Extemporaneously compound	Nitrados ed oral liquid preparations)	
QUININE SULPHATE Tab 300 mg (Extemporaneously compounde	Q 300 ed oral liquid preparations)	OXAZEPAM Tab 10 mg Tab 15 mg (Extemporaneously compound	Ox-Pam Ox-Pam ed oral liquid preparations)	
NERVOUS SYSTEM ALPRAZOLAM				
Tab 250 mcg Tab 500 mcg	Arrow-Alprazolam Arrow-Alprazolam	Oral liq 5 mg per 5 ml	OxyNorm	
Tab 1 mg (Extemporaneously compound	Arrow-Alprazolam ed oral liquid preparations)	PARACETAMOL Oral liq 120 mg per 5 ml Oral liq 250 mg per 5 ml	Ethics Paracetamol Paracare Double Strength	
CARBAMAZEPINE Oral liq 100 mg per 5 ml	Tegretol	PHENYTOIN SODIUM Oral liq 30 mg per 5 ml	Dilantin	

SODIUM VALPROATE Oral liq 200 mg per 5 ml

I Epilim S/F Liquid Epilim Syrup

TEMAZEPAM Tab 10 mg Normison (Extemporaneously compounded oral liquid preparations)

TRIAZOLAM Tab 125 mcg Hypam Tab 250 mcg Hypam (Extemporaneously compounded oral liquid preparations)

RESPIRATORY SYSTEM AND ALLERGIES

CETIRIZINE HYDROCHLORIDE Oral liq 1 mg per ml Cetirizine - AFT

CHLORPHENIRAMINE MALEATE Oral liq 2 mg per 5 ml Histafen

DEXTROCHLORPHENIRAMINE MALEATE Oral liq 2 mg per 5 ml Polaramine

PROMETHAZINE HYDROCHLORIDE Oral liq 5 mg per 5 ml Allersoothe SALBUTAMOL

Oral liq 2 mg per 5 ml Ventolin Salapin Broncolin

THEOPHYLLINE Oral liq 80 mg per 15 ml Nuelin

TRIMEPRAZINE TARTRATE Oral liq 30 mg per 5 ml Vallergan Forte

EXTEMPORANEOUSLY COMPOUNDED PREPARATIONS AND GALENICALS CODEINE PHOSPHATE

Powder Douglas (Extemporaneously compounded oral liquid preparations)

METHADONE HYDROCHLORIDE Powder AFT (Extemporaneously compounded oral liquid preparations)

PHENOBARBITONE SODIUM Powder MidWest (Extemporaneously compounded oral liquid preparations)

NATIONAL IMMUNISATION SCHEDULE

	Subsidy		Fully	Brand or
(Manufacturer's Price) \$	Sut Per	osidised V	Generic Manufacturer
Vaccinations				
 BACILLUS CALMETTE-GUERIN VACCINE – Hospital pharmacy [7 For infants at increased risk of tuberculosis. Increased risk is did 1) living in a house or family with a person with current or past I 2) have one or more household members or carers who within 40 per 100,000 for 6 months or longer or 3) during their first 5 years will be living 3 months or longer in a Note a list of countries with high rates of TB are available at www.m Inj multi-dose vial (10 dose) 0.5 ml 	efined as: history of TB or the last 5 years liver country with a rate oh.govt.nz/immunis	of TB > o	r equal /ww.bcg	to 40 per 100,000
DIPHTHERIA AND TETANUS VACCINE – Hospital pharmacy [Xph For adults aged 45 and 65 years old, and for susceptible individ Inj 0.5 ml	narm] Iuals.	1		DT Booster
IIJ 0.5 mi DIPHTHERIA, TETANUS AND PERTUSSIS VACCINE – Hospital p For children aged 11 years old and pregnant women between g Inj 0.5 ml DIPHTHERIA, TETANUS, PERTUSSIS AND POLIO VACCINE – H	oharmacy [Xpharm] gestional weeks 28 0.00	and 38 du 1	iring epi	
For children aged 4 years old. Inj 0.5 ml		1	🖌 In	fanrix-IPV
DIPHTHERIA, TETANUS, PERTUSSIS, POLIO, HEPATITIS B AND pharmacy [Xpharm] For children aged 6 weeks, 3 months, and 5 months old. Inj 0.5 ml		NFLUENZ		PE B VACCINE – Hospital
HAEMOPHILUS INFLUENZAE TYPE B VACCINE – Hospital phar For children aged 15 months old, children aged 0-16 years with Inj 0.5 ml	functional asplenia	, or for pa		re- and post-splenectomy. ct-HIB
HEPATITIS B VACCINE – Hospital pharmacy [Xpharm] For household or sexual contacts of known hepatitis B carrier antigen (HBsAg) postive.		orn to mo	thers w	ho are hepatitis B surface
Inj 0.5 ml HUMAN PAPILOMAVIRUS VACCINE – Hospital pharmacy [Xpharr Three doses over a period of six months for young women age	n]	1 9 years o		BvaxPro
Inj 0.5 ml INFLUENZA VACCINE – Hospital pharmacy [Xpharm]		1		ardasil
lnj	90.00	10		luarix luvax
 A) is available each year for patients who meet the following crit a) all people 65 years of age and over; b) people under 65 years of age who: i) have any of the following cardiovascular disease i) ischaemic heart disease, congestive heart disease, congenital heart disease, congenital heart disease; have either of the following chronic respiratory asthma, if on a regular preventative ther other chronic respiratory disease with in 	disease: 'apy, or			
iii) have diabetes;				continued

	NATIONAL	IMMUN	ISATI	ON SCHEDULE
	Subsidy (Manufacturer's Price) \$	Sub: Per	Fully sidised	Brand or Generic Manufacturer
continued				
 iv) have chronic renal disease; v) have any cancer, excluding basal and squavin have any of the following other conditions: a) autoimmune disease, b) immune suppression, c) HIV, d) transplant recipients, e) neuromuscular and CNS diseases, f) haemoglobinopathies, or g) are children on long term aspirin, or vii) are pregnant c) people under 18 years of age living within the boud of children aged four and under who have been hos ratory illness; Unless meeting the criteria set out above, the following conditional asthma not requiring regular preventative therapy b) hypertension and/or dyslipidaemia without evidem B) Doctors are the only Contractors entitled to claim paymeligible under the above criteria for subsidised immunis listed in the Pharmaceutical Schedule. C) Individual DHBs may fund patients over and above the 	, pitalised for respiratory ns are excluded from fu , ce of end-organ diseas ent from the Funder for ation and they may onl above criteria. The cla	ury District illness or l inding: e, the suppl y do so in	Health have a y of inf	history of significant respi- luenza vaccine to patients ct of the influenza vaccine
should be determined between the DHB and Contractor. D) Stock of the seasonal influenza vaccine is typically ava ensure supply until at least 30 June. Exact start and end	ilable from February un			
MEASLES, MUMPS AND RUBELLA VACCINE – Hospital pha For children aged 15 months and 4 years old or for any ind Inj 0.5 ml	ividual susceptible to m	easles, mu 1		rubella. I -M-R II
MENINGOCOCCAL A, C, Y AND W-135 VACCINE – Hospital For patients pre- and post-splenectomy or children aged 0- based outbreaks.		l asplenia.	For or	ganisation and community
Inj 0.5 ml	0.00	1	🖌 M	lenomune
PNEUMOCOCCAL (PCV13) VACCINE – Hospital pharmacy [2 For high risk children under the age of 5 and those aged less Inj 0.5 ml	s than 16 years pre- or p	ost-splene 1		or with functional asplenia. revenar 13
PNEUMOCOCCAL POLYSACCHARIDE VACCINE – Hospital For patients pre- and post-splenectomy or children aged 0- Inj 0.5 ml	16 years with functional	asplenia. 1		neumovax 23
PNEUMOCOCCAL VACCINE – Hospital pharmacy [Xpharm] For children aged 6 weeks, 3 months, and 5 months, and 1 Inj 0.5 ml		1	✔ S	ynflorix
POLIOMYELITIS VACCINE – Hospital pharmacy [Xpharm] A primary course of three doses for previously unvaccinate Inj 0.5 ml		1	🗸 IF	

- Symbols -	
-------------	--

- Symbols -
3TC105
50X 3.0 Reservoir
- A -
A-Lices
A-Scabies
Abacavir sulphate
Abacavir sulphate with
lamivudine
Abilify
ABM Hydroxocobalamin42
Acarbose
Accarb29
Accu-Chek Ketur-Test29
Accu-Chek Performa30
Accupril53
Accuretic 1053
Accuretic 2053
Acetadote193
Acetazolamide184
Acetic acid with 1, 2- propanediol
diacetate and
benzethonium 183
Acetic acid with hydroxyquinoline
and ricinoleic acid
Acetylcysteine
Aci-Jel
Aciclovir
Infection100
Sensory183
Acidex
Acipimox
Acitretin
Aclasta115
Aclin
Act-HIB226
Actinomycin D151
Actrapid28
Actrapid Penfill28
Acupan120
Adalat 1057
Adalat Oros57
Adalimumab166
Adapalene64
Adefin XL57
Adefovir dipivoxil98
ADR Cartridge 1.8
ADR Cartridge 3.0
Adrenaline
Adriamycin151
ADT Booster226
Advantan68

AFT-Pyrazinamide98
Agents Affecting the
Renin-Angiotensin System52
Agents for Parkinsonism and
Related Disorders 118
Agents Used in the Treatment of
Poisonings 44
Agrylin150
Alanase
Albay175
Albendazole
Albustix
Aldara
Alendronate sodium
Alendronate sodium with
cholecalciferol
Alfacalcidol
Alginic acid24
Alitraq203
Alkeran147
Allersoothe176
Allopurinol116
Alpha Adrenoceptor Blockers52
Alpha-Keri Lotion69
Alphamox91
Alphapharm105
Alprazolam137
Alu-Tab24
Aluminium hydroxide24
Amantadine hydrochloride118
Ambrisentan62
Amiloride hydrochloride58
Amiloride hydrochloride with
furosemide
Amiloride hydrochloride with
hydrochlorothiazide
Aminophylline
Amiodarone hydrochloride54
Amisulpride
Amitrip
Amitriptyline
Amlodipine
Amorolfine65
Amoxycillin
Amoxycillin clavulanate
Amphotericin B41
Amsacrine
Amsidine
Amyl nitrite61
Anaesthetics
Anagrelide hydrochloride150
Analgesics

Anastrozole16	0
Andriol Testocaps8	3
Androderm	3
Animas Battery Cap3	3
Animas Cartridge	8
Animas Vibe	
Antabuse14	
Antacids and Antiflatulants2	4
Anten12	
Anthelmintics8	
Antiacne Preparations6	
Antiallergy Preparations17	
Antianaemics4	
Antiandrogen Oral	-
Contraceptives	9
Antiarrhythmics	
Antibacterials	
Antibacterials Topical	
Anticholinesterases	
Antidepressants	
Antidiarrhoeals	1
Antiepilepsy Drugs	4 6
Antifibrinolytics, Haemostatics	0
and Local Sclerosants	6
Antifungals	
Antifungals Topical6	5
Antihistamines	
Antihypotensives	
Antimalarials	0
Antinaus	1
Agents13	^
Antipruritic Preparations	0
Antipsychotics	0
Antiretrovirals	3
	~
Therapies 10	6
Antirheumatoid Agents11	1
Antispasmodics and Other	
Agents Altering Gut	_
Motility	6
Antithrombotic Agents4	6
Antithymocyte globulin	
(equine)16	6
Antitrichomonal Agents9	7
Antituberculotics and	
Antileprotics9	
Antiulcerants2	
Antivirals9	
Anxiolytics13	
Anzatax15	2

			INDEX
Generic	Chemicals	and	Brands

Apidra28
Apidra SoloStar28
Apo-Allopurinol
Apo-Amlodipine
Apo-Azithromycin90
Apo-Bromocriptine
Apo-Ciclopirox
Apo-Cimetidine
Apo-Clarithromycin
Alimentary
Infection90
Apo-Clomipramine123
Apo-Clopidogrel46
Apo-Diclo110
Apo-Diltiazem CD
Apo-Doxazosin
Apo-Folic Acid
•
Apo-Gliclazide
Apo-Megestrol
Apo-Moclobemide124
Apo-Nadolol56
Apo-Nicotinic Acid59
Apo-Oxybutynin81
Apo-Perindopril
Apo-Pindolol56
Apo-Prazo52
Apo-Prednisone83
Apo-Primidone
Apo-Propranolol
Apo-Pyridoxine
Apo-Risperidone
Apo-Selegiline
Apo-Selegiline CO0
Apo-Selegiline S29119
Apo-Thiamine
Apo-Timol56
Apo-Zopiclone140
Apomine118
Apomorphine hydrochloride118
APP Pharmaceuticals93
Aprepitant130
Apresoline61
Aptamil Feed Thickener210
Aptamil Gold Pepti Junior214
Aquasun 30+
Aqueous cream
Aratac
Arava
Aremed
Arimidex160
Aripiprazole132
Aristocort68
Aromasin160
Arrow Amitriptyline123

Arrow-Alprazolam137
Arrow-Bendrofluazide59
Arrow-Brimonidine185
Arrow-Calcium43
Arrow-Citalopram124
Arrow-Diazepam
Arrow-Doxorubicin
Arrow-Etidronate113
Arrow-Lamotrigine128
Arrow-Lisinopril52
Arrow-Losartan &
Hydrochlorothiazide54
Arrow-Meloxicam111
Arrow-Morphine LA122
Arrow-Nifedipine XR
Arrow-Norfloxacin109
Arrow-Ornidazole97
Arrow-Quinapril 1053
Arrow-Quinapril 20
Arrow-Quinapril 5
Arrow-Ranitidine
Arrow-Roxithromycin91
Arrow-Sertraline124
Arrow-Simva 10mg60
Arrow-Simva 20mg60
Arrow-Simva 40mg60
Arrow-Simva 80mg60
Arrow-Sumatriptan130
Arrow-Timolol
Arrow-Tolterodine81
Arrow-Topiramate129
Arrow-Tramadol120
Arrow-Venlafaxine XR
Arrowcare110
Arsenic trioxide
Alsenic movide
Asamax25
Ascorbic acid
Aspec 300120
Aspen Adrenaline61
Aspen Ceftriaxone89
Aspirin
Blood46
Nervous120
Asthalin178
Atazanavir sulphate105
Atenolol
Atenolol AFT
ATGAM
Ativan
Atomoxetine
Atorvastatin
Atripla105

Atropine sulphate	
Cardiovascular	
Sensory1	
Atropt1	85
Atrovent1	
Augmentin	
Auranofin1	
Ava 20 ED	
Ava 30 ED	
Avanza1	
Avelox	
Avomine1	
Avonex1	
Avonex Pen1 Azathioprine1	39
Azathophine	
Azili ilonnycini	
Azopt1	
AZOpt1	
-B-	00
B-D Micro-Fine	21
B-D Ultra Fine	30 20
B-D Ultra Fine II	32 32
B-PlexADE	
Bacillus Calmette-Guerin (BCG)	74
vaccine	66
Bacillus Calmette-Guerin	
vaccine2	26
Baclofen1	17
Bactroban	
Bakels Gluten Free Health Bread	
Mix2	10
Baraclude	99
Barrier Creams and	
Emollients	
Batrafen	
BCG Vaccine2	
Beclazone 1001	
Beclazone 2501	
Beclazone 501	76
Beclomethasone	~ -
dipropionate 176, 1	81
Bee venom allergy treatment	
Bendrofluazide	
Bendroflumethiazide	59
[Bendrofluazide]	50
Benhex	
Benzathine benzylpenicillin	
benzathine benzylpenicillin	91
Benzbromaron1	
Benzbromarone1	
Benzoin	

INDEX Generic Chemicals and Brands

Benztrop119
Benztropine mesylate119
Benzydamine hydrochloride41
Benzylpenicillin sodium (penicillin
G)
Beta Adrenoceptor Blockers
Beta Cream67
Beta Ointment
Beta Scalp73
Beta-Adrenoceptor Agonists
Betadine70 Betadine Skin Prep70
Betaferon
Betagan
Betahistine dihydrochloride
Betamethasone dipropionate67
Betamethasone dipropionate
with calcipotriol72
Betamethasone sodium
phosphate with
betamethasone acetate82
Betamethasone valerate67, 73
Betamethasone valerate with
clioquinol68
Betamethasone valerate with
fusidic acid68
Betaxolol hydrochloride184
Betnovate67
Betnovate-C68
Betoptic184
Betoptic S184
Bezafibrate59
Bezalip59
Bezalip Retard
Bicalaccord159
Bicalutamide159
Bicillin LA91, 92
BiCNU
Biltricide
Bimatoprost185
Biodone
Biodone Extra Forte121
Biodone Forte121
Bisacodyl40
Bismuth trioxide27
Bisoprolol
BK Lotion
Bleomycin sulphate150
Blood Colony-stimulating
Factors 49
Blood glucose diagnostic test
meter
Blood glucose diagnostic test

strip
Blood glucose test strips (visually
impaired) 31
Blood ketone diagnostic test
meter
Bonjela41
Boostrix226
Bortezomib150
Bosentan62
Bosvate55
Breath-Alert181
Brevinor 1/2178
Brevinor 1/2878
Brevinor 2178
Bricanyl Turbuhaler178
Brimonidine tartrate185
Brimonidine tartrate with timolol
maleate 185
Brinzolamide184
Brolene183
Bromocriptine mesylate118
Broncolin178
Brufen110
Brufen SR110
BSF Alphapharm187
BSF Apo-Diltiazem CD187
BSF CareSens II187
BSF CareSens N187
BSF CareSens N POP187
BSF Nevirapine
Alphapharm187
Buccastem131
Budenocort176
Budesonide
Alimentary24
Respiratory176, 181
Budesonide with
eformoterol177
Bumetanide58
Buprenorphrine with
naloxone144
Bupropion hydrochloride145
Burinex
Buscopan26
Buspirone hydrochloride137
Busulphan
Butacort Aqueous181
- C -
Cabergoline
Cafergot130
Caffaina aitrata


- C -	
Cabergoline87	
Cafergot130	
Caffeine citrate	
Cal-d-Forte43	
Calamine66	

Calcipotriol72	2
Calcitonin	5
Calcitriol42	
Calcitriol-AFT42	2
Calcium carbonate24, 43	3
Calcium Channel Blockers	2
Calcium Disodium Versenate44	
Calcium folinate148	3
Calcium Folinate Ebewe148	3
Calcium gluconate43	
Calcium achietures a)
Calcium polystyrene	
sulphonate)
Calcium Resonium50	C
Calogen199	
Calsource	
Camptosar149	
Candesartan cilexetil53	3
Candestar53	3
Canesten	
Capecitabine148	
Capoten52	2
Capsaicin	
Dermatological75	5
Musculoskeletal System	1
Captopril52	
Carafate27	
Carbaccord147	7
Carbamazepine126	2
Carbimazole86	
Carboplatin147	
Carboplatin Ebewe147	7
Carbosorb-X44	4
Cardinol	
Cardinol LA56	
CareSens)
CareSens II	C
CareSens N)
CareSens N POP	
Carmustine147	
Carvedilol55	
Catapres58	3
Catapres-TTS-158	3
Catapres-TTS-2	2
Catapres-TTS-3)
Catapres-115-3	2
CooNU 147	3
CeeNU147	3 7
	3 7
Cefaclor monohydrate89	3 7 9
Cefaclor monohydrate89 Cefalexin Sandoz90	3 7 9 0
Cefaclor monohydrate	3 7 9 0
Cefaclor monohydrate	379999
Cefaclor monohydrate	3799999
Cefaclor monohydrate	3799999
Cefaclor monohydrate	37909999
Cefaclor monohydrate	37999999

Celiprolol	.55
Cellcept1	61
Celol	
Centrally-Acting Agents	.58
Cephalexin ABM	.90
Cephalexin monohydrate	
Ceptolate	
Cerezyme	
Cetirizine - AFT1	75
Cetirizine hydrochloride1	75
Cetomacrogol	60
Champix1	
Charcoal	
Chemotherapeutic Agents1	.44
Chlorafast1	
Chlorambucil	
Chloramphenicol1	
	00
Chlorhexidine gluconate Alimentary	44
Allmentary	.41
Dermatological	.68
Chloroform	93
Chloromycetin1	
Chlorothiazide	.59
Chlorpheniramine maleate	/5
Chlorpromazine	~~
hydrochloride1	32
Chlorsig1	83
Chlortalidone	
[Chlorthalidone]	59
Chlorthalidone	
Chlorvescent	.51
Cholecalciferol	
Cholestyramine	.59
Choline salicylate with	
cetalkonium chloride	
Cholvastin	
Ciclopirox olamine	
Cilazapril	.52
Cilazapril with	
hydrochlorothiazide	53
Cilicaine	.92
Cilicaine VK	.92
Ciloxan1	83
Cimetidine	
Cipflox	.92
Ciprofloxacin	
Infection	
Sensory1	83
Ciprofloxacin Rex	.92
Cisplatin	47
Cisplatin Ebewe	47
Citalopram hydrobromide1	24
Cladribine	

Clarithromycin
Alimentary26
Infection
Clexane
Climara 10084
Climara 5084
Clindamycin93
Clindamycin ABM93
Clobazam126
Clobetasol propionate67, 73
Clobetasone butyrate67
Clofazimine
Clomazol
Dermatological
Genito-Urinary79
Clomiphene citrate
Clomipramine hydrochloride123
Clonazepam126, 137
Clonidine
Clonidine BNM
Clonidine hydrochloride
Clopidogrel46
Clopine
Clopixol
Clotrimazole
Dermatological
Genito-Urinary
Clozapine
Clozaril
Co-Renitec
Co-trimoxazole
Coal tar
Coal tar with allantoin, menthol,
phenol and sulphur
Coal tar with salicylic acid and
sulphur
Coco-Scalp
Codeine phosphate
Extemporaneous193
Nervous120
Cogentin
Colaspase [L-asparaginase]150
Colchicine
Colestid
Colestipol hydrochloride
Colgout
Colifoam25
Colistin sulphomethate
Colistin-Link
Collodion flexible
Colofac
Coloxyl40
Combigan
oomolyan100

Combivir105
Comfort
Comfort Short36
Compound electrolytes50
Compound
hydroxybenzoate
Concerta142
Condoms
Condyline74
Contact-D
Contraceptives - Hormonal77
Contraceptives -
Non-hormonal
Copaxone139
Corangin61
Cordarone-X54
Corticosteroids and Related
Agents for Systemic Use
Corticosteroids Topical67
Cosmegen151
Cosopt
Coumadin49
Coversyl52 Creon 1000039
Creon Forte
Crixivan
Crotamiton66
Crystaderm65
Curam Duo91
Cyclizine hydrochloride130
Cyclizine lactate130
Cycloblastin147
Cyclogyl185
Cyclopentolate
bydroebloride 195
hydrochloride
Cycloserine97
Cyclosporin
Cyclosponn
Cyproterone acetate83
Cyproterone acetate
Cyproterone acetate with ethinyloestradiol
Cytotec
Cytoxan147
- D -
D-Penamine111
d4T105
Dabigatran48
Dacarbazine151
Dactinomycin [Actinomycin
D]
Daivobet72



Daivonex72	
Daktarin66	
Dalacin C93	
Dalteparin sodium47	,
Danazol87	
Danthron with poloxamer40	
Dantrium	
Dantrolene117	
Daonil	
Dapa-Tabs	
Dapsone	
Daraprim	
Darunavir105	
Dasatinib154	
Daunorubicin	
DBL Aminophylline	
DBL Bleomycin Sulfate150	
DBL Carboplatin147	
DBL Cisplatin147	
DBL Doxorubicin151	
DBL Doxorubicin S29151	
DBL Epirubicin	
Hydrochloride151	
DBL Ergometrine80	
DBL Gemcitabine149	
DBL Leucovorin Calcium148	
DBL Methotrexate149	
DBL Morphine Sulphate122	
DBL Pethidine	
Hydrochloride123	
DBL Tobramycin94	
DDI	
De Nol27	,
De-Worm	
Decozol41	
Deferiprone51	
Deoxycoformycin153	
Depo-Medrol	
Depo-Medrol with Lidocaine	
Depo-Provera	
Depo-Testosterone	
Deprim	
Dermol	
Desferrioxamine mesylate51	'
Desientoxamine mesylate	,
Desmopressin	,
Desinopressin-PH&I	
Detection of Substances in	
Urine	
Dexamethasone	
Hormone82	
Sensory184	
Dexamethasone sodium	
phosphate	

Dexamethasone with framycetin
and gramicidin183
Dexamethasone with neomycin
and polymyxin b sulphate184
Dexamphetamine sulphate141
Dextrochlorpheniramine
maleate 175
Dextrose
Dextrose with electrolytes50
DHC Continus120
Diabetes27
Diabetes Management
Diacomit
Diamide Relief24
Diamox
Diaphragm
Diasip
Diason RTH200
Diastop
Diazepam126, 137
Diazoxide
Dibenyline
Diclax SR110
Diclofenac sodium
Musculoskeletal System110
Sensory184
Didanosine [DDI]105
Didanosine [DDI]
Differm
Diflucan
Diflucortolone valerate67 Digestives Including
Enzymes
Digoxin54 Dihydrocodeine tartrate120
Dilantin
Dilantin Infatab
Dilatrend
Diltiazem hydrochloride
Dilzem
Dipentum25
Diphenoxylate hydrochloride with
atropine sulphate24
Diphtheria and tetanus
vaccine
Diphtheria, tetanus and pertussis
vaccine
Diphtheria, tetanus, pertussis
and polio vaccine
Diphtheria, tetanus, pertussis,
polio, hepatitis B and
haemophilus influenzae type B
vaccine226

Diprosone67
Diprosone OV67
Dipyridamole
Disinfecting and Cleansing
Agents
Disipal
Disopyramide phosphate54
Disulfiram
Diuretics
Diurin 40
Dixarit
Docetaxel
Docetaxel Ebewe151
Docetaxel Sandoz151
Docusate sodium40
Docusate sodium with
sennosides
Domperidone
Donepezil hydrochloride143
Donepezil-Rex
Dopergin118
Dopress
Dornase alfa
Dorzolamide hydrochloride185
Dorzolamide hydrochloride with
timolol maleate185
Dostinex
Dothiepin hydrochloride123
Doxazosin52
Doxepin hydrochloride123
Doxine
Doxorubicin151
Doxorubicin Ebewe151
Doxy-5092
Doxycycline hydrochloride92
DP Lotion69
DP Lotn HC68
DP-Anastrozole160
Dr Reddy's Olanzapine133, 136
Dr Daddy'a Omensezala 07
Dr Reddy's Omeprazole27
Dr Reddy's Ondansetron131
Dr Reddy's Ondansetron131 Dr Reddy's Pantoprazole27
Dr Reddy's Ondansetron131 Dr Reddy's Pantoprazole27 Dr Reddy's Pramipexole118
Dr Reddy's Ondansetron131 Dr Reddy's Pantoprazole27 Dr Reddy's Pramipexole118 Dr Reddy's Quetiapine
Dr Reddy's Ondansetron

Duolin HFA	.179
Durex Confidence	76
Durex Extra Safe	
Durex Select Flavours	76
Duride	
Dynacirc-SRO	01
- E -	
E-Mycin	90
Ear Preparations	.183
Ear/Eye Preparations	.183
Easiphen Liquid	.212
Econazole nitrate	66
Efavirenz	.104
Efavirenz with emtricitabine and	
tenofovir disoproxil	
fumarate	. 105
Efexor XR	
Effient	46
Eformoterol fumarate	.177
Efudix	
Egopsoryl TA	
Elecare	
Elecare LCP	213
Electral	
Elemental 028 Extra	
Eligard	
Elocon	
Eloxatin	
Eltroxin	
Emend Tri-Pack	.130
EMLA	
Emtricitabine	.105
Emtricitabine with tenofovir	
disoproxil fumarate	. 105
Emtriva	.105
Emulsifying ointment	
Enalapril maleate	52
Enalapril maleate with hydrochlorothiazide	
Enbrel	.161
Endocrine Therapy	.159
Endoxan	.147
Enfuvirtide	.106
Enoxaparin sodium	47
Ensure	
Ensure Plus	
Ensure Plus HN	
Ensure Plus RTH	.207
Entacapone	
Entapone	118
Entecavir	
Entocort CIR	
	···ć+

Epilim1	28
Epilim Crushable1	28
Epilim IV1	
Epilim S/F Liquid1	28
Epilim Syrup1	28
Epirubicin1	51
Epirubicin Ebewe1	51
	45
ERA	
Ergometrine maleate	80
Ergotamine tartrate with	
caffeine 1	
Erlotinib hydrochloride1	
Erythrocin IV	90
Erythromycin ethyl succinate	90
Erythromycin lactobionate	90
Erythromycin stearate	91
Erythropoietin alpha	45
Erythropoietin beta	
Escitalopram1	24
Eskazole	89
Estradot	
Estrofem	
Etanercept1	61
Ethambutol hydrochloride	97
Ethics Aspirin1	20
Ethics Aspirin EC	46
Ethics Paracetamol1	
Ethinyloestradiol	85
Ethinyloestradiol with desogestrel	
desogestrel	77
Ethinyloestradiol with	70
levonorgestrel	78
Ethinyloestradiol with norethisterone	70
Ethosuximide1 Etidronate disodium1	
Etopophos1	13
Etoposide1	52 51
Etoposide phosphate1	51
Etravirine1	
Eumovate	
Evista1	
Exemestane1	
Extemporaneously Compounded	00
Preparations and	
Galenicals1	93
Eye Preparations1	83
EZ-fit Paediatric Mask1	81
Ezetimibe	
Ezetimibe with simvastatin	60
Ezetrol	

- F -	
Felodipine	57
Femtran 100	84
Femtran 50	84
Fenpaed	110
Fentanyl	121
Fentanyl citrate	
Ferodan	44
Ferriprox	51
Ferro-F-Tabs	43
Ferro-tab	
Ferrograd	
Ferrograd F	44
Ferrous fumarate	43
Ferrous fumarate with folic	
acid	. 43
Ferrous sulphate	44
Ferrous sulphate with folic	
acid	. 44
Ferrum H	
Fexofenadine hydrochloride	175
Fibro-vein	46
Filgrastim	49
Finasteride	
Flagyl	
Flagyl-S	
Flamazine	65
Flecainide acetate	54
Fleet Phosphate Enema	40
Flixonase Havfever &	
Allergy	181
Flixotide	
Flixotide Accuhaler	176
Florinef	82
Fluanxol	135
Fluarix	226
Flucloxacillin sodium	91
Flucloxin	
Flucon	184
Fluconazole	95
Fludara	149
Fludara Oral	149
Fludarabine Ebewe	149
Fludarabine phosphate	149
Fludrocortisone acetate	
Fluids and Electrolytes	49
Flumetasone pivalate	
Fluocortolone caproate with	
fluocortolone pivalate and	
cinchocaine	. 26
Fluorometholone	
Fluorouracil Ebewe	149

Fluorouracil sodium
Dermatological74
Oncology149
Fluox
Fluoxetine hydrochloride124
Flupenthixol decanoate135
Fluphenazine decanoate
Flutamide
Flutamin
Flutamin S29
Fluticasone
Fluticasone propionate
Fluticasone with salmeterol177
Fluvax
Foban65
Folic acid45
Food Thickeners210
Foods And Supplements For
Inborn Errors Of
Metabolism211
Foradil177
Forteo114
Fortimel Regular201
Fortini
Fortini Multi Fibre202
Fortisip207, 208
Fortisip Multi Fibre
Fosamax
Fosamax Plus
Fragmin
Framycetin sulphate
Freestyle Optium
Freestyle Optium Ketone
Frisium
Frumil
Frusemide
Frusemide-Claris
Fucicort68
Fucidin93
Fucithalmic183
Fungilin41
Furosemide [Frusemide]58
Fusidic acid
Dermatological65
Infection93
Sensory183
Fuzeon
- G -
Gabapentin126
Gabapentin (Neurontin)127
Gamma benzene
hexachloride
Gardasil

Gastrosoothe26	1
Gaviscon Double Strength24	
Gaviscon Infant24	
Gefitinib155	
Gemcitabine Actavis 1000149	
Gemcitabine Actavis 200149	
Gemcitabine Ebewe	
Gemcitabine hydrochloride	
Gemfibrozil	
Gemzar	
Generaid Plus	
Genoptic	
Genotropin87	
Genox	
Gentamicin sulphate	
Infection93	
Sensory183	•
Ginet 8479	
Glatiramer acetate139	
Glibenclamide29	1
Gliclazide29	1
Glipizide29	
Glivec	
Glucagen Hypokit27	
Glucagon hydrochloride27	,
Glucerna Select	
Glucerna Select RTH	
Gluten Free Foods210	
Glycerin with sodium	
saccharin	
Glycerin with sucrose	•
Glycerol	
Alimentary40	
Extemporaneous193	•
Glyceryl trinitrate	
Alimentary26	
Cardiovascular61	
Glytrin61	
Gold Knight76	1
Gopten	
Goserelin acetate87	
Gutron55	
Gynaecological	
Anti-infectives79	1
- H -	
Habitrol145	
Haemophilus influenzae type B	
vaccine	
Haldol Concentrate	
Haloperidol	
Haloperidol decanoate135	•
Hamilton Sunscreen74	

HBvaxPro
healthE Fatty Cream69
Healtheries Simple Baking
Mix
Hemastix81
Heparin sodium48
Heparinised saline48
Heparon Junior201
Hepatitis B vaccine
Hepsera
Herceptin
Hexamine hippurate
Hiprex
Histafen
Holoxan147 Homatropine hydrobromide185
Home Essential
Horleys Bread Mix210
Horleys Flour210
Hormone Replacement Therapy -
Systemic 83
Humalog28
Humalog Mix 2528
Humalog Mix 5028
Human papilomavirus
vaccine
Humatin94
Humira166
HumiraPen166
Humulin 30/7028
Humulin NPH28
Humulin R28
Hybloc
Hydralazine61
Hydralazine hydrochloride61
Hydrea152
Hydrocortisone
Dermatological67
Hormone
Hydrocortisone acetate25
Hydrocortisone butyrate67, 73
Hydrocortisone with
cinchocaine
Hydrocortisone with
miconazole
Hydrocortisone with natamycin
and neomycin
Hydrocortisone with wool fat and
mineral oil 68
Hydroderm Lotion69
Hydrogen nerovide
Alimentary
Dermatological65

Hydroxocobalamin42
Hydroxychloroquine96
Hydroxyurea152
Hygroton
Hyoscine (scopolamine)130
Hyoscine hydrobromide
Hyoscine N-butylbromide
Hypam140
Hyperuricaemia and
Antigout116
Hypnovel140
Hypromellose
Hysite185
-1-
lbiamox91
Ibuprofen110
Idarubicin hydrochloride152
Ifosfamide
Igroton59
lkorel62
lloprost63
Imatinib mesylate155
Imiglucerase41
Imipramine hydrochloride123
Imiguimod
Immune Modulators106
Immunosuppressants
Imuprine161
Imuphile
Indapamide
Indinavir106
Infanrix-hexa
Infantix-IPV
Infant Formulae212
Influenza vaccine
Agents 178
Inhaled Corticosteroids
Inhaled Long-acting
Beta-adrenoceptor
Agonists 176
Inhibace Plus
Innovacon hCG One Step
Pregnancy Test 80
Inset 30
Inset II
Insulin aspart28
Insulin aspart with insulin aspart
protamine28
Insulin glargine28
Insulin glulisine28
Insulin isophane28

Insulin isophane with insulin
neutral
Insulin lispro28
Insulin lispro with insulin lispro
protamine
Insulin neutral28
Insulin pen needles31
Insulin pump32
Insulin pump accessories
Insulin pump infusion set (steel
cannula) 34
Insulin pump infusion set (teflon
cannula, angle insertion with
insertion device)
Insulin pump infusion set (teflon
cannula, angle insertion)
Insulin pump infusion set (teflon
cannula, straight insertion with
insertion device)
Insulin pump infusion set (teflon
cannula, straight insertion)
Insulin pump reservoir
Insulin syringes, disposable with
attached needle
Intal Forte CFC Free
Intal Spincaps
Intelence
Interferon alpha-2a107
Interferon alpha-2b107
Interferon beta-1-alpha
Interferon beta-1-beta
Intra-uterine device
Intron-A107
IPOL
Ipratropium bromide178, 181
Iressa155
Irinotecan149
Irinotecan Actavis 100149
Irinotecan Actavis 40149
Irinotecan-Rex149
Iron Overload51
Iron polymaltose44
Isentress106
Ismo 2061
Isoniazid97
Isoprenaline61
Isoptin57
Isopto Carpine185
Isopto Homatropine185
Isosorbide mononitrate61
Isosource Standard207
Isosource Standard RTH207
Isotretinoin64

INDEX Generic Chemicals and Brands


Isradipine	57
lsuprel	61
Itch-Soothe	66
Itraconazole	95
Itrazole	
lvermectin	70
- J -	
Jadelle	
Jevity	207
Jevity HiCal RTH	207
Jevity RTH	207

- K -

Kaletra	106
Kemadrin	119
Kenacomb	183
Kenacort-A	83
Kenacort-A40	
Ketocal 3:1	215
KetoCal 4:1	215
Ketoconazole	
Dermatological	73
Infection	95
Ketogenic Diet	215
Katana blood bata katana	
Ketone blood beta-ketone	
electrodes	
electrodes	110
electrodes Ketoprofen	110 29
electrodes Ketoprofen Ketostix	110 29 201
electrodes Ketoprofen Ketostix Kindergen	110 29 201 97
electrodes Ketoprofen Ketostix Kindergen King	110 29 201 97 105
electrodes Ketoprofen Ketostix Kindergen King Kivexa	110 29 201 97 105 90
electrodes Ketoprofen Ketostix Kindergen King Kivexa Klacid	110 29 201 97 105 90 85
electrodes Ketoprofen Ketostix Kindergen King Kivexa Klacid Klacid Kliogest Kliovance Konakion MM	110 29 201 97 105 90 85 85 46
electrodes Ketoprofen Ketostix Kindergen King Kivexa Klacid Klogest Kliovance	110 29 201 97 105 90 85 85 46

- L -

L-asparaginase	150
Labetalol	55
Lacosamide	127
Lacri-Lube	186
Lactulose	
Laevolac	40
Lamictal	128
Lamivudine	
Lamotrigine	128
Lamprene	97
Lanoxin	54
Lanoxin PG	
Lansoprazole	27
Lantus	28
Lantus SoloStar	
Lanvis	149



Lapatinib Ditosylate	156
Largactil	132
Lasix	
Latanoprost	
Lax-Sachets	
Lax-Jachers	
Laxatives	
Laxofast 120	
Laxofast 50	
Laxsol	
Leflunomide	
Letraccord	160
Letrozole	
Leukeran FC	147
Leukotriene Receptor	
Antagonists	179
Leunase	
Leuprorelin	
Leustatin	
Levetiracetam	
Levetiracetam-Rex	
Levobunolol	
Levocabastine	
Levodopa with benserazide	
Levodopa with carbidopa	118
Levomepromazine	133
Levonorgestrel	
Genito-Urinary	79
Hormone	
Levothyroxine	
Lidocaine [Lignocaine]	
hydrochloride	110
Lidocaine-Claris	
Lifestyles Flared	/0
Lignocaine	119
Lignocaine with	
chlorhexidine	
Lignocaine with prilocaine	
Lincocin	
Lincomycin	93
Lipazil	59
Lipid-Modifying Agents	59
Liquigen	
Lisinopril	
Lisuride hydrogen maleate	
Lithicarb FC	
Lithium carbonate	1.33
Livostin	
Locacorten-Viaform ED's	
	103
Local preparations for Anal and	00
Rectal Disorders	
Locasol	
Loceryl	65


Locoid67, 73	ł
Locoid Crelo	
Locoid Lipocream67	
Locorten-Vioform183	5
Lodoxamide trometamol184	
Logem128	3
Lomide	
Lomustine147	
Loniten	
Loperamide hydrochloride24	ł
Lopinavir with ritonavir106	
Lopresor56	
Loprofin212)
Loprofin Mix212	
Loraclear Hayfever Relief176	
Lorapaed176	
Loratadine176	
Lorazepam137	
Lormetazepam140	
Losartan potassium54	ŀ
Losartan potassium with	
hydrochlorothiazide	l
Lostaar	
Lovir	
Loxalate124	
Loxamine124	
Lucrin Depot87	,
Lucrin Depot PDS87	
Ludiomil	
Lumigan	
Lycinate61	
Lyderm72	
- M -	
m-Captopril52)
m-Cefuroxime90)
m-Enalapril	
m-Eslon	
M-M-R II	
m-Mometasone68	
Mabthera170	
Macrogol 335040)
Madopar 125118	3
Madopar 250118	
Madopar 62.5	2
Madopar Dispersible	2
Madopar HBS118	,
Magnesium hydroxide193	5
Magnesium sulphate	
Alimentary44	
Annontary	ŀ
Dermatological75	;
Dermatological75	;
Dermatological	;

piperonyl butoxide	72
Maprotiline hydrochloride	
Marevan	49
Marine Blue Lotion SPF 30+	
Marquis Black	
Marquis Conforma	
Marquis Protecta	76
Marquis Selecta	
Marquis Sensolite Marquis Supalite	/0
Marquis Supane	70
Marquis Titilata	70 76
Martindale Acetylcysteine	103
Marvelon 21	
Marvelon 28	
Mask for spacer device	
Mast Cell Stabilisers	180
Maxidex	184
Maxitrol	
MCT oil (Nutricia)	199
Measles, mumps and rubella	
vaccine	227
Mebendazole	89
Mebeverine hydrochloride	26
Medrol	82
Medroxyprogesterone acetate	
Genito-Urinary	79
Hormone	84, 86
Hormone Mefenamic acid	.84, 86 110
Hormone Mefenamic acid Megestrol acetate	.84, 86 110 159
Hormone Mefenamic acid Megestrol acetate Meloxicam	84, 86 110 159 111
Hormone Mefenamic acid Megestrol acetate Meloxicam Melophalan	84, 86 110 159 111
Hormone Mefenamic acid Megestrol acetate Meloxicam Melphalan Meningococcal A. C. Y and	84, 86 110 159 111 147
Hormone Mefenamic acid Megestrol acetate Meloxicam Melphalan Meningococcal A, C, Y and W-135 vaccine	84, 86 110 159 111 147 227
Hormone Mefenamic acid Megestrol acetate Meloxicam Melphalan Meningococcal A, C, Y and W-135 vaccine Menomune	84, 86 110 159 111 147 227 227
Hormone Mefenamic acid Megestrol acetate Melphalan Meningococcal A, C, Y and W-135 vaccine Menomune Menthol	84, 86 110 159 111 147 227 227 66
Hormone Mefenamic acid Megestrol acetate Melphalan Meningococcal A, C, Y and W-135 vaccine Menomune Menomune Mercaptopurine	84, 86 110 159 111 147 227 227 66 149
Hormone Mefenamic acid Megestrol acetate Melphalan Meningococcal A, C, Y and W-135 vaccine Menomune Menomune Mencaptopurine Mercaiton 21	84, 86 110 159 111 147 227 227 227 66 149 17
Hormone Mefenamic acid Megestrol acetate Meloxicam Meningococcal A, C, Y and W-135 vaccine Menomune Menomune Mercaptopurine Mercilon 21 Mercilon 28	84, 86 110 159 111 147 227 227 66 149 77
Hormone Mefenamic acid Megestrol acetate Meloxicam Melphalan Meningococcal A, C, Y and W-135 vaccine Menomune Menomune Menthol Mercaptopurine Mercilon 21 Mercilon 28 Mercury Pharma	84, 86 110 159 111 147 227 227 66 149 77 77 86
Hormone Mefenamic acid Megestrol acetate Meloxicam Meningococcal A, C, Y and W-135 vaccine Menomune Menomune Mercaptopurine Mercilon 21 Mercilon 28	84, 86 110 159 111 147 227 66 149 77 86 25
Hormone Mefenamic acid Megestrol acetate Melphalan Meningococcal A, C, Y and W-135 vaccine Menomune Menomune Mercaptopurine Mercaptopurine Mercion 21 Mercion 28 Mercury Pharma Mesalazine Mestinon	84, 86 110 159 111 227 66 149 77 77 86 25 152 110
Hormone Mefenamic acid Megestrol acetate Meloxicam Meningococcal A, C, Y and W-135 vaccine Menomune Menthol Mercaptopurine Mercilon 21 Mercilon 21 Merculon 28 Mercury Pharma Mesalazine	84, 86 110 159 111 227 66 149 77 77 86 25 152 110
Hormone Mefenamic acid Megestrol acetate Melphalan Meningococcal A, C, Y and W-135 vaccine Menomune Menomune Mercaptopurine Mercaptopurine Mercaptopurine Mercion 21 Mercion 22 Mercury Pharma Mesalazine Mesalazine Mestinon Metabolic Disorder Agents Metamide	84, 86 110 159 111 147 227 66 149 77 86 25 152 152 110 41 41
Hormone Mefenamic acid Megestrol acetate Melphalan Meningococcal A, C, Y and W-135 vaccine Menomune Menomune Mercaptopurine Mercaptopurine Mercaptopurine Mercion 21 Mercion 28 Mercury Pharma Mesalazine Mesalazine Mestinon Metabolic Disorder Agents Metamide Metformin hydrochloride	84, 86 110 159 111 147 227 66 149 77 86 25 152 152 110 41 41
Hormone	84, 86 110 159 111 147
Hormone	84, 86 110 159 111 147 227 66
Hormone Mefenamic acid Megestrol acetate Melphalan Meningococcal A, C, Y and W-135 vaccine Menomune Menomune Mercaptopurine Mercaptopurine Mercilon 21 Mercilon 21 Mercilon 22 Mercilon 28 Mercury Pharma Mesalazine Mesalazine Mesalazine Mesholic Disorder Agents Metamide Methadone hydrochloride Methadone hydrochloride Nervous	84, 86 110 159 111 147 227
Hormone Mefenamic acid Megestrol acetate Meloxicam Meningococcal A, C, Y and W-135 vaccine Menomune Menomune Mercalotopurine Mercalotopurine Mercalotopurine Mercalotopurine Mercalotopurine Mercalotopurine Mercalotopurine Mercalotopurine Mesalazine Mesalazine Mesalazine Mestanon Metanide Methadone hydrochloride Methadone hydrochloride Nervous Methatabs	84, 86 110 159 111 147 227
Hormone Mefenamic acid Megestrol acetate Meloxicam Meningococcal A, C, Y and W-135 vaccine Menomune Menomune Mercajtopurine Mercajtopurine Mercajtopurine Mercajtopurine Mercajtopurine Mercajtopurine Mercajtopurine Mercajtopurine Mercajtopurine Mercajtopurine Mesalazine Mesalazine Mesalazine Mestanon Metabolic Disorder Agents Metamide Methadone hydrochloride Nervous Methatabs Methoblastin	84, 86 110 159 111 147 227
Hormone Mefenamic acid Megestrol acetate Meloxicam Meningococcal A, C, Y and W-135 vaccine Menomune Menomune Mercalotopurine Mercalotopurine Mercalotopurine Mercalotopurine Mercalotopurine Mercalotopurine Mercalotopurine Mercalotopurine Mesalazine Mesalazine Mesalazine Mestanon Metanide Methadone hydrochloride Methadone hydrochloride Nervous Methatabs	84, 86 110 159 111 147 227

Methotrexate Ebewe149
Methyl hydroxybenzoate
Methylcellulose
Methylcellulose with glycerin and
sodium saccharin 194
Methylcellulose with glycerin and
sucrose
Methyldopa58
Methylphenidate
hydrochloride 142
Methylphenidate hydrochloride
extended-release142
Methylprednisolone82
Methylprednisolone
aceponate
Methylprednisolone acetate82
Methylprednisolone acetate with
lignocaine
Methylprednisolone sodium
succinate82
Methylxanthines180
Metoclopramide
hydrochloride 131
Metoclopramide hydrochloride
with paracetamol 130
Metolazone
Metopirone
Metopriolo - AFT CR
Metoprolol succinate
Metoprolol tartrate
Metronidazole
Metyrapone88
Mexiletine hydrochloride54
Mexiletine Hydrochloride
USP
Miacalcic113
Mianserin hydrochloride123
Micolette
Miconazole41
Miconazole nitrate
Dermatological
Genito-Urinary
Micreme
Micreme H68
Microgynon 3078
Microgynon 50 ED78
Microlut79
Midazolam140
Midodrine55
Minerals43
Minidiab29
Minirin
Mino-tabs
11110 (abo

Minocycline hydrochloride92
Minomycin
Minor Skin Infections70
Minoxidil62
Mirena85
Mirtazapine125
Misoprostol
Mitomycin C152
Mitozantrone152
Mitozantrone Ebewe152
Mixtard 3028
Moclobemide124
Modafinil143
Modavigil143
Modecate135
Moducal197
Moduretic59
Mogine128
Mometasone furoate68
Monogen200
Montelukast179
Morphine hydrochloride121
Morphine sulphate122
Morphine tartrate122
Motetis119
Mouth and Throat41
Movicol40
Moxifloxacin93
MSUD Maxamaid211
MSUD Maxamum211
Mucilaginous laxatives
Mucilaginous laxatives with
stimulants
Mucolytics180
MultiADE43
Multiload Cu 37576
Multiload Cu 375 SL76
Multiple Sclerosis
Treatments 138
Multivitamins43
Mupirocin65
Muscle Relaxants117
Myaccord161
Myambutol97
Mycobutin98
Mycophenolate mofetil161
Mycostatin
Mydriacyl185
Mylan Atenolol55
Mylan Fentanyl Patch121
Mylanta P24
Myleran147
Myocrisin111

Myometrial and Vaginal Hormone Preparations80
•
- N -
Nadolol
Nalcrom25
Naloxone hydrochloride144
Naltraccord145
Naltrexone hydrochloride145
Naphazoline hydrochloride186
Naphcon Forte186
Naprosyn SR 1000110
Naprosyn SR 750110
Naproxen110
Nardil124
Nasal Preparations181
Natulan153
Nausicalm130
Navelbine154
Navoban131
Nedocromil180
Nefopam hydrochloride120
Neo-Mercazole86
Neocate213
Neocate Advance213
Neocate Gold213
Neocate LCP213
Neoral173
NeoRecormon45
Neostigmine110
Neotigason72
Nepro (strawberry)203
Nepro (vanilla)
Nepro RTH202
Nerisone67
Neulactil133
NeuroKare43
Neurontin127
Nevirapine104
Nevirapine Alphapharm104
Next Choice
Nicorandil62
Nicotine145
Nicotinic acid59
Nifedipine57
Nifuran109
Nilstat
Alimentary41
Genito-Urinary79
Infection
Nipent153
Nitrados140
Nitrates61



Nitrazepam 140 Nitroderm TTS 61 Nitrofurantoin 109 Nizoral 95 Noctamid 140 Nodia 24 Noflam 250 110 Nor-Steroidal Anti-Inflammatory 110 Drugs 110 Norethisterone 79	
Hormone	
mestranol	
Norflex117	
Norfloxacin	
Noriday 2879	
Norimin	
Norinyl-1/2878	
Normacol Plus	
Normison	
Norpress124	
Nortriptyline hydrochloride	
Norvir	
NovaSource Renal203	
Novatretin72	
NovoFine	
NovoMix 30 FlexPen28	
NovoRapid28	
NovoRapid Penfill	
Noxafil	
Nozinan133	
Nuelin180	
Nuelin-SR180	
Nupentin126	
Nutraplus69	
Nutrient Modules197	
Nutrini Energy Multi Fibre202	
Nutrini Energy RTH202 Nutrini Low Energy Multi	
Nutrini Low Energy Multi	
Fibre	
Nutrini RTH202	
Nutrison Concentrated209	
Nutrison Energy207	
Nutrison Energy Multi Fibre207	
Nutrison Multi Fibre207	
Nutrison Standard RTH207	
Nyefax Retard57	
Nystatin	
Alimentary41	
Dermatological66	
Genito-Urinary79	


Infection95 NZB Low Gluten Bread Mix210
NZB Low Gluten Bread Mix210
- 0 -
Octreotide (somatostatin
analogue) 159
Octreotide LAR (somatostatin
analogue) 159
Octreotide MaxRx159
Oestradiol
Oestradiol valerate
Oestradiol with
norethisterone
Oestriol
Genito-Urinary80
Hormone
Oestrogens
Oestrogens with
medroxyprogesterone
Oil in water emulsion
Olanzapine133, 136
Olanzapine pamoate
monohydrate 135
Olanzine
Olanzine-D
Olbetam
Olopatadine
Olsalazine
Omeprazole
Omezol Relief27
Oncaspar152
OncoTICE166
Ondansetron131
One-Alpha42
Onelink61
Onkotrone152
Ora-Blend194
Ora-Blend SF194
Ora-Plus194
Ora-Sweet193
Ora-Sweet SF193
Orabase41
Oracort41
Oral Supplements/Complete Diet
(Nasogastric/Gastrostomy
Tube Feed)199
Oratane64
Orgran211
Ornidazole97
Orphenadrine citrate117
Orphenadrine hydrochloride119
Ortho All-flex
Ortho-tolidine81
Oruvail SR110

Osmolite	207
Osmolite RTH	207
Ospamox	91
Ospamox Paediatric Drops	
Other Endocrine Agents	
Other Oestrogen	
Preparations	85
Other Progestogen	05
Preparations	95
Other Skin Preparations	05 74
Ovestin	
Genito-Urinary	00
Hormone	
Ox-Pam	
Oxaliplatin	148
Oxaliplatin Actavis 100	148
Oxaliplatin Actavis 50	
Oxaliplatin Ebewe	148
Oxazepam	
Oxis Turbuhaler	
Oxpentifylline	62
Oxybutynin	81
Oxycodone hydrochloride	122
Oxycodone Orion OxyContin	122
OxyContin	122
OxyNorm	122
OxyNorm Oxytocin	.122 80
OxyNorm	.122 80
OxyNorm Oxytocin Ozole - P -	.122 80 95
OxyNorm Oxytocin Ozole Pacifen	.122 80 95
OxyNorm Oxytocin Ozole Pacifen	.122 80 95
OxyNorm Oxytocin Ozole - P -	.122 80 95 .117 .137
OxyNorm Oxytocin Ozole Pacifen Pacific Buspirone Paclitaxel	.122 80 95 .117 .137 .152
OxyNorm Oxytocin Ozole Pacifen Pacific Buspirone Paclitaxel Paclitaxel Actavis	.122 80 95 .117 .137 .152 .152
OxyNorm Oxytocin Ozole Pacifen Pacific Buspirone Paclitaxel Actavis Paclitaxel Ebewe	.122 80 95 .117 .137 .152 .152 .152
OxyNorm Oxytocin Ozole Pacifen Pacific Buspirone Paclitaxel Actavis Paclitaxel Ebewe Paclitaxel Ebewe	.122 80 95 .117 .137 .152 .152 .152 43
OxyNorm Oxytocin Ozole Pacifen Pacific Buspirone Paclitaxel Actavis Paclitaxel Ebewe Paclitaxel Ebewe	.122 80 95 .117 .137 .152 .152 .152 43
OxyNorm Oxytocin Ozole	122 80 95 117 137 152 152 43 113 113
OxyNorm Oxytocin Ozole	122 80 95 117 152 152 152 43 113 113
OxyNorm Oxytocin Ozole Pacifen Pacific Buspirone Paclitaxel Paclitaxel Actavis Paclitaxel Ebewe Paediatric Seravit Pamidronate BNM Pamidronate disodium Pamisol Panadol	122 80 95 117 137 152 152 152 43 113 113 113 120
OxyNorm Oxytocin Ozole Pacifen Pacific Buspirone Pacitaxel Pacitaxel Actavis Pacitaxel Ebewe Paediatric Seravit Pamidronate BNM Pamidronate BNM Pamidronate Bisodium Pamisol Panadol Pancreatic enzyme	122 80 95 117 137 152 152 43 113 113 113 120 39
OxyNorm Oxytocin Ozole Pacifen Pacific Buspirone Paclitaxel Actavis Paclitaxel Actavis Paclitaxel Ebewe Paediatric Seravit Pamidronate BNM Pamidronate BNM Pamidronate disodium Pamisol Panacol Pancreatic enzyme Pantocid IV	122 80 95 117 137 152 152 152 152 43 113 113 113 120 39 27
OxyNorm Oxytocin Ozole Pacifen Pacific Buspirone Paclitaxel Paclitaxel Actavis Paclitaxel Ebewe Pareidatric Seravit Pamidronate BNM Pamidronate BNM Pamidronate disodium Pamisol Panacol Pancreatic enzyme Pantocid IV Pantoprazole	122 80 95 117 152 152 152 43 113 113 120 39 27 27
OxyNorm Oxytocin Ozole Pacifen Pacific Buspirone Paclitaxel Actavis Paclitaxel Actavis Paclitaxel Ebewe Pacdiatric Seravit Pamidronate BNM Pamidronate disodium Pamisol Panacreatic enzyme Pantocid IV Panzytrat	122 80 95 117 152 152 152 43 113 113 120 39 27 27 39
OxyNorm Oxytocin Ozole Pacifen Pacific Buspirone Paclitaxel Paclitaxel Actavis Paclitaxel Ebewe Pacdiatric Seravit Pamidronate BNM Pamidronate BNM Pamidronate disodium Pamisol Panaceatic enzyme Panatocid IV Pantoprazole Panzytrat Papaverine hydrochloride	122 80 95 117 137 152 152 152 43 113 113 113 120 27 27 39 62
OxyNorm Oxytocin Ozole Pacifen Pacific Buspirone Paclitaxel Actavis Paclitaxel Actavis Paclitaxel Ebewe Paediatric Seravit Pamidronate BNM Pamidronate BNM Pamisol Panadol Panaceatic enzyme Pantocid IV Pantoprazole Panzytrat Papaverine hydrochloride Para Plus	122 80 95 117 152 152 152 152 43 113 113 113 120 39 27 39 62 72
OxyNorm	122 80 95 117 152 152 152 43 113 113 113 120 39 27 39 62 72 98
OxyNorm	122 80 95 117 152 152 152 152 152 152 152 43 113 113 120 39 27 39 62 72 98 120
OxyNorm	122 80 95 117 152 152 152 152 152 152 152 43 113 113 120 39 27 39 62 72 98 120 120
OxyNorm	122 80 95 117 152 152 152 152 152 152 152 43 113 113 120 39 27 39 62 72 98 120 120
OxyNorm	122 80 95 117 152 152 152 152 43 113 113 113 113 113 27 39 62 72 98 120 120
OxyNorm	122 80 95 117 152 152 152 152 152 152 152 152 152 152
OxyNorm	122 80 95 117 152 152 152 152 152 152 113 113 113 120 39 27 39 62 72 98 120 120 120 122

Paradigm 3.0 Reservoir38
Paradigm 52232
Paradigm 72232
Paradigm Mio MMT-92137
Paradigm Mio MMT-92337
Paradigm Mio MMT-92537
Paradigm Mio MMT-94137
Paradigm Mio MMT-94337
Paradigm Mio MMT-94537
Paradigm Mio MMT-96537
Paradigm Mio MMT-97537
Paradigm Quick-Set MMT-386
Paradigm Quick-Set
MMT-387
Paradiam Quick-Set
Paradigm Quick-Set MMT-396
Paradigm Quick-Set
MMT-397
Paradigm Quick-Set
Paradigm Quick-Set MMT-398
Paradigm Quick-Set
MMT-399
Paradigm Silhouette
MMT-368
Paradigm Silhouette MMT-377
MMT-377
Paradigm Silhouette
MMT-378
Paradigm Silhouette MMT-381
MINI-381
Paradigm Silhouette MMT-382
Paradigm Silhouette
MMT-383
Paradigm Silhouette
MMT-384
Paradigm Sure-T MMT-864
Paradigm Sure-T MMT-866
Paradigm Sure-T MMT-87434
Paradigm Sure-T MMT-87634
Paradigm Sure-T MMT-88434
Paradigm Sure-T MMT-88634
Parafast120
Paraffin70
Paraffin liquid with soft white
paraffin 186
Paraffin liquid with wool fat
liquid
Paraldehyde
Paramax
Parasiticidal Preparations70
Parnate124

Paromomycin Paroxetine hydrochloride	24 98 86 37 57 81 50 50
Pedialyte - Plain	
Pediasure	
Pediasure RTH2	
Pegaspargase1	
Pegasys1	08
Pegasys RBV Combination	
Pack 1	08
Pegylated interferon	
alpha-2a1	80
Penicillamine1	11
Penicillin G benzathine	
[benzathine	
benzylpenicillin]	
PenMix 30	
PenMix 40	
PenMix 50	
Pentasa Pentostatin	25
[Deoxycoformycin]1	-0
Pontovifulling [Ovpontifulling]	53
Pentoxifylline [Oxpentifylline]	62
Pentoxifylline [Oxpentifylline] Peptisoothe	62 27
Pentoxifylline [Oxpentifylline] Peptisoothe Peptisorb2	62 27 03
Pentoxifylline [Oxpentifylline] Peptisoothe Peptisorb	62 27 03 18
Pentoxifylline [Oxpentifylline] Peptisoothe Peptisorb	62 27 03 18 57
Pentoxifylline [Oxpentifylline] Peptisoothe	62 27 03 18 57 33
Pentoxifylline [Oxpentifylline] Peptisoothe	62 27 03 18 57 33 52
Pentoxifylline [Oxpentifylline] Peptisoothe	62 27 03 18 57 33 52 18
Pentoxifylline [Oxpentifylline] Peptisoothe	62 27 03 18 57 33 52 18 72
Pentoxifylline [Oxpentifylline] Peptisoothe	62 27 03 18 57 33 52 18 72 46
Pentoxifylline [Oxpentifylline] Peptisoothe	62 27 03 18 57 33 52 18 72 46 98
Pentoxifylline [Oxpentifylline] Peptisoothe	62 27 03 18 57 33 52 18 72 46 98 23
Pentoxifylline [Oxpentifylline] Peptisoothe	62 27 03 18 57 33 52 18 72 46 98 23 66
Pentoxifylline [Oxpentifylline] Peptisoothe	62 27 03 18 57 33 52 18 72 46 98 23 66 57
Pentoxifylline [Oxpentifylline] Peptisoothe	62 27 03 18 57 33 52 18 72 46 98 23 66 57 87
Pentoxifylline [Oxpentifylline] Peptisoothe	62 27 03 18 57 33 52 18 72 46 98 23 66 57 87 24
Pentoxifylline [Oxpentifylline] Peptisoothe	62 27 03 18 57 33 52 18 72 46 98 23 66 57 87 24 28
Pentoxifylline [Oxpentifylline] Peptisoothe	62 27 03 18 57 33 52 18 72 46 98 23 66 57 87 24 94
Pentoxifylline [Oxpentifylline] Peptisoothe	62 27 03 18 57 33 52 18 72 46 98 23 66 57 87 24 94
Pentoxifylline [Oxpentifylline] Peptisoothe	62 27 03 18 57 33 52 18 72 46 98 23 66 57 87 24 28 94 52
Pentoxifylline [Oxpentifylline] Peptisoothe	62 27 03 18 57 33 52 18 72 46 92 366 57 87 24 94 52 92
Pentoxifylline [Oxpentifylline] Peptisoothe	62 27 03 18 57 33 52 18 72 46 98 23 66 57 87 24 28 94 52 92 28
Pentoxifylline [Oxpentifylline] Peptisoothe	62 27 03 18 57 33 52 18 72 46 98 23 66 57 87 24 94 52 92 81 28 12
Pentoxifylline [Oxpentifylline] Peptisoothe	62 27 03 18 57 33 52 18 72 46 98 23 66 57 87 24 94 52 92 81 28 12

Phytomenadione46
Pilocarpine185
Pimafucort68
Pindolol56
Pinetarsol73
Pinorax40
Pinorax Forte40
Pioglitazone29
Piportil
Pipothiazine palmitate136
Pizaccord29
Pizotifen130
PKU Anamix Infant212
PKU Anamix Junior212
PKU Anamix Junior LQ212
PKU Lophlex LQ 10212
PKU Lophlex LQ 20212
Plaquenil96
Plendil ER57
pms-Bosentan62
Pneumococcal (PCV13)
vaccine
Pneumococcal polysaccharide
vaccine
Pneumococcal vaccine227
Pneumovax 23227
Podophyllotoxin74
Polaramine175
Poliomyelitis vaccine227
Poloxamer40
Poly-Tears186
Poly-Visc
Polycal197
Polyvinyl alcohol186
Ponstan110
Ponstan
Posaconazole
Posaconazole
Posaconazole95
Posaconazole



Prednisone83
Pregnancy Tests - hCG Urine80
Premarin
Premia 2.5 Continuous85
Premia 5 Continuous85
Prevenar 13
Prezista
Priadel
Primacin
Primaquine phosphate96 Primidone128
Primolut N86
Prohonosid 117
Probenecid117 Probenecid-AFT117
Procaine penicillin
Procarbazine hydrochloride153
Prochlorperazine131
Proctosedyl26
Procyclidine hydrochloride119
Prodopa58
Proglicem27
Prograf174
Progynova84
Prokinex130
Promethazine hydrochloride176
Promethazine theoclate131
Promod199
Propafenone hydrochloride54
Propamidine isethionate183
Propranolol
Propylene glycol194
Propylthiouracil86
Protamine sulphate48
Protaphane
Protaphane Penfill
Protifar
Protionamide
Provera
PSO216–219
Psoriasis and Eczema
Psoriasis and Eczema Preparations72
PTU
Pulmicort Turbuhaler
Pulmocare
Pulmozyme180
Purinethol149
Pyrazinamide
Pyridostigmine bromide
Pyridostigmine bromide110 PyridoxADE42
PyridoxADE42 Pyridoxine hydrochloride42
Pyrimethamine
F yiazeli on40

	~	
-	Q	-

Q 300	117
Questran-Lite	59
Quetapel	134
Quetiapine	134
Quick-Set MMT-390	38
Quick-Set MMT-391	38
Quick-Set MMT-392	38
Quick-Set MMT-393	38
Quinapril	53
Quinapril with	
hydrochlorothiazide	53
Quinine sulphate	117

- R -

- K -	
RA-Morph121	
Raloxifene hydrochloride113	
Raltegravir potassium106	
Ranbaxy-Cefaclor	
Ranitidine hydrochloride27	
Rapamune	
Reandron 100083	
Rectogesic26	
Redipred82	
Renilon 7.5203	
Resonium-A51	
Resource Beneprotein199	
Resource Diabetic200	
Respigen178	
Respiratory Devices181	
Respiratory Stimulants182	
ReTrieve64	
Retrovir105	
Rex Medical80	
Rexacrom184	
Reyataz105	
Ridal	
Ridaura s29111	
Rifabutin	
Rifadin	
Rifampicin	
Rifinah97	
Riodine	
Risperdal	
Risperdal Consta	
Risperdal Quicklet	
Risperidone134, 136	
Risperon	
Ritalin	
Ritalin LA	
Ritalin SR	
Ritonavir	
Rituximab170	

Rivaroxaban4	8
Rivotril12	
Rizamelt13	
Rizatriptan13	0
Rocaltrol solution4	2
Roferon-A10	
Ropin11	
Ropinirole hydrochloride11	8 8
Roxane	
Alimentary2	1
Cardiovascular5	6
Roxithromycin9	1
Rubifen14	
Rubifen SR14	
Rythmodan5	
Rytmonorm5	
,	4
- S -	
S-26 Gold Premgro21	
Sabril12	
Salamol17	
Salapin17	8
Salazopyrin2	5
Salazopyrin EN2	5
Salbutamol17	8
Salbutamol with ipratropium	
bromide 17	9
Salicylic acid7	3
Salmeterol17	7
Sandomigran13	0
Sandostatin LAR15	9
Scalp Preparations7	3
Scopoderm TTS13	0
Sebizole7	
Sedatives and Hypnotics14	0
Selegiline hydrochloride11	9
Senna4	0
Senokot4	
SensoCard3	
Serenace13	
Seretide17	
Seretide Accuhaler17	
Serevent	7
Serevent Accuhaler17	7
Serophene	7
Seroquel	
Sertraline12	
Sevredol12	
Sex Hormones Non	-
Contraceptive	3
Shield 497	6
Shield Blue7	
Shield XL7	
	5

Silagra63
Sildenafil63
Silhouette MMT-37136
Silhouette MMT-373
Silver sulphadiazine
Simethicone
Simvastatin60
Sindopa118
Sinemet118
Sinemet CR118
Singulair179
Sirolimus174
Siterone83
Slow-Lopresor
Sodibic
Sodium acid phosphate40
Soulum aciu phosphale40
Sodium alginate24
Sodium aurothiomalate111
Sodium bicarbonate
Blood50-51
Extemporaneous194
Sodium calcium edetate44
Sodium
carboxymethylcellulose41
Sodium chloride
Blood
Respiratory
Sodium citrate with sodium lauryl
sulphoacetate 40
Sodium citro-tartrate81
Sodium cromoglycate
Alimentary25
Respiratory180-181
Sensory184
Sodium fluoride43
Sodium nitroprusside
Sodium polystyrene
sulphonate
Suprioriate
Sodium tetradecyl sulphate46
Sodium valproate128
Sofradex183
Soframycin183
Solian132
Solifenacin succinate81
Solox27
Solu-Cortef
Solu-Medrol
Somatropin
Sotacor
Sotalol
Space Chamber181
Space Chamber Plus181
Spacer device181
,

Spacer device autoclavable181
Span-K51
Spiriva178
Spironolactone58
Spirotone
Sporanox95
Sprycel154
Staphlex
Stavudine [d4T]105
Stelazine
Stemetil
Stesolid
Stimulants/ADHD
Treatments 140
Stiripentol
Stocrin
Stomahesive
Strattera
Stromectol70
Suboxone144
Sucralfate27
Sulfadiazine sodium94
Sulindac111
Sulphasalazine25
Sulphur73
Sumatriptan130
Sunitinib
Sunscreens74
Sunscreens, proprietary74
Suplena204
Sure-T MMT-863
Sure-T MMT-865
Sure-T MMT-873
Sure-T MMT-875
Sure-T MMT-883
Sure-T MMT-885
Surgam111 Sustagen Hospital Formula207
Sustanon Ampoules
Sutent
Symbicort Turbuhaler 100/6
Symbicort Turbuhaler 200/6177
Symbicort Turbuhaler
400/12 177
Symmetrel118
Sympathomimetics61
Synacthen83
Synacthen Depot83
Synflorix227
Synthroid86
Syntocinon80
Syntometrine80
Syrup (pharmaceutical

grade)	194
- T -	
Tacrolimus	174
Tambocor	
Tambocor CR	
Tamoxifen citrate	
Tamsulosin hydrochloride	001
Tamsulosin-Rex	00
Tap water	
Tar with triethanolamine lauryl	194
sulphate and fluorescein	72
Tarceva	155
Tasmar	
Taxotere	
Tegretol	
Tegretol CR	
Telfast	
Temaccord	
Temazepam	
Temozolomide	153
Tenofovir disoproxil	100
fumarate	102
Tenoxicam	
Terazosin	
Terbinafine	
Terbutaline sulphate	
Teriparatide	
Testosterone	
Testosterone cypionate	
Testosterone esters	
Testosterone undecanoate	
Tetrabenazine	
Tetrabromophenol	
Tetracosactrin	
Tetracyclin Wolff	92
Tetracycline	
Teva	
Thalidomide	
Thalomid	
Theophylline	
Thiamine hydrochloride	42
THIO-TEPA	148
Thioguanine	
Thiotepa	
Thymol glycerin	
Thyroid and Antithyroid	
Agents	86
Tiaprofenic acid	111
Tilade	180
Tilcotil	
Timolol maleate	
Cardiovascular	56



Sensory 184 Timoptol XE 184 Tiotropium bromide 178 TMP 94 Tobramvcin 18
Infection
Tolcapone
Topamax129 Topical Products for Joint and
Muscular Pain
(TPN)
Tramadol hydrochloride 120 Tramal SR 100 120 Tramal SR 150 120
Tramal SR 200 120 Trandate 55 Trandolapril 53
Tranexamic acid46 Tranylcypromine sulphate124 Trastuzumab172
Travatan
Treatments for Opioid Overdose
Dependence
Tretinoin Dermatological64 Oncology153
Triamcinolone acetonide Alimentary41 Dermatological68
Hormone
Dermatological68 Sensory
Triazolam
Trifluoperazine hydrochloride135

Trimeprazine tartrate	176
Trimethoprim	94
Trisequens	85
Trisul	93
Trophic Hormones	86
Tropicamide	185
Tropisetron	131
Trusopt	185
Truvada	105
Two Cal HN	209
Two Cal HN RTH	
Tykerb	156

- U -

•	
Ultraproct	26
Univent	178, 181
Ural	81
Urea	69
Urex Forte	58
Urinary Agents	80
Urinary Tract Infections	109
Uromitexan	152
Ursodeoxycholic acid	
Ursosan	39

- V -

Vaccinations	226
Valaciclovir	101
Valcyte	101
Valganciclovir	
Vallergan Forte	176
Valtrex	
Vancomycin hydrochloride .	94
Vannair	
Varenicline tartrate	145
Various	187
Vasodilators	61
Vasopressin Agonists	87
Velcade	150
Venlafaxine	
Ventavis	63
Ventolin	178
Vepesid	151
Veracol	89
Verapamil hydrochloride	57
Vergo 16	130
Vermox	89
Verpamil SR	57
Vesanoid	153
Vesicare	81
Vfend	96
Viaderm KC	68
Videx EC	105
Vigabatrin	129

Vimpat	127
Vinblastine sulphate	154
Vincristine sulphate	154
Vinorelbine	154
Vinorelbine Ebewe	154
Viramune Suspension	104
Viread	102
Vistil	186
Vistil Forte	186
Vitabdeck	.43
Vitadol C	.42
Vital HN	203
Vitala-C	.42
Vitamin A with vitamins D and	
C	42
C Vitamin B complex	.42
Vitamins42-	-43
Vivonex Pediatric	213
Vivonex TEN	203
Volibris	.62
Voltaren	110
Voltaren D	110
Voltaren Ophtha	184
Volumatic	181
Voriconazole	.96
Vosol	183
Votrient	157
Vytorin	.60
- W -	
Warfarin sodium	49
Wart Preparations	74
Wasp venom allergy	
treatment	175
Water	175
Blood	50
Extemporaneous	10/
Wockhardt	0/
Wool fat with mineral oil	60
- X -	.03
- ۸ - Xarelto	10
Xeloda	
XMET Maxamum	240
XP Maxamaid	≤11 010
XP Maxamum	212
Xylocaine	110
Xylocaine Viscous	110
	119
- Z -	07
Zantac	.27
Zapril Zarator	
(OROTOR	.52
Zaration	.60
Zarator Zarontin Zaroxolyn	.60 126

Zarzio Zavedos Zeffix Zeldox	152 .99
Zerit	105 .99 175
Zidovudine [AZT]1 Zidovudine [AZT] with Iamivudine1	105

Zinacef	90
Zinc and castor oil	
Zinc sulphate	
Zincaps	44
Zinnat	
Ziprasidone	135
Zithromax	90
Zofran Zydis	131
Zoladex	87
Zoledronic acid	115
Zopiclone	140

Zostrix Zostrix HP	
Zovirax	183
Zuclopenthixol decanoate	136
Zuclopenthixol	
hydrochloride	135
Zyban	145
Zyprexa	133
Zyprexa Relprevv	135
Zyprexa Zydis	136











